<SEC-DOCUMENT>0001193125-17-075811.txt : 20170309
<SEC-HEADER>0001193125-17-075811.hdr.sgml : 20170309
<ACCEPTANCE-DATETIME>20170309090104
ACCESSION NUMBER:		0001193125-17-075811
CONFORMED SUBMISSION TYPE:	40-F
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20161231
FILED AS OF DATE:		20170309
DATE AS OF CHANGE:		20170309

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aurinia Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001600620
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		40-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36421
		FILM NUMBER:		17676945

	BUSINESS ADDRESS:	
		STREET 1:		#1203-4464 MARKHAM STREET
		CITY:			VICTORIA BC
		STATE:			A1
		ZIP:			V8Z 7X8
		BUSINESS PHONE:		250-708-4272

	MAIL ADDRESS:	
		STREET 1:		#1203-4464 MARKHAM STREET
		CITY:			VICTORIA BC
		STATE:			A1
		ZIP:			V8Z 7X8
</SEC-HEADER>
<DOCUMENT>
<TYPE>40-F
<SEQUENCE>1
<FILENAME>d313671d40f.htm
<DESCRIPTION>FORM 40-F
<TEXT>
<HTML><HEAD>
<TITLE>FORM 40-F</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 40-F
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B>&#9744;<B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>REGISTRATION STATEMENT PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B>&#9746;<B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>ANNUAL REPORT PURSUANT TO SECTION 13(A) OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the fiscal year ended December&nbsp;31, 2016 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-36421 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>AURINIA
PHARMACEUTICALS INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of Registrant as specified in its charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Alberta, Canada</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2834</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Not Applicable</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Province or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Primary standard industrial</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>classification code number,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>if applicable)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. employer identification</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>number, if applicable)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>#1203-4464 Markham Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Victoria, British Columbia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>V8Z 7X8 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(250) 708-4272
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address and telephone number of registrant&#146;s principal executive offices) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CT Corporation System </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>111 &#150; 8th Avenue </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>New York, New York 10011 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(212) 590-9331 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name,
address (including zip code) and telephone number (including area code) of agent for service in the United States) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Securities
registered pursuant to Section&nbsp;12(b) of the Act: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:62.75pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of each class:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:151.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name of each exchange on which
registered:</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Common Shares, no par value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>The NASDAQ Stock Market LLC</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Common Shares, no par value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Toronto Stock Exchange</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Securities registered pursuant to Section&nbsp;12(g) of the Act: None </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Securities for which there is a reporting obligation pursuant to Section&nbsp;15(d) of the Act: None </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For annual reports, indicate by check mark the information filed with this form: </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B></B>&#9746;<B></B><B>&nbsp;&nbsp;Annual Information Form</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B></B>&#9746;<B></B><B>&nbsp;&nbsp;Audited Annual Financial Statements</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate the number of outstanding shares of the issuer&#146;s classes of capital or common stock as of the close of the period covered by the annual report:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52,808,235 Common Shares (as at December&nbsp;31, 2016). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Exchange Act during the
preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2)&nbsp;has been subject to such filing requirements for the past 90 days. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;<B></B>&#9746;<B></B><B></B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;
<B></B><B></B>&#9744;<B></B><B></B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if
any, every Interactive Data File required to be submitted and posted pursuant to Rule&nbsp;405 of Regulation S-T (s.232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit and
post such files). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;<B></B>&#9744;<B></B><B></B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;
<B></B>&#9744;<B></B><B></B> </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRINCIPAL DOCUMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following documents are filed as part of this Annual Report on Form <FONT STYLE="white-space:nowrap">40-F:</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A.&nbsp;Annual Information Form </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the
Registrant&#146;s Annual Information Form for the year ended December&nbsp;31, 2016, see Exhibit 99.1 of this Annual Report on Form <FONT STYLE="white-space:nowrap">40-F.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>B.&nbsp;Audited Annual Financial Statements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For
the Registrant&#146;s Audited Consolidated Financial Statements for the year ended December&nbsp;31, 2016, including the report of its Independent Auditor with respect thereto, see Exhibit 99.2 of this Annual Report on Form <FONT
STYLE="white-space:nowrap">40-F.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>C.&nbsp;Management&#146;s Discussion and Analysis </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the Registrant&#146;s Management&#146;s Discussion and Analysis of the operating and financial results for the year ended December&nbsp;31, 2016, see
Exhibit&nbsp;99.3 of this Annual Report on Form <FONT STYLE="white-space:nowrap">40-F.</FONT> </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONTROLS AND PROCEDURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A.&nbsp;Certifications </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The required disclosure is
included in Exhibits 99.5 and 99.6 of this Annual Report on Form <FONT STYLE="white-space:nowrap">40-F.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>B. Disclosure Controls and
Procedures </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the end of the Registrant&#146;s year ended December&nbsp;31, 2016, an internal evaluation was conducted under the supervision of
and with the participation of the Registrant&#146;s management, including the Chairman and Chief Executive Officer and the Chief Financial Officer, of the effectiveness of the design and operation of the Registrant&#146;s &#147;disclosure controls
and procedures&#148; as defined in Rule <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> under Securities and Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;).&nbsp;Based on that evaluation, the Chairman and Chief Executive Officer
and the Chief Financial Officer concluded that the design and operation of the Registrant&#146;s disclosure controls and procedures were effective in ensuring that the information required to be disclosed in the reports that the Registrant files
with or submits to the Securities and Exchange Commission (the &#147;Commission&#148;) is recorded, processed, summarized and reported, within the required time periods. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It should be noted that while the Chairman and Chief Executive Officer and the Chief Financial Officer believe
that the Registrant&#146;s disclosure controls and procedures provide a reasonable level of assurance that they are effective, they do not expect that the Registrant&#146;s disclosure controls and procedures will prevent all errors and fraud. A
control system, no matter how well conceived or operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>C.&nbsp;Management&#146;s Annual Report on Internal Control over Financial Reporting </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Registrant&#146;s management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over
financial reporting is a process designed by, or under the supervision of, the Chairman and Chief Executive Officer and the Chief Financial Officer and effected by the Registrant&#146;s Board of Directors, management and other personnel to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with International Financial Reporting Standards as issued by the International Accounting
Standards Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management assessed the effectiveness of the registrant&#146;s internal control over financial reporting as of December&nbsp;31, 2016,
based on the criteria set forth in <I>Internal Control &#150; Integrated Framework (2013)</I>&nbsp;issued by the Committee of Sponsoring Organizations of the Treadway Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on this assessment, management concluded that, as of December&nbsp;31, 2016, the Registrant&#146;s internal control over financial reporting was
effective. In addition, management determined that there were no material weaknesses in the Registrant&#146;s internal control over financial reporting as of December&nbsp;31, 2016. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>D.&nbsp;Attestation Report of the Registered Public Accounting firm </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This annual report on Form <FONT STYLE="white-space:nowrap">40-F</FONT> does not include an attestation report of the Registrant&#146;s independent registered
public accounting firm due to an exemption established by the JOBS Act for &#147;emerging growth companies&#148;. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>E.&nbsp;Changes in Internal
Control over Financial Reporting </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2016, there were no changes in the Registrant&#146;s internal control
over financial reporting that have materially affected, or are reasonably likely to materially affect, the Registrant&#146;s internal control over financial reporting. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AUDIT COMMITTEE FINANCIAL EXPERT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Registrant&#146;s Board of Directors has determined that Mr.&nbsp;Lorin Jeffry Randall is an &#147;audit committee financial expert&#148; (as that term is defined in paragraph 8(b) of General Instruction B to Form
<FONT STYLE="white-space:nowrap">40-F)</FONT> serving on its audit committee and is &#147;independent&#148; (as defined by the New York Stock Exchange corporate governance rules&nbsp;applicable to foreign private issuers).&nbsp;For a description of
Mr.&nbsp;Randall&#146;s relevant experience in financial matters, see the biographical description for Mr.&nbsp;Lorin Jeffry Randall under &#147;Directors and Officers&#148; in the Registrant&#146;s Annual Information Form for the year ended
December&nbsp;31, 2016, which is filed as Exhibit 99.1 to this Annual Report on Form <FONT STYLE="white-space:nowrap">40-F.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC has indicated
that the designation of Mr.&nbsp;Lorin Jeffry Randall as an audit committee financial expert does not make him an &#147;expert&#148; for any purpose, impose any duties, obligations or liability on him that are greater than those imposed on members
of the audit committee and board of directors who do not carry this designation or affect the duties, obligations or liability of any other member of the audit committee. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CODE OF ETHICS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Registrant has
adopted a &#147;code of ethics&#148; (as that term is defined in paragraph 9(b) of General Instruction B to Form <FONT STYLE="white-space:nowrap">40-F)</FONT> (&#147;Code of Ethics&#148;), which is applicable to the directors, officers, employees
and consultants of the Registrant and its affiliates (including, its principal executive officer, principal financial officer, principal accounting officer or controller, and persons performing similar functions).&nbsp;The Code of Ethics entitled
&#147;Code of Ethics and Conduct&#148; is available on the Registrant&#146;s website at <U>www.auriniapharma.com.</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the past fiscal year, the
Registrant has not granted any waiver, including an implicit waiver, from any provision of its Code of Ethics. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRINCIPAL ACCOUNTANT
FEES AND SERVICES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The required disclosure is included under the heading &#147;External Auditor Services Fees&#148; on Schedule 1 &#150; Audit
Committee Information in the Registrant&#146;s Annual Information Form for the year ended December&nbsp;31, 2016, filed as Exhibit 99.1 to this Annual Report on Form <FONT STYLE="white-space:nowrap">40-F,</FONT> and is incorporated herein by
reference. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">OFF-BALANCE</FONT> SHEET ARRANGEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Registrant does not have any <FONT STYLE="white-space:nowrap">&#147;off-balance</FONT> sheet arrangements&#148; (as that term is defined in paragraph
11(ii) of General Instruction B to Form <FONT STYLE="white-space:nowrap">40-F)</FONT> that have or are reasonably likely to have a current or future effect on its financial condition, changes in financial condition, revenues or expenses, results of
operations, liquidity, capital expenditures or capital resources that is material to investors. For a discussion of the Registrant&#146;s other <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements, see page 17 of the
Registrant&#146;s Management&#146;s Discussion and Analysis for the fiscal year ended December&nbsp;31, 2016, attached as Exhibit 99.3. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABULAR DISCLOSURE OF CONTRACTUAL OBLIGATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The required disclosure is included under the heading &#147;Contractual Obligations&#148; in the Registrant&#146;s Management&#146;s Discussion and Analysis
of the operating and financial results for the year ended December&nbsp;31, 2016, filed as Exhibit 99.3 to this Annual Report on Form <FONT STYLE="white-space:nowrap">40-F,</FONT> and is incorporated herein by reference. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See note 4 &#147;Critical Accounting Estimates and Judgments&#148; to the Audited Consolidated Financial Statements for the fiscal year ended
December&nbsp;31, 2016, filed as Exhibit 99.2 to this Annual Report on Form <FONT STYLE="white-space:nowrap">40-F.</FONT> </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IDENTIFICATION OF THE AUDIT COMMITTEE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Registrant has a separately designated standing audit committee established in accordance with Section&nbsp;3(a)(58)(A) of the Exchange Act.&nbsp;The
Registrant&#146;s Audit Committee members consist of Mr.&nbsp;Lorin Jeffry Randall, Mr.&nbsp;Benjamin Rovinski, and Dr.&nbsp;Gregory Ayers. See &#147;Directors and Executive Officers&#148; and &#147;Audit Committee Information&#148; in the
Registrant&#146;s Annual Information Form for the fiscal year ended December&nbsp;31, 2016, which is filed as Exhibit 99.1 to this Annual Report on Form <FONT STYLE="white-space:nowrap">40-F.</FONT> </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DIFFERENCES IN NASDAQ AND CANADIAN CORPORATE GOVERNANCE REQUIREMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Registrant is a foreign private issuer and its common shares are listed on the NASDAQ Stock Market (&#147;NASDAQ&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NASDAQ Rule 5615(a)(3) permits a foreign private issuer to follow its home country practice in lieu of the requirements of the Rule 5600 Series, the
requirement to distribute annual and interim reports set forth in Rule 5250(d), and the Direct Registration Program requirement set forth in Rules 5210(c) and 5255; provided, however, that such a company shall comply with the Notification of
Material Noncompliance requirement (Rule 5625), the Voting Rights requirement (Rule 5640), have an audit committee that satisfies Rule 5605(c)(3), and ensure that such audit committee&#146;s members meet the independence requirement in Rule
5605(c)(2)(A)(ii). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Registrant does not follow Rule 5620(c) (shareholder quorum) but instead follows its home country practice, as described below.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Shareholder Meeting Quorum Requirements: The NASDAQ minimum quorum requirement under Rule 5620(c) for a shareholder meeting is <FONT
STYLE="white-space:nowrap">33-1/3%</FONT> of the outstanding shares of common stock. In addition, a registrant listed on NASDAQ is required to state its quorum requirement in its <FONT STYLE="white-space:nowrap">by-laws.</FONT> The Registrant&#146;s
quorum requirement is set forth in its <FONT STYLE="white-space:nowrap">by-laws.</FONT> A quorum for a meeting of shareholders of the Registrant is shareholders or proxyholders holding ten percent of the issued and outstanding shares entitled to be
voted at the meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the Registrant does not follow Rule 5635, which establishes shareholder approval requirements prior to the issuance of
securities in certain circumstances. In lieu of following Rule 5635, the Registrant follows the rules of the Toronto Stock Exchange. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing is
consistent with the laws, customs and practices in Canada. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain statements in this Annual Report on Form <FONT STYLE="white-space:nowrap">40-F</FONT> are forward-looking statements within the meaning of Section 21E
of the Exchange Act and Section 27A of the Securities Act of 1933, as amended. Please see &#147;Forward Looking Information&#148; in the Annual Information Form of the Registrant for the year ended December&nbsp;31, 2016, filed as Exhibit 99.1 to
this Annual Report on Form <FONT STYLE="white-space:nowrap">40-F</FONT> for a discussion of risks, uncertainties, and assumptions that could cause actual results to vary from those forward-looking statements. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNDERTAKING </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Registrant undertakes to
make available, in person or by telephone, representatives to respond to inquiries made by the Commission staff, and to furnish promptly, when requested to do so by the Commission staff, information relating to the securities in relation to which
the obligation to file an annual report on Form <FONT STYLE="white-space:nowrap">40-F</FONT> arises or transactions in said securities. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSENT TO SERVICE OF PROCESS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Registrant has previously filed a Form <FONT STYLE="white-space:nowrap">F-X</FONT> in connection with the class of securities in relation to which the obligation to file this report arises. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any change to the name or address of the Registrant&#146;s agent for service shall be communicated promptly to the Commission by amendment to Form <FONT
STYLE="white-space:nowrap">F-X</FONT> referencing the file number of the Registrant. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Exchange Act, the Registrant certifies that it meets all of the requirements for filing on Form <FONT
STYLE="white-space:nowrap">40-F</FONT> and has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:<B></B>&nbsp;March&nbsp;9, 2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>Aurinia Pharmaceuticals Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Dennis Bourgeault</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dennis Bourgeault</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chief Financial
Officer</P></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Form <FONT STYLE="white-space:nowrap">40-F</FONT> Table of Contents </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:23.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit<BR>No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:33.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Document</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><A HREF="d313671dex991.htm">99.1<BR></A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Annual Information Form of the Registrant for the fiscal year ended December&nbsp;31, 2016.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><A HREF="d313671dex992.htm">99.2<BR></A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Audited Consolidated Financial Statements of the Registrant for the year ended December&nbsp;31, 2016 together with the Auditors&#146; Report thereon.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><A HREF="d313671dex993.htm">99.3<BR></A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Management&#146;s Discussion and Analysis of the operating and financial results of the Registrant for the year ended December&nbsp;31, 2016.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><A HREF="d313671dex994.htm">99.4<BR></A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of PricewaterhouseCoopers LLP, Independent Auditor</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><A HREF="d313671dex995.htm">99.5<BR></A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certifications of Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial Officer) pursuant to Section&nbsp;302 of the <I>Sarbanes-Oxley Act of 2002.</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><A HREF="d313671dex996.htm">99.6<BR></A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certifications of Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial Officer) under Section&nbsp;906 of the <I>Sarbanes-Oxley Act of 2002.</I></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d313671dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g313671ex99aif.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">Annual Information Form </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">Aurinia Pharmaceuticals </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">YEAR END 16 </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">For the year ended December 31, 2016 </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">Aurinia Pharmaceuticals </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A><U>TABLE OF CONTENTS</U> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="97%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex99_1toc313671_1">BASIS OF PRESENTATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex99_1toc313671_2">FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex99_1toc313671_3">OVERVIEW</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex99_1toc313671_4">THREE YEAR HISTORY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex99_1toc313671_5">REGULATORY AND BUSINESS MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex99_1toc313671_6">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex99_1toc313671_7">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex99_1toc313671_8">CAPITAL STRUCTURE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex99_1toc313671_9">TRADING PRICE AND VOLUME OF AURINIA SHARES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex99_1toc313671_10">ESCROWED SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex99_1toc313671_11">PRIOR SALES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex99_1toc313671_12">DIRECTORS AND OFFICERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex99_1toc313671_13">CEASE TRADE ORDERS, BANKRUPTCIES, PENALTIES OR
SANCTIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex99_1toc313671_14">LEGAL PROCEEDINGS AND REGULATORY ACTIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex99_1toc313671_15">INTEREST OF MANAGEMENT AND OTHERS IN MATERIAL
TRANSACTIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex99_1toc313671_16">CONFLICTS OF INTEREST</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex99_1toc313671_17">TRANSFER AGENT AND REGISTRAR</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex99_1toc313671_18">MATERIAL CONTRACTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex99_1toc313671_19">INTERESTS OF EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex99_1toc313671_20">ADDITIONAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex99_1toc313671_21">SCHEDULE 1 - AUDIT COMMITTEE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex99_1toc313671_22">SCHEDULE 2 - AUDIT COMMITTEE CHARTER</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex99_1toc313671_23">SCHEDULE 3 - GLOSSARY OF TERMS AND DEFINITIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="ex99_1toc313671_1"></A>BASIS OF PRESENTATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise stated, the information in this Annual Information Form (&#147;<B>AIF</B>&#148;) is as of March&nbsp;6, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In this AIF, unless stated otherwise or the context requires, all dollar amounts are expressed in U.S. dollars. All references to &#147;$ or &#147;US$&#148;
are to the lawful currency of the United States and all references to &#147;CDN$&#148; are to the lawful currency of Canada. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;6, 2017 the
exchange rate for conversion of US dollars into Canadian dollars was US$1.00 = CDN$0.7457 based upon the Bank of Canada noon rate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Market data and
certain industry forecasts used in this AIF were obtained from market research, publicly available information and industry publications. We believe that these sources are generally reliable, but the accuracy and completeness of this information is
not guaranteed. We have not independently verified such information, and we do not make any representation as to the accuracy of such information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
this AIF, unless the context otherwise requires, references to &#147;<B>we</B>&#148;, &#147;<B>us</B>&#148;, &#147;<B>our</B>&#148; or similar terms, as well as references to &#147;<B>Aurinia</B>&#148; or the &#147;<B>Company</B>&#148;, refer to
Aurinia Pharmaceuticals Inc., together with our subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This AIF describes the Company and its operations, its prospects, risks and other factors
that affect its business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Capitalized terms that are not otherwise defined in this AIF have the meanings attributed thereto in Schedule 3 to this AIF.
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="ex99_1toc313671_2"></A>FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A statement is forward-looking when it uses what we know and expect today to make a statement about the future. Forward-looking statements may include words
such as &#147;anticipate&#148;, &#147;believe&#148;, &#147;intend&#148;, &#147;expect&#148;, &#147;goal&#148;, &#147;may&#148;, &#147;outlook&#148;, &#147;plan&#148;, &#147;seek&#148;, &#147;should&#148;, &#147;strive&#148;, &#147;target&#148;,
&#147;could&#148;, &#147;continue&#148;, &#147;potential&#148; and &#147;estimated&#148;, or the negative of such terms or comparable terminology. You should not place undue reliance on the forward-looking statements, particularly those concerning
anticipated events relating to the development, clinical trials, regulatory approval, and marketing of our products and the timing or magnitude of those events, as they are inherently risky and uncertain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities laws encourage companies to disclose forward-looking information so that investors can get a better understanding of our future prospects and make
informed investment decisions. These forward-looking statements made in this AIF may include, among other things, statements with respect to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">plans to fund our operations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">statements concerning strategic alternatives and future operations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">partnering activities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">summary statements relating to results of the past voclosporin trials or plans to advance the development of voclosporin; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">statements concerning partnership activities and health regulatory discussions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing of commencement, enrollment, completion and release of results of clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our intention to seek regulatory approvals in the United States and Europe for voclosporin; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our intention to seek additional corporate alliances and collaborative agreements to support the commercialization and development of our product; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our plans to generate future revenues from products licensed to pharmaceutical and biotechnology companies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our intention to demonstrate that voclosporin possesses pharmacologic properties with the potential to demonstrate <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT>
differentiation with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> status for the treatment of lupus nephritis (&#147;<B>LN</B>&#148;) outside of Japan; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our intention to initiate, and the timing of, the LN Phase 3 clinical trial; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our belief that recent granted formulation patents regarding the delivery of voclosporin to the ocular surface for conditions such as dry eye have the potential to be of therapeutic value; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our belief that voclosporin has further potential to be of therapeutic value in other autoimmune indications and in the prevention of transplant rejection; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our belief that the AURA trial resulted in positive results; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our belief that the LN Phase 3 clinical trial will be <FONT STYLE="white-space:nowrap">de-risked</FONT> based upon the AURA results; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our belief in the market size and potential of LN, and the price range for voclosporin; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our intention to seek regulatory approval in other jurisdictions in the future and initiate clinical studies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs of our LN Phase 3 clinical trial (including continuation study); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our belief that the low dose of voclosporin is the optional dosage for our LN Phase 3 clinical trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our anticipated future financial position, future revenues and projected costs; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">plans and objectives of management. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Such statements reflect our current views with respect to future events
and are subject to risks and uncertainties and are necessarily based on a number of estimates and assumptions that, while considered reasonable by management, as at the date of such statements, are inherently subject to significant business,
economic, competitive, political, scientific and social uncertainties and contingencies, many of which, with respect to future events, are subject to change. The factors and assumptions used by management to develop such forward-looking statements
include, but are not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the assumption that we will be able to reach agreements with regulatory agencies on executable development programs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the assumption that recruitment to clinical trials will occur as projected; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the assumption that we will successfully complete our clinical programs on a timely basis, including conducting the required LN Phase 3 clinical trial and meet regulatory requirements for approval of marketing
authorization applications and new drug approvals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the assumption the regulatory requirements will be maintained; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the assumption that we will be able to manufacture and secure a sufficient supply of voclosporin to successfully complete the development and commercialization of voclosporin; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the assumption that our patent portfolio is sufficient and valid; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the assumption that there is a potential commercial value for other indications for voclosporin; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the assumption that market data and reports reviewed by us are accurate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the assumption that our current good relationships with our suppliers, service providers and other third parties will be maintained; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the assumptions relating to the availability of capital on terms that are favourable to us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the assumption that we will be able to attract and retain skilled staff; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the assumption that general business and economic conditions will be maintained; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the assumptions relating to the feasibility of future clinical trials. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is important to know that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">actual results could be materially different from what we expect if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. As a result, we cannot guarantee that any
forward-looking statement will materialize and, accordingly, you are cautioned not to place undue reliance on these forward-looking statements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">forward-looking statements do not take into account the effect that transactions or <FONT
STYLE="white-space:nowrap">non-recurring</FONT> or other special items announced or occurring after the statements are made may have on our business. For example, they do not include the effect of mergers, acquisitions, other business combinations
or transactions, dispositions, sales of assets, asset write-downs or other charges announced or occurring after the forward-looking statements are made. The financial impact of </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
such transactions and <FONT STYLE="white-space:nowrap">non-recurring</FONT> and other special items can be complex and necessarily depends on the facts particular to each of them. Accordingly,
the expected impact cannot be meaningfully described in the abstract or presented in the same manner as known risks affecting our business; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we disclaim any intention and assume no obligation to update any forward-looking statements even if new information becomes available, as a result of future events, new information, or for any other reason except as
required by law. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The factors discussed below and other considerations discussed in the &#147;<I>Risk Factors</I>&#148; section of this AIF
could cause our actual results to differ significantly from those contained in any forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Such forward-looking statements involve
known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to differ materially from any further results, performance or achievements expressed or implied by such forward-looking
statements. Important factors that could cause such differences include, among other things, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the need for additional capital in the longer term to fund our development programs and the effect of capital market conditions and other factors on capital availability; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties, delays, or failures we may experience in the conduct of and reporting of results of our clinical trials for voclosporin; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties in the manufacture and securing a sufficient supply of voclosporin on a timely basis to successfully complete the development and commercialization of voclosporin; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties, delays or failures in obtaining regulatory approvals for the initiation of clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties in gaining alignment among the key regulatory jurisdictions, EMA, FDA and PMDA which may require further clinical activities; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties, delays or failures in obtaining regulatory approvals to market voclosporin; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties we may experience in completing the development and commercialization of voclosporin; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">insufficient acceptance of and demand for voclosporin; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties, delays, or failures in obtaining appropriate reimbursement from payors for voclosporin; and/or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties we may experience in identifying and successfully securing appropriate corporate alliances to support the development and commercialization of our product. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity,
performance or achievements. These forward-looking statements are made as of the date hereof. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>For additional information on risks and uncertainties in
respect of the Company and its business, please see the &#147;Risks Factors&#148; section of this AIF. Although we believe that the expectations reflected in such forward-looking statements and information are reasonable, undue reliance should not
be placed on forward-looking statements or information because the Company can give no assurance that such expectations will prove to be correct. </I></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="ex99_1toc313671_3"></A>OVERVIEW </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CORPORATE STRUCTURE </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aurinia is a clinical stage
biopharmaceutical company with its head office located at #1203-4464 Markham Street, Victoria, British Columbia V8Z 7X8, where clinical, regulatory and business development functions of the Company are conducted. Aurinia has its registered office
located at #201, <FONT STYLE="white-space:nowrap">17904-105</FONT> Avenue, Edmonton, Alberta T5S 2H5, where the finance function is performed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aurinia is
organized under the <I>Business Corporations Act </I>(Alberta). Aurinia&#146;s <FONT STYLE="white-space:nowrap">By-Law</FONT> No.&nbsp;2 was amended at a shareholder&#146;s meeting held on August&nbsp;15, 2013 to include provisions requiring advance
notice for any nominations of directors by shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aurinia&#146;s Common Shares are currently listed and traded on the NASDAQ under the symbol
&#147;AUPH&#148; and on the TSX under the symbol &#147;AUP&#148;. The Company&#146;s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular LN. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Aurinia has the following wholly-owned subsidiaries: Aurinia Pharma Corp. (British Columbia incorporated), Aurinia Pharma U.S., Inc. (Delaware incorporated) and Aurinia Pharma Limited (UK
incorporated). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>RECENT DEVELOPMENTS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>AURA <FONT
STYLE="white-space:nowrap">48-week</FONT> results </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;1, 2017, we announced top-line results from our Phase 2b AURA-LV (AURA) study in
LN. At 48 weeks, the trial met the complete and partial remission (&#147;CR&#148;/ &#147;PR&#148;) endpoints, demonstrating statistically significantly greater CR and PR in patients in both low dose (23.7mg of voclosporin twice daily (p&lt;.001))
and high dose (39.5mg twice daily (p=.026)) cohorts versus the control group. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 24 and 48-week top-line efficacy results are summarized below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Endpoint</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Treatment</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>24&nbsp;weeks</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Odds&nbsp;ratio</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B>P-value*</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>48&nbsp;weeks</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Odds&nbsp;Ratio</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B>P-value*</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Complete Remission</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">23.7mg&nbsp;VCS&nbsp;BID</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.03</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">p=.045</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.21</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>p&lt;.001</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">39.5mg VCS BID</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">1.59</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">p=.204</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>p=.026</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Control Arm</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>NA</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>NA</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>NA</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>NA</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Partial Remission</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">23.7mg VCS BID</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.33</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">p=.007</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.34</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>p=.007</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">39.5mg VCS BID</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.03</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">p=.024</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.68</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>p=.002</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Control Arm</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>NA</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>NA</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>NA</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>NA</I></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>*</I></TD>
<TD ALIGN="left" VALIGN="top"><I>All p-values are vs control</I> </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The results of the AURA study at 48 weeks demonstrate the highest complete
remission rate of any global LN study of which we are aware, although we note that the criteria to measure remission differed among the studies. The below chart compares the results of the AURA study vs. the other global LN studies of which we are
aware. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="29%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><B>Name of Global Study</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;Number&nbsp;&nbsp;&nbsp;&nbsp;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;of&nbsp;weeks&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Criteria&nbsp;to&nbsp;Measure&nbsp;Remission<BR>and Response Rate</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>Results</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">Efficacy and Safety of Ocrelizumab in Active Proliferative Lupus Nephritis</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">48 weeks</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;UP:CR(gm/gm)&nbsp;&lt;&nbsp;.5</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;SCr&nbsp;<FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT>&nbsp;25% increase from baseline</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;Steroid taper (not forced)</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" COLSPAN="3" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Control = 34.7%</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">LD OCR = 42.7%
(NS)</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">HD OCR = 31.5% (NS)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">Mycophenolate Mofetil<I> versus </I>Cyclophosphamide for Induction Treatment of Lupus Nephritis</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">24 weeks</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;UP:CR(gm/gm)&nbsp;<FONT
STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT>&nbsp;.5</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;Normal eGFR</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;Normal Urinalysis</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;Steroid taper (not forced)</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" COLSPAN="3" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">MMF =
8.6% (NS)</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">IVC = 8.1% (NS)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">Efficacy and Safety of Abatacept in Lupus Nephritis</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">52 weeks</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;UP:CR(gm/gm)&nbsp;<FONT
STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT>&nbsp;.26</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;eGFR within 10% of screening/baseline</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;Normal Urinalysis</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;Criteria to be met on 2 successive visits</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;No mandated steroid taper</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" COLSPAN="3" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Control = 8.0%</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">LD ABT = 11.1%
(NS)</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">HD ABT = 9.1% (NS)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">AURA-LV: Aurinia Urine Protein Reduction in Active Lupus Nephritis Study</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">24 and 48&nbsp;weeks</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;UP:CR(gm/gm)&nbsp;<FONT
STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT>&nbsp;.5</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;No decrease in eGFR&nbsp;<FONT
STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>&nbsp;20%</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;No use of rescue medications</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;Forced steroid taper</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>24 weeks</U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Control&nbsp;=&nbsp;19.3%</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LD&nbsp;Voc=32.6%</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(p=.045)</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HD&nbsp;Voc&nbsp;=&nbsp;27.3%</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(NS)</B></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>48&nbsp;weeks</U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Control&nbsp;=&nbsp;23.9%</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LD&nbsp;Voc&nbsp;=&nbsp;49.4% (p&lt;.001)</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HD&nbsp;Voc&nbsp;=&nbsp;39.8% (p=.026)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each arm of the study included the current standard of care of MMF as background therapy and a forced steroid taper to 5mg/day
by week 8 and 2.5mg by week 16. No unexpected safety signals were observed beyond the 24 week treatment period and there were no additional deaths in the voclosporin treated patients beyond the 24 week treatment period; however, there were three
deaths and one malignancy reported in the control arm after completion of the study treatment period. The table below outlines the Serious Adverse Events as recorded beyond the 24 week time-point of the study. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="10%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER:1px solid #000000; padding-left:8pt"><B>Safety beyond 24 weeks</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;Control&nbsp;&nbsp;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;N = 88&nbsp;&nbsp;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;n (%)&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Voclosporin</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>23.7&nbsp;mg&nbsp;BID</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N&nbsp;=&nbsp;89&nbsp;n&nbsp;(%)</B></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Voclosporin</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>39.5&nbsp;mg&nbsp;BID</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N&nbsp;=&nbsp;88&nbsp;n&nbsp;(%)</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Any Serious Adverse Event (SAE)</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">1 (1.1)</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">2 (2.2)</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">0 (0.0)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Malignancies</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">1 (1.1)</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">0 (0)</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">0 (0.0)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deaths</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">3 (3.4)</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">0 (0)</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">0 (0.0)</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Results from Japanese Phase I Ethnic Bridging Study for Voclosporin </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;14, 2017, we announced the results of a Phase I safety, pharmacokinetic (&#147;<B>PK</B>&#148;) and pharmacodynamic (&#147;<B>PD</B>&#148;)
study in healthy Japanese patients which supports further development of voclosporin in Japanese patients. Based on evaluations comparing the Japanese ethno-bridging data to previous PK and PD studies in
<FONT STYLE="white-space:nowrap">non-Japanese</FONT> patients, voclosporin demonstrated no statistically significant differences in exposure with respect to Area Under the Curve (&#147;<B>AUC</B>&#148;) measurements. Furthermore, the PK parameters
in Japanese volunteers were generally consistent with previously evaluated PK parameters in <FONT STYLE="white-space:nowrap">non-Japanese</FONT> patients. There were no unusual or unexpected safety signals in the study. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Appointment of New Chief Executive Officer </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
February&nbsp;6, 2017, we announced the appointment of Dr.&nbsp;Richard&nbsp;M. Glickman L.LD (Hon), our founder and Chairman of the Board, as our Chairman and Chief Executive Officer. The board of directors accepted the resignation of Charles
Rowland as Chief Executive Officer and a member of the board of directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BUSINESS OF THE COMPANY </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are focused on the development of our novel therapeutic immunomodulating drug candidate, voclosporin, for the treatment of LN. Voclosporin is a next
generation calcineurin inhibitor (&#147;<B>CNI</B>&#148;) which has clinical data in over 2,200 patients across multiple indications. It has been studied in kidney rejection following transplantation, psoriasis and in various forms of uveitis (an
ophthalmic disease). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Voclosporin is an immunosuppressant, with a synergistic and dual mechanism of action that has the potential to improve near- and
long-term outcomes in LN when added to mycophenolate mofetil (&#147;<B>MMF</B>&#148;), the current standard of care for LN. By inhibiting calcineurin, voclosporin blocks <FONT STYLE="white-space:nowrap">IL-2</FONT> expression and <FONT
STYLE="white-space:nowrap">T-cell</FONT> mediated immune responses. Voclosporin is made by a modification of a single amino acid of the cyclosporine molecule which has shown a more predictable pharmacokinetic and pharmacodynamic relationship, an
increase in potency, an altered metabolic profile, and potential for flat dosing. Clinical doses </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of voclosporin studied to date range from 13 &#150; 70 mg BID. The mechanism of action of voclosporin, a CNI, has been validated with certain first generation CNIs for the prevention of rejection
in patients undergoing solid organ transplants and in several autoimmune indications, including dermatitis, keratoconjunctivitis sicca (Dry Eye Syndrome), psoriasis, rheumatoid arthritis, and for LN in Japan. We believe that voclosporin possesses
pharmacologic properties with the potential to demonstrate <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> differentiation with
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> regulatory approval status for the treatment of LN outside of Japan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on published data, we believe the potential key benefits of voclosporin in the treatment of LN are as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Increased potency compared to cyclosporine A, allowing lower dosing requirements and fewer off target effects; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Limited inter and intra patient variability, allowing flat dosing; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Less cholesterolemia than cyclosporine A; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Limited incidence of glucose intolerance and diabetes at targeted doses compared to tacrolimus. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are also
pursuing <FONT STYLE="white-space:nowrap">out-license</FONT> opportunities for our topical nanomicellar drug delivery technology patents. This technology allows for the delivery of voclosporin and other immunomodulators to the ocular surface for
conditions such as dry eye. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Lupus Nephritis (LN) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LN is an inflammation of the kidney caused by systemic lupus erythematosus (&#147;<B>SLE</B>&#148;) and represents a serious manifestation of SLE. SLE is a
chronic, complex and often disabling disorder that affects over 500,000 people in the United States (mostly women). SLE is highly heterogeneous, affecting a wide range of organs and tissue systems. It is estimated that as many as 60% of all SLE
patients have LN that requires urgent treatment. Unlike SLE, LN has straightforward disease measures (readily assessable and easily identified by specialty treaters) where an early response correlates with long-term outcomes, measured by
proteinuria. In patients with LN, renal damage results in proteinuria and/or hematuria and a decrease in renal function as evidenced by reduced estimated glomerular filtration rate (&#147;<B>eGFR</B>&#148;), and increased serum creatinine levels.
eGFR is assessed through the Chronic Kidney Disease Epidemiology Collaboration equation. Rapid control and reduction of proteinuria in LN patients measured at 6 months shows a reduction in the need for dialysis at 10 years. LN can be debilitating
and costly and if poorly controlled, can lead to permanent and irreversible tissue damage within the kidney. Recent literature suggests severe LN progresses to <FONT STYLE="white-space:nowrap">end-stage</FONT> renal disease
(&#147;<B>ESRD</B>&#148;), within 15 years of diagnosis in <FONT STYLE="white-space:nowrap">10%-30%</FONT> of patients, thus making LN a serious and potentially life-threatening condition. SLE patients with renal damage have a 14-fold increased risk
of premature death, while SLE patients with ERSD have a greater than 60-fold increased risk of premature death. Mean annual medical cost for patients (both direct and indirect) with SLE (with no nephritis) have been estimated to exceed US$20,000 per
patient, while the mean annual medical cost for patients (both direct and indirect) with LN who progress to ESRD have been estimated to exceed US$60,000 per patient. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>LN Standard of Care </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While at Aspreva, certain members of
Aurinia&#146;s management team executed the ALMS study which established CellCept<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> as the current standard of care for treating LN. The ALMS study was published in 2009 in the Journal of the
American Society of Nephrology and in 2011 in the New England Journal of Medicine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The American College of Rheumatology recommends that intravenous
cyclophosphamide or MMF/CellCept<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> be used as first-line immunosuppressive therapy for LN. MMF is typically paired with hydroxychloroquine and steroids. Despite their use, the ALMS study showed
that the vast majority of patients failed to achieve complete remission (&#147;<B>CR</B>&#148;), and almost half failed to have a renal response at 24 weeks for both of these therapeutics. Based upon the results of the ALMS study, we believe that a
better solution is needed to improve renal response rates for LN. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on available data from the AURA clinical trial, we believe that voclosporin has
the potential to address several critical needs for LN patients by controlling active disease rapidly, lowering the overall steroid burden, impacting extra-renal disease and doing so with a convenient oral twice-daily treatment regimen. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Market Potential and Commercial Considerations </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
recently conducted our own market research which surveyed approximately 900 rheumatologists and nephrologists across the United States, Europe and Japan to better define the potential market size, estimated pricing and treatment paradigms in those
jurisdictions. Using the U.S. MarketScan<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> data set (with approximately 170,000,000 insured lives in the United States) there were 445,346 SLE patients in the United States (between January
2006 and December 2015) based on specific SLE diagnosis codes. The National Institute of Diabetes and Digestive and Kidney Diseases estimates that up to 60% of people with SLE are diagnosed with LN. Using claims database research and additional
physician research, we believe the diagnosed range of LN patients to be approximately 125,000 to 200,000 in the United States and 175,000 to 250,000 in the European Union. In both the United States and the European Union, 1 in 5 patients are thought
to be undiagnosed due to referring physicians being inefficient and inaccurate in diagnosing the condition. Mean frequency of LN flares in otherwise controlled patients as reported by the surveyed nephrologists and rheumatologists was approximately
every 14 months. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g313671g02v84.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the survey results, it is estimated that 58% of LN patients are controlled (maintenance phase); 25% poorly
controlled and 17% have active disease (induction phase). The rheumatologist and nephrologist specialists indicated that if available, they would use voclosporin in a portion of patients in both the maintenance and induction phases. Only 18% of
those surveyed were very satisfied or extremely satisfied with currently available and unapproved therapies&#146; ability to achieve a CR within six months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the pricing research we have conducted, we believe that the price range for voclosporin can be between US$50,000 and US$100,000 per patient per year
in the United States. We believe that the US market will provide the most opportunity and while the European population is likely larger than the United States, the pricing and market opportunity is more limited. We believe that the initial
estimates of voclosporin peak sales may yield a global opportunity in excess of $1&nbsp;billion. (with greater than $1 billion in the United States; over $300 million in the European Union; and over $80 million in Japan) </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Strategy </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our business strategy is to optimize the
clinical and commercial value of voclosporin. In particular, the Company is focused on the development of voclosporin as an <FONT STYLE="white-space:nowrap">add-on</FONT> therapy to the current standard of care in LN, CellCept<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The key elements of our corporate strategy include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Focusing our resources on advancing voclosporin through a robust LN Phase 3 clinical trial. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mitigate development risk by leveraging the ALMS database and management team&#146;s experience &#150; the Company has certain rights to utilize the ALMS database including its use in planning, designing and informing
the LN Phase 3 clinical trial.</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Evaluate other voclosporin indications &#150; while we intend to deploy our operational and financial resources to develop voclosporin for LN, we believe that recent granted formulation patents regarding the delivery of
voclosporin to the ocular surface for conditions such as dry eye have the potential to be of therapeutic value. The Company will explore its strategic options to exploit shareholder value from this intellectual property. We also believe that
voclosporin has further potential to be of therapeutic value in other autoimmune indications and in the prevention of transplant rejection. Management will consider strategic opportunities for these other potential indications on an ongoing basis.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consider other business development opportunities that would be a strategic fit for the Company or voclosporin under the right circumstances and timing. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>About LN </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LN is one of the most serious
progressions of Systemic Lupus Erythematosus (SLE). The Lupus Foundation of America estimates that &gt;500&nbsp;thousand people in the United States of America and up to 5.0&nbsp;million people worldwide suffer from SLE. Approximately 90% of these
patients are women of child-bearing age. The disease causes severe impairments on quality of life and wellbeing. Of the patients suffering from SLE, <FONT STYLE="white-space:nowrap">40-60%</FONT> experience renal manifestations of the disease
resulting in inflammation of the kidney. These patients are considered to have LN and have a high probability of advancing to end stage renal disease (ESRD), dialysis, renal transplant and death, if left untreated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ALMS data has been reported in several respected journals, including, the New England Journal of Medicine and the Journal of the American Society of
Nephrology </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
These publications and subsequent alterations in treatment strategies by physicians caring for patients suffering from LN have established
CellCept<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>/MMF as the standard of care for the treatment of LN. This shift in the treatment paradigm for LN and the establishment of
CellCept<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> use as a relatively uniform treatment approach for these patients has, in the view of the Company, caused the LN market to evolve into an attractive and mature market opportunity.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Despite CellCept<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> being the current SoC for the treatment of LN, it remains far from adequate
with fewer than 20% of patients on therapy actually achieving disease remission after six months of therapy. Data suggests that a LN patient who does not achieve rapid disease remission upon treatment is more likely to experience renal failure or
require dialysis at 10 years. Therefore, it is critically important to achieve disease remission as quickly and as effectively as possible. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voclosporin mechanism of action </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Voclosporin reversibly
inhibits immunocompetent lymphocytes, particularly <FONT STYLE="white-space:nowrap">T-Lymphocytes</FONT> in the G0 and G1 phase of the cell-cycle, and also reversibly inhibits the production and release of lymphokines. Through a number of processes
voclosporin inhibits and prevents the activation of various transcription factors necessary for the induction of cytokine genes during <FONT STYLE="white-space:nowrap">T-cell</FONT> activation. It is believed that the inhibition of activation of <FONT
STYLE="white-space:nowrap">T-cells</FONT> will have a positive modulatory effect in the treatment of LN. In addition to these immunologic impacts recent data suggests that CNIs have another subtle but important impact on the structural integrity of
the podocytes. This data suggests that inhibition of calcineurin in patients with autoimmune kidney diseases helps stabilize the cellular actin-cytoskeleton of the podocytes thus having a structural impact on the podocyte and the subsequent leakage
of blood proteins into the urine, which is a key marker of patients suffering from LN. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Potential voclosporin clinical benefits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that voclosporin has shown a number of key potential clinical benefits over the existing commercially available CNIs (tacrolimus&nbsp;&amp;
cyclosporine). Firstly, CNI assay results have indicated that voclosporin is approximately four times more potent than its parent molecule cyclosporine, which would indicate an ability to give less drug and produce fewer potentially harmful
metabolites. Secondly, cyclosporine inhibits the enterohepatic recirculation of mycophenolic acid (&#147;MPA&#148;), the active metabolite of MMF. The net effect of <FONT STYLE="white-space:nowrap">co-administration</FONT> of CsA with MMF is reduced
MPA systemic exposure by as much as 50%. This drug interaction has not been observed with voclosporin and it is not expected that MPA blood exposure levels will be reduced with voclosporin <FONT STYLE="white-space:nowrap">co-administration.</FONT>
This is an important fact to consider as most patients being treated with voclosporin for LN will already be taking MMF. Furthermore, pharmacokinetic and pharmacodynamics <FONT STYLE="white-space:nowrap">(&#147;PK-PD&#148;)</FONT> analysis indicate
lower <FONT STYLE="white-space:nowrap">PK-PD</FONT> variability for voclosporin versus tacrolimus or cyclosporine, to the extent that the Company believes flat-dosing can be achieved for voclosporin. The currently available CNIs require extensive
therapeutic drug monitoring which can often be costly, confusing and time consuming for treating physicians. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">head-to-head</FONT></FONT> study comparing voclosporin against cyclosporine in the treatment of psoriasis, cyclosporine was shown to cause significant increases in lipid levels as compared to voclosporin. The difference
was statistically significant. This is important considering most lupus patients die of cardiovascular disease. In another study comparing voclosporin against tacrolimus in patients undergoing renal transplantation, the voclosporin group experienced
a statistically significantly lower incidence of glucose intolerance and diabetes than tacrolimus treated patients. Additionally, in the Japanese tacrolimus study that led to the approval of this drug in Japan, almost 15% of tacrolimus patients
experienced glucose intolerance. This is a major limitation for physicians wanting to use this agent in lupus and is a well described side effect of tacrolimus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that voclosporin can be differentiated from the older CNIs and thus possess a unique position in the market as it relates to inducing remissiion in
patients suffering from LN. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Scientific Rationale for Treatment of LN with voclosporin </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While SLE is a highly heterogeneous autoimmune disease (often with multiple organ and immune system involvement), LN has straightforward disease outcomes
(readily assessable and easily identified by specialty treaters). <FONT STYLE="white-space:nowrap">T-cell</FONT> mediated immune response is an important feature of the pathogenesis of LN while the podocyte injury that occurs in conjunction with the
ongoing immune insult in the kidney is an important factor in the clinical presentation of the disease. An early response in LN correlates with long-term outcomes and is clearly measured by proteinuria. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The use of voclosporin in combination with the current SoC for the treatment of LN provides a novel approach to treating this disease (similar to the standard
approach in preventing kidney transplant rejection). Voclosporin has shown to have potent effects on <FONT STYLE="white-space:nowrap">T-cell</FONT> activation leading to its immunomodulatory effects. Additionally, recent evidence suggests that
inhibition of calcineurin has direct physical impacts on the podocytes within the kidney. Inhibition of calcineurin within the podocytes can prevent the dephosphorylation of synaptopodin which in turn inhibits the degradation of the actin
cytoskeleton within the podocyte. This process is expected to have a direct impact on the levels of protein in the urine which is a key marker of LN disease activity. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voclosporin Development History </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Voclosporin has
been tested in more than 2,200 patients, including studies where it was compared to placebo or active control. The safety and tolerability profile of the drug therefore is well characterized. Phase 2 or later clinical studies that have been
completed include studies in the following indications: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Psoriasis:</B> To date, two Phase 3 clinical studies in patients with moderate to severe
psoriasis have been completed. The primary efficacy endpoint in both studies was a reduction in Psoriasis Area and Severity Index, which is a common measure of psoriasis disease severity. The first study treatment with voclosporin resulted in
statistically significantly greater success rates than treatment with placebo by the twelfth week. In a second study comparing voclosporin against cyclosporine, the drug was not shown to be statistically
<FONT STYLE="white-space:nowrap">non-inferior</FONT> to cyclosporine in terms of efficacy; however, voclosporin proved superior in terms of limiting elevations in hyperlipidemia. Due to the evolving psoriasis market dynamics and the changing
standard of care for the treatment of this disease the Company has decided not to pursue further Phase 3 development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Renal Transplantation:</B> A
Phase 2b clinical trial in de novo renal transplant recipients was completed. Study <FONT STYLE="white-space:nowrap">ISA05-01,</FONT> the PROMISE Study was a six month study with a six month extension comparing voclosporin directly against
tacrolimus on a background of MMF and corticosteroids. Voclosporin was shown to be equivalent in efficacy, but superior to tacrolimus with respect to the incidence of new onset diabetes after transplantation. In 2010, tacrolimus lost its exclusivity
in most world markets and as a result, the competitive pricing environment for voclosporin for this indication has come into question. Additionally, the more expensive development timelines for this indication has made it a less attractive business
proposition as compared to the LN indication, even when considering the fact that a special protocol assessment has been agreed to by the FDA for this indication. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Uveitis:</B> Multiple studies in various forms of <FONT STYLE="white-space:nowrap">non-infectious</FONT> uveitis have been completed over the past several
years by Lux, a former licensee of the Company, indicating mixed efficacy. In all but one of the studies, completed by the licensee, an impact on disease activity was shown in the voclosporin group. However achievement of the primary <FONT
STYLE="white-space:nowrap">end-points</FONT> in multiple studies could not be shown. Uveitis is a notoriously difficult disease to study due to the heterogeneity of the patient population and the lack of validated clinical <FONT
STYLE="white-space:nowrap">end-points.</FONT> However in all of the uveitis studies completed, the safety results were consistent and the drug was well tolerated. The Company has now successfully terminated its licensing agreement with Lux. In
conjunction with this termination the Company has retained a portfolio of additional patents that Lux had been prosecuting that are focused on delivering effective concentrations of voclosporin to various ocular tissues. The Company will continue to
evaluate these patents and make strategic recommendations on how they fit into the ongoing strategic directives of the Company. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="ex99_1toc313671_4">
</A>THREE YEAR HISTORY </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CORPORATE DEVELOPMENTS IN 2016 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>FDA End of Phase 2 Meeting and Plans for Single LN Phase 3 Clinical Trial </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;2, 2016, we announced the FDA&#146;s preference for a single double-blind, randomized, placebo controlled Phase&nbsp;3 clinical trial for
voclosporin in the treatment of LN, to be entitled &#147;<B>AURORA</B>&#148;. This trial will be blinded for up to 52 weeks of treatment. That preference resulted from multiple discussions with the agency and followed the submission to and review of
a comprehensive clinical and safety package relating to voclosporin by the FDA Division of Pulmonary, Allergy and Rheumatology Products. Pursuant to our recent End of Phase 2 meeting with the FDA Division of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Pulmonary, Allergy and Rheumatology Products, we believe this LN Phase 3 clinical trial, the design of which is consistent with the AURA clinical trial, will, if successful, support a New Drug
Application (&#147;<B>NDA</B>&#148;) submission. We also expect to enroll the first patients into the Phase 3 clinical trial sometime during the second quarter of 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The AURORA clinical trial will be a global <FONT STYLE="white-space:nowrap">52-week</FONT> double-blind, placebo controlled study of approximately 320
patients. We are finalizing the study protocol and regulatory submissions and in parallel are working on site selection with trial initiation anticipated in Q2 2017. Patients will be randomized 1:1 to either 23.7 mg of voclosporin (administered
twice a day) (&#147;<B>BID</B>&#148;) and MMF or MMF and placebo, with both arms receiving a stringent oral corticosteroid taper. The study population will be comprised of patients with biopsy-proven active LN who will be evaluated on the primary
efficacy endpoint of renal response at 24 weeks, a composite which includes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Urinary/protein creatinine ratio (&#147;<B>UPCR</B>&#148;) of <FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT>0.7 mg/mg; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Normal, stable renal function (<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>60 mL/min/1.73 m2 or no confirmed decrease from baseline in eGFR of &gt;20%); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Presence of sustained, low dose steroids (<FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT>10 mg prednisone from week <FONT STYLE="white-space:nowrap">16-24);</FONT> and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">No administration of rescue medications. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The readout of the primary endpoint of renal response at 24 weeks
will occur after database lock at 52 weeks. Patients completing the 52 week study will then have the option to roll-over into a 104 week blinded continuation study. These data will allow us to assess long-term outcomes in LN patients that will be
valuable in a post- marketing setting in addition to future interactions with various regulatory authorities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While voclosporin has received fast track
designation, the FDA has informed us that voclosporin is not eligible for breakthrough therapy designation at this time. We will continue to benefit from fast track designation, which includes more frequent communications with the FDA, potential for
priority review of the NDA and an option to submit a rolling NDA submission, which may expedite the review process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our initial forecast is that the
AURORA clinical trial will cost in the range of $70&nbsp;million to $80&nbsp;million. However, we are still in the process of obtaining quotes from suppliers and CROs and determining the optimum number of countries and sites in which to conduct the
AURORA clinical trial and as a result this forecast may change. In addition, the initial estimate of the cost of the continuation study is in the range of $20&nbsp;million to $25&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;13, 2016, we announced that we had received the final End of Phase 2 meeting minutes from the FDA Division of Pulmonary, Allergy and
Rheumatology Products and that the minutes are consistent with the preliminary responses that were issued to us prior to the meeting which took place on October&nbsp;25, 2016. We are currently having ongoing discussions and correspondence with the
EMA. We are working towards final discussions with their scientific advice working party and are currently awaiting official feedback. We also plan to have a regulatory meeting with the PMDA regarding requirements for Japan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>AURION Clinical Trial Update </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The AURION trial is
a <FONT STYLE="white-space:nowrap">single-arm,</FONT> twin center, exploratory study assessing the predictive value of an early reduction in proteinuria in subjects receiving 23.7 mg of voclosporin BID with the current standard of care in patients
with active LN. The primary objective of the AURION clinical trial is to examine biomarkers of disease activity at eight weeks and their ability to predict response at 24 and 48 weeks. Based on our recently released 48 week topline results for the
AURA study, we are re-evaluating specific endpoints to optimize trial design and success. We do not believe this will affect the timing for the initiation or completion of the AURORA study. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Study Design: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g313671g81w35.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The primary analysis is the number of patients achieving each of the following biomarkers and the number of these patients
who go on to achieve week 24 or week 48 remission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Biomarkers: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">25% reduction in UPCR at eight weeks; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">C3 complement normalization at 8 weeks; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">C4 complement normalization at 8 weeks; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Anti-dsDNA (double-stranded DNA) normalization at eight weeks. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The secondary analysis includes the 24 and 48
week outcomes, markers of SLE and pharmacokinetics and pharmacodynamics (PK/PD) of voclosporin. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;6, 2016, we announced 24 week data in all
10 patients from the AURION clinical trial, an open-label exploratory study to assess the short-term predictors of response using voclosporin (23.7 mg BID) in combination with MMF and oral corticosteroids in patients with active LN. The data was
presented by Robert Huizinga, Vice President of Clinical Affairs at Aurinia Pharmaceuticals at the 10th Annual European Lupus Meeting in Venice, Italy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The primary objective of the trial is to examine biomarkers of disease activity at eight weeks and their ability to predict response at 24 and 48 weeks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In this trial, 70% (7/10) of patients achieved CR at 24 weeks as measured by a UPCR of <FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT>0.5mg/mg, eGFR within 20%
of baseline and concomitant steroid dose of &lt;5 mg/day. Of the 10 patients that achieved a reduction of UPCR of <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>25% at 8 weeks, 80% were responders (<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>50%
reduction in UPCR over baseline) at 24 weeks and 70% were in CR at 24 weeks, proteinuria levels decreased by a mean of 61% from baseline through the first 24 weeks of the study. In addition, inflammatory markers such as C3, C4 and anti- dsDNA all
continued to normalize to 24 weeks. Voclosporin was well-tolerated with no unexpected safety signals observed. Patients were generally improving while function, as measured by eGFR, remained stable over the 24 weeks. We believe that the results of
the AURION study supports the use of the 23.7 mg twice daily dose in further studies, and we believe that the AURION study also supports that this dosage is optimal for the AURORA study. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Details of the results are below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="53%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:28.40pt; font-size:8pt; font-family:Times New Roman"><B>Patient#</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Attained&nbsp;</B><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT><B></B><B>25%</B><br><B>reduction&nbsp;in</B><br><B>UPCR&nbsp;at&nbsp;8&nbsp;weeks</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Attained</B><br><B>PR*</B><br><B>at&nbsp;8&nbsp;weeks</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Attained</B><br><B>PR*</B><br><B>at&nbsp;24&nbsp;weeks</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Attained</B><br><B>CR</B><br><B>at&nbsp;8&nbsp;weeks</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Attained</B><br><B>CR</B><br><B>at&nbsp;24&nbsp;weeks</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>TOTALS:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>100%&nbsp;(10/10)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>70%&nbsp;(7/10)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>80%&nbsp;(8/10)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>50%&nbsp;(5/10)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>70%&nbsp;(7/10)</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>*</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Retrospectively defined by </I><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT><I></I><I>50% reduction in UPCR</I> </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>AURA &#150; Positive <FONT STYLE="white-space:nowrap">Top-Line</FONT> Results For 24 Week Data </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;15, 2016, we announced positive <FONT STYLE="white-space:nowrap">top-line</FONT> results from the AURA clinical trial in patients with active
LN. The trial achieved its primary endpoint, demonstrating statistically significantly greater CR at 24 weeks (and confirmed at 26 weeks) in patients treated with 23.7 mg of voclosporin twice daily (p=0.045). This was the first global study of LN to
meet its primary endpoint. Both treatment arms, 23.7 mg and 39.5 mg twice daily also showed a statistically significant improvement in the rate of achieving partial remission (&#147;<B>PR</B>&#148;) at 24 weeks (p=0.007; p=0.024). Each arm of the
study included the current standard of care of MMF as background therapy, and a forced steroid taper. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>AURA Trial Design </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The AURA clinical trial or &#147;Aurinia Urinary protein Reduction Active &#150; Lupus with Voclosporin&#148; compared the efficacy of voclosporin added to
current standard of care of MMF, also known as CellCept<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, against standard of care with placebo in achieving CR in patients with active LN. It enrolled 265 patients at centers in 20 countries
worldwide. On entry to the trial, patients were required to have a diagnosis of LN according to established diagnostic criteria (American College of Rheumatology) and clinical and biopsy features indicative of active LN. Patients also either had
proteinura of greater than or equal to 1.5 mg/mg or, in the case of Class&nbsp;V LN patients, greater than or equal to 2 mg/mg. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patients were randomized
to one of two dosage groups of voclosporin (23.7 mg BID and 39.5 mg BID) or placebo, with all patients also receiving MMF and oral corticosteroids as background therapy. All patients had an initial IV dose of steroids
<FONT STYLE="white-space:nowrap">(500-1000</FONT> mg) and then were started on <FONT STYLE="white-space:nowrap">20-25</FONT> mg/daily, which was tapered down to a low dose of 5 mg daily by week 8 and 2.5 mg daily by week 16. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g313671g87w15.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The primary endpoint was a measure of the number of patients who achieved CR at 24 weeks which had to be confirmed at
26&nbsp;weeks. CR required the following four elements: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">protein/creatinine ratio of <FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT>0.5 mg/mg; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">normal stable renal function (eGFR <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>60 mL/min/1.73m2 or no confirmed decrease from baseline in eGFR of <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>20%); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Presence of sustained, low dose steroids (<FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT>10mg/day of prednisone from week 16 - 24); and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">No administration of rescue medications throughout the treatment period. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Summary of 24 Week Results
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The groups were generally well-balanced for age, gender and race, however, when considered together, the proteinuria and eGFR data suggest that
disease severity was greater for the <FONT STYLE="white-space:nowrap">low-dose</FONT> voclosporin group. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Efficacy </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The primary endpoint of CR was met for the <FONT STYLE="white-space:nowrap">low-dose</FONT> voclosporin group in the ITT analysis (p=0.045). 32.6% of patients on low dose achieved CR, compared to 27.3% on high dose and
19.3% in the control arm. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The odds ratio indicates that patients were twice as likely to achieve CR at 24 weeks compared to the control arm (OR=2.03). </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The primary endpoint was <FONT STYLE="white-space:nowrap">re-analyzed</FONT> using the <FONT STYLE="white-space:nowrap">24-hour</FONT> urine data in place of First Morning Void collections, confirming the finding that
patients were twice as likely to achieve CR at 24 weeks compared to the control arm (p=0.047; OR=2.12). </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Both voclosporin groups had a statistically significantly faster time to CR (UPCR <FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT> 0.5 mg/mg) than the control arm. Results of time to CR for
<FONT STYLE="white-space:nowrap">co-variate</FONT> analyses were broadly consistent with overall efficacy rates in those <FONT STYLE="white-space:nowrap">sub-groups.</FONT> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The secondary endpoint of PR (50% reduction in UPCR over baseline with no administration of rescue medication throughout the treatment period) was met for both voclosporin groups in the ITT analysis with 69.7% of
patients on low dose achieving PR (p=0.007) and 65.9% in the high dose group (p=0.024). 49.4% of patients in the control arm achieved PR. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Time to PR was similar (4 weeks) in the two voclosporin groups and was statistically significantly faster than what was observed in the control group (6.6 weeks). </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Safety </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The overall rate of adverse events (&#147;<B>AEs</B>&#148;) was similar across all groups. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The overall rate of serious adverse events (&#147;<B>SAEs</B>&#148;) was higher in both voclosporin groups but the nature of SAEs is consistent with highly active LN. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The overall pattern of AEs and SAEs was consistent with that observed in other LN studies. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">There were 13 deaths across the trial: two in the high-dose voclosporin arm; 10 in the <FONT STYLE="white-space:nowrap">low-dose</FONT> voclosporin arm; and one in the control arm, with the majority of overall deaths
(11/13) occurring at sites with compromised access to standard of care. All deaths were assessed by the study investigator as being unrelated to study treatment. No dose-dependent relationship was observed. The pattern of death in the study is
consistent with other global LN studies. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;29, 2016, we announced that in addition to voclosporin (23.7 mg BID) achieving
its primary endpoint of CR at 24 weeks, both doses of voclosporin when added to the current standard of care of MMF and a forced oral corticosteroid taper have met all <FONT STYLE="white-space:nowrap">24-week</FONT>
<FONT STYLE="white-space:nowrap">pre-specified</FONT> secondary endpoints vs the control group making AURA the first global study of LN to meet both its primary and secondary endpoints at 24 weeks. These
<FONT STYLE="white-space:nowrap">pre-specified</FONT> endpoints include: PR, which is measured by a <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>50% reduction in UPCR with no concomitant use of rescue medication; time to CR and PR; reduction in
Systemic Lupus Erythematosus Disease Activity Index or SLEDAI score; and reduction in UPCR over the <FONT STYLE="white-space:nowrap">24-week</FONT> treatment period. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:116.35pt; font-size:8pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Pre-specified</FONT> Secondary
Endpoint</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Control</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Low&nbsp;Dose&nbsp;VCS</B><br><B>(23.7mg BID)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>High&nbsp;Dose&nbsp;VCS</B><br><B>(39.5mg BID)</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Time to CR</B> [median]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Not&nbsp;achieved</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">19.7&nbsp;weeks<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>p&lt;.001</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">23.4&nbsp;weeks<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>p=.001</I></B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>PR</B> (as measured by UPCR reduction of <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> 50%
from baseline)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">49%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">70%<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>p=.007</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">66%<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>p=.024</I></B></P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Time to PR</B> [median]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">6.6 weeks</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">4.1 weeks<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>p=.002</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">4.4 weeks<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>p=.003</I></B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SLEDAI Reduction</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">-4.5</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">-6.3<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>p=.003</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">-7.1<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>p=.003</I></B></P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Reduction in UPCR</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">-2.216&nbsp;mg/mg</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">-3.769&nbsp;mg/mg<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>p&lt;.001</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">-2.792&nbsp;mg/mg<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>p=.006</I></B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP ALIGN="center"><I><FONT STYLE="white-space:nowrap">All&nbsp;p-values&nbsp;are&nbsp;vs&nbsp;control</FONT></I></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SLEDAI reduction and reduction in UPCR in the low does voclosporin arm were each statistically significant when compared
to the control group. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;30, 2016, we presented detailed 24 week results on the AURA clinical trial. These included a number of <FONT
STYLE="white-space:nowrap">pre-specified</FONT> subset and <FONT STYLE="white-space:nowrap">co-variate</FONT> analyses and <FONT STYLE="white-space:nowrap">post-hoc</FONT> analyses on the data, which show rapid proteinuria reduction and early
remission. Based on recent literature suggesting that using a UPCR of <FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT>.7mg/mg has better predictive power regarding long-term renal </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
outcomes in LN patients, we performed a post hoc analysis applying this measure. In doing so, we saw both a greater treatment difference between the 23.7 mg BID voclosporin arm and the control
arm, and better statistical power, which improves from a <FONT STYLE="white-space:nowrap">p-value</FONT> of .045 to less than .01. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on these data
and the 48 week data we believe: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">voclosporin has shown statistically significant efficacy in multiple dimensions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">pre-specified</FONT> and <FONT STYLE="white-space:nowrap">post-hoc</FONT> analyses have provided valuable insight; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the LN Phase 3 clinical trial will be <FONT STYLE="white-space:nowrap">de-risked</FONT> based upon the AURA results; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">biomarker data suggest significant effect on the underlying immunologic process of the disease. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also
released detailed safety data for the trial including an <FONT STYLE="white-space:nowrap">in-depth</FONT> mortality assessment. The safety and tolerability of voclosporin has been well-documented in numerous studies. In previous studies, over 2,200
patients have been treated with voclosporin across multiple indications with no unexpected SAEs. Clinical doses of voclosporin studies to date range from <FONT STYLE="white-space:nowrap">13-70</FONT> mg BID. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No new safety signals were observed with the use of voclosporin in LN patients and voclosporin was well- tolerated. The overall safety profile of voclosporin
is consistent with other immunomodulators. The summary of AEs by system organ class (&#147;<B>SOC</B>&#148;) across arms in the study is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="28%"></TD>
<TD VALIGN="bottom" WIDTH="17%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="17%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="17%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Control</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Voclosporin&nbsp;23.7mg&nbsp;BID</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Voclosporin&nbsp;39.5&nbsp;mg&nbsp;BID</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SOC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N=88</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N=89</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N=88</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Any AE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">74&nbsp;(84.1)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">81&nbsp;(91.0)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">84&nbsp;(95.5)</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thirteen deaths have been reported in the AURA clinical trial which is a pattern that is consistent with other global active
LN studies. Eleven of thirteen deaths occurred at sites with compromised access to standard of care; and patients who died in the trial had a statistically different clinical baseline picture, indicating a more severe form of LN, potential comorbid
conditions and poor nutrition. The last death in the study occurred in February 2016. Both the FDA and Data Safety Monitoring Board have reviewed in detail each death that occurred in the trial. No dose-dependant relationship was observed. Between
the 24 and 48 week end points, there was one SAE in the control arm and two SAEs in the low-dose voclosporin arm of the study. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;15, 2016,
at the American College of Rheumatology annual meeting, we presented speed of remission data from the AURA trial in a late-breaking abstract titled &#147;<I>Speed of Remission with the Use of Voclosporin, MMF and Low Dose Steroids: Results of a
Global Lupus Nephritis Study</I>.&#148; The data presented are a <FONT STYLE="white-space:nowrap">post-hoc</FONT> responder analysis (median time to CR for those who achieve CR), demonstrating 7.3 weeks to CR for voclosporin 23.7mg BID vs the
control arm of 12 weeks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;21, 2016, at the American Society of Nephrology Kidney Week 2016, we presented renal function data for the AURA
trial in a late breaking session titled &#147;<I>High Impact Clinical Trials</I>&#148;. These data showed that in the voclosporin treatment arms, the renal function as measured by eGFR was stable and not significantly different from the control arm
during the course of the trial. Mean blood pressure was slightly reduced and was similar between all treatment groups. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>June 2016 Private Placement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;22, 2016,
we completed a private placement of 3,000,000 units at US$2.36 per unit for aggregate gross proceeds of US$7,080,000 (the &#147;<B>June 2016 Private Placement</B>&#148;). Each unit consisted of one common share and a 0.35 of one common share
purchase warrant exercisable for a period of two years from the date of issuance at an exercise price of US$2.77<B>.</B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>July 2016 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">At-the-Market</FONT></FONT>
Facility </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;22, 2016, we announced that we had entered into a controlled equity offering sales agreement with Cantor
Fitzgerald&nbsp;&amp; Co. pursuant to which the Company was authorized to sell, from time to time, through <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">at-the-market</FONT></FONT> offerings (the &#147;<B>July ATM</B>&#148;) with
Cantor Fitzgerald&nbsp;&amp; Co. acting as sales agent, such common shares as would have an aggregate offer price of up to US$10,000,000. We also filed a prospectus supplement with securities regulatory authorities in Canada in the provinces of
British Columbia, Alberta and Ontario, and with the United States Securities and Exchange Commission, which supplemented our short form base shelf prospectus dated October&nbsp;16, 2015, and our shelf registration statement on Form <FONT
STYLE="white-space:nowrap">F-10</FONT> dated October&nbsp;16, 2015, declared effective on November&nbsp;5, 2015 (the &#147;<B>Shelf Prospectus</B>&#148;). Sales in the July ATM were only conducted in the United States through NASDAQ at market
prices. No sales were conducted in Canada or through the Toronto Stock Exchange. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of October&nbsp;3, 2016, sales pursuant to the July ATM were
concluded. We issued 3,306,085 common shares, receiving gross proceeds in the aggregate of US$8,000,000 ($6,142,000 in the third quarter of 2016 and $1,858,000 subsequent to the quarter end), being the maximum value permissible in accordance with
Canadian securities laws. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>November&nbsp;9, 2016 <FONT STYLE="white-space:nowrap">At-the</FONT> Market Facility </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company entered into a second controlled equity offering&nbsp;sales agreement with Cantor Fitzgerald&nbsp;&amp; Co. dated November&nbsp;9, 2016 (the
&#147;<B>November ATM</B>&#148;) pursuant to which the Company is authorized to offer and sell our common shares having an aggregate offering price of up to $8.0&nbsp;million. We also filed a prospectus supplement on November&nbsp;9, 2016 with
securities regulatory authorities in Canada in the provinces of British Columbia, Alberta and Ontario, and with the United States Securities and Exchange Commission, which supplemented our Shelf Prospectus. The prospectus supplement was amended and
an amended and restated prospectus supplement was filed on February&nbsp;24, 2017 to update changes to Company information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The sales under the November
ATM are only conducted in the United States through NASDAQ at market prices. No sales will be conducted in Canada or through the Toronto Stock Exchange. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As at December&nbsp;31, 2016 and March&nbsp;6, 2017, we had issued 138,986 common shares and received gross proceeds of $396,000 leaving the Company
authorized to sell such common shares as would have an aggregate offer price of up to $7.6&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>December 2016 Public Offering </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;28, 2016, we announced that we closed our US$28.75&nbsp;million financing (including US$3.75&nbsp;million pursuant to an exercise of the
underwriters&#146; over-allotment option), for the sale of 12,777,775 units at a price of US$2.25 per unit (the &#147;<B>December 2016 Offering</B>&#148;). Each unit consisted of one common share and one half of one common share purchase warrant
(each whole warrant, a &#147;<B>December 2016</B> <B>Warrant&#148;</B>). Each December 2016 Warrant entitles the holder to purchase one common share at the exercise price of US$3.00 per common share for a period of five years after the closing of
the offering. H.C. Wainwright&nbsp;&amp; Co., LLC acted as sole book-running manager, and Cormark Securities Inc., acted as <FONT STYLE="white-space:nowrap">co-manager.</FONT> The underwriters received a fee of 7.0% of the gross proceeds of the
offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Appointment of New Director
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;12, 2016, we announced the appointment of Lorin Jeffry &#147;Jeff&#148; Randall to our board of directors and Chairman of the
Audit Committee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CORPORATE DEVELOPMENTS IN 2015 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Filing of Base Shelf Prospectus - October 19, 2015 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company received a final receipt from the British Columbia Securities Commission on October&nbsp;19, 2015 for the Shelf Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Shelf Prospectus and corresponding shelf registration statement allows Aurinia to offer common shares of Aurinia, warrants to purchase common shares of
Aurinia and subscription receipts that entitle the holder to receive upon satisfaction of certain release conditions, and for no additional consideration, common shares of Aurinia or any combination thereof during the
<FONT STYLE="white-space:nowrap">25-month</FONT> period that the Shelf Prospectus is effective, with a total offering price, in the aggregate, of up to US$250&nbsp;million. The Shelf Prospectus is intended to give Aurinia the capability to access
new capital from time to time. The amount and timing of any future offerings will be based on the Company&#146;s financial requirements and market conditions at the time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The specific terms of any future offering under the Shelf Prospectus will be established at the time of such
offering. At the time any of the securities covered by the Shelf Prospectus are offered for sale, a prospectus supplement containing specific information about the terms of such offering will be filed with applicable Canadian securities regulatory
authorities and the SEC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CORPORATE DEVELOPMENTS IN 2014 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Listing on NASDAQ - September 2, 2014 </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aurinia
received approval from the NASDAQ Listing Qualifications Department to list its common shares on the NASDAQ and commenced trading on September&nbsp;2,<SUP STYLE="font-size:85%; vertical-align:top"> </SUP>2014 under the trading symbol
&#147;AUPH&#148;. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Listing on the TSX - June 2, 2014 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aurinia applied to the TSX for the relisting of its common shares and subsequently the common shares were listed on the TSX as of the open of trading on
June&nbsp;2, 2014. The common shares of Aurinia continue to trade on the TSX under the trading symbol &#147;AUP&#148;. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Private Placement Financing
- February 14, 2014 </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;14, 2014, Aurinia completed a $52&nbsp;million private placement (the &#147;<B>February 2014</B>
<B>Offering</B>&#148;). The proceeds from the February 2014 Offering are being used for the LN Phase 2b clinical trial currently underway, general corporate and working capital purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financing was led by venBio, New Enterprise Associates, Redmile Group, RA Capital Management, Great Point Partners, and Apple Tree Partners, with
participation from various other institutional investors, including existing shareholders Lumira Capital, ILJIN and Difference Capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms
of the February 2014 Offering, Aurinia issued 18.92&nbsp;million units at a subscription price per unit of $2.7485, each unit consisting of one common share and <FONT STYLE="white-space:nowrap">one-quarter</FONT> (0.25) of a common share purchase
warrant, exercisable for a period of five years from the date of issuance at an exercise price of $3.2204. All securities issued in connection with the February 2014 Offering were subject to a four-month hold period from the date of issuance in
accordance with applicable securities law, which expired on June&nbsp;15, 2014 for the securities issued at closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC acted as lead
placement agent and Canaccord Genuity Inc. acted as <FONT STYLE="white-space:nowrap">co-placement</FONT> agent for the February 2014 Offering. The placement agents were paid a 7.5% cash commission on subscriptions excluding those from existing
shareholders for a total commission of $3.86&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Termination of Distribution and License Agreement with Lux &#150; February&nbsp;27, 2014
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;27, 2014 Aurinia signed a Termination and Assignment Agreement (the &#147;<B>Lux Agreement</B>&#148;) with Lux which returned
worldwide rights to develop and commercialize voclosporin for the treatment and prophylaxis of all ophthalmic diseases back to the Company. The return of this license further consolidates the intellectual property related to voclosporin which was a
key consideration in the acquisition of Aurinia Pharma Corp. by the Company in 2013. Coincident with the termination of the Lux Agreement the Company has retained a portfolio of patents focused around delivering voclosporin in high concentrations to
various tissues of the eye. We will evaluate this intellectual property and define its role as it relates to the defined corporate strategy of the Company. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="ex99_1toc313671_5"></A>REGULATORY AND BUSINESS MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>REGULATORY REQUIREMENTS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The development, manufacturing
and marketing of voclosporin is subject to regulations relating to the demonstration of safety and efficacy of the products as established by the government (or regulatory) authorities in those jurisdictions where this product is to be marketed. The
Company would require regulatory approval in the United States and Europe where activities would be conducted by the Company or on the Company&#146;s behalf. Depending upon the circumstances surrounding the clinical evaluation of the product
candidate, the Company itself may undertake clinical trials, contract clinical trial activities to contract research organizations, or rely upon corporate partners for such development. We believe this approach will allow us to make cost effective
developmental decisions in a timely fashion. We cannot predict or give any assurances as to whether regulatory approvals will be received or how long the process of seeking regulatory approvals will take. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although only the jurisdictions of the United States and Europe are discussed in this section, the Company also
intends to seek regulatory approval in other jurisdictions in the future and will initiate clinical studies where appropriate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>United States
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States, all drugs are regulated under the Code of Federal Regulations and are enforced by the FDA. The regulations are similar to
those in Canada and require that <FONT STYLE="white-space:nowrap">non-clinical</FONT> and clinical studies be conducted to demonstrate the safety and effectiveness of products before marketing, and that the manufacturing be conducted according to
certain &#147;Good Manufacturing Practice&#148; standards provided by the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsequent to the initial <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> and preliminary safety studies, the application submitted to the FDA prior to conducting human clinical trials of new drugs is referred to as an IND application. This application contains
similar information to the Canadian CTA, and the FDA has 30 days in which to notify the Company if the application is unsatisfactory. If the application is deemed satisfactory, then we may proceed with the clinical trials. As in Canada, before a
clinical trial can commence at each participating clinical trial site, the site&#146;s IRB/IEC must approve the clinical protocol and other related documents. The FDA or an IRB/IEC may place a hold on a clinical trial at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After completing all required <FONT STYLE="white-space:nowrap">non-clinical</FONT> and clinical trials, and prior to selling a novel drug in the United
States, the Company must also comply with NDA procedures required by the FDA. The NDA procedure includes the submission of a package containing similar information as to that required in the new drug submission in Canada to demonstrate safety and
efficacy of the novel drug and describe the manufacturing processes and controls. FDA approval of the submission, including agreement on labelling, is required prior to commercial sale or commercial distribution of the product in the United States. <FONT
STYLE="white-space:nowrap">Pre-</FONT> and/or post-approval inspections of manufacturing and testing facilities are necessary. The FDA may also conduct inspections of the clinical trial sites and the
<FONT STYLE="white-space:nowrap">non-clinical</FONT> laboratories conducting pivotal safety studies to ensure compliance with good clinical practice and good laboratory practice requirements. The FDA has the authority to impose certain post-approval
requirements, such as post-market surveillance clinical trials. In addition, FDA approval can be withdrawn for failure to comply with any post-marketing requirements or for other reasons, such as the discovery of significant adverse effects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Europe </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In Europe, the evaluation of new products
is coordinated by the EMA. The regulations are similar to those in Canada and the United States and require that <FONT STYLE="white-space:nowrap">non-clinical</FONT> and clinical studies be conducted to demonstrate the safety and effectiveness of
products before marketing, and that the manufacturing be conducted according to good manufacturing practice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsequent to the initial <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> and preliminary safety studies, and prior to conducting human clinical trials, a CTA must be submitted to the competent authority in the country where the
clinical trial will be conducted. This application contains similar information to the Canadian CTA and United States IND. In Europe, the clinical trials are regulated by the European Clinical Trial Directive (2001/20/EC). As in Canada and the
United States, before a clinical trial can commence at each participating clinical trial site, the site&#146;s IRB/IEC must approve the clinical protocol and other related documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A major difference in Europe, when compared to Canada and the United States, is with the approval process. In Europe, there are different procedures that can
be used to gain marketing authorization in the EU. The first procedure is referred to as the centralized procedure and requires that a single application be submitted to the EMA and, if approved, allows marketing in all countries of the EU. The
centralized procedure is mandatory for certain types of medicines and optional for others. The second procedure is referred to as national authorization and has two options; the first is referred to as the mutual recognition procedure and requires
that approval is gained from one member state, after which a request is made to the other member states to mutually recognize the approval, whilst the second is referred to as the decentralised procedure which requires a member state to act as the
reference member state through a simultaneous application made to other member states. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>DRUG DEVELOPMENT PROCESS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clinical trials involve the administration of an investigational pharmaceutical product to individuals under the supervision of qualified medical
investigators. Clinical studies are conducted in accordance with protocols that detail the objectives of a study, the parameters to be used to monitor safety, and the efficacy criteria to be evaluated. Each protocol is submitted to the appropriate
regulatory body and to a relevant IRB/IEC prior to the commencement of each clinical trial. Clinical studies are typically conducted in three sequential phases which may overlap in time-frame. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In summary, the following steps must be completed prior to obtaining approval for marketing in the United States
and Europe: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Nonclinical Animal Studies</B> - These studies evaluate the safety and potential efficacy of a therapeutic product and form part of the application which must be reviewed by the appropriate regulatory authority prior
to initiation of human clinical trials. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Phase 1 Clinical Trials</B> - These trials test the product in a small number of healthy volunteers to determine toxicity (safety), maximum dose tolerance, and pharmacokinetic properties. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Phase 2 Clinical Trials</B> - These trials are conducted in the intended patient population and include a larger number of subjects than in Phase 1. The primary goal is to determine the safety of a product in a
larger number of patients and ultimately in the intended patient population. These trials may also provide early information on the potential effectiveness of a product. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"><B>Phase 3 Clinical Trials</B> - These trials are conducted in an expanded patient population at multiple sites to determine longer-term clinical safety and efficacy of the product. It is from the data generated in
these trials that the benefit/risk relationship of a product is established and the final drug labelling claims are defined. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the course
of conducting clinical trials for a drug candidate, a company may conduct more than one trial of a particular phase in order to evaluate the drug against a variety of indications or in different patient populations. In such a case, industry practice
is to differentiate these trials by way of designations such as &#147;Phase 2a&#148; or &#147;Phase 2b&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A key factor influencing the rate of
progression of clinical trials is the rate at which patients can be recruited to participate in the research program. Patient recruitment is largely dependent upon the incidence and severity of the disease and the alternative treatments
available.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even after marketing approval for a drug has been obtained, further trials may be required (referred to as Phase 4 trials). Post-market trials
may provide additional data on safety and efficacy necessary to gain approval for the use of the product as a treatment for clinical indications other than those for which the product was initially tested. These trials may also be used for marketing
purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aurinia expects that it will be required to conduct additional studies for the LN clinical program in order to submit for marketing approval in
the United States and Europe. The costs and timing of the program will be dependent on a number of variables including the results of the AURA clinical trial, and the number and size of the additional studies. The additional studies will be
determined subsequent to the AURA primary endpoint data results based on meetings with the regulators. The costs of conducting the additional studies are expected to be at least as much as those required for the current AURA clinical trial. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MANUFACTURING, ENCAPSULATING AND PACKAGING OF VOCLOSPORIN </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Drug supply costs are comprised of third party charges for manufacturing, encapsulating and packaging of voclosporin. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Voclosporin, requires a specialized manufacturing process. Lonza is currently the Company&#146;s sole manufacturer of voclosporin and has manufactured the
active pharmaceutical ingredient (&#147;API&#148;) for the Company&#146;s clinical trials since 2004. Pricing for clinical supply is determined through negotiations between Lonza and the Company and is based on the size of specific API production
runs and the cost of the raw materials used in the API manufacturing process. As at the date of this AIF, we have not experienced any difficulty in obtaining the raw materials required with respect to the manufacturing of voclosporin. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Lonza Manufacturing Collaboration Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
November, 2016, we entered into a long-term manufacturing collaboration and services agreement with Lonza for the manufacture of API. This agreement follows a successful multi-year clinical manufacturing relationship where the Company and Lonza have
been refining the process and analytical methods to produce clinical and commercial supplies of voclosporin. Under the terms of the agreement, Lonza has agreed to produce cGMP-grade voclosporin drug substance for use in our Phase 3 LN clinical trial
program and for future commercial use. The agreement also provides an option to have Lonza exclusively supply API for up to 20 years. In December, 2016, we submitted a binding purchase order in the amount of CHF 2.05&nbsp;million to Lonza in
addition to a deposit of CHF 1.00&nbsp;million made earlier in the year for the manufacture of API for future use. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Encapsulating and Packaging of Voclosporin </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have contracted Catalent to encapsulate and package voclosporin for our LN Phase 3 clinical trial program (we also used Catalent for our LN Phase 2b
clinical trial.). It is our intention that Catalent will provide services with respect to encapsulating and packaging the voclosporin required for future clinical and commercial supply needs. Catalent is currently the sole supplier for encapsulating
and packaging the Company&#146;s clinical drug supply. Pricing for these services is determined by negotiations between Catalent and the Company and is based on the specific production run size. As at the date of this AIF, we have not experienced
any difficulty in obtaining the raw materials used in the encapsulating and packaging process. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INTELLECTUAL PROPERTY RIGHTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patents and other proprietary rights are essential to our business. Our policy has been to file patent applications to protect technology, inventions, and
improvements to our inventions that are considered important to the development of our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2016, we owned 11 granted United
States patents and two United States patent applications related to cyclosporin analogs, including granted United States patents covering voclosporin composition of matter, methods of use, formulations and synthesis, which expire between 2018 and
2024, and 151 corresponding granted patents and four corresponding patent applications in other jurisdictions, excluding Canada, South Africa and Israel, which expire between 2018 and 2022. The corresponding Canadian, South African and Israeli
patents are owned by Paladin Labs Inc. We anticipate that upon regulatory approval, patent protection for voclosporin will be extended in the United States and certain other major markets, including Europe and Japan, until at least October 2027
under the Hatch-Waxman Act and comparable laws in other countries. In addition to patent rights, we also expect to receive &#147;new chemical entity&#148; exclusivity for voclosporin in certain countries, which provides from five years in the United
States to up to ten years in Europe of data exclusivity beyond the date of regulatory approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have licensed the development and distribution rights
to voclosporin for China, Hong Kong and Taiwan to 3Sbio Inc. This license is royalty bearing and we will also supply finished product to 3Sbio Inc. on a cost plus basis. We do not expect to receive any royalty revenue pursuant to this license in the
foreseeable future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2016, we also owned two granted United States patents related to ophthalmic formulations of calcineurin
inhibitors or mTOR inhibitors, including voclosporin, and one granted United States patent related to ophthalmic formulations of dexamethasone, which expire between 2028 and 2031. We also own 14 corresponding granted patents and four corresponding
patent applications in other jurisdictions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>COMPETITIVE ENVIRONMENT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The pharmaceutical and biotechnology industries are characterized by rapidly evolving technology and intense competition. Many companies, including major
pharmaceutical as well as specialized biotechnology companies, are engaged in activities focused on medical conditions that are the same as, or similar to, those targeted by us. Many of these companies have substantially greater financial and other
resources, larger research and development staff, and more extensive marketing and manufacturing organization than we do. Many of these companies have significant experience in preclinical testing, human clinical trials, product manufacturing,
marketing and distribution, and other regulatory approval procedures. In addition, colleges, universities, government agencies, and other public and private research organizations conduct research and may market commercial products on their own or
through collaborative agreements. These institutions are becoming more active in seeking patent protection and licensing arrangements to collect royalties for use of technology that they have developed. These institutions also compete with us in
recruiting and retaining highly qualified scientific personnel. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>EMPLOYEES </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;at&nbsp;December&nbsp;31,</B><br><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;at&nbsp;December&nbsp;31,</B><br><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;at&nbsp;December&nbsp;31,</B><br><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Number of Employees</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As at December&nbsp;31, 2016 the Company employed 20 employees, 16 of whom held advanced degrees in science and business,
including one with a Ph.D. degree and one with an MD. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Of our total 20 employees as at December&nbsp;31, 2016, 10 employees were engaged in, or directly
support, clinical trial activities; and 10&nbsp;employees were engaged in corporate, administration and business development activities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our employees are not governed by a collective agreement. We have not experienced a work stoppage and believe our
employee relations are satisfactory given the current economic conditions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FACILITIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We entered into an agreement, effective June&nbsp;1, 2014, to sublease 4,418 square feet of office and storage space at our head office location in Victoria,
British Columbia. The sublease is for a term of five years, with the Company having the right to terminate after the third year at no cost. The estimated base rent plus operating costs on a monthly basis for the period January&nbsp;1, 2016 to
May&nbsp;31, 2017 is approximately $9,000 per month. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We entered into an agreement on November&nbsp;14, 2014 to lease 1,247 square feet of office space
for the Edmonton, Alberta registered office where our finance group is located. The lease was for a term of two years commencing on January&nbsp;1, 2015 at a cost of approximately $1,300 per month. We have extended the lease for an additional year
at the same rental amount. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="ex99_1toc313671_6"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investing in our securities involves a high degree of risk. You should carefully consider the following risks in addition to the other information included
in this AIF, our historical consolidated financial statements and related notes, before you decide to purchase our common shares. The risks and uncertainties described below are those that we currently believe may materially affect the Company and
are set out in no particular order. Additional risks and uncertainties that we are unaware of or that we currently deem immaterial may also become important factors that materially and adversely affect our business, financial condition and results
of operations. If any of the following events were to actually occur, our business, operating results or financial condition could be adversely affected in a material manner. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>RISKS RELATING TO AURINIA&#146;S BUSINESS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our
financial statements for the year ended December&nbsp;31, 2016 contain a going concern note which may have an adverse effect on our relationships with current and future collaborators, contract suppliers and investors. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since its inception, the Company has experienced recurring operating losses and negative cash flows, and expects to continue to generate operating losses and
consume significant cash resources for the foreseeable future. As at December&nbsp;31, 2016, we had net working capital of $33,490,000 compared to $12,917,000 as at December&nbsp;31, 2015. For the year ended December&nbsp;31, 2016, we reported a
loss of $23,295,000 (December 31, 2015 &#150; $18,607,000) and a cash outflow from operating activities of $18,713,000 (December 31, 2015 &#150; $17,766,000). As at December&nbsp;31, 2016, we had an accumulated deficit of $281,048,000 (December 31,
2015 &#150; $257,753,000). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The proceeds received from the December 2016 Offering, November ATM, July ATM, June 2016 Private Placement and warrant
exercises in 2016 have provided us with liquidity in the short-term and sufficient funding to complete the Phase 2b LN trial and fund the planned activities for the Phase 3 LN clinical trial into the fourth quarter of 2017. However, we will need to
seek additional funding from such potential sources as debt financing, licensing of specific territories and /or additional equity offerings within the next 12 months in order to continue the development and commercialization of voclosporin for LN,
and in particular, the Phase 3 clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The outcome of these offerings is dependent on a number of factors outside of our control. The nature of
the biotechnology sector and current financial equity market conditions make the success of any future financing ventures uncertain. There is no assurance the November ATM or any new financings will be successful. This uncertainty casts significant
doubt upon our ability to continue as a going concern and, accordingly, the appropriateness of the use of accounting principles applicable to a going concern. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The success of the Company and recoverability of amounts expended on research and development to date, including capitalized intangible assets, are dependent
on our ability to raise additional cash, then to complete development activities, receive regulatory approval and to be able to commercialize voclosporin in the key markets and indications, whereby we can achieve future profitable operations.
Depending on the results of the research and development programs and availability of financial resources, we may accelerate, terminate, cut back on certain areas of research and development, commence new areas of research and development or curtail
certain or all of our operations. There is no assurance these initiatives will be successful. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These conditions raise substantial doubt about our ability
to continue as a going concern without raising these additional funds. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result, our consolidated financial statements for the year ended December&nbsp;31, 2016 contain a going
concern note with respect to this uncertainty. Substantial doubt about our ability to continue as a going concern may materially and adversely affect the price of our common shares, and it may be more difficult for us to obtain financing. The going
concern note in our consolidated financial statements may also adversely affect our relationships with current and future collaborators, contract manufacturers and investors, who may grow concerned about our ability to meet our ongoing financial
obligations. If potential collaborators decline to do business with us or potential investors decline to participate in any future financings due to such concerns, our ability to increase our financial resources may be limited. We have prepared our
financial statements on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. Our consolidated financial statements do not include any adjustment to
reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical Trial Progress and Results &#150; Heavy Dependence on Voclosporin </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have invested a significant portion of our time and financial resources in the development of voclosporin. Voclosporin is currently our only product
candidate. We anticipate that our ability to generate revenues and meet expectations will depend on the successful development and commercialization of voclosporin. The successful development and commercialization of voclosporin will depend on
several factors, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">successful completion of clinical programs, and in particular, the planned Phase 3 LN clinical trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">receipt of marketing approvals from the FDA and other regulatory authorities with a commercially viable label; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">securing and maintaining partners with sufficient expertise and resources to help in the continuing development and eventual commercialization of voclosporin for autoimmune indications and/or transplant;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintaining suitable manufacturing and supply agreements to ensure commercial quantities of the product through validated processes; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acceptance and adoption of the product by the medical community and third-party payors. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is possible that
we may decide to discontinue the development of voclosporin at any time for commercial, scientific, or regulatory reasons. If voclosporin is developed, but not marketed, we will have invested significant resources and our future operating results
and financial conditions would be significantly adversely affected. If we are not successful in commercializing voclosporin, or significantly delayed in doing so, our business will be materially harmed and we may need to curtail or cease operations.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Product Development Goals and Time Frames </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
set goals for, and make public statements regarding, timing of the accomplishment of objectives material to our success, such as the commencement and completion of clinical trials, anticipated regulatory approval dates, and time of product launch.
The actual timing of these events can vary dramatically due to factors such as delays or failures in clinical trials, the uncertainties inherent in the regulatory approval process, and delays in achieving product development, manufacturing, or
marketing milestones necessary to commercialize our product. There can be no assurance that our clinical trials will be completed, that regulatory submissions will be made or receive regulatory approvals as planned, or that we will be able to adhere
to the current schedule for the validation of manufacturing and launch of our product. If we fail to achieve one or more of these milestones as planned, the price of our common shares could decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>No Assurance of Successful Development </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have
not completed the development of any therapeutic products and in particular, voclosporin, and therefore there can be no assurance that any product will be successfully developed. Voclosporin has not received regulatory approval for our commercial
use and sale for any indication, in any jurisdiction. We cannot market a pharmaceutical product in any jurisdiction until it has completed thorough preclinical testing and clinical trials in addition to that jurisdiction&#146;s extensive regulatory
approval process. In general, significant research and development and clinical studies are required to demonstrate the safety and effectiveness of our product before submission of any regulatory applications. We may never obtain the required
regulatory approvals for our product in any indication. Product candidates require significant additional research and development efforts, including clinical trials, prior to regulatory approval and potential commercialization, however, there can
be no assurance that the results of all required clinical trials will demonstrate that these product candidates are safe and effective or, even if the results of all required clinical trials do demonstrate that these product candidates are safe and
effective, or even if the results of the clinical trials are considered successful by us, that the regulatory authorities will not require us to conduct additional clinical trials before they will consider approving such product candidates for
commercial use. Approval or consent by regulatory </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
authorities to commence a clinical trial does not indicate that the device, drug, or treatment being studied can or will be approved. Preparing, submitting, and advancing applications for
regulatory approval is complex, expensive, time intensive and entails significant uncertainty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The results of our completed preclinical studies and
clinical trials may not be indicative of future clinical trial results. A commitment of substantial resources to conduct time-consuming research, preclinical studies, and clinical trials will be required if we are to complete the development of our
product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There can be no assurance that unacceptable toxicities or adverse side effects will not occur at any time in the course of preclinical studies
or human clinical trials or, if any products are successfully developed and approved for marketing, during commercial use of our product. The appearance of any such unacceptable toxicities or adverse side effects could interrupt, limit, delay, or
abort the development of our product or, if previously approved, necessitate its withdrawal from the market. Furthermore, there can be no assurance that disease resistance or other unforeseen factors will not limit the effectiveness of our product.
Any products resulting from our programs are not expected to be successfully developed or made commercially available in the near term and may not be successfully developed or made commercially available at all. Should our product prove to have
insufficient benefit and/or have an unsafe profile, its development will likely be discontinued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The future performance of the Company will be impacted
by a number of important factors, including, in the short-term, our ability to continue to generate cash flow from financings, and in the longer term, our ability to generate royalty or other revenues from licensed technology and bring new products
to the market. Our future success will require efficacy and safety of our product and regulatory approval for the product. Future success of commercialization of any product is also dependent on our ability to obtain patents, enforce such patents,
avoid patent infringement, and obtain patent extensions where applicable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will have significant additional future capital needs and there are
uncertainties as to our ability to raise additional funding. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will require significant additional capital resources to expand our business, in
particular the further development of our product candidate, voclosporin. Advancing our product candidate, market for our product, or acquisition and development of any new products or product candidates will require considerable resources and
additional access to capital markets. In addition, our future cash requirements may vary materially from those now expected. For example, our future capital requirements may increase if: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we experience unexpected or increased costs relating to preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, or other lawsuits, brought by either us or our competition; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we experience scientific progress sooner than expected in our discovery, research and development projects, if we expand the magnitude and scope of these activities, or if we modify our focus as a result of our
discoveries; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we are required to perform additional <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and clinical trials; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we elect to develop, acquire or license new technologies, products or businesses. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We could potentially seek
additional funding through corporate collaborations and licensing arrangements or through public or private equity or debt financing. However, if capital market conditions in general, or with respect to life sciences companies such as ours, are
unfavourable, our ability to obtain significant additional funding on acceptable terms, if at all, will be negatively affected. Additional financing that we may pursue may involve the sale of common shares which could result in significant dilution
to our shareholders. If sufficient capital is not available, we may be required to delay our research and development projects, which could have a material adverse effect on our business, financial condition, prospects or results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patents and Proprietary Technology </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patents and
other proprietary rights are essential to our business. Our policy has been to file patent applications to protect technology, inventions, and improvements to our inventions that are considered important to the development of our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our success will depend in part on our ability to obtain patents, defend patents, maintain trade secret protection and operate without infringing on the
proprietary rights of others. Interpretation and evaluation of pharmaceutical patent claims present complex and often novel legal and factual questions. Accordingly, there is some question as to the extent to which biopharmaceutical discoveries and
related products and processes can be effectively protected by patents. As a result, there can be no assurance that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">patent applications will result in the issuance of patents; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additional proprietary products developed will be patentable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">patents issued will provide adequate protection or any competitive advantages; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">patents issued will not be successfully challenged by third parties; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our products do not infringe the patents or intellectual property of others; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">that we will be able to obtain any extensions of the patent term. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A number of pharmaceutical, biotechnology,
medical device companies and research and academic institutions have developed technologies, filed patent applications or received patents on various technologies that may be related to our business. Some of these technologies, applications or
patents may conflict with or adversely affect the technologies or intellectual property rights of the Company. Any conflicts with the intellectual property of others could limit the scope of the patents, if any, that we may be able to obtain or
result in the denial of patent applications altogether. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, there may be uncertainty as to whether we may be able to successfully defend any
challenge to our patent portfolio. Moreover, we may have to participate in interference proceedings in the various jurisdictions around the world. An unfavorable outcome in an interference or opposition proceeding or a conflict with the intellectual
property of others could preclude us or our collaborators or licensees from making, using or selling products using the technology, or require us to obtain license rights from third parties. It is not known whether any prevailing party would offer a
license on commercially acceptable terms, if at all. Further, any such license could require the expenditure of substantial time and resources and could harm our business. If such licenses are not available, we could encounter delays or prohibition
of the development or introduction of our product. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical trials for our product candidate are expensive and time-consuming, and their outcome is
uncertain. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before we can obtain regulatory approval for the commercial sale of any product candidate currently under development, we are required
to complete extensive clinical trials to demonstrate its safety and efficacy. Clinical trials are very expensive and difficult to design and implement. The clinical trial process is also time-consuming. If we find a collaboration partner for the
development of voclosporin, the clinical trials are expected to continue for several years, although costs associated with voclosporin may well be shared with our collaboration partner. The timing of the commencement, continuation and completion of
clinical trials may be subject to significant delays relating to various causes, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability to find collaboration partners; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability to manufacture or obtain sufficient quantities of materials for use in clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties in gaining alignment among the key regulatory jurisdictions, FDA, EMA and PMDA which may require further clinical activities; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in obtaining regulatory approvals to commence a study, or government intervention to suspend or terminate a study; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays, suspension, or termination of the clinical trials imposed by the IRB/IEC responsible for overseeing the study to protect research subjects at a particular study site; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in identifying and reaching agreement on acceptable terms with prospective clinical trial sites; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">slower than expected rates of patient recruitment and enrollment; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">uncertain dosing issues; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">inability or unwillingness of medical investigators to follow our clinical protocols; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">variability in the number and types of subjects available for each study and resulting difficulties in identifying and enrolling subjects who meet trial eligibility criteria; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">scheduling conflicts with participating clinicians and clinical institutions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulty in maintaining contact with subjects after treatment, which results in incomplete data; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unforeseen safety issues or side effects; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">lack of efficacy during the clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our reliance on clinical research organizations to conduct clinical trials, which may not conduct those trials with good clinical or laboratory practices; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">other regulatory delays. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The results of <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies
and initial clinical trials are not necessarily predictive of future results, and our current product candidate may not have favourable results in later trials or in the commercial setting. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Pre-clinical</FONT> tests and Phase 1 and Phase 2 clinical trials are primarily designed to test safety, to study
pharmacokinetics and pharmacodynamics and to understand the side effects of product candidates at various doses and schedules. Success in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> or animal studies and early clinical trials does not
ensure that later large scale efficacy trials will be successful nor does it predict final results. Favourable results in early trials may not be repeated in later trials. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A number of companies in the life sciences industry have suffered significant setbacks in advanced clinical
trials, even after positive results in earlier trials. Clinical results are frequently susceptible to varying interpretations that may delay, limit or prevent regulatory approvals. Negative or inconclusive results or adverse medical events during a
clinical trial could cause a clinical trial to be delayed, repeated or terminated. In addition, failure to construct appropriate clinical trial protocols could result in the test or control group experiencing a disproportionate number of adverse
events and could cause a clinical trial to be repeated or terminated. <FONT STYLE="white-space:nowrap">Pre-clinical</FONT> data and the clinical results we have obtained for voclosporin may not predict results from studies in larger numbers of
subjects drawn from more diverse populations or in a commercial setting, and also may not predict the ability of our product to achieve its intended goals, or to do so safely. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will be required to demonstrate in Phase 3 clinical trials that voclosporin is safe and effective for use in a diverse population before we can seek
regulatory approvals for its commercial sale. There is typically an extremely high rate of attrition from the failure of product candidates proceeding through clinical and post-approval trials. If voclosporin fails to demonstrate sufficient safety
and efficacy in ongoing or future clinical trials, we could experience potentially significant delays in, or be required to abandon development of, our product candidate currently under development. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our industry is subject to health and safety risks. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We produce a product for human ingestion. While we take substantial precautions such as laboratory and clinical testing, toxicology studies, quality control
and assurance testing and controlled production methods, the associated health and safety risks cannot be eliminated. Products produced by the Company may be found to be, or to contain substances that are harmful to the health of our patients and
customers and which, in extreme cases, may cause serious health conditions or death. This sort of finding may expose the Company to substantial risk of litigation and liability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, we would be forced to discontinue production of our product, which would harm our profitability. Aurinia maintains product liability insurance
coverage; however, there is no guarantee that our current coverage will be sufficient or that we can secure insurance coverage in the future at commercially viable rates or with the appropriate limits. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our product may not achieve or maintain expected levels of market acceptance, which could have a material adverse effect on our business, financial
condition and results of operations and could cause the market value of our Securities to decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if we are able to obtain regulatory
approvals for our product, the success of the product is dependent upon achieving and maintaining market acceptance. New product candidates that appear promising in development may fail to reach the market or may have only limited or no commercial
success. Levels of market acceptance for our product could be impacted by several factors, many of which are not within our control, including but not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">safety, efficacy, convenience and cost-effectiveness of our product compared to products of our competitors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">scope of approved uses and marketing approval; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">timing of market approvals and market entry; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulty in, or excessive costs to, manufacture; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">infringement or alleged infringement of the patents or intellectual property rights of others; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">availability of alternative products from our competitors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acceptance of the price of our product; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ability to market our product effectively at the retail level. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, by the time any products are
ready to be commercialized, what we believe to be the market for these products may have changed. Our estimates of the number of patients who have received or might have been candidates to use a specific product may not accurately reflect the true
market or market prices for such products or the extent to which such products, if successfully developed, will actually be used by patients. Our failure to successfully introduce and market our product that is under development would have a
material adverse effect on our business, financial condition, and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are dependent upon our key personnel to achieve our
business objectives. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a technology-driven company, intellectual input from key management and personnel is critical to achieve our business
objectives. Consequently, our ability to retain these individuals and attract other qualified individuals is critical to our success. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
The loss of the services of key individuals might significantly delay or prevent achievement of our business objectives. In addition, because of a relative scarcity of individuals with the high
degree of education and scientific achievement required for our business, competition among life sciences companies for qualified employees is intense and, as a result, we may not be able to attract and retain such individuals on acceptable terms,
or at all. In addition, because we do not maintain &#147;key person&#148; life insurance on any of the Company&#146;s officers, employees, or consultants, any delay in replacing such persons, or an inability to replace them with persons of similar
expertise, would have a material adverse effect on our business, financial condition, and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also have relationships with
scientific collaborators at academic and other institutions, some of whom conduct research at our request or assist us in formulating our research and development strategies. These scientific collaborators are not our employees and may have
commitments to, or consulting or advisory contracts with, other entities that may limit their availability to the Company. In addition, even though our collaborators are required to sign confidentiality agreements prior to working with us, they may
have arrangements with other companies to assist such other companies in developing technologies that may prove competitive to the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Incentive
provisions for our key executives include the granting of stock options that vest over time, designed to encourage such individuals to stay with the Company. However, a low share price, whether as a result of disappointing progress in our
development programs or as a result of market conditions generally, could render such agreements of little value to our key executives. In such event, our key executives could be susceptible to being hired away by our competitors who could offer a
better compensation package. If we are unable to attract and retain key personnel, our business, financial conditions and results of operations may be adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are exposed to risks relating to the write-down of intangible assets, which comprises a significant portion of our total assets. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A significant amount of our total assets relate to the Company&#146;s intellectual property. As of December&nbsp;31, 2016, the carrying value of the
Company&#146;s intangible assets was approximately US$15.6&nbsp;million. In accordance with IFRS, the Company is required to review the carrying value of its intangible assets for impairment periodically or when certain triggers occur. Such
impairment will result in a write-down of the intangible asset and the write-down is charged to income during the period in which the impairment occurs. The write-down of any intangible assets could have a material adverse effect on our business,
financial condition, and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we were to lose our foreign private issuer status under U.S. federal securities laws, we would
likely incur additional expenses associated with compliance with the U.S. securities laws applicable to U.S. domestic issuers. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a foreign
private issuer, as defined in Rule <FONT STYLE="white-space:nowrap">3b-4</FONT> under the <I>Exchange Act</I>, the Company is exempt from certain of the provisions of the U.S. federal securities laws. For example, the U.S. proxy rules and the
Section&nbsp;16 reporting and &#147;short swing&#148; profit rules do not apply to foreign private issuers. However, if we were to lose our status as a foreign private issuer, these regulations would immediately apply and we would also be required
to commence reporting on forms required of U.S. companies, such as Forms <FONT STYLE="white-space:nowrap">10-K,</FONT> <FONT STYLE="white-space:nowrap">10-Q</FONT> and <FONT STYLE="white-space:nowrap">8-K,</FONT> rather than the forms currently
available to us, such as Forms <FONT STYLE="white-space:nowrap">40-F</FONT> and <FONT STYLE="white-space:nowrap">6-K.</FONT> Compliance with these additional disclosure and timing requirements under these securities laws would likely result in
increased expenses and would require our management to devote substantial time and resources to comply with new regulatory requirements. Further, to the extent that we were to offer or sell our Securities outside of the United States, we would have
to comply with the more restrictive Regulation S requirements that apply to U.S. companies, and we would no longer be able to utilize the multijurisdictional disclosure system forms for registered offerings by Canadian companies in the United
States, which could limit our ability to access the capital markets in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Legislative actions, potential new accounting pronouncements,
and higher insurance costs are likely to impact our future financial position or results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Future changes in financial accounting
standards may cause adverse, unexpected revenue fluctuations and affect our financial position or results of operations. New pronouncements and varying interpretations of pronouncements have occurred with greater frequency and are expected to occur
in the future. Compliance with changing regulations of corporate governance and public disclosure may result in additional expenses. All of these uncertainties are leading generally toward increasing insurance costs, which may adversely affect our
business, results of operations and our ability to purchase any such insurance, at acceptable rates or at all, in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely on third parties for the supply and manufacture of voclosporin, which can be unpredictable in terms
of quality, cost, timing and availability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our drug, voclosporin, requires a specialized manufacturing process. Lonza is currently the sole source
manufacturer of voclosporin. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have contracted Catalent to encapsulate and package voclosporin for our LN Phase 3 clinical trial program. It is our
intention that Catalent will provide services with respect to encapsulating and packaging the voclosporin required for future clinical and commercial supply needs. Catalent is currently the sole supplier for encapsulating and packaging our clinical
drug supply. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA and other regulatory authorities require that drugs be manufactured in accordance with the current good manufacturing practices
regulations, as established from time to time. Accordingly, in the event we receive marketing approvals for voclosporin, it may need to rely on a limited number of third parties to manufacture and formulate voclosporin. We may not be able to arrange
for our product to be manufactured on reasonable terms or in sufficient quantities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Manufacturers of pharmaceutical products often encounter difficulties
in production, especially in scaling up initial production. These problems include difficulties with production costs and yields, stability, quality control and assurance, and shortages of qualified personnel, as well as compliance with strictly
enforced federal, provincial and foreign regulations. We rely on a limited number of third parties to manufacture and supply raw materials for our product. The third parties we choose to manufacture and supply raw materials for our product are not
under our control, and may not perform as agreed or may terminate their agreements with us, and we may not be able to find other third parties to manufacture and supply raw materials on commercially reasonable terms, or at all. If either of these
events were to occur, our operating results and financial condition would be adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, drug and chemical manufacturers are subject
to various regulatory inspections, including those conducted by the FDA, to ensure strict compliance with good manufacturing practices (&#147;<B>GMP</B>&#148;) and other government regulations. While we are obligated to audit the performance of our
third-party contractors, we do not have complete control over their compliance. We could be adversely impacted if our third-party manufacturers do not comply with these standards and regulations. For
<FONT STYLE="white-space:nowrap">non-compliance,</FONT> the regulatory authority may levy penalties and sanctions, including fines, injunctions, civil penalties, failure of the government to grant review of submissions or market approval of drugs,
or cause delays, suspension or withdrawal of approvals, product seizures or recalls, operating restrictions, facility closures and criminal prosecutions. Any of this will have a material adverse impact on our business, financial condition, and
results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Anticipated Revenues may be derived from Licensing Activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We anticipate that our revenues in the future may be derived from products licensed to pharmaceutical and biotechnology companies. Accordingly, these revenues
will depend, in large part, upon the success of these companies, and our operating results may fluctuate substantially due to reductions and delays in their research, development and marketing expenditures. These reductions and delays may result
from factors that are not within our control, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in economic conditions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in the regulatory environment, including governmental pricing controls affecting health care and health care providers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pricing pressures; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">other factors affecting research and development spending. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Lack of Operating Profits </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have incurred losses and anticipates that our losses will increase as we continue the development of voclosporin and clinical trials and seek regulatory
approval for the sale of our therapeutic product. There can be no assurance that we will have earnings or positive cash flow in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As at
December&nbsp;31, 2016, we had an accumulated deficit of $281&nbsp;million. The net operating losses over the near-term and the next several years are expected to continue as a result of initiating new clinical trials and activities necessary to
support regulatory approval and commercialization of our product. There can be no assurance that we will be able to generate sufficient product revenue to become profitable at all or on a sustained basis. We expect to have <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">quarter-to-quarter</FONT></FONT> fluctuations in expenses, some of which could be significant, due to research, development, and clinical trial activities, as well as regulatory and
commercialization activities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Negative Cash Flow </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We had negative operating cash flow for the financial year ended December&nbsp;31, 2016. We anticipate that we will continue to have negative cash flow as we
continue our development of voclosporin. To the extent that we have negative operating cash flow in future periods, we may need to allocate a portion of our cash reserves to fund such negative cash flow. We may also be required to raise additional
funds through the issuance of equity or debt securities. There can be no assurance that we will be able to generate a positive cash flow from our operations, that additional capital or other types of financing will be available when needed or that
these financings will be on terms favourable to the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business depends heavily on the use of information technologies. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Several key areas of our business depend on the use of information technologies, including production, manufacturing and logistics, as well as clinical and
regulatory matters. Despite our best efforts to prevent such behavior, third parties may nonetheless attempt to hack into our systems and obtain data relating to our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies, clinical trials,
patients using our product or our proprietary information on voclosporin. If we fail to maintain or protect our information systems and data integrity effectively, we could have problems in determining product cost estimates and establishing
appropriate pricing, have difficulty preventing, detecting, and controlling fraud, have disputes with physicians, and other health care professionals, have regulatory sanctions or penalties imposed, have increases in operating expenses, incur
expenses or lose revenues as a result of a data privacy breach, or suffer other adverse consequences. While we have invested in the protection of data and information technology, there can be no assurance that our efforts or those of our third-party
collaborators, if any, or manufacturers, to implement adequate security and quality measures for data processing would be sufficient to protect against data deterioration or loss in the event of a system malfunction, or to prevent data from being
stolen or corrupted in the event of a security breach. Any such loss or breach could have a material adverse effect on our business, operating results and financial condition<B>.</B> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Competition and Technological Change </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The industry
in which we operate is highly competitive and we have numerous domestic and foreign competitors, including major pharmaceutical and chemical companies, specialized biotechnology companies, universities, academic institutions, government agencies,
public and private research organizations and large, fully-integrated pharmaceutical companies which have extensive resources and experience in research and development, process development, clinical evaluation, manufacturing, regulatory affairs,
distribution and marketing. Many of our potential competitors possess substantially greater research and development skills, financial, technical and marketing expertise and human resources than the Company, and may be better equipped to develop,
manufacture and market products. There is a risk that new products and technologies may be developed which may be more effective or commercially viable than the product being developed or marketed by the Company, thus making our product <FONT
STYLE="white-space:nowrap">non-competitive</FONT> or obsolete. There may also be market resistance to the acceptance of our new product in any indication and a risk that the product, even though clinically effective, is not economically viable in
the commercial production stage. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Reliance on Partners </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our strategy and success for the research, development, and commercialization of voclosporin in China, Canada, South Africa and Israel is dependent upon our
partners performing their respective contractual responsibilities. The Company has partnered with 3SBio in China and Paladin in Canada, South Africa and Israel. The amount and timing of resources such partners will devote to these activities may not
be within our control. There can be no assurance that our partners will perform their obligations as expected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The license, research and development
agreements with the partners noted above include indemnification and obligation provisions that are customary in the industry. These guarantees generally require us to compensate the other party for certain damages and costs incurred as a result of
third party claims or damages arising from these transactions. These provisions may survive termination of the underlying agreement. The nature of the potential obligations prevents us from making a reasonable estimate of the maximum potential
amount we could be required to pay. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Reliance on Other Third Parties </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We depend on third parties for the sourcing of components or for the product itself. Furthermore, as with other pharmaceutical companies, we rely on medical
institutions for testing and clinically validating our prospective product. We do not anticipate any difficulties in obtaining required components or products or any difficulties in the validation and clinical testing of our product but there is no
guarantee that they will be obtained. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently rely on CROs for the conduct of our clinical trials. These CROs operate in accordance with good
clinical management practices mandated by the regulatory authorities and are subject to regular audits by regulatory authorities and by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
also have arrangements for the encapsulation, packaging and labeling of voclosporin through a third party supplier. Contract manufacturers must operate in compliance with regulatory requirements. Failure to do so could result in, among other things,
the disruption of product supplies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Marketing and Distribution </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have limited experience in the sales, marketing, and distribution of pharmaceutical products. There can be no assurance that we will be able to establish
sales, marketing, and distribution capabilities or make arrangements through collaborations, licensees, or others to perform such activities, or that such efforts would be successful. If we decide to market our product directly, we must either
acquire or internally develop a marketing and sales force with technical expertise and provide supporting distribution capabilities. The acquisition or development of a sales and distribution infrastructure would require substantial resources, which
may divert the attention of management and key personnel, and have a negative impact on product development. If we contract with third parties for the sales and marketing of our product, our revenue will be dependent on the efforts of these third
parties, whose efforts may not be successful. If we fail to establish successful marketing and sales capabilities or to make arrangements with third parties, the business, financial condition and results of operations will be materially adversely
affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Health Care Reimbursement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In both
domestic and foreign markets, sales of our product, if any, will be dependent in part on the availability of reimbursement from third party payors, such as government and private insurance plans. Third party payors are increasingly challenging the
prices charged for medical products and services. There can be no assurance that our product will be considered cost effective by these third party payors, that reimbursement will be available or if available that the payor&#146;s reimbursement
policies will not adversely affect our ability to sell our product on a profitable basis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Government Regulation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The production and marketing of our product and our ongoing research and development activities are subject to regulation by numerous federal, provincial,
state and local governmental authorities in Canada, the United States and any other countries where we may test or market our product. These laws require the approval of manufacturing facilities, including adhering to &#147;good manufacturing&#148;
and/or &#147;good laboratory&#148; practices during production and storage, the controlled research and testing of products, governmental review and approval of submissions requiring manufacturing,
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical data to establish the safety and efficacy of the product for each use sought in order to obtain marketing approval, and the control of marketing activities, including advertising and
labeling. The process of obtaining required approvals (such as, but not limited to, the approval of the FDA, the EMA,<B> </B>and Health Canada) can be costly and time consuming and there can be no assurance that future products will be successfully
developed, proven safe and effective in clinical trials or receive applicable regulatory approvals. Potential investors should be aware of the risks, problems, delays, expenses and difficulties which may be encountered by us in view of the extensive
regulatory environment which controls our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, there can be no assurance that we will be able to achieve or maintain regulatory
compliance with respect to all or any part of our current or future products or that we will be able to timely and profitably produce our product while complying with applicable regulatory requirements. If we fail to maintain compliance, regulatory
authorities may not allow the continuation of the drug development programs, or require us to make substantial changes to the drug. Any such actions could have a material adverse effect on the business, financial condition, and results of
operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unauthorized Disclosure of Confidential Information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There may be an unauthorized disclosure of the significant amount of confidential information under our control. We maintain and manage confidential
information relating to our technology, research and development, production, marketing and business operations and those of our collaborators, in various forms. Although we have implemented controls to protect the confidentiality of such
information, there can be no assurance that such controls will be effective. Unauthorized disclosures of such information could subject us to complaints or lawsuits for damages, in Canada or other jurisdictions, or could otherwise have a negative
impact on our business, financial condition, results of operations, reputation and credibility. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of Hazardous Materials </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Drug manufacturing processes involve the controlled use of hazardous materials. We and our third party manufacturing contractors are subject to regulations
governing the use, manufacture, storage, handling and disposal of such materials and certain waste products. Although we believe that our third party manufacturers have the required safety procedures for handling and disposing of such materials and
comply with the standards prescribed by such laws and regulations, the risk of accidental contamination or injury from these materials cannot be completely eliminated. In the event of such an accident, we could be held liable for any damages that
result and such liability could exceed our resources. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liability and Insurance </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The testing, marketing and sale of human pharmaceutical products involves unavoidable risks. If we succeeds in developing new pharmaceutical products, the sale
of such products may expose the Company to potential liability resulting from the use of such products. Such liability might result from claims made directly by consumers or by regulatory agencies, pharmaceutical companies or others. The obligation
to pay any product liability claim in excess of whatever insurance we are able to acquire, or the recall of any of our products, could have a material adverse effect on the business, financial condition and future prospects of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company entered into indemnification agreements with its officers and directors. The maximum potential amount of future payments required under these
indemnification agreements is unlimited. However, the Company currently maintains director and officer liability insurance coverage of US$20&nbsp;million to reduce the exposure of the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>RISKS RELATED TO OUR SECURITIES </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The adverse
capital market conditions could continue to affect our liquidity. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adverse capital market conditions could continue to affect our ability to meet
our liquidity needs, as well as our access to capital and cost of capital. We need additional funding to continue development of our internal pipeline and collaborations. Our results of operations, financial condition, cash flows and capital
position could be materially affected by continued disruptions in the capital markets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Raising additional capital may cause dilution to our
shareholders, restrict our operations or require us to relinquish rights to our technologies or drug candidate. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to meet our financing
needs, we may issue a significant amount of additional common shares and warrants to purchase common shares. The precise terms of any future financing will be determined by us and potential investors and such future financings may significantly
dilute our shareholders&#146; percentage ownership in the Company. Additionally, if we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to
relinquish valuable rights to our technologies, future revenue streams, research programs or drug candidate or grant licenses on terms that may not be favourable to us and/or that may reduce the value of our common shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Volatility of Share Price </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The market prices for
the securities of biotechnology companies, including ours, have historically been volatile. The market has from time to time experienced significant price and volume fluctuations that are unrelated to the operating performance of any particular
company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The trading price of our common shares could continue to be subject to wide fluctuations in price in response to various factors, many of which
are beyond our control, including the results and adequacy of our preclinical studies and clinical trials, as well as those of our collaborators, or our competitors; other evidence of the safety or effectiveness of our products or those of our
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
competitors; announcements of technological innovations or new products by us or our competitors; governmental regulatory actions; developments with collaborators; developments (including
litigation) concerning our patent or other proprietary rights of competitors; concern as to the safety of our products; <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT> fluctuations in operating
results; changes in estimates of our performance by securities analysts; market conditions for biotechnology stocks in general; and other factors not within our control could have a significant adverse impact on the market price of our common
shares, regardless of our operating performance. In the past, following periods of volatility in the market price of a company&#146;s securities, securities class action litigation has often been instituted. A class action suit against us could
result in substantial costs, potential liabilities and the diversion of management&#146;s attention and resources. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is no guarantee that an active
trading market for our common shares will be maintained on the TSX and /or NASDAQ. Investors may not be able to sell their common shares quickly or at the latest market price if the trading in our common shares is not active. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to issue common shares in the future. Future issuances of common shares, or the perception that such issuances are likely to occur, could affect the
prevailing trading prices of the common shares. In addition, the existence of warrants may encourage short selling by market participants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sales of
common shares could cause a decline in the market price of our common shares. Two of our major shareholders (venBio Global Strategic Fund, L.P. and ILJIN SNT Co., Ltd. and its affiliates) own an aggregate of approximately 24.63% of our outstanding
common shares as at March&nbsp;6, 2017. Any sales of common shares by these shareholders or other existing shareholders or holders of options may have an adverse effect on our ability to raise capital and may adversely affect the market price of our
common shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>There is no assurance of a sufficient liquid trading market for our common shares in the future. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our shareholders may be unable to sell significant quantities of common shares into the public trading markets without a significant reduction in the price of
their common shares, or at all. There can be no assurance that there will be sufficient liquidity of our common shares on the trading market, and that we will continue to meet the listing requirements of the TSX or the NASDAQ or achieve listing on
any other public listing exchange. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future issuances of equity securities by us or sales by our existing shareholders may cause the price of the
common shares to fall. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The market price of the common shares could decline as a result of issuances of securities or sales by our existing
shareholders in the market, or the perception that these sales could occur. Sales of common shares by shareholders might also make it more difficult for us to sell common shares at a time and price that we deem appropriate. With an additional sale
or issuance of common shares, investors will suffer dilution of their voting power and may experience dilution in earnings per share. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may have
broad discretion in the use of the net proceeds of an offering of the common shares and may not use them to effectively manage our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
may have broad discretion over the use of the net proceeds from a future offering of common shares. Because of the number and variability of factors that will determine our use of such proceeds, our ultimate use might vary substantially from our
planned use. Investors may not agree with how we allocate or spend the proceeds from an offering of common shares. We may pursue acquisitions, collaborations or clinical trials that do not result in an increase in the market value of the common
shares, and may increase our losses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We do not intend to pay dividends in the foreseeable future. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have never declared or paid any dividends on our common shares. We intend, for the foreseeable future, to retain our future earnings, if any, to finance our
commercial activities and further research and the expansion of our business. As a result, the return on an investment in common shares will likely depend upon any future appreciation in value, if any, and on a shareholder&#146;s ability to sell
common shares. The payment of future dividends, if any, will be reviewed periodically by our board of directors and will depend upon, among other things, conditions then existing including earnings, financial conditions, cash on hand, financial
requirements to fund our commercial activities, development and growth, and other factors that our board of directors may consider appropriate in the circumstances. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be a passive foreign investment company, which may result in adverse U.S. federal income tax
consequences for U.S. Holders. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Generally, if for any taxable year 75% or more of our gross income is passive income, or at least 50% of the
average quarterly value of our assets are held for the production of, or produce, passive income, we would be characterized as a passive foreign investment company (&#147;<B>PFIC</B>&#148;) for U.S. federal income tax purposes. Based on the nature
of our income and the value and composition of our assets, we do not believe we were a PFIC during 2016. While we also do not believe we will be a PFIC for the current taxable year, because PFIC status is determined on an annual basis and generally
cannot be determined until the end of the taxable year, there can be no assurance that we will not be a PFIC for the current or future taxable years. If we are characterized as a PFIC, our shareholders who are U.S. Holders may suffer adverse tax
consequences, including the treatment of gains realized on the sale of our ordinary shares as ordinary income, rather than as capital gain, the loss of the preferential rate applicable to dividends received on our ordinary shares by individuals who
are U.S. Holders, and the addition of interest charges to the tax on such gains and certain distributions. A U.S. shareholder of a PFIC generally may mitigate these adverse U.S. federal income tax consequences by making a &#147;qualified electing
fund&#148; election, or, to a lesser extent, a &#147;mark to market&#148; election. However, we do not intend to provide the information necessary for U.S. Holders to make qualified electing fund elections if we are classified as a PFIC. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="ex99_1toc313671_7"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not paid dividends on our outstanding common shares in the past and have no established dividend policy for our common shares. We plan to use future
earnings, if any, to finance further research and development and the expansion of our business and do not anticipate paying out dividends on our common shares in the foreseeable future. The payment of dividends in the future will depend upon the
earnings and financial condition of the Company and such other factors as the Board considers appropriate. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="ex99_1toc313671_8"></A>CAPITAL STRUCTURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s authorized share capital consists of an unlimited number of common shares, all without nominal or par value. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of common shares are entitled to receive notice of and attend all meetings of shareholders, with each common share held entitling the holder to
vote on any resolution to be passed at such shareholder meetings. The holders of common shares are entitled to dividends if, as and when declared by the Board. The common shares are entitled upon liquidation, dissolution or winding up of Aurinia, to
receive the remaining assets of Aurinia available for distribution to shareholders. There are no <FONT STYLE="white-space:nowrap">pre-emptive,</FONT> redemption, purchase or conversion rights attached to our common shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As at March&nbsp;6, 2017, we had 53,428,444 common shares issued and outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition as of March&nbsp;6, 2017 there were 5,622,081 common shares issuable upon the exercise of outstanding stock options and 1,256,474 common shares
reserved for future grant or issuance under our stock option plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also have 10,783,247 Warrants (convertible into 10,783,247 common shares)
outstanding as at March&nbsp;6, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For additional information on stock options and warrants, please see note 12 to our annual consolidated financial
statements for the year ended December&nbsp;31, 2016 which can be retrieved under the Company&#146;s profile on either of the SEDAR or EDGAR websites. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="ex99_1toc313671_9"></A>TRADING PRICE AND VOLUME OF AURINIA SHARES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s common shares are listed and posted for trading on the NASDAQ under the symbol &#147;AUPH&#148;, and on the TSX under the symbol
&#147;AUP&#148;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth, for the 12 month period ended December&nbsp;31, 2016, the reported high and low
prices (in United States dollars) and the volume of shares traded for each month on NASDAQ. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>NASDAQ </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:23.10pt; font-size:8pt; font-family:Times New Roman"><B>Month</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Price&nbsp;Range&nbsp;(US$)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Volume</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>High</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Low</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">January 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">677,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">February 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,558,681</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,068,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">April 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">393,816</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">May 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">580,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">918,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">July, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">926,959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">August 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,368,734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,439,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">October 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,162,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">November 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,439,641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,417,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth, for the 12 month period ended December&nbsp;31, 2016, the reported high and low prices (in
Canadian dollars) and the volume of shares traded for each month on the TSX. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>TSX </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:23.10pt; font-size:8pt; font-family:Times New Roman"><B>Month</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Price&nbsp;Range&nbsp;(CDN$)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Volume</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>High</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Low</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">January 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">158,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">February 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">138,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">238,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">April 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">149,635</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">May 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">285,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">July, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">183,469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">August 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,985,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,121,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">October 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,274,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">November 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,585,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,405,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="ex99_1toc313671_10"></A>ESCROWED SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no securities of the Company subject to escrow. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="ex99_1toc313671_11"></A>PRIOR SALES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the distribution of securities other than common shares that were issued during the most recently completed financial year,
identifying the type of security, the price per security, the number of securities issued, expiry date and the date on which the securities were issued. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Stock Options </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman"><B>Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Type of Security</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Price per</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Security</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(CDN$)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Expiry Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March&nbsp;23, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Stock Options</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.96</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">March&nbsp;23,&nbsp;2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March&nbsp;30, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Stock Options</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.91</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">220,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">March&nbsp;30, 2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Stock Options</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.76</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">March&nbsp;31, 2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">May&nbsp;2, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Stock Options</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.66</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">May&nbsp;2, 2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June&nbsp;17, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Stock Options</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.20</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">June&nbsp;17, 2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">July&nbsp;12, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Stock Options</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.00</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">July&nbsp;12, 2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">July&nbsp;21, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Stock Options</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.95</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">July&nbsp;21, 2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;14, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Stock Options</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.65</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">December&nbsp;14,&nbsp;2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,670,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Warrants </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman"><B>Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Type&nbsp;of&nbsp;Security</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Price&nbsp;per</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Security</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(US$)</B></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Expiry Date</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June&nbsp;22, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Warrants</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.02</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,050,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">June&nbsp;22, 2018</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;28, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Warrants</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.02</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,388,887</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">December&nbsp;28,&nbsp;2021</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,388,887</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="ex99_1toc313671_12"></A>DIRECTORS AND OFFICERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The directors of the Company are elected by the shareholders at each annual meeting and hold office until the next annual meeting, at which time they may be <FONT
STYLE="white-space:nowrap">re-elected</FONT> or replaced, unless they resign earlier. The officers are appointed by the Board and hold office pursuant to individual contractual obligations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As at March&nbsp;6, 2017, the names and municipalities of residence of the directors and officers of the Company and their principal occupations within the
five preceding years are set forth below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="34%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Name, province or state,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:84.15pt; font-size:8pt; font-family:Times New Roman"><B>and country of residence</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Position&nbsp;with&nbsp;the</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Company</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Director/Officer</B><br><B>since</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Principal Occupation for Five
Preceding&nbsp;Years</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard Glickman</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Victoria, British Columbia</I> <I>Canada</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">Director, Chairman of the Board and CEO</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">August&nbsp;2013</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chairman of the Board at the Company since August, 2013; CEO of the Company since February 2017.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dennis Bourgeault <I></I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Edmonton, Alberta, Canada</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">CFO</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">May 1998</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">CFO of the Company since May, 1998.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Name, province or state,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:84.15pt; font-size:8pt; font-family:Times New Roman"><B>and country of residence</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Position&nbsp;with&nbsp;the</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Company</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Director/Officer</B><br><B>since</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Principal Occupation for Five
Preceding&nbsp;Years</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Michael R. Martin</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Victoria, British
Columbia</I></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Canada</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">COO</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">September,&nbsp;2013</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">COO of the Company since September 2013; prior thereto was CEO of privately-held Aurinia Pharmaceuticals Inc.; Director, Global Business Development&nbsp;&amp; Licensing at Vifor Pharma, formerly Aspreva.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neil Solomons</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Victoria, British
Columbia</I></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Canada</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">CMO</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">September 2013</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">CMO of the Company since September 2013; prior thereto was Vice President, Research and Development at Vifor Pharma, formerly Aspreva.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Robert Huizinga</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>North Saanich, British
Columbia,</I></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Canada</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">Vice President, Clinical Affairs</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">August 2011</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Vice President, Clinical Affairs of the Company since August 2011.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lawrence D. Mandt</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Qualicum Beach, British
Columbia</I></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Canada</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">Vice President, Quality&nbsp;&amp; Regulatory Affairs</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">September 2013</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Vice President Quality&nbsp;&amp; Regulatory Affairs of the Company since September 2013; independent regulatory consultant from 2010-2013.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rashieda Gluck</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Mercer Island,
Washington</I></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>US</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">Vice President, Clinical Operations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">January 2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Vice President, Clinical Operations of the Company since January&nbsp;1, 2016; Lead of Clinical Operations for the Company from April 2015 to December 2015; independent clinical trial consultant for the Company from May 2014 to
March 2015; prior thereto was Vice President Clinical Operations at Qu Biologics; Vice President and Head of Global Clinical Operations at Vifor Pharmaceuticals, Zurich; Vice President Clinical Operations at Aspreva.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Benjamin Rovinski</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Toronto, Ontario</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Canada</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">September&nbsp;2013</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Managing Director at Lumira Capital, a North American health care and life science venture capital firm.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">David R.W. Jayne</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Cambridge, UK</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">May 2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certified nephrologist, Director of the Vasculitis and Lupus Clinic and Reader at The University of Cambridge, UK.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gregory M. Ayers</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Eastsound, WA</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>US</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">May 2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consultant to device and biopharmaceutical industry providing clinical and regulatory advice to various companies; Chief of Medical Affairs, Emergency Cardiac Resuscitation, Philips Healthcare.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hyuek Joon Lee</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Seoul, South
Korea</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">May 2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director of New Business Development for ILJIN Group, a Korean industrial conglomerate.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lorin J. Randall</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>West Chester, PA</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>US</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">Director, Chairman of the Audit Committee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">November 2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Independent Financial Consultant.</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Directors and officers of the Company, as of March&nbsp;6, 2017, beneficially own, directly or indirectly,
2,539,252 common shares in the aggregate, representing 4.75% of the outstanding common shares of the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>EXECUTIVE OFFICERS AND DIRECTORS
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following are brief biographies of our executive officers and directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Richard M. Glickman, LLD (Hon), Director, Chairman of the Board, CEO </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Glickman presently serves as the Company&#146;s CEO and Chairman of the Board. He brings over 30 years of experience in the creation and operation of
healthcare ventures, founding and <FONT STYLE="white-space:nowrap">co-founding</FONT> numerous companies during his career. In addition to being a founder of the company, he previously served as the Interim Executive Chairman of the Company for the
period September&nbsp;20, 2013 to February&nbsp;28, 2014 and as Acting Interim CEO for the period October&nbsp;22, 2013 to November&nbsp;5, 2013. He was a <FONT STYLE="white-space:nowrap">co-founder,</FONT> Chairman and CEO of Aspreva, playing an
integral role in the development and establishment of CellCept<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, or MMF, as the current standard of care for LN. Aspreva was acquired by Swiss pharmaceutical company Galenica for nearly
$1.0&nbsp;billion in 2008.&nbsp;He currently serves as founding Chairman of Essa Pharmaceuticals Inc., Chairman of the Board of Engene Corporation and a Director of Cardiome Pharma.&nbsp;He is also a Partner at Lumira Capital, one of Canada&#146;s
most successful healthcare focused venture capital firms.&nbsp;Dr.&nbsp;Glickman has served on numerous biotechnology and community boards, including member of the federal government&#146;s National Biotechnology Advisory Committee, Director of the
Canadian Genetic Disease Network, Chairman of Life Sciences B.C. and a member of the British Columbia Innovation Council. Dr.&nbsp;Glickman is the recipient of numerous awards including the Ernst and Young Entrepreneur of the Year, a recipient
of&nbsp;both BC and Canada&#146;s Top 40 under 40 award,&nbsp;the BC Lifesciences Leadership Award and the Corporate Leadership Award from the Lupus Foundation of America. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dennis Bourgeault, <FONT STYLE="white-space:nowrap">CPA-CA,</FONT> CFO </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dennis Bourgeault has been the CFO of the Company since 1998 and is responsible for the financial and administrative operations of the Company. During his
tenure, he contributed significantly to one of the largest Canadian biotechnology PIPE transactions, totaling $52&nbsp;million US dollars and was involved in the multi-million dollar Roche licensing agreement of voclosporin in 2002. In addition, he
played a crucial role in executing the merger of Isotechnika and then privately held Aurinia Pharmaceuticals in November 2013.&nbsp;For six years prior to joining Isotechnika, he was the controller for a private industrial distribution company and a
Senior Manager in public accounting at KPMG. Mr.&nbsp;Bourgeault obtained his chartered accountant designation in 1984. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Michael R. Martin, COO
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Michael Martin is currently COO of Aurinia Pharmaceuticals Inc. He was formerly CEO, director and
<FONT STYLE="white-space:nowrap">co-founder</FONT> of the privately held Aurinia Pharmaceuticals Inc., which merged in 2013 with the former Isotechnika Pharma Inc. Michael is a biotech/pharmaceutical executive with over 20 years of industry
experience. Michael joined Aurinia from Vifor Pharma where he held the position of Director, Global Business Development&nbsp;&amp; Licensing. Prior to Vifor, Michael was a key member of the business development team that saw Aspreva sold to
Galenica for $915M. Upon joining Aspreva in 2004, Michael initiated the strategic launch planning process for CellCept<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> in &#147;less-common&#148; autoimmune diseases. These included such
indications as pemphigus vulgaris, myasthenia gravis, and LN. Prior to this, Michael held a variety of progressively senior commercial positions at Schering-Plough. Most recently, he was responsible for the Rheumatology business unit for Remicade<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> in France. In this role, he had full profit and loss responsibilities and had direct responsibility for the sales team, the marketing team and the infusion access team. In addition, while at
Schering-Plough, Michael was the brand manager responsible for the Canadian launch of Remicade (infliximab), which ultimately became the most successful product launch in Canadian history. Michael started his career in the industry in the sales
organization of Schering-Plough where he received multiple awards and recognition while rapidly progressing towards the prior mentioned roles. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Neil
Solomons, MD, CMO </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Neil Solomons <FONT STYLE="white-space:nowrap">co-founded</FONT> privately-held Aurinia Pharmaceuticals in 2012. He is
an experienced pharmaceutical physician with 18 years of clinical development and medical affairs experience in both large pharma and biotech. He is a recognized expert in rare-disease drug development and is widely published in this field. Neil
joined Aurinia from Vifor Pharma, formerly Aspreva Pharmaceuticals (NASDAQ:ASPV) where he held the position of Vice President, Research and Development, being the lead clinician in the development of CellCept<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> in rare diseases. Neil led the CellCept<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Clinical Development teams of over 50 people that saw the completion, reporting, and publication
of studies in pemphigus vulgaris and myasthenia gravis (both industry firsts), and the successful landmark LN study called the ALMS study. He was responsible for all clinical development activities </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
from Phases 1 to 3, as well as participating in the formulation of R&amp;D strategy, portfolio management, and due diligence efforts. Prior to Vifor&nbsp;&amp; Aspreva, Neil held a variety of
positions at Roche in both Global Clinical Development and Medical Affairs in transplantation, virology, and auto-immune diseases. While at Roche, Mr.&nbsp;Solomons led a diverse team in the development and implementation of post-marketing studies
with a budget exceeding $15&nbsp;million for its transplantation (CellCept<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and Zenapax<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) and virology (Cytovene<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) franchises. Neil qualified in medicine in 1991 receiving his MB BS (MD)&nbsp;at Guys Hospital Medical School, London. He subsequently worked as a physician in London UK, completing specialist
training in anesthesia and intensive care. His research interests included sepsis and chronic pain. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Robert B. Huizinga, RN NNC, MSc(Epi), CNeph(C),
Vice President, Clinical Affairs </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Robert Huizinga has more than 24 years of clinical research, and has been with the Company since 2002 focusing on
managing the global clinical development of voclosporin. Before joining Aurinia, Rob was an Investigator in nephrology and transplantation clinical trials where he was involved in more than 60 clinical trials from Phase I through Phase IV and the
successful development of numerous compounds. He has acted as a consultant to nephrology and transplantation pharmaceutical companies and has lectured extensively. Over the years, Rob has established and nurtured close relationships in the
nephrology and transplant communities and has fostered strong connections with both investigators and clinical trial sites. Rob has numerous articles published in leading medical journals, including the New England Journal of Medicine, Lancet and
the American Journal of Transplantation. He is a member of many professional societies related to nephrology, transplantation, and nursing and has served on many nephrology and transplantation committees and is the founder of RenalPro, a moderated
forum for renal professionals. Rob holds a M.Sc. in Medicine (Epidemiology) from the University of Alberta, is certified in Nephrology and a member of Sigma Theta Tau (Honor Society of Nursing). He is completing his doctorate in Organizational
Leadership. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Lawrence D. Mandt, Vice President Regulatory and Quality </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Larry Mandt has been with Aurinia since its inception in 2012 and brings 30+ years&#146; experience in global regulatory affairs, in large and small companies,
across a variety of therapeutic areas. During his career, he has operated at the executive level for 10+ years. Prior to Aurinia, Larry worked as an independent regulatory consultant after leaving Vifor Pharma as Senior Vice President, Global
Regulatory Affairs in 2010. During his time with Vifor Pharma, he served as a member of the Leadership Team and successfully led the consolidation of the regulatory affairs function after the acquisition of Aspreva where he was Vice President,
Regulatory Affairs. He was a key contributor to the regulatory strategies, tactics and operational activities associated with the CellCept<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> autoimmune programs, conducted in collaboration with
Roche. Before joining Aspreva in 2004, Larry was Senior Vice President, Regulatory and Quality Affairs at QLT, Inc. where he gained approval for Visudyne, the first drug ever approved for the treatment of
<FONT STYLE="white-space:nowrap">age-related</FONT> macular degeneration. Prior to QLT, Larry led the regulatory and medical affairs function for CIBA Vision Ophthalmics (which ultimately became Novartis Ophthalmics) for eight years, gaining
approval of the company&#146;s first entirely internally developed new drug, Zaditor, for the treatment of ocular allergies. Previous to his time at CIBA/Novartis, Larry worked in R&amp;D and regulatory positions with increasing responsibilities at
Bausch&nbsp;&amp; Lomb Inc., eventually becoming Director, Regulatory Affairs. Highlights during his career at Bausch include launching major new OTC and Rx products and gaining approval for a new state of the art manufacturing facility. Larry began
his career as a microbiologist at Merck, Sharp, and Dohme, at their vaccine facility in West Point, PA, USA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Rashieda Gluck, Vice President
Clinical Operations </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rashieda Gluck has over 20 years of industry experience in the strategic planning and delivery of successful global clinical
programs and extensive experience in building and leading high performing global teams. Most recently, she served as Vice President of Clinical Operations for a privately held clinical stage biopharmaceutical company, where she was responsible for
leading and providing strategic direction and execution in the clinical development of their platform immunotherapeutic treatments in multiple disease indications.&nbsp;Previously, Rashieda was based in Zurich, Switzerland as Vice President and Head
of Global Clinical Operations at Vifor Pharma where she retained overall accountability for the execution and delivery of the company&#146;s global clinical programs.&nbsp;She also held the position of Vice President of Clinical Operations at
Aspreva in New Jersey and was responsible for the integration of the global clinical operations department post acquisition by&nbsp;Swiss-based Vifor Pharmaceuticals.&nbsp;Earlier in her career, Rashieda served in increasingly senior positions at
major pharmaceutical companies including Novartis, GSK, and Organon. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Lorin Jeffry (&#147;Jeff&#148;) Randall, Director, Chairman of the Audit Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jeff Randall has over 30 years of experience serving in financial and operating roles spanning biotechnology, pharmaceuticals and manufacturing. He has led a
number of companies through multi-million dollar financings and mergers and acquisitions. In addition to his current board positions, Mr.&nbsp;Randall served on the board of directors of Nanosphere, Inc. from 2008 to 2016, most recently as Chairman
of the Board. From 2004 to 2006, Mr.&nbsp;Randall, a financial consultant, was Senior Vice President and Chief Financial Officer of Eximias Pharmaceutical Corporation, a development-stage drug development company. Mr.&nbsp;Randall holds a
Bachelor&#146;s of Science in Mathematics and Accounting from Pennsylvania State University and a Master&#146;s in Business Administration from Northeastern University. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Benjamin Rovinski, Ph.D., Director </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Benjamin Rovinski has 28 years of investment, operational, managerial and research experience in the healthcare sector. Dr.&nbsp;Rovinski joined
Lumira Capital in 2001, where he is a Managing Director, with an investment focus on <FONT STYLE="white-space:nowrap">mid-</FONT> to late-stage private&nbsp;and public life sciences companies. Prior to joining Lumira Capital, he held several senior
management positions in the biotechnology sector, including 13&nbsp;years at Sanofi Pasteur where he was a senior scientist and director of molecular virology. Dr.&nbsp;Rovinski led global R&amp;D programs in the areas of HIV/AIDS and therapeutic
cancer vaccines, bringing several of them through to clinical-stage. Dr.&nbsp;Rovinski holds a Ph.D. in Biochemistry from McGill University in Montr&eacute;al and did post-doctoral studies in Molecular Oncology and Retrovirology at the Ontario
Cancer Institute in Toronto. He obtained his undergraduate degree from Rice University in Houston. His current and past board roles and investment responsibilities include several private and public companies, including GI Therapeutics; Vascular
Pharmaceuticals; KAI Pharmaceuticals (acquired by Amgen); Morphotek (acquired by Eisai); Cervelo Pharmaceuticals; Health Hero Network (acquired by Bosch); Avalon Pharmaceuticals (NASDAQ: AVRX; acquired by Clinical Data, Inc.); Inovise Medical, Inc.;
Protana; Signature Biosciences; and SGX Pharmaceuticals (NASDAQ: SGXP; acquired by Eli Lilly). He also serves on the board of directors of Life Sciences Ontario and the steering committee of the Toronto Regional Board of Trade&#146;s Health Science
Cluster initiative. Dr.&nbsp;Rovinski has published over 25 scientific articles and reviews and is the recipient of 31 issued patents. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>David R.W.
Jayne, MD FRCP FRCPE FMedSci, Director </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;David Jayne is Director of the Vasculitis and Lupus Clinic and Reader in Vasculitis at The
University of Cambridge, UK. Dr.&nbsp;Jayne received his B.S. in Surgery and Medicine from Cambridge University, Cambridge, England. He received postgraduate training at several London hospitals and Harvard University. He is a fellow of the Royal
Colleges of Physicians of London and Edinburgh, and the Academy of Medical Science. He is a certified nephrologist and an Honorary Consultant Physician at Addenbrooke&#146;s Hospital, Cambridge UK. Dr.&nbsp;Jayne&nbsp;is a medical advisor to UK,
U.S. and EU regulatory bodies, patient groups and professional organizations.&nbsp;He has published more than 250 peer-reviewed journal articles, book chapters and reviews. He was elected the first President of the European Vasculitis Society in
2011 and is a member of the <FONT STYLE="white-space:nowrap">ERA-EDTA</FONT> immunopathology working group. Dr.&nbsp;Jayne&#146;s research includes investigator-initiated international trials and the introduction of newer therapies in vasculitis and
SLE with collaborators on five continents. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Gregory M. Ayers, MD, Ph.D., Director </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Gregory Ayers is the Chief of Medical Affairs, Emergency Cardiac Resuscitation, Philips Healthcare and is a consultant to the medical device and
biopharmaceutical industry providing clinical and regulatory advice to various companies. He has more than 25 years of experience working with medical device <FONT STYLE="white-space:nowrap">start-up</FONT> companies. He began his career in the
industry at InControl, Inc., the developer of the first implantable atrial defibrillator, where he served as Vice President of Clinical Affairs. InControl was acquired by Guidant in 1999. He was a Venture Partner at MPM Capital when he founded
CryoCor, Inc. (NasdaqNM: CRYO), a medical technology company headquartered in San Diego, CA that developed products using cryogenic technology to treat arrhythmias, where he also served as President&nbsp;&amp; CEO until March 2006. CryoCor was sold
to Boston Scientific in 2007. He served on the board of directors of Hemosense, Inc. (AMEX: HEM), where he also served as interim CEO until April 2002. Hemosense was sold to Inverness Medical in 2008. While at MPM he served as medical director,
interim CEO or member of the board of directors for eight other portfolio companies including Alsius and ARYX pharmaceuticals (Nasdaq: ARYX). Dr.&nbsp;Ayers is also <FONT STYLE="white-space:nowrap">Co-Founder</FONT> of IMedPro, a German-based
consulting company for small U.S. companies seeking European approval or early marketing of their medical products, where he has worked with seven additional <FONT STYLE="white-space:nowrap">start-up</FONT> medical device companies. He has served as
a medical consultant for Heartstream, a company that pioneered the use of AEDs (automatic external defibrillator). He is a founder of SonarMed, Inc. an Indianapolis-based medical device company developing products for critical care medicine, where
he served as Executive and Chairman of the Board until April 2008. He served as acting Medical Director of Catheter Robotics, Inc., a New Jersey-based company. He was President and CEO of ViewRay, a Cleveland-based oncology company. Dr.&nbsp;Ayers
served as Chief Medical Officer of Heart Metabolics, Ltd., an Irish company focused on securing registration for perhexiline in the treatment of hypertropic cardiomyopathy. Dr.&nbsp;Ayers is a fellow of the American College of Cardiology, the
American Institute of Medical and Biological Engineering and the Heart Rhythm Society. He holds 21 U.S. patents and has published more than 200 book chapters, scientific abstracts, and manuscripts. Dr.&nbsp;Ayers received his B.S. and Ph.D. in
Biomedical Engineering from Purdue University and his M.D. from Indiana University. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Hyuek Joon Lee, Ph.D., Director </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Joon Lee is the Director of New Business Development for ILJIN Group and is responsible for mergers and acquisitions, and managing overseas
investments, joint ventures and subsidiaries. As of October 2014, he joined the board of directors of Life Science Enterprises in Massachusetts, a privately held company focusing on advanced biomaterials that promote bone repair. Dr.&nbsp;Lee has
more than 18 years of experience in consulting, management, business development and strategic planning in a number of industries including information technology, chemical and media. Dr.&nbsp;Lee received his B.S. in Chemistry from Seoul National
University, and his M.S.E. and Ph.D. in Chemical Engineering from the University of Michigan, Ann Arbor. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>COMMITTEES OF THE BOARD </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have three standing committees: the Audit Committee, the Governance and Nomination Committee and the Compensation Committee. Current members of these
committees are identified in the following table: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.70pt; font-size:8pt; font-family:Times New Roman"><B>Committee</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:32.40pt; font-size:8pt; font-family:Times New Roman"><B>Members</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Audit Committee <SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jeff Randall (Chair)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Benjamin Rovinski</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Gregory M. Ayers</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Governance and Nomination Committee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Benjamin Rovinski (Chair)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">David Jayne</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Hyuek Joon Lee</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Compensation Committee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Benjamin Rovinski (Chair)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gregory M.
Ayers</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Hyuek Joon Lee</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Detailed information on the Audit Committee is attached as Schedule 1. </TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="ex99_1toc313671_13">
</A>CEASE TRADE ORDERS, BANKRUPTCIES, PENALTIES OR SANCTIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the knowledge of the directors and officers of the Company, no director or executive
officer of the Company: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">is, or has been within 10 years before the date of this AIF, a director, CEO or CFO of any company that, while that person was acting in that capacity </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">was subject to a cease trade order, an order similar to a cease trade order or an order that denied the relevant company access to any exemption under securities legislation, that was issued while the proposed director
was acting in the capacity as a director, CEO or CFO; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">was subject to a cease trade order, an order similar to a cease trade order or an order that denied the relevant company access to any exemption under securities legislation, that was issued after the proposed director
ceased to be a director, CEO or CFO and which resulted from an event that occurred while he was acting in the capacity of a director, CEO or CFO; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">is, or has been within 10 years before the date of this AIF, a director, CEO or CFO of any company that while that person was acting in that capacity, or within a year of that person ceasing to act in that capacity,
became bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency, or was subject to or instituted any proceedings, arrangement or compromise with creditors, or had a receiver, receiver manager or trustee appointed to hold
its assets; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">has, within 10 years before the date of this AIF, become bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency, or become subject to or instituted any proceedings, arrangement or
compromise with creditors, or had a receiver, receiver manager or trustee appointed to hold the assets of the proposed director. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No director has been subject to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">any penalties or sanctions imposed by a court relating to securities legislation or by a securities regulatory authority or has entered into a settlement agreement with a securities regulatory authority; or
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top">any other penalties or sanctions imposed by a court or regulatory body that would likely be considered important to a reasonable security holder in deciding whether to vote for a proposed director. </TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="ex99_1toc313671_14"></A>LEGAL PROCEEDINGS AND REGULATORY ACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&nbsp;6, 2017, we are not aware of any legal proceedings against the Company that would involve a claim for damages that exceed ten per cent of the
current assets of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No penalties or sanctions have been imposed against the Company by a court relating to securities legislation or any
securities regulatory authority during the financial year ended December&nbsp;31, 2016, nor has the Company entered into any settlement agreements with a court relating to securities legislation or with a securities regulatory authority during such
financial year. No other penalties or sanctions have been imposed by a court or regulatory body against the Company which would likely be considered important to a reasonable investor in making an investment decision respecting the Company. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="ex99_1toc313671_15"></A>INTEREST OF MANAGEMENT AND OTHERS IN MATERIAL TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None of the directors or executive officers of the Company, persons or companies that beneficially own, control, or direct more than 10% of the voting
securities of the Company, or an associate or affiliate of any of such directors, executive officers, persons or companies, had a material interest, directly or indirectly, in the transactions conducted by the Company within the three most recently
completed financial years or during the current financial year that has materially affected or is reasonably expected to materially affect the Company. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="ex99_1toc313671_16"></A>CONFLICTS OF INTEREST </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the knowledge of the Company, and other than as disclosed herein, there is no known existing or potential material conflicts of interest among the Company,
its directors and officers, or a subsidiary of the Company or other members of management as a result of their outside business interests, except that certain of its directors may serve as directors of other companies and therefore it is possible
that a conflict may arise between their duties to the Company and their duties as a director of such other companies. <I>See &#147;Risk Factors - The Company is dependent upon its key personnel to achieve its business objectives&#148;.</I> </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="ex99_1toc313671_17"></A>TRANSFER AGENT AND REGISTRAR </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">co-transfer</FONT> agents and <FONT STYLE="white-space:nowrap">co-registrars</FONT> of the Company are Computershare
Investor Services Inc. located at its principal offices in Calgary, Alberta and Toronto, Ontario and Computershare Trust Company, N.A. located at its principal offices in Golden, Colorado. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="ex99_1toc313671_18"></A>MATERIAL CONTRACTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company currently has the following material contracts: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">Pursuant to the R&amp;D Agreement dated June&nbsp;18, 2009,<B> </B>between Paladin and the Company, as amended by Second Amendment to R&amp;D Agreement dated January&nbsp;17, 2011, Paladin is required to make payments
to the Company equal to: (i) 20% of net sales of voclosporin, in Canada, Israel and South Africa, less manufacturing costs, until June&nbsp;18, 2016; and (ii) 20% of net royalties received from third party sales, in the Paladin Territories until
June&nbsp;18, 2016. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Pursuant to the License Agreement dated June&nbsp;18, 2009, between Paladin and the Company, as amended by Second Amendment to License Agreement dated January&nbsp;17, 2011, Paladin will receive 2% of any milestone
payments, development payments, royalties, and net profit splits paid to the Company, related to voclosporin outside Canada, Israel and South Africa. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Under the terms of an agreement dated February&nbsp;14, 2014 between the Company and Dr.&nbsp;Robert Foster,
whereby Dr.&nbsp;Robert Foster&#146;s employment as CSO was terminated by the Company, it was confirmed that effective March&nbsp;8, 2012, Dr.&nbsp;Foster was entitled to receive 2% of royalty licensing revenue for royalties received on the sale of
voclosporin by </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
licensees and/or 0.3% of net sales of voclosporin sold directly by the Company, to be paid quarterly as that revenue is received by the Company. Should the Company sell substantially all of the
assets of voclosporin to a third party or transfer those assets to another party in a merger in a manner such that this payment obligation is no longer operative, then Dr.&nbsp;Foster will be entitled to receive 0.3% of the value attributable to
voclosporin in the transaction. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The manufacturing collaboration and services agreement, dated November&nbsp;22, 2016 between Lonza and the Company as described under the heading &#147;Manufacturing, Encapsulating And Packaging Of Voclosporin - Lonza
Manufacturing Collaboration Agreement&#148;.<I> </I> </TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="ex99_1toc313671_19"></A>INTERESTS OF EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PricewaterhouseCoopers LLP, the Company&#146;s auditor, issued an auditor&#146;s report dated March&nbsp;6, 2017 in respect of our Consolidated Financial
Statements, which comprise the Consolidated Statements of Financial Position as at December&nbsp;31, 2016 and December&nbsp;31, 2015, and the Consolidated Statements of Operations and Comprehensive Loss, Consolidated Statements of Changes in
Shareholders&#146; Equity and Cash Flows for the years ended December&nbsp;31, 2016 and December&nbsp;31, 2015, and the related notes. PricewaterhouseCoopers LLP has advised us that they are independent with respect to the Company within the meaning
of the Rules of Professional Conduct of the Chartered Professional Accountants of Alberta and the rules of the U.S. Securities and Exchange Commission. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="ex99_1toc313671_20"></A>ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additional information with respect to the Company, including directors&#146; and officers&#146; remuneration and indebtedness, principal holders of the
Company&#146;s common shares and securities authorized for issuance under equity compensation plans will be contained in the most recently filed management information circular of the Company. Additional financial information is also available in
the Company&#146;s comparative audited consolidated financial statements, together with the auditor&#146;s report thereon, and the related Management Discussion and Analysis for its most recently completed fiscal year ended December&nbsp;31, 2016.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additional information regarding the Company is available on the SEDAR website located at www.sedar.com, on EDGAR at <U>www.sec.gov,</U> or on the
Company&#146;s corporate website located at <U>www.auriniapharma.com</U>,or upon request addressed to Michael Martin, COO, at 1203, 4464 Markham Street, Victoria, British Columbia V8Z 7X8. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="ex99_1toc313671_21"></A>SCHEDULE 1 - AUDIT COMMITTEE INFORMATION </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>The Audit Committee&#146;s Charter </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s Audit Committee Charter is available in the
governance section of our website at <U>www.auriniapharma.com</U> and is attached as Schedule 2 to this AIF. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Composition and Relevant Education and Experience </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Audit Committee is comprised of three independent
directors: Jeff Randall (Chair), Gregory Ayers and Benjamin Rovinski. A description of the education and experience of each Audit Committee member that is relevant to the performance of his responsibilities as an Audit Committee member may be found
above under the heading &#147;Directors and Executive Officers&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the SEC rules implementing the <I>Sarbanes-Oxley Act of 2002</I>, Canadian
issuers filing reports in the United States must disclose whether their audit committees have at least one audit committee financial expert. The Board has determined that Jeff Randall qualifies as an audit committee financial expert under such
rules. In addition, all members of the Audit Committee are considered financially literate under applicable Canadian and U.S. laws. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><FONT STYLE="white-space:nowrap">Pre-approval</FONT> Policies and Procedures </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Audit Committee is
authorized by the Board to review the performance of our external auditor and approve in advance the provision of services other than auditing and to consider the independence of the external auditor, including reviewing the range of services
provided in the context of all consulting services bought by us. Such advance approval authority may be delegated by the Audit Committee to the Chair of the Audit Committee who is &#147;independent&#148; and &#147;unrelated&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All fees for audit and audit related services performed by the external auditor for the year ended December&nbsp;31, 2016 were
<FONT STYLE="white-space:nowrap">pre-approved</FONT> by the Audit Committee. All fees for <FONT STYLE="white-space:nowrap">non-audit</FONT> related services performed by the external auditor for the year ended December&nbsp;31, 2016 were <FONT
STYLE="white-space:nowrap">pre-approved</FONT> by the Audit Committee and/or Audit Chair as delegated by the Audit Committee. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>External Auditor Service Fees (By Category) </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The aggregate fees recorded for professional services
rendered by the external auditor, PricewaterhouseCoopers LLP, for the Company and its subsidiaries for the years ended December&nbsp;31, 2016 and 2015, respectively are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:59.50pt; font-size:8pt; font-family:Times New Roman"><B>Fiscal year ended</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%&nbsp;of&nbsp;Total</B><br><B>Fees</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%&nbsp;of&nbsp;Total</B><br><B>Fees</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit fees (for audit of the Company&#146;s annual financial statements and services provided in
connection with statutory and regulatory filings)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">66,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">84,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit related fees, including review of the Company&#146;s quarterly financial statements<SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">38,732</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax fees (tax compliance, tax advice and
planning)<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All other fees<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55,353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total fees</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>171,089</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>100</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>166,256</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>100</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">These fees include professional services provided by the external auditor for the statutory audits of the annual financial statements. The total for 2016 is comprised of $39,900 related to interim billings for the 2016
audit and $26,736 related to fees for the 2015 audit billed in 2016. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">These fees relate to performing review engagement services on the Company&#146;s quarterly financial statements and other audit related services. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">These fees include professional services for tax compliance, tax advice, tax planning and various taxation matters. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">These fees for 2016 include professional services for assistance in filing prospectus supplements 2,3 and 4 in the amount of $49,305 and other advisory services in the amount of $6,048. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="ex99_1toc313671_22"></A>SCHEDULE 2 - AUDIT COMMITTEE CHARTER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AURINIA PHARMACEUTICALS INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>AUDIT COMMITTEE CHARTER </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>JANUARY&nbsp;1, 2016 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PURPOSE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purpose of the Audit
Committee of the Board of Directors of Aurinia Pharmaceuticals Inc. (the &#147;<B><I>Company</I></B>&#148;) shall be to assist the Board of Directors of the Company (the &#147;<B><I>Board</I></B>&#148;) in its oversight of (i)&nbsp;the quality and
integrity of the financial statements of the Company, (ii)&nbsp;the Company&#146;s compliance with legal and regulatory requirements, (iii)&nbsp;the accounting and financial management processes of the Company, and the effectiveness of the
Company&#146;s internal controls over financial reporting, (iv)&nbsp;the quality and integrity of the annual audit of the Company&#146;s financial statements, including the independence and qualifications of the Company&#146;s independent auditor.
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MEMBERSHIP </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Composition </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Committee shall consist of no fewer than three (3)&nbsp;members. None of the members of
the Committee shall be an officer or employee of the Company or any of its subsidiaries, and each member of the Committee shall be an &#147;independent director&#148; (in accordance with the definition of &#147;independent director&#148; established
from time to time under the requirements or guidelines for audit committee service under applicable securities laws and the rules of any stock exchange on which the Company&#146;s shares are listed for trading). </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Appointment and Replacement of Committee Members </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any member of the Committee may be removed or replaced
at any time by the Board and shall automatically cease to be a member of the Committee upon ceasing to be a director. The Board may fill vacancies on the Committee by election from among its members. The Board shall fill any vacancy if the
membership of the Committee is less than three directors. If and whenever a vacancy shall exist on the Committee, the remaining members may exercise all its power so long as a quorum remains in office. Subject to the foregoing, the members of the
Committee shall be elected by the Board annually and each member of the Committee shall hold office as such until the next annual meeting of shareholders after his or her election or until his or her successor shall be duly elected and qualified.
</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial literacy </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All members of the Committee should be &#147;financially literate&#148; (as that
term is interpreted by the Board in its reasonable judgment or as may be defined from time to time under the requirements or guidelines for audit committee service under securities laws and the rules of any stock exchange on which the Company&#146;s
shares are listed for trading) or must become financially literate within a reasonable period of time after his or her appointment to the Committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
addition, at least one member must have past employment experience in finance or accounting, requisite professional certification in accounting or any other comparable experience or background which results in the individual&#146;s financial
sophistication. Unless otherwise determined by the Board, at least one member of the Audit Committee shall be an &#147;audit committee financial expert&#148;. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RESPONSIBILITIES AND DUTIES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
principal responsibilities and duties of the Committee in serving the purposes outlined above in this charter are set forth below. These duties are set forth as a guide with the understanding that the Committee will carry them out
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in a manner that is appropriate given the Company&#146;s needs and circumstances. The Committee may supplement them as appropriate and may establish policies and procedures from time to time that
it deems necessary or advisable in fulfilling its responsibilities. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>INDEPENDENT AUDITOR </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.</B> <B><I>Appointment and Oversight of Independent Auditor. </I></B>The
Committee appoints the independent auditor to examine the Company&#146;s accounts, controls and financial statements. The Committee has sole responsibility for the appointment, compensation, retention, oversight and, if necessary, termination of any
registered public accounting firm engaged (including resolution of disagreements between the Company&#146;s management and the firm regarding financial reporting) for the purpose of preparing or issuing an audit report or performing other audit,
review or attest services for the Company, and the independent auditor and each such registered public accounting firm will report directly to the Committee. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. </B><B><I>Auditor Independence and Qualifications</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Committee is responsible for assessing the independent auditor&#146;s qualifications, performance and independence annually, and for
taking, or recommending that the full board take, appropriate action to oversee the independence of the independent auditor. In connection therewith, the Committee will make sure it reviews, on an annual basis, all relationships between the
independent auditor and the Company, including those described in the formal written statement that the Committee obtains annually from the independent auditor under applicable requirements of the Canadian generally accepted auditing standards (CAS)
and since the Company is registered with the U.S. Securities Exchange Commission, the Public Company Accounting Oversight Board (the &#147;<I>PCAOB</I>&#148;) related to the independent auditor&#146;s communications with the Committee concerning
independence, and actively engaging in a dialogue with the independent auditor with respect to any disclosed relationships or services that may impact the objectivity and independence of the independent auditor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Committee will obtain and review, at least annually, a report from the independent auditor describing: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">i. the firm&#146;s internal quality-control procedures; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">ii. any material issues raised by the most recent internal quality-control review, peer review, Canadian Public Accountability Board (CPAB) or
PCAOB review of the firm, or by any governmental or professional authority in any inquiry or investigation, within the preceding five years, regarding any independent audit carried out by the independent auditor, and any steps taken to address any
such issues. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Committee is responsible for reviewing and evaluating the lead audit partner of the independent auditor and
overseeing the rotation of the lead audit partner as required by applicable law and the Commission Rules. In making its evaluation, the Committee should take into account the opinions of management and the independent auditor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The Committee will set policies for the Company&#146;s hiring of employees or former employees of the independent auditor. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. </B><B><I>Approval of Audit and <FONT STYLE="white-space:nowrap">Non-Audit</FONT> Services</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Committee will review the independent auditor&#146;s audit planning, scope and staffing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Committee must <FONT STYLE="white-space:nowrap">pre-approve</FONT> all audit and <FONT STYLE="white-space:nowrap">non-audit</FONT> related
services provided to the Company by the independent auditor. The Committee may establish <FONT STYLE="white-space:nowrap">pre-approval</FONT> policies and procedures, as permitted by the Exchange Rules, Commission Rules and applicable law, for the
engagement of the independent auditor to render services to the Company, including without limitation policies that would allow the delegation of <FONT STYLE="white-space:nowrap">pre-approval</FONT> authority to one or more members of the Committee,
provided that any <FONT STYLE="white-space:nowrap">pre-approval</FONT> decision is reported to the Committee at its next scheduled meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. </B><B><I>Interaction with Independent Auditor</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Committee will, to the extent warranted, discuss with the independent auditor the above referenced reports and any other matters required
to be reviewed under applicable legal and regulatory requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Committee will periodically consult with the independent auditor,
out of the presence of the Company&#146;s management, about the Company&#146;s internal controls, the fullness and accuracy of the Company&#146;s financial statements, the responsibilities, budget and staffing of the Company&#146;s finance function,
and any other matters that the Committee or independent auditor believes should be discussed privately with the Committee. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>B.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>FINANCIAL STATEMENTS AND DISCLOSURES </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. </B><B><I>Annual Financial Statements and
Disclosures</I></B><B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Committee will meet to review and discuss with the independent auditor and the Company&#146;s
management the Company&#146;s audited consolidated financial statements and the notes and Managements&#146; Discussion and Analysis relating to such consolidated financial statements, the annual report, the annual information form, the financial
information of the Company contained in any prospectus or information circular or other disclosure documents or regulatory filings of the Company, the recommendations for approval of each of the foregoing from each of the President and Chief
Executive Officer, and Chief Financial Officer of the Company and based on such recommendations provide, where applicable, its own recommendations to the Board for their approval and release of each of the foregoing to the public. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Committee will discuss with the independent auditor and the Company&#146;s management any items appropriate or required to be
discussed in accordance with applicable auditing and CPAB standards in connection with the preparation of the Company&#146;s annual financial statements, including any problems or difficulties encountered during the course of the audit, including
any restrictions on the scope of work or access to required information, and any significant disagreements with management and management&#146;s response to such difficulties. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. </B><B><I>Quarterly Financial Statements and Disclosures</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Committee will meet to review and discuss with the independent auditor and the Company&#146;s management the Company&#146;s interim
consolidated financial statements and the notes and Managements&#146; Discussion and Analysis relating to such consolidated financial statements, and either, in the discretion of the Audit Committee, (A)&nbsp;approve and release each of the
foregoing to the public, or (B)&nbsp;provide, where applicable, its own recommendation to the Board for their approval and release of each of the foregoing to the public. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Committee will discuss with the independent auditor and the Company&#146;s management any items appropriate or required to be
discussed in accordance with applicable auditing and CPAB standards in connection with the preparation of the Company&#146;s quarterly financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.</B> <B><I>Earnings Announcements and Guidance. </I></B>The Committee will discuss generally with the Company&#146;s management and the independent
auditor, as appropriate, the type of information to be disclosed and type of presentation to be made regarding the Company&#146;s earnings press releases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4</B>. <B><I>Ongoing Reviews.</I></B> In connection with the foregoing, the Committee will review the Company&#146;s financial reporting and accounting
standards and principles and financial statement presentations, significant changes in the selection of such standards or principles or in their application and the key accounting decisions affecting the Company&#146;s financial statements,
including alternatives to, and the rationale for, the decisions made. As part of this review, the Committee will discuss with the Company&#146;s management and the independent auditor the reasonableness of judgments and estimates used in the
preparation of financial statements, and alternative accounting treatments, principles or practices that were considered or may be preferred by the independent auditor, the Committee or the Company&#146;s management. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>C.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>CONTROLS AND PROCEDURES </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.</B> <B><I>Review of Processes, Systems, Controls and Procedures.
</I></B>The Committee will periodically review and meet separately with the independent auditor, or other personnel primarily responsible for the internal control , and the Company&#146;s management to discuss their periodic reviews of the
integrity, adequacy and effectiveness of the Company&#146;s accounting and financial reporting processes, systems of internal control (including any significant deficiencies and material weaknesses in their design or operation), and disclosure
controls and procedures (and management&#146;s reports thereon), as well as any special audit steps adopted in light of material control deficiencies. The Audit Committee shall receive and review the required applicable annual or quarterly CEO and
CFO certification reports prior to these documents being filed as required by the regulators. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2. Legal Matters </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Committee will periodically review with the Company&#146;s management and the Company&#146;s General Counsel, the nature and status of
significant legal matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Committee will review and monitor any significant pending or threatened litigation that could have a
material impact on the Company&#146;s financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.</B> <B><I>Risk Assessment and Risk Management. </I></B>The Committee is responsible for
overseeing the management of risks associated with the Company&#146;s financial reporting, accounting and auditing matters, reviewing as required the Company&#146;s processes around the management and monitoring of such risks, including but not
limited to, review and assessment of the company investment policy and performance and review and assessment of the company&#146;s insurance policies. The Committee will discuss with the Company&#146;s management the Company&#146;s major financial,
accounting and reporting risk exposures and the steps management has taken to monitor and control such exposures, including the Company&#146;s risk assessment and risk management policies and guidelines. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.</B> <B><I>Whistleblower Procedures. </I></B>The Committee is responsible for establishing and overseeing procedures for the receipt, retention and
treatment of complaints received by the Company regarding accounting, internal accounting controls or auditing matters, the prompt internal reporting of violations of the Code of Business Conduct and Ethics and for the confidential, anonymous
submission by Company employees of concerns regarding questionable accounting or auditing matters. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>D.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>OTHER DUTIES AND RESPONSIBILITIES </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.</B> <B><I>Code of Conduct. </I></B>The Committee will
periodically review and recommend to the Board any changes to the Code of Conduct applicable to the Company, including all of its directors, officers and employees. The Committee will also consider waivers of the Code of Conduct requested for
executive officers and directors and retain sole authority to grant any waivers for executive officers and directors (other than where the potential waiver involves a member of the Committee, in which event such waiver shall be subject to the review
of the Board). The Committee will also periodically review and recommend to the Board any changes to the Company&#146;s Insider Trading Policy and Anti-Bribery Policy, which are referenced in the Company&#146;s Code of Conduct. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.</B> <B><I>Related Party Transactions. </I></B>The Committee will review and, where appropriate, approve any transaction between the Company and any
related party (other than transactions that are subject to review by the Board as a whole or any other committee of the Board), as defined by applicable law, the Commission Rules and the Exchange Rules, and will periodically review the business
interests and activities of members of the Board and management. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.</B> <B><I>Review of Composition and Performance. </I></B>The Committee will
evaluate the Committee&#146;s composition and performance on an annual basis and submit a report to the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.</B> <B><I>Review of this Charter.
</I></B>The Committee will review and reassess the adequacy of this charter annually and recommend to the Board any changes the Committee determines are appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.</B> <B><I>Other Actions. </I></B>The Committee will perform any other activities required by applicable law, rules or regulations, including the
Commission Rules and the Exchange Rules, and take such other actions and perform and carry out any other responsibilities and duties delegated to it by the Board or as the Committee deems necessary or appropriate consistent with its purpose. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STUDIES AND ADVISERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In discharging its responsibilities, the Committee may conduct, direct, supervise or authorize studies of, or investigations into, any matter that the
Committee deems appropriate, with full and unrestricted access to all books, records, documents, facilities and personnel of the Company. The Committee has the sole authority to retain and terminate independent legal counsel and other consultants,
accountants, experts and advisers of its choice to assist the Committee in connection with its functions, including any studies or investigations. The Committee will have the sole authority to approve the fees and other retention terms of such
advisers. The Company will also provide for appropriate funding, as determined by the Committee, for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">payment of compensation to the independent auditor and any legal and other consultants, accountants, experts and advisers retained by the Committee; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ordinary administrative expenses of the Committee that are necessary and appropriate in carrying out its functions. </TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MEETINGS AND ACTIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Meetings of the
Committee shall be held at least once each quarter or more frequently, as determined to be appropriate by the Committee. The Board may appoint a member of the Committee to serve as the chairperson of the Committee (the
&#147;<B><I>Chair</I></B>&#148;); if the Board does not appoint a Chair, the Committee members may designate a Chair by their majority vote. The Chair, in consultation with the other members of the Committee, will set the dates, time, places and
agenda for Committee meetings. The Chair or any other member of the Committee may call meetings of the Committee by notice and the Committee may act by unanimous written consent in lieu of a meeting in accordance with the Company&#146;s Bylaws. A
quorum of the Committee for the transaction of business will be a majority of its members. Meetings may be held in person or via telephone or video conference. The Committee also may act by unanimous written consent in lieu of a meeting in
accordance with the Company&#146;s Bylaws. Subject to the requirements of this charter, applicable law, the Exchange Rules and the Commission Rules, the Committee and the Chair may invite any director, executive or employee of the Company, or such
other person, as it deems appropriate in order to carry out its responsibilities, to attend and participate (in a <FONT STYLE="white-space:nowrap">non-voting</FONT> capacity) in all or a portion of any Committee meeting. The Committee may meet in
executive session at its discretion and may exclude from all or a portion of its meetings any person it deems appropriate in order to carry out its responsibilities. The Chair will designate a secretary for each meeting, who need not be a member of
the Committee. The Company shall provide the Committee such staff support as it may require. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MINUTES AND REPORTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Committee will maintain written minutes of its meetings and copies of its actions by written consent, and will cause such minutes and copies of written
consents to be filed with the minutes of the meetings of the Board. The Committee will report regularly to the Board with respect to its activities, including on significant matters related to the Committee&#146;s responsibilities and the
Committee&#146;s deliberations and actions. The minutes of the Committee and actions by the unanimous written consent of the Committee members will be made available to the other members of the Board. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DELEGATION OF AUTHORITY </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Committee
may from time to time, as it deems appropriate and to the extent permitted under applicable law, the Exchange Rules and the Commission Rules, and the Company&#146;s Certificate of Incorporation and Bylaws, form and delegate authority to
subcommittees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Members of the Committee will receive such fees, if any, for their service as Committee members as may be determined by the Board, which may include
additional compensation for the Chair. Such fees may include retainers or per meeting fees and will be paid in such form of consideration as is determined by the Board in accordance with applicable law, the Exchange Rules and the Commission Rules.
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PUBLICATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company shall make
this charter freely available to stockholders on request and shall publish it on the Company&#146;s web site. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OVERSIGHT FUNCTION
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This charter sets forth the authority and responsibility of the Committee in fulfilling the purposes described herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While the Committee has the responsibilities and powers set forth in this Charter, it is not the duty of the Committee to plan or conduct audits or to
determine that the Company&#146;s consolidated financial statements are complete and accurate or are in accordance with IFRS and applicable rules and regulations. These are the responsibilities of Management and the Company&#146;s external auditors.
The Committee, its Chair and any Committee members identified as having accounting or related financial expertise are members of the Board, appointed to the Committee to provide broad oversight of the financial, risk and control related activities
of the Company, and are specifically not accountable or responsible for the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> operation or performance of such activities. Although the designation of a
Committee member as having accounting or related financial expertise for disclosure purposes or otherwise is based on that individual&#146;s education and experience which that individual will bring to bear in carrying out his or her duties on the
Committee, such designation does not impose on such person any duties, obligations or liability that are greater than the duties, obligations and liability imposed on such person as a member of the Committee and Board in the absence of such
designation. Rather, the role of a Committee member who is identified as having accounting or related financial expertise, like the role of all Committee members, is to oversee the process, not to certify or guarantee the internal or external audit
of the Company&#146;s financial information or public disclosure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the Company&#146;s management is responsible for managing its risk
function and for reporting on its processes and assessments with respect to the Company&#146;s management of risk. Each member of the Committee shall be entitled to rely on (a)&nbsp;the integrity of those persons and organizations within and outside
of the Company from which it receives information, (b)&nbsp;the accuracy of the financial and other information provided to the Committee by such persons or organizations absent actual knowledge to the contrary (which shall be promptly reported to
the Board) and (c)&nbsp;representations made by management as to any audit and <FONT STYLE="white-space:nowrap">non-audit</FONT> services provided by the independent auditor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board has formed the Committee to assist the Board in directing the Company&#146;s affairs and this charter has been adopted in furtherance of this
purpose. While this charter should be interpreted in the context of all applicable laws, regulations and listing requirements, as well as in the context of the Company&#146;s Certificate of Incorporation and Bylaws, it is not intended to establish
by its own force any legally binding obligations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="ex99_1toc313671_23"></A>SCHEDULE 3 - GLOSSARY OF TERMS AND DEFINITIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In this annual information form, the following capitalized words and terms shall have the following meanings: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>AEs</B>&#148; means adverse events; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>AIF</B>&#148; means the Annual Information Form of the Company dated March&nbsp;6, 2017 for the fiscal year ended December&nbsp;31, 2016; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;ALMS&#148;</B> means the Aspreva Lupus Management Study; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>API</B>&#148; means active pharmaceutical ingredient; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;Aspreva&#148;</B> means Aspreva Pharmaceuticals Inc.; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">&#147;AURA-LV</FONT> (AURA)&#148;</B> means a Phase 2b clinical trial. The protocol is titled <B>A Randomized, Controlled
Double-blind Study Comparing the Efficacy and Safety of Voclosporin (23.7 mg BID, or 39.5 mg BID) with Placebo in Achieving remission in Patients with Active Lupus Nephritis</B>; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;AURION&#148;</B> means an open label exploratory study. The protocol is titled <B>An Exploratory study assessing the Short term Predictors of
Remission of Voclosporin 23.7 mg BID in combination with standard of care in Patients with Active Lupus Nephritis. </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>AUC</B>&#148; means area
under the curve; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>BID</B>&#148; means administered twice a day; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Board</B>&#148; means the board of directors of the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>calcineurin</B>&#148; means a specific enzyme (phosphatase enzyme) that can have its activity inhibited by immunosuppressive (anti-organ rejection)
drugs, including, for example, cyclosporine; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Catalent</B>&#148; means Catalent Pharma Solutions; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>CellCept</B><B><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP></B>&#148;<B> </B>means the brand name of MMF; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>CEO</B>&#148; means Chief Executive Officer; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>CFO</B>&#148; means Chief Financial Officer; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>CMO</B>&#148; means Chief Medical Officer; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>CNI</B>&#148; means calcineurin inhibitors, the cornerstone of therapy for the prevention of organ transplant rejection; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Company</B>&#148; means Aurinia Pharmaceuticals Inc. and (unless the context specifies or implies otherwise) its subsidiaries; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>COO</B>&#148; means Chief Operating Officer; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>CR</B>&#148;<B> </B>means complete remission; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>CRO</B>&#148; means Contract Research Organization; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>CsA</B>&#148; means cyclosporine A; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>CSO</B>&#148; means Chief Scientific Officer; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>CTA</B>&#148; means Clinical Trial Application; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>cyclosporine</B>&#148; means a drug that suppresses the immune system and is used to prevent rejection
following organ transplantation; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>eGFR</B>&#148; means estimated glomerular filtration rate; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>EMA</B>&#148; means the European Medicines Agency; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>ESRD</B>&#148; means <FONT STYLE="white-space:nowrap">end-stage</FONT> renal disease; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;EU&#148;</B> means European Union; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>FDA</B>&#148; means the Food and Drug Administration of the United States Government; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>GMP</B>&#148; means good manufacturing practices; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>IEC</B>&#148; means Independent Ethics Committee; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>ILJIN</B>&#148; means ILJIN Life Science Co., Ltd.; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>IND</B>&#148; means investigational new drug; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>IRB</B>&#148; means Institutional Review Board; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>LFA</B>&#148; means Lupus Foundation of America; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;LN&#148;</B> means lupus nephritis; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Lonza</B>&#148; means Lonza Ltd. a Swiss-based contract drug manufacturer; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Lux</B>&#148; means Lux BioSciences, Inc.; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;MMF&#148;</B> means mycophenolate mofetil; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;MPA&#148;</B> means mycophenolic acid, the active metabolite of MMF; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;MTT&#148;</B> means multi-targeted therapeutic; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;NASDAQ&#148;</B> means the NASDAQ Global Market Exchange; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>NDA</B>&#148; means New Drug Application made to a regulatory agency; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Paladin</B>&#148; means Paladin Labs Inc.; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Paladin Territories</B>&#148; means Canada, Israel, Central and South America, South Africa and Mexico prior to January&nbsp;28, 2011; and Canada,
Israel and South Africa after January&nbsp;28, 2011; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Pharmacokinetics</B>&#148; means the processes of drug absorption, distribution, metabolism
and escretion in a living system (e.g., in humans); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>PFIC</B>&#148; means a passive foreign investment company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">&#147;PK-PD&#148;</FONT></B> means pharmacokinetic and pharmacodynamics analysis; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;PMDA&#148;</B> means the Japanese Pharmaceuticals and Medical Devices Agency; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>PR</B>&#148; means partial remission; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>SAEs</B>&#148; means serious adverse events; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;SEC&#148;</B> means the U.S. Securities and Exchange Commission; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>SEDAR</B>&#148; means the System for Electronic Document Analysis and Retrieval; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;SLE&#148;</B> means systemic lupus erythematosus; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>SOC</B>&#148; means system organ class; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>TSX</B>&#148; means the Toronto Stock Exchange; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>UPCR</B>&#148; means Urinary/protein creatinine ratio; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Vifor</B>&#148; means Vifor (International) AG; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Warrants</B>&#148; means warrants to purchase common shares in the capital of the Company, with each whole warrant being exercisable to purchase one
common share. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>d313671dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g313671g64o35.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">Financial Statements </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">Aurinia Pharmaceuticals </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">YEAR END 16 </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">For the year ended December 31, 2016 </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">Aurinia Pharmaceuticals </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December&nbsp;31, 2016
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in thousands of US dollars) </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MANAGEMENT&#146;S RESPONSIBILITY FOR FINANCIAL REPORTING </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements of Aurinia Pharmaceuticals Inc. (the Company) are the responsibility of management. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements have been prepared in accordance with International Financial Reporting Standards as issued by the International
Accounting Standards Board and reflect, where appropriate, management&#146;s best estimates and judgments based on currently available information. Management has prepared the financial information presented elsewhere in the Management&#146;s
Discussion and Analysis and has ensured it is consistent with the consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company maintains systems of internal accounting
and administrative controls. These systems are designed to provide reasonable assurance that the financial information is relevant, reliable and accurate and that the Company&#146;s assets are appropriately accounted for and adequately safeguarded.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors (the Board) exercises its responsibility over the consolidated financial statements and over financial reporting and internal
controls principally through the Company&#146;s Audit Committee. The Board appoints the Audit Committee and its members are outside and unrelated directors. The Audit Committee meets periodically with management to discuss internal controls over the
financial reporting process and financial reporting issues and to satisfy itself that each party is properly discharging its responsibilities. The Audit Committee reviews the annual consolidated financial statements with both management and the
independent auditors and reports its findings to the Board before such statements are approved by the Board. The Audit Committee also considers, for review by the Board and approval by the shareholders, the engagement or reappointment of the
external auditors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements have been audited by PricewaterhouseCoopers LLP, the Company&#146;s independent auditors, in
accordance with Canadian generally accepted auditing standards on behalf of the shareholders. Their report outlines the scope of their audit and gives their opinion on the consolidated financial statements. PricewaterhouseCoopers LLP has full and
free access to the Audit Committee. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(Signed) &#147;Richard Glickman&#148;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(Signed) &#147;Dennis Bourgeault&#148;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chief Executive Officer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Victoria, British Columbia</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">March&nbsp;6,
2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;6, 2017 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Independent Auditor&#146;s Report </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>To the Shareholders
of </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited
the accompanying consolidated financial statements of Aurinia Pharmaceuticals Inc. and its subsidiaries, which comprise the consolidated statements of financial position as at December&nbsp;31, 2016 and 2015 and the consolidated statements of
operations and comprehensive loss, changes in shareholders&#146; equity (deficit) and cash flows for the years then ended, and the related notes, which comprise a summary of significant accounting policies and other explanatory information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Management&#146;s responsibility for the consolidated financial statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with International Financial
Reporting Standards as issued by the International Accounting Standards Board, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material
misstatement, whether due to fraud or error. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Auditor&#146;s responsibility </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We conducted our audits in accordance with Canadian
generally accepted auditing standards. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material
misstatement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial
statements. The procedures selected depend on the auditor&#146;s judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the
auditor considers internal control relevant to the entity&#146;s preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of
expressing an opinion on the effectiveness of the entity&#146;s internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as
evaluating the overall presentation of the consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that the audit evidence we have obtained in our audits is
sufficient and appropriate to provide a basis for our audit opinion. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g313671ex992p03.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;PwC&#148; refers to PricewaterhouseCoopers LLP, an Ontario limited liability partnership. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opinion </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of Aurinia Pharmaceuticals Inc. and its subsidiaries as at December&nbsp;31, 2016 and 2015 and their financial performance and their
cash flows for the years then ended in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Emphasis of matter </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Without qualifying our opinion, we
draw attention to note 2 to the consolidated financial statements, which describes matters and conditions that indicate the existence of a material uncertainty that may cast significant doubt about Aurinia Pharmaceuticals Inc.&#146;s ability to
continue as a going concern. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(signed) &#147;PricewaterhouseCoopers LLP&#148; </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Chartered Professional Accountants </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Consolidated Statements of Financial Position </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>As at
December&nbsp;31, 2016 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in
thousands of US dollars) </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2016</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2015</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,756</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investment (note 5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and deposits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,683</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,418</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,534</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Property and equipment </B>(note 6)<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Acquired intellectual property and other intangible assets </B>(note 7)<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable and accrued liabilities (note 8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of deferred revenue (note 9)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contingent consideration (note 10)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for restructuring costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Deferred revenue </B>(note 9)<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">678</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Contingent consideration </B>(note 10)<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Derivative warrant liabilities </B>(note 11)<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Shareholders&#146; Equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Share capital</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common shares (note 12)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">299,815</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">261,645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants (note 12)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">971</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Contributed surplus</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Accumulated other comprehensive loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(805</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(805</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(281,048</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(257,753</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Going concern </B>(note 2)<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Commitments and contingencies </B>(note 20)<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Subsequent events </B>(note 23)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Approved by the Board of Directors </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>(signed)&nbsp;Lorin&nbsp;J.&nbsp;Randall</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><U>(signed) Benjamin Rovinski</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD></TR>
</TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying notes are an integral part of these consolidated financial statements. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Consolidated Statements of Operations and Comprehensive Loss </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For the years ended December&nbsp;31, 2016 and December&nbsp;31, 2015 </B></P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in thousands of US dollars, except per
share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2016</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2015</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Revenue</B> (note 9)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Licensing revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development (note 13)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,534</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate, administration and business development (note 13)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of acquired intellectual property and other intangible assets (note 7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,457</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense (income) (note 14)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,943</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss before gain on derivative warrant liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,027</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,708</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Gain on derivative warrant liabilities</B> (note 11)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,732</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss and comprehensive loss for the year</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,295</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,607</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss per common share </B>(note 16) (expressed in $ per share)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted loss per common share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.66</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.58</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying notes are an integral part of these consolidated financial statements. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Consolidated Statements of Changes in Shareholders&#146; Equity (Deficit) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For the years ended December&nbsp;31, 2016 and December&nbsp;31, 2015 </B></P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in thousands of US dollars) </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Common</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>shares</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Warrants</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Contributed</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>surplus</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Deficit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Accumulated</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>other</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>comprehensive</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>loss</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Shareholders&#146;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>equity</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(deficit)</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance &#150; January&nbsp;1, 2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">261,645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(257,753</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(805</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issue of units pursuant to bought deal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share issue costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,951</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,951</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issue of units pursuant to private placement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,080</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share issue costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(389</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(440</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issue of common shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share issue costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(575</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(575</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(947</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of cashless warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expiry of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(148</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(93</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss for the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,295</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,295</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance &#150; December&nbsp;31, 2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">299,815</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">971</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(281,048</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(805</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance &#150; January&nbsp;1, 2015</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">259,712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(239,146</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(805</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,871</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(335</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of cashless warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expiry of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(172</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(123</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss for the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,607</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,607</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance &#150; December&nbsp;31, 2015</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">261,645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(257,753</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(805</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying notes are an integral part of these consolidated financial statements. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Consolidated Statements of Cash Flows </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For the years ended
December&nbsp;31, 2016 and December&nbsp;31, 2015 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in thousands of US dollars) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flow provided by (used in)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss for the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,295</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,607</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments for</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(168</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(218</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of acquired intellectual property and other intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,457</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in value of short-term investment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share issue costs allocated to derivative warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revaluation of contingent consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in provision for restructuring costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(116</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(155</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on disposal of equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on derivative warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,732</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,101</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,183</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,987</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net change in other operating assets and liabilities (note 18)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash used in operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,713</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,766</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase of short-term investment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,138</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,983</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds on disposal of short-term investment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds on disposal of equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase of equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capitalized patent costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(44</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash generated from (used in) investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net proceeds from issuance of bought deal units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net proceeds from issuance of private placement units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net proceeds from issuance of shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,821</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from exercise of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash generated from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Increase (decrease) in cash and cash equivalents during the year</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,893</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,950</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash and cash equivalents &#150; Beginning of year</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,756</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash and cash equivalents &#150; End of year</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,756</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying notes are an integral part of these consolidated financial statements. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December&nbsp;31,
2016 and December&nbsp;31, 2015 </B></P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed
in US dollars, tabular amounts in thousands) </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Corporate information </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Aurinia Pharmaceuticals Inc. or the Company is a clinical stage
pharmaceutical company with its head office located at #1203-4464 Markham Street, Victoria, British Columbia, V8Z 7X8 where clinical, regulatory and business development functions of the Company are conducted. The Company has its registered office
located at #201, <FONT STYLE="white-space:nowrap">17904-105</FONT> Avenue, Edmonton, Alberta, T5S 2H5 where the finance function is performed. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Aurinia Pharmaceuticals Inc. is incorporated pursuant to the Business Corporations Act (Alberta). The Company&#146;s common shares are
currently listed and traded on the NASDAQ Global Market (NASDAQ) under the symbol AUPH and on the Toronto Stock Exchange (TSX) under the symbol AUP. The Company&#146;s primary business is the development of a therapeutic drug to treat autoimmune
diseases, in particular lupus nephritis (LN). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">These consolidated financial statements include the accounts of the Company and its wholly
owned subsidiaries, Aurinia Pharma Corp., Aurinia Pharmaceuticals, Inc. (Delaware incorporated) and Aurinia Pharma Limited (UK incorporated). </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Going concern </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">These consolidated financial statements have been prepared using
International Financial Reporting Standards (IFRS) applicable to a going concern, which assumes the Company will continue its operations for the foreseeable future and will be able to realize its assets and discharge its liabilities and commitments
in the ordinary course of business. The Company has no source of operating cash flows and operations to date have been funded primarily from the issue of share capital. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As at December&nbsp;31, 2016, the Company had net working capital of $33,488,000 compared to $12,917,000 as at December&nbsp;31, 2015. For the
year ended December&nbsp;31, 2016, the Company reported a loss of $23,295,000 (December 31, 2015 &#150; $18,607,000) and a cash outflow from operating activities of $18,713,000 (December&nbsp;31, 2015 &#150; $17,766,000). As at December&nbsp;31,
2016, the Company had an accumulated deficit of $281,048,000 (December 31, 2015 &#150; $257,753,000). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;16, 2015, the
Company filed a Short Form Base Shelf Prospectus (the Shelf Prospectus). The Shelf Prospectus and corresponding shelf registration statement allows the Company to offer up to $250,000,000 of common shares, warrants and subscription receipts or any
combination thereof during the <FONT STYLE="white-space:nowrap">25-month</FONT> period that the Shelf Prospectus is effective. The Shelf Prospectus is intended to give the Company the capability to access new capital from time to time. The Shelf
Prospectus has been utilized for a Bought Deal public offering and two ATM facilities, and as result, the remaining amount currently available under the Shelf Prospectus is $205,000,000. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The proceeds received in 2016 from the Bought Deal public offering, the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">at-the-market</FONT></FONT> (ATM) facilities, warrant exercises and private placement have provided the Company with liquidity in the short-term and sufficient funding to complete the
Phase 2b LN trial and the planned activities for the Phase 3 LN clinical trial into the fourth quarter of 2017. In order to complete the remainder of this trial and be able to undertake further commercialization of voclosporin, the Company will need
to raise additional funding within the next 12 months from sources such as debt financing, <FONT STYLE="white-space:nowrap">out-licensing</FONT> of specific territories and /or additional equity offerings. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(1) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2016
and December 31, 2015 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The outcome of such offerings is dependent on a number of factors outside of the
Company&#146;s control. The nature of the biotechnology sector and current financial equity market conditions make the success of any future financing ventures uncertain. There is no assurance the ATM financing or any new financings will be
successful. This uncertainty casts significant doubt upon the Company&#146;s ability to continue as a going concern and, accordingly, the appropriateness of the use of accounting principles applicable to a going concern. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The success of the Company and recoverability of amounts expended on research and development to date, including capitalized intangible assets,
are dependent on the ability of the Company to raise additional cash, then to complete development activities, receive regulatory approval and to be able to commercialize voclosporin in the key markets and indications, whereby the Company can
achieve future profitable operations. Depending on the results of the research and development programs and availability of financial resources, the Company may accelerate, terminate, cut back on certain areas of research and development, commence
new areas of research and development or curtail certain or all of the Company&#146;s operations. There is no assurance these initiatives will be successful. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">These consolidated financial statements do not reflect the adjustments to the carrying values of assets and liabilities and the reported
revenues and expenses and statement of financial position classifications that would be necessary if the Company were unable to realize its assets and settle its liabilities as a going concern in the normal course of operations. Such adjustments
could be material. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Basis of preparation </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Statement of compliance </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of the Company have been prepared in accordance with IFRS as issued by the International Accounting
Standards Board (IASB). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements were authorized for issue by the Board of Directors on March&nbsp;6, 2017.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Basis of measurement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements have been prepared on a going concern and historical cost basis, other than certain financial instruments
recognized at fair value. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Functional and presentation currency </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">These consolidated financial statements are presented in United States (US) dollars, which is the Company&#146;s functional currency. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(2) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2016
and December 31, 2015 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Summary of significant accounting policies and changes in accounting policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Consolidation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">These
consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. Subsidiaries are all entities over which the Company has the power to govern the financial and operating policies. The Company has a 100% voting
interest in all of its subsidiaries. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Intercompany transactions, balances and unrealized gains on transactions between companies are
eliminated. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Translation of foreign currencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The monetary assets and liabilities of operations denominated in foreign currencies are translated into US dollars at rates of exchange in
effect at the end of the period. Revenues and expenses related to monetary assets and liabilities are translated at average rates of exchange during the period. Exchange gains and losses arising on translation are included in the consolidated
statements of operations and comprehensive loss. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Revenue recognition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Payments received under collaboration agreements may include upfront payments, milestone payments, contract services, royalties and licence
fees. Revenues for each unit of accounting are recorded as described below: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Licensing and research and development revenues </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The Company has agreements in specific regions
with strategic partners. Licensing agreements usually include <FONT STYLE="white-space:nowrap">one-time</FONT> payments (upfront payments), payments for research and development services in the form of cost reimbursements, milestone payments and
royalty receipts. Revenues associated with those multiple-element arrangements are allocated to the various elements based on their relative fair value. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Agreements containing multiple elements are divided into separate units of accounting if certain criteria are met, including whether the
delivered element has stand-alone value to the customer and whether there is objective and reliable evidence of the fair value of the undelivered obligation(s). The consideration received is allocated among the separate units based on each
unit&#146;s fair value, and the applicable revenue recognition criteria are applied to each of the separate units. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Licence fees
representing <FONT STYLE="white-space:nowrap">non-refundable</FONT> payments received at the time of signature of licence agreements are recognized as revenue upon signature of the licence agreements when the Company has no significant future
performance obligations and collectability of the fees is assured. Upfront payments received at the beginning of licensing agreements are deferred and recognized as revenue on a systematic basis over the period during which the related services are
rendered and all obligations are performed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(3) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2016
and December 31, 2015 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Milestone payments </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Milestone payments, which are generally based on developmental or
regulatory events, are recognized as revenue when the milestones are achieved, collectability is assured, and when the Company has no significant future performance obligations in connection with the milestones. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Contract services </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Revenues from contract services are recognized as services are rendered, the
price is fixed or determinable and collection is reasonably assured. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Royalty payments </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Royalty income is recognized on the accrual basis in accordance with the
substance of the relevant agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Cash and cash equivalents </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents consist of cash on hand, deposits held with banks and other short-term highly liquid investments with original
maturities of three months or less. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Property and equipment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Property and equipment are stated at cost less accumulated amortization and accumulated impairment losses. Cost includes expenditures that are
directly attributable to the acquisition of the asset. The carrying amount of a replaced asset is derecognized when replaced. Repair and maintenance costs are charged to the consolidated statements of operations and comprehensive loss during the
period in which they are incurred. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The major categories of property and equipment are amortized on a straight-line basis as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">term&nbsp;of&nbsp;the&nbsp;lease</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Scientific and office equipment and furniture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Acquired intellectual property and other intangible assets </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">External patent costs specifically associated with the preparation, filing and obtaining of patents are capitalized and amortized straight-line
over the shorter of the estimated useful life and the patent life, commencing in the year of the grant of the patent. Other intellectual property expenditures are recorded as research and development expenses on the consolidated statements of
operations and comprehensive loss as incurred. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Separately acquired intellectual property is shown at historical cost. The initial
recognition of a reacquired right is recognized as an intangible asset measured on the basis of the remaining contractual term of the related contract. If the terms of the contract giving rise to a reacquired right are favourable or unfavourable
relative to the terms of current market transactions for the same or similar items, the difference is recognized as a gain or loss in the consolidated statements of operations and comprehensive loss. Purchased intellectual property and reacquired
rights are capitalized and amortized on a straight-line basis in the consolidated statements of operations and comprehensive loss over periods ranging from 10 to 20 years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(4) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2016
and December 31, 2015 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Impairment of <FONT STYLE="white-space:nowrap">non-financial</FONT> assets </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Property and equipment and acquired intellectual property and other intangible assets with a finite useful life are tested for impairment when
events or changes in circumstances indicate the carrying amount may not be recoverable. An impairment loss is recognized for the amount by which the asset&#146;s carrying amount exceeds its recoverable amount. The Company evaluates impairment losses
for potential reversals when events or circumstances warrant such consideration. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Share capital </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Common shares are classified as equity. Transaction costs directly attributable to the issue of common shares are recognized as a deduction
from equity, net of any tax effects. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Proceeds from the issue of common share purchase warrants (warrants) treated as equity are recorded
as a separate component of equity. Costs incurred on the issue of warrants are netted against proceeds. Warrants issued with common shares are measured at fair value at the date of issue using the Black-Scholes pricing model, which incorporates
certain input assumptions including the warrant price, risk-free interest rate, expected warrant life and expected share price volatility. The fair value is included as a component of equity and is transferred from warrants to common shares on
exercise. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Provisions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">A provision is recognized when the Company has a present legal or constructive obligation that can be estimated reliably, and it is probable an
outflow of economic benefits will be required to settle the obligation. Provisions are measured at the present value of the expenditures expected to be required to settle the obligation using a <FONT STYLE="white-space:nowrap">pre-tax</FONT> rate
that reflects current market assessments of the time value of money and the risks specific to the obligation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Research and development
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Research costs are expensed in the year incurred. These costs include salaries and benefits for research and development personnel,
costs associated with clinical trials managed by contract research organizations, and other costs associated with research, development and regulatory activities. The Company uses external service providers to conduct clinical trials, to manufacture
supplies of product candidates and to provide various other research and development related products and services. Development costs are expensed in the year incurred unless they meet the criteria for capitalization, which include technical
feasibility, the intention to use or sell, the ability to use or sell, probable future economic benefits and the ability to develop the intangible asset. No development costs have been capitalized to date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(5) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2016
and December 31, 2015 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Stock-based compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company records stock-based compensation related to employee stock options granted using the estimated fair value of the options at the
date of grant. The estimated fair value is expensed as employee benefits over the period in which employees unconditionally become entitled to the award. The amount recognized as an expense is adjusted to reflect the number of awards for which the
related service conditions are expected to be met, such that the amount ultimately recognized as an expense is based on the number of awards that do meet the related services and <FONT STYLE="white-space:nowrap">non-market</FONT> performance
conditions at the vesting date. The corresponding charge is to contributed surplus. Any consideration paid on the exercise of stock options is credited to share capital. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Leases </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Operating lease
payments are recognized in net income (loss) on a straight-line basis over the term of the lease. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Income tax </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Income tax comprises current and deferred tax. Income tax is recognized in the consolidated statements of operations and comprehensive loss
except to the extent that it relates to items recognized directly in shareholders&#146; equity (deficit), in which case the income tax is also recognized directly in shareholders&#146; equity (deficit). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Current tax is the expected tax payable on the taxable income for the period, using tax rates enacted at the end of the reporting period, and
any adjustments to tax payable in respect of previous years. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In general, deferred tax is recognized in respect of temporary differences
arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. Deferred income tax is determined on a <FONT STYLE="white-space:nowrap">non-discounted</FONT> basis using the tax rates and
laws that have been enacted or substantively enacted at the consolidated statements of financial position dates and are expected to apply when the deferred tax asset or liability is settled. Deferred tax assets are recognized to the extent that it
is probable the assets can be recovered. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Deferred income tax assets and liabilities are presented as
<FONT STYLE="white-space:nowrap">non-current.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Earnings (loss) per share </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Basic earnings (loss) per share (EPS) is calculated by dividing the net income (loss) for the period attributable to equity owners of the
Company by the weighted average number of common shares outstanding during the period. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Diluted EPS is calculated by adjusting the weighted
average number of common shares outstanding for dilutive instruments. The number of shares included with respect to options, warrants and similar instruments is computed using the treasury stock method. The Company&#146;s potentially dilutive common
shares comprise stock options and warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(6) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2016
and December 31, 2015 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Financial instruments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Financial assets and liabilities are recognized when the Company becomes a party to the contractual provisions of the instrument. Financial
assets are derecognized when the rights to receive cash flows from the assets have expired or have been transferred and the Company has transferred substantially all risks and rewards of ownership. Financial liabilities are derecognized when the
obligation specified in the contract is discharged, cancelled or expires. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">A derivative is a financial instrument whose value changes in
response to a specified variable, requires little or no net investment and is settled at a future date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">At initial recognition, the
Company classifies its financial instruments in the following categories: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i)</TD>
<TD ALIGN="left" VALIGN="top">Financial assets and liabilities at fair value through profit or loss: a financial asset or liability is classified in this category if acquired principally for the purpose of selling or repurchasing in the short-term.
</TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Derivatives are also included in this category unless they are designated as hedges. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Financial instruments in this category are recognized initially and subsequently at fair value. Gains and losses arising from changes in fair
value are presented in the consolidated statements of operations and comprehensive loss within other expense (income) in the period in which they arise. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">ii)</TD>
<TD ALIGN="left" VALIGN="top">Loans and receivables: Loans and receivables are <FONT STYLE="white-space:nowrap">non-derivative</FONT> financial assets with fixed or determinable payments that are not quoted in an active market. The Company&#146;s
loans and receivables comprise accounts receivable, cash and cash equivalents and short-term investment and are included in current assets due to their short-term nature. Loans and receivables are initially recognized at the amount expected to be
received, less, when material, a discount to reduce the loans and receivables to fair value. Subsequently, loans and receivables are measured at amortized cost using the effective interest rate method less a provision for impairment.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">iii)</TD>
<TD ALIGN="left" VALIGN="top">Available for sale financial assets: Available for sale assets are <FONT STYLE="white-space:nowrap">non-derivative</FONT> financial assets that are designated as available for sale and are not categorized into any of
the other categories described above. They are initially recognized at fair value including direct and incremental transaction costs. They are subsequently recognized at fair value. Gains and losses arising from changes in fair value are included as
a separate component of equity until sale, when the cumulative gain or loss is transferred to the consolidated statements of operations and comprehensive loss. Interest is determined using the effective interest method, and impairment losses and
translation differences on monetary items are recognized in the consolidated statements of operations and comprehensive loss. The Company does not have any available for sale assets. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">iv)</TD>
<TD ALIGN="left" VALIGN="top">Financial liabilities at amortized cost: Financial liabilities at amortized cost are composed of accounts payable and accrued liabilities. Trade payables and accrued liabilities are initially recognized at the amount
required to be paid, less, when material, a discount to reduce payables to fair value. Subsequently, accounts payables are measured at amortized cost using the effective interest method. These are classified as current liabilities if payment is due
within 12 months. Otherwise, they are presented as <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">v)</TD>
<TD ALIGN="left" VALIGN="top">Financial liabilities at fair value: Contingent consideration provided to ILJIN Life Science Co., Ltd. (ILJIN) (see note 10) and derivative warrant liabilities (see note 11) are financial liabilities recorded at fair
value with subsequent changes in fair value recorded in the consolidated statements of operations and comprehensive loss. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(7) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2016
and December 31, 2015 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Impairment of financial assets </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Financial assets carried at amortized cost </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">At each statement of financial position date, the
Company assesses whether there is objective evidence a financial asset or group of financial assets is impaired. A financial asset or group of financial assets is impaired and impairment losses are incurred if, and only if, there is objective
evidence of impairment as a result of one or more events that occurred after the initial recognition of the asset (a loss event), and that loss event (or events) has an impact on the estimated future cash flows of the financial asset or group of
financial assets that can be reliably estimated. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The amount of the loss is measured as the difference between the asset&#146;s carrying
amount and the present value of estimated future cash flows (excluding future credit losses) discounted at the financial asset&#146;s original effective interest rate. The asset&#146;s carrying amount is reduced and the amount of the loss is
recognized in the consolidated statements of operations and comprehensive loss. If a loan has a variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate determined under the contract. For
practical reasons, the Company may measure impairment on the basis of an instrument&#146;s fair value using an observable market price. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>New standards, amendments and interpretations not yet adopted </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">A number of new standards and amendments to standards and interpretations are effective for annual periods beginning on or after
January&nbsp;1, 2017 and have not been applied in preparing these consolidated financial statements. None of these new standards or amendments is expected to have a significant effect on the consolidated financial statements of the Company, except
the following set out below: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>International Accounting Standards (IAS) 7, Statement of cash flows </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Effective for years beginning on or after January&nbsp;1, 2017, IAS 7, <I>Statement of cash flows,</I> was amended to require disclosures about
changes in liabilities arising from financing activities, including both changes arising from cash flows and <FONT STYLE="white-space:nowrap">non-cash</FONT> changes. Management is assessing the potential impact that the adoption of IAS 7 will have
on the Company&#146;s consolidated financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>IFRS 9 Financial instruments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In July 2014, IASB revised IFRS 9, <I>Financial Instruments</I>. IFRS 9 is a three-part standard to replace IAS 39, <I>Financial Instruments:
Recognition and Measurement</I>, addressing new requirements for: i) classification and measurement, ii) impairment, iii) hedge accounting. The standard is effective for annual periods beginning on or after January&nbsp;1, 2018. Management is
assessing the potential impact that the adoption of IFRS 9 will have on the Company&#146;s consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(8) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2016
and December 31, 2015 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>IFRS 15, Revenue from contracts with customers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">IFRS 15, Revenue from Contracts with Customers, deals with revenue recognition and establishes principles for reporting useful information to
users of financial statements about the nature, amount, timing and uncertainty of revenue and cash flows arising from an entity&#146;s contracts with customers. Revenue is recognized when a customer obtains control of goods or services and thus has
the ability to direct the use and obtain the benefits from the goods or services. The standard replaces IAS 18, Revenue, and IAS 11, Construction Contracts, and related interpretations. The standard is effective for annual periods beginning on or
after January&nbsp;1, 2018 and earlier application is permitted. Management is assessing the potential impact that the adoption of IFRS 15 will have on the Company&#146;s consolidated financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>IFRS 16, Leases </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In January 2016, IASB issued IFRS 16, <I>Leases</I>, which will replace IAS 17, <I>Leases</I>. Under IFRS 16, a contract is, or contains, a
lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Under IAS 17, lessees were required to make a distinction between a finance lease and an operating lease. IFRS 16
now requires lessees to recognize a lease liability reflecting future lease payments and a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset for virtually all lease contracts. There is optional
exemption for certain short-term leases and leases of <FONT STYLE="white-space:nowrap">low-value</FONT> assets; however, this exemption can only be applied by lessees. The standard is effective for annual periods beginning on or after
January&nbsp;1, 2019, with earlier adoption if IFRS 15 is also applied. Management is assessing the potential impact that the adoption of IFRS 16 will have on the Company&#146;s consolidated financial statements. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">There are no other IFRS or International Financial Reporting Interpretations Committee interpretations that are not yet effective that would be
expected to have a material impact on the Company. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Critical accounting estimates and judgments </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The preparation of consolidated financial
statements in accordance with IFRS often requires management to make estimates about, and apply assumptions or subjective judgment to, future events and other matters that affect the reported amounts of the Company&#146;s assets, liabilities,
revenues, expenses and related disclosures. Assumptions, estimates and judgments are based on historical experience, expectations, current trends and other factors that management believes to be relevant at the time at which the Company&#146;s
consolidated financial statements are prepared. Management reviews, on a regular basis, the Company&#146;s accounting policies, assumptions, estimates and judgments in order to ensure the consolidated financial statements are presented fairly and in
accordance with IFRS. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Critical accounting estimates and judgments are those that have a significant risk of causing material adjustment
and are often applied to matters or outcomes that are inherently uncertain and subject to change. As such, management cautions that future events often vary from forecasts and expectations and that estimates routinely require adjustment. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Management considers the following areas to be those where critical accounting policies affect the significant judgments and estimates used in
the preparation of the Company&#146;s consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(9) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2016
and December 31, 2015 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Critical estimates in applying the Company&#146;s accounting policies </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Contingent consideration </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Contingent consideration is a financial liability recorded at fair
value (note 10). The amount of contingent consideration to be paid is based on the occurrence of future events, such as the achievement of certain development, regulatory and sales milestones. Accordingly, the estimate of fair value contains
uncertainties as it involves judgment about the likelihood and timing of achieving these milestones as well as the discount rate used. Changes in fair value of the contingent consideration obligation result from changes to the assumptions used to
estimate the probability of success for each milestone, the anticipated timing of achieving the milestones and the discount period and rate to be applied. A change in any of these assumptions could produce a different fair value, which could have a
material impact on the results from operations. The impact of changes in key assumptions is described in note 10. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Warrants issued pursuant
to equity offerings that are potentially exercisable in cash or on a cashless basis resulting in a variable number of shares being issued are considered derivative liabilities and therefore measured at fair value. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The Company uses the Black-Scholes pricing model to estimate fair value at each reporting date. The key assumptions used in the model are the
expected future volatility in the price of the Company&#146;s shares and the expected life of the warrants. The impact of changes in key assumptions is described in note 11. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Fair value of stock options </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Determining the fair value of stock options on the grant date,
including performance based options, requires judgment related to the choice of a pricing model, the estimation of stock price volatility and the expected term of the underlying instruments. Any changes in the estimates or inputs utilized to
determine fair value could result in a significant impact on the Company&#146;s reported operating results, liabilities or other components of shareholders&#146; equity (deficit). The key assumption used by management is the stock price volatility.
If the stock price volatility was higher by a factor of 10% on the option grant dates in 2016, this would have increased annual stock compensation expense by approximately $43,000. If the stock price volatility was lower by a factor of 10% on the
grant date, this would have decreased annual stock compensation expense by approximately $28,000. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Critical judgments in applying the
Company&#146;s accounting policies </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Revenue recognition </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Management&#146;s assessments related to the recognition of revenues for
arrangements containing multiple elements are based on estimates and assumptions. Judgment is necessary to identify separate units of accounting and to allocate related consideration to each separate unit of accounting. Where deferral of upfront
payments or licence fees is deemed appropriate, subsequent revenue recognition is often determined based on certain assumptions and estimates, the Company&#146;s continuing involvement in the arrangement, the benefits expected to be derived by the
customer and expected patent lives. To the extent that any of the key assumptions or estimates change, future operating results could be affected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(10) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2016
and December 31, 2015 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Impairment of intangible assets </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The Company follows the guidance of IAS 36 to determine when
impairment indicators exist for its intangible assets. When impairment indicators exist, the Company is required to make a formal estimate of the recoverable amount of its intangible assets. This determination requires significant judgment. In
making this judgment, management evaluates external and internal factors, such as significant adverse changes in the technological, market, economic or legal environment in which the Company operates as well as the results of its ongoing development
programs. Management also considers the carrying amount of the Company&#146;s net assets in relation to its market capitalization as a key indicator. In making a judgment as to whether impairment indicators exist as at December&nbsp;31, 2016,
management concluded there were none. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Derivative warrant liabilities </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Management has determined that derivative warrant liabilities
are classified as long term as these derivative warrant liabilities will ultimately be settled for common shares and therefore the classification is not relevant. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Short-term investment </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">There were no short-term investments outstanding as at
December&nbsp;31, 2016. The short-term investment as at December&nbsp;31, 2015 was recorded initially at fair value and subsequently at amortized cost using the effective interest method, The investment was a
<FONT STYLE="white-space:nowrap">six-month</FONT> HSBC Bank US denominated discount note due on February&nbsp;10, 2016, with an amortized cost of $9,997,000 and an initial cost of $9,984,000 with an effective interest rate of 0.311%. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Property and equipment </B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Leasehold</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>improvements</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Scientific</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>and office</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>equipment</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>and</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>furniture</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Computer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>equipment</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>and</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>software</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Total</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Year ended December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As at January&nbsp;1, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net book value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As at December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(36</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(120</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(185</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net book value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(11) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2016
and December 31, 2015 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Leasehold</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>improvements</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Scientific</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>and office</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>equipment</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>and</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>furniture</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Computer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>equipment</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>and</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>software</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Total</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Year ended December&nbsp;31, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As at January&nbsp;1, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net book value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As at December&nbsp;31, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,711</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,161</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(137</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,009</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net book value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2016, the Company disposed of fully depreciated equipment for proceeds of
$19,000, resulting in a gain of $19,000 (2015 &#150; $nil resulting in a gain of $nil). </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Acquired intellectual property and other intangible assets </B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Patents</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Acquired</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>intellectual</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>property&nbsp;and</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>reacquired</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>rights</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Total</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Year ended December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Opening net book value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,084</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization for the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(172</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,285</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,457</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Closing net book value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As at December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,270</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,273</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,447</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,720</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net book value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Year ended December&nbsp;31, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Opening net book value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization for the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(251</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,285</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,536</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Closing net book value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,084</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(12) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2016
and December 31, 2015 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Patents</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Acquired</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>intellectual</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>property&nbsp;and</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>reacquired</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>rights</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Total</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As at December&nbsp;31, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,190</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,162</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,352</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net book value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,084</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2016, the Company wrote off $88,000 of fully amortized patent costs
related to specific <FONT STYLE="white-space:nowrap">non-core</FONT> abandoned voclosporin patents/ patent applications (2015 &#150; $136,000). </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Accounts payable and accrued liabilities </B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2016</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2015</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employee accruals</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Revenue and deferred revenue </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Licensing and research and development fee revenues
represent the amortization of deferred revenue from fee payments received by the Company. The deferred revenue is recorded as revenue as the Company incurs the costs related to meeting its obligations under the terms of the applicable agreements.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Development, distribution and licence agreement with 3SBio, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">On August&nbsp;23, 2010, the Company and 3SBio, Inc. (3SBio) completed a Development, Distribution and Licence Agreement for voclosporin for
the territories of China, Hong Kong and Taiwan. The transaction with 3SBio included a <FONT STYLE="white-space:nowrap">non-refundable</FONT> licensing fee of $1,500,000, which was originally recorded as deferred revenue. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Under the agreement, the primary substantive obligations of the Company are to grant the licence and transfer intellectual knowledge to 3SBio.
Management believes it had fulfilled these obligations by December&nbsp;31, 2010. However, under the agreement, the Company is also required to maintain the patent portfolio in China, Taiwan and Hong Kong, and to provide further support and
cooperation to 3SBio over the life of the agreement, which coincides with the life of the patents. Any additional assistance that may be provided to 3SBio will be performed on a full cost recovery basis. For accounting purposes, when services are to
be performed by an indeterminate number of acts over a specific period of time, revenue is recognized on a straight-line basis over this future period. As a result, the balance in deferred revenue is amortized into licensing revenue on a
straight-line basis to 2022. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(13) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2016
and December 31, 2015 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Plan of arrangement with Paladin Labs Inc. (Paladin) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Research and development revenues represent the amortization of the deferred monthly research and development fee payments received by the
Company from Paladin for the period from July&nbsp;1, 2009 to June&nbsp;30, 2010, pursuant to the terms of the Research and Development Agreement. Under the agreement, the primary substantive obligations of the Company had been achieved by the
Company by December&nbsp;31, 2010. However, under the agreement, the Company is also required to maintain the patent portfolio in Canada, South Africa and Israel and to provide further support and cooperation to Paladin over the life of the
agreement. As a result, the balance in deferred revenue as at January&nbsp;1, 2011 was being amortized into research and development revenue on a straight-line basis over the remaining life of the agreement, which ended in June 2016. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Contingent consideration </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The outstanding fair value of contingent consideration payable
to ILJIN is the result of an Arrangement Agreement (the Agreement) completed on September&nbsp;20, 2013 between the Company, Aurinia Pharma Corp. and ILJIN. Pursuant to the Agreement, payments of up to $10,000,000 are to be paid dependent on the
achievement of <FONT STYLE="white-space:nowrap">pre-defined</FONT> clinical and marketing milestones. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If all milestones are met, the
timing of these payments is estimated to occur as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="91%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The fair value of this contingent consideration as at December&nbsp;31, 2016 was estimated to be $5,440,000
(December 31, 2015 - $3,810,000) and was determined by estimating the probability and timing of achieving the milestones and applying the income approach with a discount rate of 10% (2015 - 10%). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company achieved a positive <FONT STYLE="white-space:nowrap">24-week</FONT> primary endpoint result in the Phase 2b clinical LN trial
during the third quarter of 2016. As such while no milestone was attached to this positive primary endpoint result, it was an event that triggered an adjustment of the probability of success of the milestones such that the probability of success
factors were increased for the milestones. As a result of the adjustments to the probability factors, the probability adjusted payment ranges were increased to 50% to 95% as at December&nbsp;31, 2016 from 35% to 70% as at December&nbsp;31, 2015. The
current portion of the contingent consideration liability of $2,021,000 represents the first milestone and a portion of a second milestone that are expected to be achieved within the year. The change in probability factors for the milestones and the
passage of time resulted in a revaluation of contingent consideration expense of $1,630,000 (2015 - $337,000) </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">This is a Level&nbsp;3
recurring fair value measurement. If the probability for success were to increase by a factor of 10% for each milestone, this would increase the net present value (NPV) of the obligation by approximately
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(14) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2016
and December 31, 2015 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
$737,000 as at December&nbsp;31, 2016. If the probability for success were to decrease by a factor of 10% for each milestone, this would decrease the NPV of the obligation by approximately
$739,000 as at December&nbsp;31, 2016. If the discount rate were to increase to 12%, this would decrease the NPV of the obligation by approximately $261,000. If the discount rate were to decrease to 8%, this would increase the NPV of the obligation
by approximately $284,000. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Derivative warrant liabilities </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In accordance with IFRS, a contract to issue a variable
number of shares fails to meet the definition of equity and must instead be classified as a derivative liability and measured at fair value with changes in fair value recognized in the consolidated statements of operations and comprehensive loss at
each <FONT STYLE="white-space:nowrap">period-end.</FONT> The derivative liability will ultimately be converted into the Company&#146;s equity (common shares) when the warrants are exercised, or will be extinguished on the expiry of the outstanding
warrants, and will not result in the outlay of any cash by the Company. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>December&nbsp;28, 2016<BR>Warrants</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>February&nbsp;14, 2014<BR>Warrants</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>#&nbsp;of&nbsp;warrants</B><br><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">$</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>#&nbsp;of&nbsp;warrants</B><br><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">$</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>#&nbsp;of&nbsp;warrants<BR>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">$</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at January&nbsp;1, 2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of warrants pursuant to December&nbsp;28, 2016 financing</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion to equity (common shares) upon exercise of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(800</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,852</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(800</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,852</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss (gain) on revaluation of derivative warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,914</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,732</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at January&nbsp;1, 2015</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion to equity (common shares) upon exercise of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(182</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(635</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(182</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(635</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on revaluation of derivative warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,101</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,101</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2015</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Derivative warrant liability related to December&nbsp;28, 2016 Bought Deal public offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;28, 2016, the Company completed a $28,750,000 Bought Deal public offering (the Offering). Under the terms of the Offering, the
Company issued 12,778,000 units at a subscription price per Unit of $2.25, each Unit consisting of one common share and <FONT STYLE="white-space:nowrap">one-half</FONT> (0.50) of a common share purchase warrant (a Warrant), exercisable for a period
of five years from the date of issuance at an exercise price of $3.00. The holders of the Warrants issued pursuant to this offering may elect, if the Company does not have an effective registration statement registering or the prospectus contained
therein is not available for the issuance of the Warrant Shares to the holder, in lieu of exercising the Warrants for cash, a cashless exercise option to receive common shares equal to the fair value of the Warrants based on the number of Warrants
to be exercised </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(15) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2016
and December 31, 2015 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
multiplied by the weighted average market price less the exercise price with the difference divided by the weighted average market price. If a Warrant holder exercises this option, there will be
variability in the number of shares issued per Warrant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">At initial recognition on December&nbsp;28, 2016, the Company recorded a
derivative warrant liability of $7,223,000 based on the estimated fair value of the Warrants with allocated share issuance costs of $655,000 recognized as other expense. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As at December&nbsp;31, 2016, the Company revalued a derivative warrant liability of $7,405,000 which resulted in a loss on revaluation of a
derivative warrant liability of $182,000 for the period from December&nbsp;28, 2016 to December&nbsp;31, 2016. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company uses the
Black-Scholes pricing model to estimate fair value. The Company considers expected volatility of its common shares in estimating its future stock price volatility. The risk-free interest rate for the life of the Warrants was based on the yield
available on government benchmark bonds with an approximate equivalent remaining term at the time of issue. The life of warrant is based on the contractual term. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The following assumptions were used to estimate the fair value of the derivative warrant liability on December&nbsp;31, 2016 and
December&nbsp;28, 2016. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>December&nbsp;31,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2016</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>December&nbsp;28,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2016</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Annualized volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.92</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Life of warrants in years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Market price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value per Warrant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Derivative warrant liability related to February&nbsp;14, 2014 private placement offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;14, 2014, the Company completed a $52,000,000 private placement. Under the terms of the Offering, the Company issued
18,919,404 units at a subscription price per Unit of $2.7485, each Unit consisting of one common share and <FONT STYLE="white-space:nowrap">one-quarter</FONT> (0.25) of a common share purchase warrant (a Warrant), exercisable for a period of five
years from the date of issuance at an exercise price of $3.2204. The holders of the Warrants issued pursuant to the February&nbsp;14, 2014 private placement may elect, in lieu of exercising the Warrants for cash, a cashless exercise option to
receive common shares equal to the fair value of the Warrants based on the number of Warrants to be exercised multiplied by a <FONT STYLE="white-space:nowrap">five-day</FONT> weighted average market price less the exercise price with the difference
divided by the weighted average market price. If a Warrant holder exercises this option, there will be variability in the number of shares issued per Warrant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In 2016, two holders of these Warrants elected this option and the Company issued 256,860 common shares on the cashless exercise of 800,432
Warrants. These Warrants had an estimated fair value of $1,852,000 at the dates of exercise, determined using the Black-Scholes warrant pricing model. This amount was transferred from </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(16) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2016
and December 31, 2015 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
derivative warrant liability to common shares. In 2015, a holder of these Warrants elected this option and the Company issued 66,000 common shares on the cashless exercise of 182,000 Warrants
with an estimated fair value of $635,000. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As at December&nbsp;31, 2016, the Company revalued the remaining erivative warrant liability at
$1,733,000 (December 31, 2015 &#150; $5,499,000), which resulted in a gain on revaluation of a derivative warrant liability for the year ended December&nbsp;31, 2016 of $1,914,000 related to these outstanding derivative liability warrants (December
31, 2015 &#150; gain on revaluation of a derivative warrant liability of $5,101,000). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company considers expected volatility of its
common shares in estimating its future stock price volatility. The risk-free interest rate for the expected life of the Warrants was based on the yield available on government benchmark bonds with an approximate equivalent remaining term at the time
of the grant. The expected life is based on the contractual term. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company uses the Black-Scholes pricing model to estimate fair value.
The following assumptions were used to estimate the fair value of the derivative warrant liability on December&nbsp;31, 2016 and December&nbsp;31, 2015. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2016</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2015</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Annualized volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.21</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.19</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Life of warrants in years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Market price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value per Warrant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">These derivative warrant liabilities are Level&nbsp;3 recurring fair value measurements. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The key Level&nbsp;3 inputs used by management to determine the fair value are the market price and the expected volatility. If the market
price were to increase by a factor of 10%, this would increase the estimated NPV of the obligation by approximately $1,435,000 as at December&nbsp;31, 2016. If the market price were to decrease by a factor of 10%, this would decrease the estimated
NPV of the obligation by approximately $1,375,000. If the volatility were to increase by 10%, this would increase the estimated NPV of the obligation by approximately $967,000. If the volatility were to decrease by 10%, this would decrease estimated
NPV of the obligation by approximately $1,017,000 as at December&nbsp;31, 2016. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(17) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2016
and December 31, 2015 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Share capital </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>a)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Common shares </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Authorized </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Unlimited common shares without par value </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Issued </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">(in&nbsp;thousands)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as at January&nbsp;1, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">261,645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issued pursuant to Bought Deal public offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,778</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issued pursuant to ATM Facilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,821</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issued pursuant to June&nbsp;22, 2016 private placement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,871</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issued pursuant to exercise of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issued pursuant to exercise of derivative liability warrants (note&nbsp;11)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issued pursuant to exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as at December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">299,815</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as at January&nbsp;1, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">259,712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issued pursuant to exercise of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issued pursuant to exercise of derivative liability warrant (note&nbsp;11)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issued pursuant to exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as at December&nbsp;31, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">261,645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Bought Deal public offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;28, 2016, the Company completed a Bought Deal public offering for gross proceeds of $28,750,000 as described in note 11. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Share issue costs of $2,606,000 included a 7.0% cash commission of $2,012,000 paid to the placement agents and filing, legal and other
professional fees of $594,000 directly related to the Offering of which $655,000 was allocated to the derivative warrant liability and expensed in 2016 in other expense (income). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company intends to use the net proceeds from this offering for research and development activities including the LN Phase&nbsp;3 clinical
trial and for corporate and working capital purposes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(18) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2016
and December 31, 2015 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>ATM Facilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;22, 2016 the Company entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald&nbsp;&amp; Co. (Cantor
Fitzgerald) pursuant to which the Company may from time to time sell common shares, through ATM offerings with Cantor Fitzgerald acting as sales agent. Pursuant to Canadian securities rules, the Company was limited to raising $8,000,000 under this
specific ATM offering. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Pursuant to this agreement, the Company issued 3,306,000 common shares, receiving proceeds of $7,529,000 net of
share issue costs of $471,000. Share issue costs of $471,000 included a 3% commission of $240,000 paid to the agent and professional fees and filing fees of $231,000 directly related to the ATM. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company intends to use the net proceeds from the ATM to continue development of its lead drug candidate, voclosporin, as a therapy for LN,
and for general corporate purposes. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;9, 2016 the Company entered into a second Controlled Equity Offering Sales Agreement
with Cantor Fitzgerald pursuant to which the Company may from time to time sell common shares, through ATM offerings with Cantor Fitzgerald acting as sales agent. Pursuant to Canadian securities rules, the Company was limited to raising $8,000,000
under this specific ATM offering. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Pursuant to this agreement the Company issued 139,000 common shares as at December&nbsp;31, 2016,
receiving proceeds of $292,000 net of share issue costs of $104,000. Share issue costs of $104,000 included a 3% commission of $12,000 paid to the agent and professional fees and filing fees of $92,000 directly related to the ATM. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company intends to use the net proceeds from the ATM to continue development of its lead drug candidate, voclosporin, as a therapy for LN,
and for general corporate purposes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Private placement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;22, 2016, the<B> </B>Company completed a private placement for net proceeds of $6,640,000. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the private placement, the Company issued 3,000,000 units (the Units) at a price of $2.36 per Unit. Each Unit consisted of
one common share and 0.35 of a common share purchase warrant (a Warran), exercisable for a period of two years from the date of issuance at an exercise price of $2.77. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Share issue costs of $440,000 included a cash commission of $250,000 paid to the agent and legal and filing fees of $190,000 directly related
to the private placement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(19) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2016
and December 31, 2015 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>b)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Warrants </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Issued </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Warrants</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">(in&nbsp;thousands)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as at January&nbsp;1, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issued pursuant to June&nbsp;22, 2016 private placement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">769</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,001</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(947</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants expired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(160</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(148</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as at December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">971</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as at January&nbsp;1, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(348</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(335</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants expired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(172</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as at December&nbsp;31, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;22, 2016, pursuant to the private placement noted above, the Company issued 1,050,000 warrants to
purchase common shares at a price of $2.77 per common share. The warrants have a term of two years from the date of issuance. The fair value attributed to the warrants using the Black-Scholes option pricing model was $769,000, net of share issue
costs of $51,000. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The following assumptions were used to estimate the fair value of the warrants issued pursuant to the June&nbsp;22, 2016
private placement: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>June&nbsp;22,&nbsp;2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.75</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected life of warrants in years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Market price on date of issue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value per warrant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(20) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2016
and December 31, 2015 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">A summary of the outstanding warrants as at December&nbsp;31, 2016 is presented below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Expiry date</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Number<BR></B>(in&nbsp;thousands)<B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Weighted</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>average</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>exercise</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>price</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable in CA$</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June&nbsp;26, 2018 (CA$2.25 and CA$2.50)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;31, 2018 (CA$2.00)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable in US$</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June&nbsp;22, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">February&nbsp;14, 2019 (note 11)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;28, 2021 (note 11)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>c)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Stock options and compensation expense </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">A summary of the stock options outstanding as at
December&nbsp;31, 2016 and 2015 and changes during the years ended on those dates is presented below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Weighted</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>average</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>exercise</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>price in</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>CA$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Weighted</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>average</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>exercise</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>price in</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>CA$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding &#150; Beginning of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted pursuant to Stock Option Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted pursuant to Section 613(c) of TSX manual</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(55</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(70</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(195</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding &#150; End of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options exercisable &#150; End of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,857</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,063</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">On June&nbsp;8, 2016, the Shareholders of the Company approved the amendment to the Stock Option Plan to
increase the maximum number of Common Shares reserved for issuance under the Stock Option Plan from 10% to 12.5% of the outstanding Common Shares of the Company at the time of granting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(21) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2016
and December 31, 2015 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Therefore, the maximum number of Common Shares issuable under the Stock Option Plan is equal
to 12.5% of the issued and outstanding Common Shares at the time the Common Shares are reserved for issuance. As at December&nbsp;31, 2016, there were 52,808,000 Common Shares of the Company issued and outstanding, resulting in a maximum of
6,601,000 options available for issuance under the Stock Option Plan. An aggregate total of 3,852,000 options are presently outstanding in the Stock Option Plan, representing 7.3% of the issued and outstanding Common Shares of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">In addition, on May&nbsp;2, 2016, the Company granted 200,000 inducement stock options to a new employee pursuant to Section 613(c) of the TSX
Company Manual at a price of $2.92 (CA$3.66). These options vest in equal amounts over 36 months and are exercisable for a term of five years. These options are recorded outside of the Company&#146;s stock option plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The Stock Option Plan requires the exercise price of each option to be determined by the Board of Directors and not to be less than the closing
market price of the Company&#146;s stock on the day immediately prior to the date of grant. Any options which expire may be <FONT STYLE="white-space:nowrap">re-granted.</FONT> The Board of Directors approves the vesting criteria and periods at its
discretion. The options issued under the plan are accounted for as equity-settled share-based payments. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">A summary of the stock options
granted pursuant to the Stock Option Plan for the years ended December&nbsp;31, 2016 and 2015 is presented below: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Year ended
December&nbsp;31, 2016 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Grant date</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Grant&nbsp;price</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Grant&nbsp;price</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>CA$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March&nbsp;23, 2016<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March&nbsp;30, 2016<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March&nbsp;31, 2016<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June&nbsp;17, 2016<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">July&nbsp;12, 2016<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">July&nbsp;21, 2016<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;14, 2016<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Year ended December&nbsp;31, 2015 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Grant Date</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Grant&nbsp;price</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Grant&nbsp;Price</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>CA$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">January&nbsp;6, 2015<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">April&nbsp;7, 2015<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June&nbsp;2, 2015<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">August&nbsp;17, 2015<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;18, 2015<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(22) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2016
and December 31, 2015 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">These options vest in equal amounts over 12 months and are exercisable for a term of five years. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">These options vest in equal amounts over 36 months and are exercisable for a term of five years. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">These options vest in equal amounts over 12 months and are exercisable for a term of ten years. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Application of the fair value method resulted in charges to stock-based compensation expense of $1,383,000 for the year ended December&nbsp;31,
2016 (2015 &#150; $3,224,000) with corresponding credits to contributed surplus. For the year ended December&nbsp;31, 2016, stock compensation expense has been allocated to research and development expense in the amount of $330,000 (2015 &#150;
$862,000) and corporate, administration and business development expense in the amount of $1,053,000 (2015 &#150; $2,362,000). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The Company
used the Black-Scholes option pricing model to estimate the fair value of the options granted in 2016 and 2015. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The Company considers
historical volatility of its common shares in estimating its future stock price volatility. The risk-free interest rate for the expected life of the options was based on the yield available on government benchmark bonds with an approximate
equivalent remaining term at the time of the grant. The expected life is based upon the contractual term, taking into account expected employee exercise and expected post-vesting employment termination behavior. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The following weighted average assumptions were used to estimate the fair value of the options granted during the year ended December 31: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Annualized volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.60</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.92</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected life of options in years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.0&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.9&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated forfeiture rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Market price on date of grant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value per common share option</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(23) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2016
and December 31, 2015 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The following table summarizes information on stock options outstanding as at
December&nbsp;31, 2016: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="26%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="26%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="26%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Options outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Options</B><br><B>exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Range&nbsp;of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>exercise</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>prices</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>CA$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>outstanding</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Weighted</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>average</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>remaining</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>contractual</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>life&nbsp;(years)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>outstanding</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">(in&nbsp;thousands)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">(in&nbsp;thousands)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">3.20-3.66</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">3.91-4.00</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">4.25-4.45</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,857</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Nature of expenses </B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2016</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2015</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Study contracts, consulting and other outside services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Drug supply and distribution</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,983</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wages and employee benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patent annuity and legal fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Travel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,534</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2016</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2015</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate, administration and business development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wages, benefits and severance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,721</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional and consulting fees and services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,053</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trustee fees, filing fees and other public company costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Directors fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office, insurance, information technology costs and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">457</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Travel and promotion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rent, utilities and other facility costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(24) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2016
and December 31, 2015 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>14</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Other expense (income) </B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2016</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2015</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revaluation adjustment on contingent consideration (note 10)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share issue costs allocated to Derivative warrants (note 12)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign exchange gain and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(159</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on disposal of equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>15</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Income taxes </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As at December&nbsp;31, 2016, the Company has available Canadian <FONT
STYLE="white-space:nowrap">non-capital</FONT> losses in the amount of $73,002,000 (2015 &#150; $51,848,000) to reduce Canadian taxable income in future years. The Company has unclaimed investment tax credits of $1,158,000 (2015 &#150; $952,000)
available to reduce future Canadian income taxes otherwise payable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The losses and credits will expire as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Non-capital</FONT><BR>losses<BR>carried<BR>forward</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Federal<BR>investment<BR>tax credits</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2029</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,294</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2030</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2031</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2032</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2033</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2034</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2035</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,747</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2036</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,062</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(25) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2016
and December 31, 2015 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As at December&nbsp;31, 2016 and December&nbsp;31, 2015, temporary differences for which no
deferred tax asset was recognized were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2016</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2015</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets (liabilities)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss carry-forwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share issue costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue and contingent consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">606</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">564</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Potential tax assets not recognized</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,324</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,504</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Given the Company&#146;s past losses, management does not believe that it is more probable than not that the
Company can realize its deferred tax assets and therefore it has not recognized any amount in the consolidated statements of financial position. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The difference between the expected income tax recovery based on a 26.5% (2015 &#150; 26.0%) Canadian statutory tax rate and the actual income
tax recovery is summarized as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2016</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2015</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected recovery at the statutory rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,184</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,931</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-taxable</FONT> revaluation of warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(459</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(291</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-deductible</FONT> expenses including stock
compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrecognized deductible temporary differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total income tax recovery</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>16</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Net loss per common share </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per common share is computed by
dividing net loss by the weighted average number of common shares outstanding for the year. In determining diluted net loss per common share, the weighted average number of common shares outstanding is adjusted for stock options and warrants
eligible for exercise where the average market price of common shares for the year ended December&nbsp;31, 2016 exceeds the exercise price. Common shares that could potentially dilute basic net loss per common share in the future that could be
issued from the exercise of stock options and warrants were not included in the computation of the diluted loss per common share for the year ended December&nbsp;31, 2016 because to do so would be anti-dilutive. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(26) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2016
and December 31, 2015 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The numerator and denominator used in the calculation of historical basic and diluted net
loss amounts per common share are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2016</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2015</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss for the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,295</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,607</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average common shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per common share (expressed in $ per share)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.66</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.58</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The outstanding number and type of securities that would potentially dilute basic loss per common share in the
future and which were not included in the computation of diluted loss per share, because to do so would have reduced the loss per common share (anti-dilutive) for the years presented, are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants (derivative liabilities)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants (equity)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">759</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>17</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Segment disclosures </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s operations comprise a single reporting segment
engaged in the research, development and commercialization of therapeutic drugs. As the operations comprise a single reporting segment, amounts disclosed in the consolidated financial statements represent those of the single reporting unit. In
addition, all of the Company&#146;s long-lived assets are located in Canada. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The following geographic information reflects revenue based
on customer location. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2016</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2015</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Canada</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">China</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(27) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2016
and December 31, 2015 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>18</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Supplementary cash flow information </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Net change in other operating assets and
liabilities </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2016</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2015</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and deposits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(949</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable and accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest received</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>19</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Related parties </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Compensation of key management </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Key management includes directors and officers of the Company. Compensation awarded to key management was composed of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2016</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2015</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Salaries, short-term employee benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,681</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bonuses accrued or paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Severance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">572</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,752</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Other </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Stephen P. Robertson, a partner at Borden Ladner Gervais (BLG) acts as the Company&#146;s corporate secretary. The Company incurred legal fees
in the normal course of business to BLG of $308,000 for the year ended December&nbsp;31, 2016 ($101,000 for the year ended December&nbsp;31, 2015). Mr.&nbsp;Robertson receives no additional compensation for acting as the corporate secretary. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>20</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Commitments and contingencies </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company entered into an agreement, effective
June&nbsp;1, 2014, to sublease 4,418 square feet of office and storage space at its head office location in Victoria, British Columbia. The sublease is for a term of five years, with the Company having the right to terminate after the third year at
no cost. The estimated base rent plus operating costs on a monthly basis for the period from January&nbsp;1, 2016 to May&nbsp;31, 2017 is approximately $9,000 per month. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(28) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2016
and December 31, 2015 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company entered into an agreement on November&nbsp;14, 2014 to lease 1,247 square feet of
office space for a term of two years commencing on January&nbsp;1, 2015 at a cost of approximately $1,300 per month for the Edmonton, Alberta registered office where the Company&#146;s finance group is located. The lease was extended for a term of
one year to December&nbsp;31, 2016 on the same terms as the original lease. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company has entered into contractual obligations for
services and materials required for its clinical trial program, drug manufacturing and other operational activities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Future minimum lease
payments for its premises and the minimum amount to exit the Company&#146;s contractual commitments are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Operating</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>lease</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Purchase</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>obligations</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Contingencies </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">i)</TD>
<TD ALIGN="left" VALIGN="top">The Company may, from time to time, be subject to claims and legal proceedings brought against it in the normal course of business. Such matters are subject to many uncertainties. Management believes the ultimate
resolution of such contingencies will not have a material adverse effect on the consolidated financial position of the Company. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">ii)</TD>
<TD ALIGN="left" VALIGN="top">The Company entered into indemnification agreements with its officers and directors. The maximum potential amount of future payments required under these indemnification agreements is unlimited. However, the Company
does maintain liability insurance to limit the exposure of the Company. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">iii)</TD>
<TD ALIGN="left" VALIGN="top">The Company has entered into licence and research and development agreements with third parties that include indemnification and obligation provisions that are customary in the industry. These guarantees generally
require the Company to compensate the other party for certain damages and costs incurred as a result of third party claims or damages arising from these transactions. These provisions may survive termination of the underlying agreement. The nature
of the obligations prevents the Company from making a reasonable estimate of the maximum potential amount it could be required to pay. Historically, the Company has not made any payments under such agreements and no amount has been accrued in the
accompanying consolidated financial statements. </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>21</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Capital management </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s objective in managing capital is to ensure a
sufficient liquidity position to safeguard the Company&#146;s ability to continue as a going concern in order to provide returns for shareholders and benefits for other stakeholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(29) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2016
and December 31, 2015 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company defines capital as net equity, comprised of issued common shares, warrants,
contributed surplus and deficit. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s objective with respect to its capital management is to ensure it has sufficient cash
resources to maintain its ongoing operations and finance its research and development activities, corporate and administration expenses, working capital and overall capital expenditures. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Since inception, the Company has primarily financed its liquidity needs through public offerings and private placements of common shares. The
Company has also met its liquidity needs through <FONT STYLE="white-space:nowrap">non-dilutive</FONT> sources such as debt financings, licensing fees from its partners and research and development fees. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">There have been no changes to the Company&#146;s objectives and what it manages as capital since the prior fiscal year. The Company is not
subject to externally imposed capital requirements. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>22</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial instruments and fair values </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As explained in note 3, financial assets and
liabilities have been classified into categories that determine their basis of measurement and for items measured at fair value, whether changes in fair value are recognized in the consolidated statements of operations and comprehensive loss. Those
categories are fair value through profit or loss; loans and receivables; and, for most liabilities, amortized cost. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In establishing fair
value, the Company used a fair value hierarchy based on levels defined below: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Level&nbsp;1 &#150; defined as observable inputs such as quoted prices in active markets. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Level&nbsp;2 &#150; defined as inputs other than quoted prices in active markets that are either directly or indirectly observable. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Level&nbsp;3 &#150; defined as inputs that are based on little or no observable market data, therefore requiring entities to develop their own assumptions. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company has determined the carrying values of its short-term financial assets and financial liabilities, including cash and cash
equivalents, accounts receivable and accounts payable and accrued liabilities approximate their fair value because of the relatively short period to maturity of the instruments. Information on the fair value of contingent consideration is included
in note 10, and information on the fair value of derivative warrant liability is included in note 11. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Financial risk factors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s activities can expose it to a variety of financial risks: market risk (including currency risk, interest rate risk and other
price risk), credit risk and liquidity risk. Risk management is carried out by management under policies approved by the Board of Directors. Management identifies and evaluates the financial risks. The Company&#146;s overall risk management program
seeks to minimize adverse effects on the Company&#146;s financial performance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(30) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2016
and December 31, 2015 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Liquidity risk </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Liquidity risk is the risk the Company will not be able to meet its financial
obligations as they fall due. The Company manages its liquidity risk through the management of its capital structure and financial leverage, as discussed in note 21. It also manages liquidity risk by continuously monitoring actual and projected cash
flows. The Board of Directors reviews and approves the Company&#146;s budget, as well as any material transactions out of the ordinary course of business. The Company invests its cash equivalents in bankers&#146; acceptances and/or guaranteed
investment certificates with 30 to <FONT STYLE="white-space:nowrap">90-day</FONT> maturities to ensure the Company&#146;s liquidity needs are met. The short-term investment consisted of a discount bank note with a term of 180 days. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The Company&#146;s activities have been financed through a combination of the cash flows from licensing and development fees and the issuance
of equity and/or debt. As described in note 2, the Company is dependent on raising additional financing to sustain operations and complete the LN development program, including the Phase 3 clinical trial. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">All of the Company&#146;s financial liabilities are due within one year except for the contingent consideration, as described in note 10, and
the derivative warrant liability, as described in note 11. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Interest rate risk </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Interest rate risk is the risk the fair value or future cash flows of a
financial instrument will fluctuate because of changes in market interest rates. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Financial assets and financial liabilities with variable
interest rates expose the Company to cash flow interest rate risk. The Company&#146;s cash and cash equivalents are comprised of highly liquid investments that earn interest at market rates. Accounts receivable and accounts payable and accrued
liabilities bear no interest. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The Company manages its interest rate risk by maximizing the interest income earned on excess funds while
maintaining the liquidity necessary to conduct operations on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> basis. The Company&#146;s policy limits the investing of excess funds to liquid guaranteed
investment certificates and bankers&#146; acceptances. The Company&#146;s exposure to interest rate risk as at December&nbsp;31, 2016 is considered minimal. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Foreign currency risk </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The Company is exposed to financial risk related to the fluctuation of
foreign currency exchange rates. Foreign currency risk is the risk variations in exchange rates between the US dollars and foreign currencies, primarily with the Canadian dollar, will affect the Company&#146;s operating and financial results. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(31) </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aurinia Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 31, 2016
and December 31, 2015 </B></P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(expressed in US dollars, tabular amounts in thousands) </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The following table presents the Company&#146;s exposure to the Canadian dollar: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2016</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2015</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable and accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,184</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(803</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net exposure</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,073</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(648</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Reporting</B><br><B>date rate</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2016</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2015</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CA$ &#150; US$</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.723</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Based on the Company&#146;s foreign currency exposures noted above, varying the foreign exchange rates to
reflect a ten percent strengthening of the CA$ would have increased the net loss by $107,000 assuming all other variables remained constant. An assumed 10% weakening of the CA$ would have had an equal but opposite effect to the amounts shown above,
on the basis all other variables remain constant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Credit risk </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash and cash
equivalents. The Company&#146;s cash and cash equivalents were held at a major Canadian bank. The Company regularly monitors the credit risk exposure and takes steps to mitigate the likelihood of these exposures resulting in actual loss. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>23</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Subsequent events </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Change in Management and Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;6, 2017, the President and Chief Executive Officer, who was also a Director of the Company, resigned from his positions as an
Officer and Director of the Company. The Company entered into a Separation and Release Agreement with him whereby the Company will pay him approximately $519,000 over 12 months. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Grant of stock options </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Subsequent to <FONT STYLE="white-space:nowrap">year-end,</FONT> the Company granted 1,970,000 stock options to the new Chief Executive Officer,
other officers, directors and employees at a weighted average price of $3.21 (CA $4.22). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Exercise of warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Subsequent to <FONT STYLE="white-space:nowrap">year-end,</FONT> the Company issued 610,000 common shares for proceeds of $1,814,000 upon the
exercise of 74,000 warrants and 536,000 derivative warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(32) </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>4
<FILENAME>d313671dex993.htm
<DESCRIPTION>EX-99.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.3 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g313671ex99mda.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">Managements&#146; Discussion and Analysis </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">Aurinia Pharmaceuticals </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">YEAR END 16 </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">For the year ended December 31, 2016 </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">Aurinia Pharmaceuticals </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDITION AND RESULTS OF OPERATIONS FOR THE YEAR </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENDED DECEMBER&nbsp;31, 2016 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>In this
Management&#146;s Discussion and Analysis of Financial Condition or MD&amp;A and Results of Operations, unless the context otherwise requires, references to &#147;</I><B><I>we</I></B><I>&#148;, &#147;</I><B><I>us</I></B><I>&#148;,
&#147;</I><B><I>our</I></B><I>&#148; or similar terms, as well as references to &#147;</I><B><I>Aurinia</I></B><I>&#148; or the &#147;</I><B><I>Company</I></B><I>&#148;, refer to Aurinia Pharmaceuticals Inc., together with our subsidiaries. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following MD&amp;A and Results of Operations provides information on the activities of Aurinia on a consolidated basis and should be read in
conjunction with our audited consolidated financial statements and accompanying notes for the year ended December&nbsp;31, 2016 and our annual MD&amp;A and audited financial statements for the year ended December&nbsp;31, 2015. All amounts are
expressed in United States (US) dollars unless otherwise stated. Dollar amounts in tabular columns are expressed in thousands of US dollars. This document is current in all material respects as of March&nbsp;6, 2017. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial information contained in this MD&amp;A and in our audited consolidated financial statements has been prepared in accordance with International
Financial Reporting Standards or IFRS as issued by the International Accounting Standards Board or IASB. The audited consolidated financial statements and MD&amp;A have been reviewed and approved by the Company&#146;s Audit Committee. This MD&amp;A
has been prepared with reference to National Instrument <FONT STYLE="white-space:nowrap">51-102</FONT> &#147;Continuous Disclosure Obligations&#148; of the Canadian Securities Administrators. Under the U.S./Canada Multijurisdictional Disclosure
System, Aurinia is permitted to prepare this MD&amp;A in accordance with the disclosure requirements of Canada, which are different from those in the United States. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORWARD-LOOKING STATEMENTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities
laws encourage companies to disclose forward-looking information so that investors can get a better understanding of our future prospects and make informed investment decisions. These forward-looking statements, made in this MD&amp;A may include,
among other things, statements with respect to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">plans to fund our operations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">statements concerning strategic alternatives and future operations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">partnering activities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">summary statements relating to results of the past voclosporin trials or plans to advance the development of voclosporin; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">statements concerning partnership activities and health regulatory discussions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing of commencement, enrollment, completion and release of results of clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our intention to seek regulatory approvals in the United States and Europe for voclosporin; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our intention to seek additional corporate alliances and collaborative agreements to support the commercialization and development of our product; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our plans to generate future revenues from products licensed to pharmaceutical and biotechnology companies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our intention to demonstrate that voclosporin possesses pharmacologic properties with the potential to demonstrate best-in-class differentiation with first-in-class status for the treatment of lupus nephritis
(&#147;<B>LN</B>&#148;) outside of Japan; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our intention to initiate, and the timing of, the LN Phase 3 clinical trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our belief that recent granted formulation patents regarding the delivery of voclosporin to the ocular surface for conditions such as dry eye have the potential to be of therapeutic value; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our belief that voclosporin has further potential to be of therapeutic value in other autoimmune indications and in the prevention of transplant rejection; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our belief that the LN Phase 3 clinical trial will be de-risked based upon the AURA-LV Phase 2b clinical trial (AURA) results; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our belief that the AURA study resulted in positive results; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our belief in the market size and potential of LN, and the price range for voclosporin; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our intention to seek regulatory approval in other jurisdictions in the future and initiate clinical studies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs of our LN Phase 3 clinical trial (including continuation study); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our belief that the low dose of voclosporin is the optimal dosage for our LN Phase 3 clinical trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our anticipated future financial position, future revenues and projected costs; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">plans and objectives of management. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Such statements reflect our current views with respect to future events and are subject to risks and
uncertainties and are necessarily based on a number of estimates and assumptions that, while considered reasonable by management, as at the date of such statements, are inherently subject to significant business, economic, competitive, political,
scientific and social uncertainties and contingencies, many of which, with respect to future events, are subject to change. The factors and assumptions used by management to develop such forward-looking statements include, but are not limited to:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the assumption that we will be able to reach agreements with regulatory agencies on executable development programs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the assumption that recruitment to clinical trials will occur as projected; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the assumption that we will successfully complete our clinical programs on a timely basis, including conducting the required LN Phase 3 clinical trial and meet regulatory requirements for approval of marketing
authorization applications and new drug approvals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the assumption the regulatory requirements will be maintained; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the assumption that we will be able to manufacture and secure a sufficient supply of voclosporin to successfully complete the development and commercialization of voclosporin; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the assumption that our patent portfolio is sufficient and valid; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the assumption that there is a potential commercial value for other indications for voclosporin; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the assumption that market data and reports reviewed by us are accurate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the assumption that our current good relationships with our suppliers, service providers and other third parties will be maintained; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the assumptions relating to the availability of capital on terms that are favourable to us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the assumption that we will be able to attract and retain skilled staff; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the assumption that general business and economic conditions will be maintained; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the assumptions relating to the feasibility of future clinical trials. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is important to know that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">actual results could be materially different from what we expect if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. As a result, we cannot guarantee that any
forward-looking statement will materialize and, accordingly, you are cautioned not to place undue reliance on these forward-looking statements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">forward-looking statements do not take into account the effect that transactions or <FONT STYLE="white-space:nowrap">non-recurring</FONT> or other special items announced or occurring after the statements are made may
have on our business. For example, they do not include the effect of mergers, acquisitions, other business combinations or transactions, dispositions, sales of assets, asset write-downs or other charges announced or occurring after the
forward-looking statements are made. The financial impact of such transactions and <FONT STYLE="white-space:nowrap">non-recurring</FONT> and other special items can be complex and necessarily depends on the facts particular to each of them.
Accordingly, the expected impact cannot be meaningfully described in the abstract or presented in the same manner as known risks affecting our business; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we disclaim any intention and assume no obligation to update any forward-looking statements even if new information becomes available, as a result of future events, new information, or for any other reason except as
required by law. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The factors discussed below and other considerations discussed in the &#147;<I>Risks &amp; Uncertainties</I>&#148; section
of this MD&amp;A could cause our actual results to differ significantly from those contained in any forward-looking statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause
our actual results, performance, or achievements to differ materially from any further results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause such differences include, among
other things, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the need for additional capital in the longer term to fund our development programs and the effect of capital market conditions and other factors on capital availability; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties, delays, or failures we may experience in the conduct of and reporting of results of our clinical trials for voclosporin; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties in the manufacture and securing a sufficient supply of voclosporin on a timely basis to successfully complete the development and commercialization of voclosporin; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties in gaining alignment among the key regulatory jurisdictions, FDA, EMA and PMDA which may require further clinical activities </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties, delays or failures in obtaining regulatory approvals for the initiation of clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties, delays or failures in obtaining regulatory approvals to market voclosporin; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties we may experience in completing the development and commercialization of voclosporin; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">insufficient acceptance of and demand for voclosporin; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties, delays, or failures in obtaining appropriate reimbursement from payors for voclosporin; and/or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties we may experience in identifying and successfully securing appropriate corporate alliances to support the development and commercialization of our product. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity,
performance or achievements. These forward-looking statements are made as of the date hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>For additional information on risks and uncertainties in
respect of the Company and its business, please see the &#147;Risks and Uncertainties&#148; section of this MD&amp;A. Although we believe that the expectations reflected in such forward-looking statements and information are reasonable, undue
reliance should not be placed on forward-looking statements or information because we can give no assurance that such expectations will prove to be correct. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Additional information related to Aurinia, including its most recent Annual Information Form (&#147;AIF&#148;), is available by accessing the Canadian
Securities Administrators&#146; System for Electronic Document Analysis and Retrieval (&#147;SEDAR&#148;) website at www.sedar.com or the U.S. Securities and Exchange Commission&#146;s (&#147;SEC&#148;) Electronic Document Gathering and Retrieval
System (&#147;EDGAR&#148;) website at www.sec.gov/edgar. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OVERVIEW </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE COMPANY </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Structure
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Name, Address and Incorporation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aurinia
is a clinical stage biopharmaceutical company with its head office located at #1203-4464 Markham Street, Victoria, British Columbia V8Z 7X8 where clinical, regulatory and business development functions of the Company are conducted. Aurinia has its
registered office located at #201, <FONT STYLE="white-space:nowrap">17904-105</FONT> Avenue, Edmonton, Alberta T5S 2H5 where the finance function is performed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aurinia Pharmaceuticals Inc. is organized under the <I>Business Corporations Act </I>(Alberta). Our common shares are currently listed and traded on the
NASDAQ Global Market (&#147;NASDAQ&#148;) under the symbol &#147;AUPH&#148; and on the Toronto Stock Exchange (&#147;TSX&#148;) under the symbol &#147;AUP&#148;. Our primary business is the development of a therapeutic drug to treat autoimmune
diseases, in particular LN. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has the following wholly-owned subsidiaries: Aurinia Pharma Corp. (British Columbia incorporated), Aurinia Pharma
U.S., (Delaware incorporated) and Aurinia Pharma Limited (UK incorporated). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BUSINESS OF THE COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are focused on the development of our novel therapeutic immunomodulating drug candidate, voclosporin, for the treatment of LN. Voclosporin is a next
generation calcineurin inhibitor (&#147;<B>CNI</B>&#148;) which has clinical data in over 2,200 patients across multiple indications. It has been studied in kidney rejection following transplantation, psoriasis and in various forms of uveitis (an
ophthalmic disease). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Voclosporin is an immunosuppressant, with a synergistic and dual mechanism of action that has the potential to improve near- and
long-term outcomes in LN when added to mycophenolate mofetil (&#147;<B>MMF</B>&#148;), the current standard of care for LN. By inhibiting calcineurin, voclosporin blocks <FONT STYLE="white-space:nowrap">IL-2</FONT> expression and <FONT
STYLE="white-space:nowrap">T-cell</FONT> mediated immune responses. Voclosporin is made by a modification of a single amino acid of the cyclosporine molecule which has shown a more predictable pharmacokinetic and pharmacodynamic relationship, an
increase in potency, an altered metabolic profile, and potential for flat dosing. Clinical doses of voclosporin studied to date range from 13 &#150; 70 mg BID. The mechanism of action of voclosporin, a CNI, has been validated with certain first
generation CNIs for the prevention of rejection in patients undergoing solid organ transplants and in several autoimmune indications, including dermatitis, keratoconjunctivitis sicca (Dry Eye Syndrome), psoriasis, rheumatoid arthritis, and for LN in
Japan. We believe that voclosporin possesses pharmacologic properties with the potential to demonstrate <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> differentiation with
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> regulatory approval status for the treatment of LN outside of Japan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on published data, we believe the key potential benefits of voclosporin in the treatment of LN are as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Increased potency compared to cyclosporine A, allowing lower dosing requirements and fewer off target effects; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Limited inter and intra patient variability, allowing flat dosing; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Less cholesterolemia than cyclosporine A; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Limited incidence of glucose intolerance and diabetes at targeted doses compared to tacrolimus. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are also
pursuing <FONT STYLE="white-space:nowrap">out-licensing</FONT> opportunities for our topical nanomicellar drug delivery technology patents. This technology allows for the delivery of voclosporin and other immunomodulators to the ocular surface for
conditions such as dry eye. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Lupus Nephritis </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LN is an inflammation of the kidney caused by systemic lupus erythematosus (&#147;<B>SLE</B>&#148;) and represents a serious manifestation of SLE. SLE is a
chronic, complex and often disabling disorder that affects over 500,000 people in the United States (mostly women). SLE is highly heterogeneous, affecting a wide range of organs and tissue systems. It is estimated that as many as 60% of all SLE
patients have LN that requires urgent treatment. Unlike SLE, LN has straightforward disease measures (readily assessable and easily identified by specialty treaters) where an early response correlates with long-term outcomes, measured by
proteinuria. In patients with LN, renal damage results in proteinuria and/or hematuria and a decrease in renal function as evidenced by reduced estimated glomerular filtration rate (&#147;<B>eGFR</B>&#148;), and increased serum creatinine levels.
eGFR is assessed through the Chronic Kidney Disease Epidemiology Collaboration equation. Rapid control and reduction of proteinuria in LN patients measured at 6 months shows a reduction in the need for dialysis at 10 years. LN can be debilitating
and costly and if poorly controlled, can lead to permanent and irreversible tissue damage within the kidney. Recent literature suggests severe LN progresses to end-stage renal disease (&#147;<B>ESRD</B>&#148;), within 15 years of diagnosis in
10%-30% of patients, thus making LN a serious and potentially life-threatening condition. SLE patients with renal damage have a 14-fold increased risk of premature death, while SLE patients with ESRD have a greater than 60-fold increased risk of
premature death. Mean annual medical cost for patients (both direct and indirect) with SLE (with no nephritis) have been estimated to exceed US$20,000 per patient, while the mean annual medical cost for patients (both direct and indirect) with LN
who progress to intermittent ESRD have been estimated to exceed US$60,000 per patient. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>LN Standard of Care </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While at Aspreva Pharmaceuticals, certain members of Aurinia&#146;s management team executed the Aspreva Lupus Management Study (&#147;<B>ALMS</B>&#148;) which
established CellCept <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, or mycophenolate mofetil (&#147;<B>MMF</B>&#148;) as the current standard of care for treating LN. The ALMS study was published in 2009 in the Journal of the American
Society of Nephrology and in 2011 in the New England Journal of Medicine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The American College of Rheumatology recommends that intravenous
cyclophosphamide or MMF/CellCept<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> be used as first-line immunosuppressive therapy for LN. MMF is typically paired with hydroxychloroquine and steroids. Despite their use, the ALMS study showed
that the vast majority of patients failed to achieve Complete Remission (&#147;<B>CR</B>&#148;), and almost half failed to have a renal response at 24 weeks for both of these therapeutics. Based upon the results of the ALMS study, we believe that a
better solution is needed to improve renal response rates for LN. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on available data from the AURA clinical trial, we believe that voclosporin has
the potential to address several critical needs for LN patients by controlling active disease rapidly, lowering the overall steroid burden, impacting extra-renal disease and doing so with a convenient oral twice-daily treatment regimen. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Market Potential and Commercial Considerations </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
recently conducted our own market research which surveyed approximately 900 rheumatologists and nephrologists across the United States, Europe and Japan to better define the potential market size, pricing estimated and treatment paradigms in the
United States, Europe and Japan. Using the U.S. MarketScan<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> data set (with approximately 170,000,000 insured lives in the United States) there were 445,346 SLE patients (between January 2006
and December 2015) based on specific SLE diagnosis codes. The National Institute of Diabetes and Digestive and Kidney Diseases estimates that up to 60% of people with SLE are diagnosed with LN. Using claims database research and additional physician
research, we believe the diagnosed range of LN patients to be approximately 125,000 to 200,000 in the United States and 175,000 to 250,000 in the European Union. In both the United States and the European Union, 1 in 5 LN patients are thought to be
undiagnosed due to referring physicians being inefficient and inaccurate in diagnosing the condition. Mean frequency of LN flares in controlled LN patients as reported by the surveyed rheumatologists and nephrologists was approximately every
14&nbsp;months. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g313671g02v84.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the survey results, it is estimated that 58% of LN patients are controlled (maintenance phase); 25% poorly
controlled and 17% have active disease (induction phase). The rheumatologist and nephrologist specialists indicated that if available, they would use voclosporin in a portion of patients in both the maintenance and induction phases. Only 18% of
those surveyed physicians were very satisfied or extremely satisfied with currently available and unapproved therapies&#146; ability to achieve a CR within 6 months. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>About LN </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LN is one of the most serious
progressions of Systemic Lupus Erythematosus (SLE). The Lupus Foundation of America estimates that &gt;500&nbsp;thousand people in the United States of America and up to 5.0&nbsp;million people worldwide suffer from SLE. Approximately 90% of these
patients are women of child-bearing age. The disease causes severe impairments on quality of life and wellbeing. Of the patients suffering from SLE, <FONT STYLE="white-space:nowrap">40-60%</FONT> experience renal manifestations of the disease
resulting in inflammation of the kidney. These patients are considered to have LN and have a high probability of advancing to end stage renal disease (ESRD), dialysis, renal transplant and death, if left untreated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ALMS data has been reported in several respected journals, including, the New England Journal of Medicine
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and the Journal of the American Society of Nephrology<I></I>. These publications and subsequent alterations in treatment strategies by physicians caring for patients suffering from LN have
established CellCept<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>/MMF as the standard of care for the treatment of LN. This shift in the treatment paradigm for LN and the establishment of CellCept<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> use as a relatively uniform treatment approach for these patients has, in our view, caused the LN market to evolve into an attractive and mature market opportunity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Despite CellCept<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> being the current SoC for the treatment of LN, it remains far from adequate with
fewer than 20% of patients on therapy actually achieving disease remission after six months of therapy. Data suggests that a LN patient who does not achieve rapid disease remission upon treatment is more likely to experience renal failure or require
dialysis at 10 years . Therefore, it is critically important to achieve disease remission as quickly and as effectively as possible. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voclosporin
mechanism of action </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Voclosporin reversibly inhibits immunocompetent lymphocytes, particularly <FONT STYLE="white-space:nowrap">T-Lymphocytes</FONT> in
the G0 and G1 phase of the cell-cycle, and also reversibly inhibits the production and release of lymphokines. Through a number of processes voclosporin inhibits and prevents the activation of various transcription factors necessary for the
induction of cytokine genes during <FONT STYLE="white-space:nowrap">T-cell</FONT> activation. It is believed that the inhibition of activation of <FONT STYLE="white-space:nowrap">T-cells</FONT> will have a positive modulatory effect in the treatment
of LN. In addition to these immunologic impacts recent data suggests that CNIs have another subtle but important impact on the structural integrity of the podocytes. This data suggests that inhibition of calcineurin in patients with autoimmune
kidney diseases helps stabilize the cellular actin-cytoskeleton of the podocytes thus having a structural impact on the podocyte and the subsequent leakage of blood proteins into the urine, which is a key marker of patients suffering from LN. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Potential voclosporin clinical benefits </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that
voclosporin has shown a number of key clinical benefits over the existing commercially available CNIs (tacrolimus&nbsp;&amp; cyclosporine). Firstly, CNI assay results have indicated potential that voclosporin is approximately four times more potent
than its parent molecule cyclosporine, which would indicate an ability to give less drug and produce fewer potentially harmful metabolites. Secondly, cyclosporine inhibits the enterohepatic recirculation of mycophenolic acid (&#147;MPA&#148;), the
active metabolite of MMF. The net effect of <FONT STYLE="white-space:nowrap">co-administration</FONT> of CsA with MMF is reduced MPA systemic exposure by as much as 50%. This drug interaction has not been observed with voclosporin and it is not
expected that MPA blood exposure levels will be reduced with voclosporin <FONT STYLE="white-space:nowrap">co-administration.</FONT> This is an important fact to consider as most patients being treated with voclosporin for LN will already be taking
MMF. Furthermore, pharmacokinetic and pharmacodynamics <FONT STYLE="white-space:nowrap">(&#147;PK-PD&#148;)</FONT> analysis indicate lower <FONT STYLE="white-space:nowrap">PK-PD</FONT> variability for voclosporin versus tacrolimus or cyclosporine,
to the extent that we believe flat-dosing can be achieved for voclosporin. The currently available CNIs require extensive therapeutic drug monitoring which can often be costly, confusing and time consuming for treating physicians. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> study comparing voclosporin against cyclosporine in the
treatment of psoriasis, cyclosporine was shown to cause significant increases in lipid levels as compared to voclosporin. The difference was statistically significant. This is important considering most lupus patients die of cardiovascular disease.
In another study comparing voclosporin against tacrolimus in patients undergoing renal transplantation, the voclosporin group experienced a statistically significantly lower incidence of glucose intolerance and diabetes than tacrolimus treated
patients. Additionally, in the Japanese tacrolimus study that led to the approval of this drug in Japan, almost 15% of tacrolimus patients experienced glucose intolerance. This is a major limitation for physicians wanting to use this agent in lupus
and is a well described side effect of tacrolimus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that voclosporin can be differentiated from the older CNIs and thus possess a unique
position in the market as it relates to inducing remission in patients suffering from LN. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Scientific Rationale for Treatment of LN with voclosporin
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While SLE is a highly heterogeneous autoimmune disease (often with multiple organ and immune system involvement), LN has straightforward disease
outcomes (readily assessable and easily identified by specialty treaters). <FONT STYLE="white-space:nowrap">T-cell</FONT> mediated immune response is an important feature of the pathogenesis of LN while the podocyte injury that occurs in conjunction
with the ongoing immune insult in the kidney is an important factor in the clinical presentation of the disease. An early response in LN correlates with long-term outcomes and is clearly measured by proteinuria. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The use of voclosporin in combination with the current SoC for the treatment of LN provides a novel approach to
treating this disease (similar to the standard approach in preventing kidney transplant rejection). Voclosporin has shown to have potent effects on <FONT STYLE="white-space:nowrap">T-cell</FONT> activation leading to its immunomodulatory effects.
Additionally, recent evidence suggests that inhibition of calcineurin has direct physical impacts on the podocytes within the kidney. Inhibition of calcineurin within the podocytes can prevent the dephosphorylation of synaptopodin which in turn
inhibits the degradation of the actin cytoskeleton within the podocyte. This process is expected to have a direct impact on the levels of protein in the urine which is a key marker of LN disease activity. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STRATEGY </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our business strategy is to
optimize the clinical and commercial value of voclosporin. In particular, we are focused on the development of voclosporin as an <FONT STYLE="white-space:nowrap">add-on</FONT> therapy to the current standard of care, CellCept<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The key elements of our corporate strategy include: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Focusing the Company&#146;s resources on advancing voclosporin through a robust LN Phase 3 clinical trial. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mitigate development risk by leveraging the ALMS database and management team&#146;s experience &#150; the Company has certain rights to utilize the ALMS database including its use in planning, designing and informing
the LN Phase 3 clinical trial.</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Initiate the required Phase 3 clinical trial for LN in the second quarter of 2017 </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Evaluate other voclosporin indications &#150; while we intend to deploy our operational and financial resources to develop voclosporin for LN, we believe that recent granted formulation patents regarding the delivery of
voclosporin to the ocular surface for conditions such as dry eye have the potential to be of therapeutic value. We will explore our strategic options to exploit shareholder value from this intellectual property. We also believe that voclosporin has
further potential to be of therapeutic value in other autoimmune indications and in the prevention of transplant rejection. Management will consider strategic opportunities for these other potential indications on an ongoing basis.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consider other business development opportunities that would be a strategic fit for the Company or voclosporin under the right circumstances and timing. </TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECENT DEVELOPMENTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>AURA <FONT
STYLE="white-space:nowrap">48-week</FONT> results </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;1, 2017, we announced top-line results from our Phase 2b AURA-LV (AURA) study in
LN. At 48 weeks, the trial met the complete and partial remission (&#147;CR&#148;/ &#147;PR&#148;) endpoints, demonstrating statistically significantly greater CR and PR in patients in both low dose (23.7mg of voclosporin twice daily (p&lt;.001))
and high dose (39.5mg twice daily (p=.026)) cohorts versus the control group. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 24 and 48-week top-line efficacy results are summarized below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Endpoint</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Treatment</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>24&nbsp;weeks</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Odds&nbsp;ratio</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B>P-value*</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>48&nbsp;weeks</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Odds&nbsp;Ratio</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B>P-value*</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Complete Remission</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">23.7mg&nbsp;VCS&nbsp;BID</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.03</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">p=.045</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.21</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>p&lt;.001</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">39.5mg VCS BID</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">1.59</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">p=.204</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>p=.026</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Control Arm</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>NA</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>NA</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>NA</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>NA</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Partial Remission</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">23.7mg VCS BID</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.33</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">p=.007</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.34</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>p=.007</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">39.5mg VCS BID</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.03</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">p=.024</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.68</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>p=.002</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Control Arm</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>NA</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>NA</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>NA</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>NA</I></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"><I>All <FONT STYLE="white-space:nowrap">p-values</FONT> are vs control</I> </TD></TR></TABLE> <P STYLE="margin-top:0pt;margin-bottom:0pt;page-break-before:always"></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The results of the AURA study at 48 weeks demonstrate the highest complete remission rate of any global LN study of which we are aware, although we note that
the criteria to measure remission differed among the studies. The below chart compares the results of the AURA study vs. the other global LN studies of which we are aware. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="28%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER:1px solid #000000; padding-left:8pt"><B>Name of Global Study</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;Number&nbsp;&nbsp;&nbsp;&nbsp;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;of&nbsp;weeks&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Criteria&nbsp;to&nbsp;Measure&nbsp;Remission<BR>and Response Rate</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>Results</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">Efficacy&nbsp;and&nbsp;Safety&nbsp;of Ocrelizumab in Active Proliferative Lupus Nephritis</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">48&nbsp;weeks</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;UP:CR(gm/gm) &lt; .5</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;SCr&nbsp;<FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT>&nbsp;25%&nbsp;increase&nbsp;from
baseline</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;Steroid taper (not forced)</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" COLSPAN="3" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Control = 34.7%</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">LD OCR = 42.7%
(NS)</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">HD OCR = 31.5% (NS)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">Mycophenolate Mofetil<I> versus </I>Cyclophosphamide for Induction Treatment of Lupus Nephritis</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">24 weeks</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;UP:CR(gm/gm)&nbsp;<FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT>&nbsp;.5</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;Normal eGFR</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;Normal Urinalysis</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;Steroid taper (not forced)</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" COLSPAN="3" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">MMF =
8.6% (NS)</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">IVC = 8.1% (NS)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">Efficacy and Safety of Abatacept in Lupus Nephritis</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">52 weeks</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;UP:CR(gm/gm) <FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT> .26</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;eGFR&nbsp;within 10% of screening/baseline</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;Normal Urinalysis</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;Criteria to be met on 2 successive visits</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;No mandated steroid taper</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" COLSPAN="3" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Control = 8.0%</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">LD ABT = 11.1%
(NS)</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">HD ABT = 9.1% (NS)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">AURA-LV: Aurinia Urine Protein Reduction in Active Lupus Nephritis Study</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 and</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48&nbsp;weeks</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;UP:CR(gm/gm)&nbsp;<FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT>&nbsp;.5</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;No&nbsp;decrease&nbsp;in&nbsp;eGFR&nbsp;<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>&nbsp;20%</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;No&nbsp;use&nbsp;of&nbsp;rescue medications</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;Forced steroid taper</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>24 weeks</U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Control&nbsp;=&nbsp;19.3%</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LD
Voc=32.6%</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(p=.045)</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HD&nbsp;Voc&nbsp;=&nbsp;27.3%</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(NS)</B></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>48&nbsp;weeks</U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Control&nbsp;=&nbsp;23.9%</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LD&nbsp;Voc&nbsp;=&nbsp;49.4% (p&lt;.001)</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HD&nbsp;Voc&nbsp;=&nbsp;39.8% (p=.026)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each arm of the study included the current standard of care of MMF as background therapy and a forced steroid taper to 5mg/day
by week 8 and 2.5mg by week 16. No unexpected safety signals were observed beyond the 24 week treatment period and there were no additional deaths in the voclosporin treated patients beyond the 24 week treatment period; however, there were three
deaths and one malignancy reported in the control arm after completion of the study treatment period. The table below outlines the Serious Adverse Events as recorded beyond the 24 week time-point of the study. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="10%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><B>Safety beyond 24 weeks</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;Control&nbsp;&nbsp;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;N = 88&nbsp;&nbsp;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;n (%)&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Voclosporin</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>23.7&nbsp;mg&nbsp;BID</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N&nbsp;=&nbsp;89&nbsp;n&nbsp;(%)</B></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Voclosporin</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>39.5 mg
BID</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N&nbsp;=&nbsp;88&nbsp;n&nbsp;(%)</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Any&nbsp;Serious&nbsp;Adverse&nbsp;Event&nbsp;(SAE)</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 (1.1)</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">2 (2.2)</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">0&nbsp;(0.0)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Malignancies</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">1 (1.1)</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">0 (0)</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">0 (0.0)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deaths</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">3 (3.4)</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">0 (0)</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">0 (0.0)</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Results from Japanese Phase I Ethnic Bridging Study for Voclosporin </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;14, 2017, we announced the results of a supportive Phase I safety, pharmacokinetic (&#147;PK&#148;) and pharmacodynamic (&#147;PD&#148;) study
in healthy Japanese patients which supports further development of voclosporin in this patient population. Based on evaluations comparing the Japanese ethno-bridging data vs. previous PK and PD studies in
<FONT STYLE="white-space:nowrap">non-Japanese</FONT> patients, voclosporin demonstrated no statistically significant differences in exposure with respect to Area Under the Curve (&#147;AUC&#148;) measurements. Furthermore, the PK parameters in
Japanese patients were generally consistent with previously evaluated PK parameters in <FONT STYLE="white-space:nowrap">non-Japanese</FONT> volunteers. There were no unusual or unexpected safety signals in the study. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Appointment of New Chief Executive Officer </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;6, 2017, we announced the appointment of Dr.&nbsp;Richard&nbsp;M. Glickman L.LD (Hon), the Company&#146;s founder and Chairman of the Board,
as our Chairman and Chief Executive Officer. The board accepted the resignation of Charles Rowland as Chief Executive Officer and an executive member of the board. Dr.&nbsp;Glickman brings over 30 years of experience in the creation and operation of
healthcare ventures, founding and <FONT STYLE="white-space:nowrap">co-founding</FONT> numerous companies during his career. As the <FONT STYLE="white-space:nowrap">co-founder,</FONT> Chairman and Chief Executive Officer of Aspreva Pharmaceuticals,
he played an integral role in developing and establishing CellCept<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, or MMF, as the current standard of care for the treatment of LN. Aspreva Pharmaceuticals was acquired by Swiss
pharmaceutical company Galenica for nearly $1B in 2008. He currently serves as founding Chairman of Essa Pharmaceuticals Inc., Chairman of the Board of Engene Corporation and a Director of Cardiome Pharma. He is also a Partner at Lumira Capital.
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2016 OPERATIONAL AND CLINICAL DEVELOPMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>FDA End of Phase 2 Meeting and Plans for Single LN Phase 3 Clinical Trial </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;2, 2016, we announced the FDA&#146;s preference for a single double-blind, randomized, placebo controlled Phase&nbsp;3 clinical trial for
voclosporin in the treatment of LN, to be entitled &#147;<B>AURORA</B>&#148;. This trial will be blinded for up to 52 weeks of treatment. That preference resulted from multiple discussions with the agency and followed the submission to and review of
a comprehensive clinical and safety package relating to voclosporin by the FDA Division of Pulmonary, Allergy and Rheumatology Products. Pursuant to our recent End of Phase 2 meeting with the FDA Division of Pulmonary, Allergy and Rheumatology
Products, we believe this LN Phase 3 clinical trial, the design of which is consistent with the AURA clinical trial, will, if successful, support a New Drug Application (&#147;<B>NDA</B>&#148;) submission. We also expect to enroll the first patients
into the Phase 3 clinical trial sometime during the second quarter of 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The AURORA clinical trial will be a global
<FONT STYLE="white-space:nowrap">52-week</FONT> double-blind, placebo controlled study of approximately 320 patients. We are finalizing the study protocol and regulatory submissions and in parallel are working on site selection with trial initiation
anticipated in Q2 2017. Patients will be randomized 1:1 to either 23.7 mg of voclosporin (administered twice a day) (&#147;BID&#148;) and MMF or MMF and placebo, with both arms receiving a stringent oral corticosteroid taper. The study population
will be comprised of patients with biopsy-proven active LN who will be evaluated on the primary efficacy endpoint of renal response at 24 weeks, a composite which includes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Urinary/protein creatinine ratio (&#147;UPCR&#148;) of <FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT>0.7 mg/mg </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Normal, stable renal function (<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>60 mL/min/1.73 m2 or no confirmed decrease from baseline in eGFR of &gt;20%) </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Presence of sustained, low dose steroids (<FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT>10 mg prednisone from week <FONT STYLE="white-space:nowrap">16-24)</FONT> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">No administration of rescue medications </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The readout of the primary endpoint of renal response at 24 weeks
will occur after database lock at 52 weeks. Patients completing the 52 week study will then have the option to roll-over into a 104 week blinded continuation study. These data will allow us to assess long-term outcomes in LN patients that will be
valuable in a post- marketing setting in addition to future interactions with various regulatory authorities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While voclosporin has received fast track
designation, the FDA has informed us that voclosporin is not eligible for breakthrough therapy designation at this time. We will continue to benefit from fast track designation, which includes more frequent communications with the FDA, potential for
priority review of the NDA and an option to submit a rolling NDA submission, which may expedite the review process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our initial forecast is that the
AURORA clinical trial will cost in the range of $70&nbsp;million to $80&nbsp;million. However, we are still in the process of obtaining quotes from suppliers and CROs and determining the optimum number of countries and sites in which to conduct the
AURORA clinical trial and as a result this forecast may change. In addition, the initial estimate of the cost of the continuation study is in the range of $20&nbsp;million to $25&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;13, 2016, we announced that we had received the final End of Phase 2 meeting minutes from the FDA Division of Pulmonary, Allergy and
Rheumatology Products and that the minutes are consistent with the preliminary responses that were issued to us prior to the meeting which took place on October&nbsp;25, 2016. We are currently having ongoing discussions and correspondence with the
European Medicines Agency (&#147;EMA&#148;). We are working towards final discussions with their scientific advice working party and are currently awaiting official feedback. We also plan to have a regulatory meeting with the Japanese
Pharmaceuticals and Medical Devices Agency (&#147;PMDA&#148;) regarding requirements for Japan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>AURION Study Update </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;AURION&#148; means an open label exploratory study. The protocol is titled An Exploratory study assessing the Short term Predictors of Remission of
Voclosporin 23.7 mg BID in combination with standard of care in Patients with Active Lupus Nephritis. The AURION trial is a single-arm, twin center, exploratory study assessing the predictive value of an early reduction in proteinuria in subjects
receiving 23.7mg of voclosporin BID with the current standard of care in patients with active LN. The primary objective of the AURION clinical trial is to examine biomarkers of disease activity at eight weeks and their ability to predict response at
24 and 48 weeks. Based on our recently released 48 week topline results for the AURA clinical trial, we are re-evaluating specific endpoints to optimize trial design and success. We do not believe that this will affect the timing for the initiation
or completion of the AURORA study. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Study Design: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g313671g0307140354059.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The primary analysis is the number of patients achieving each of the following biomarkers and the number of these patients
who go on to achieve week 24 or week 48 remission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Biomarkers: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">25% reduction in urinary protein creatinine ratio (UPCR) at 8 weeks; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">C3 complement normalization at 8 weeks; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">C4 complement normalization at 8 weeks; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Anti-dsDNA (double-stranded DNA) normalization at 8 weeks. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The secondary analysis includes the 24 and 48 week
outcomes, markers of SLE and pharmacokinetics and pharmacodynamics (PK/PD) of voclosporin. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;6, 2016, we announced 24 week data in all 10
patients from the AURION clinical trial, an open-label exploratory study to assess the short-term predictors of response using voclosporin (23.7 mg BID) in combination with MMF and oral corticosteroids in patients with active LN. The data was
presented by Robert Huizinga, Vice President of Clinical Affairs at Aurinia Pharmaceuticals at the 10th Annual European Lupus Meeting in Venice, Italy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The primary objective of the trial is to examine biomarkers of disease activity at eight weeks and their ability to predict response at 24 and 48 weeks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In this trial, 70% (7/10) patients achieved complete remission (&#147;<B>CR</B>&#148;) at 24 weeks as measured by a UPCR of
<FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT>0.5mg/mg, eGFR within 20% of baseline and concomitant steroid dose of &lt;5 mg/day. Of the 10 patients that achieved a reduction of UPCR of <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>25% at 8 weeks,
80% were responders (<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>50% reduction in UPCR over baseline) at 24 weeks and 70% were in CR at 24 weeks, proteinuria levels decreased by a mean of 61% from baseline through the first 24 weeks of the study.
In addition, inflammatory markers such as C3, C4 and anti- dsDNA all continued to normalize to 24 weeks. Voclosporin was well-tolerated with no unexpected safety signals observed. Patients were generally improving while renal function, as measured
by eGFR, remained stable over the 24 weeks. We believe that the results of the AURION study supports the use of the 23.7 mg twice daily dose in further studies and we believe that the AURION study also supports that this dosage is optimal for the
AURORA study. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Details of the results are below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:28.40pt; font-size:8pt; font-family:Times New Roman"><B>Patient#</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Attained&nbsp;</B><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT><B></B><B>25%<BR>reduction in<BR>UPCR&nbsp;at&nbsp;8&nbsp;weeks</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Attained<BR>Partial&nbsp;Remission*<BR>at 8 weeks</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Attained<BR>Partial&nbsp;Remission*<BR>at 24 weeks</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Attained<BR>CR<BR>at&nbsp;8&nbsp;weeks</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Attained<BR>CR<BR>at&nbsp;24&nbsp;weeks</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>TOTALS:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>100%&nbsp;(10/10)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>70%&nbsp;(7/10)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>80%&nbsp;(8/10)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>50%&nbsp;(5/10)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>70%&nbsp;(7/10)</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>*</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Retrospectively defined by </I><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT><I></I><I>50% reduction in UPCR</I> </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>AURA Phase 2b Clinical Trial &#150; Positive <FONT STYLE="white-space:nowrap">Top-Line</FONT> Results </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;15, 2016, we announced positive <FONT STYLE="white-space:nowrap">top-line</FONT> results from the AURA clinical trial in patients with active
LN. The trial achieved its primary endpoint, demonstrating statistically significantly greater CR at 24 weeks (and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
confirmed at 26 weeks) in patients treated with 23.7 mg of voclosporin twice daily (p=0.045). This was the first global study of LN to meet its primary end point. Both treatment arms, 23.7 mg and
39.5 mg twice daily also showed a statistically significant improvement in the rate of achieving partial remission (&#147;<B>PR</B>&#148;) at 24 weeks (p=0.007; p=0.024). Each arm of the study included the current standard of care of MMF as
background therapy, and a forced steroid taper. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>AURA </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The AURA clinical trial compared the efficacy of voclosporin added to current standard of care of MMF, also known as CellCept<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, against standard of care with placebo in achieving CR in patients with active LN. It enrolled 265 patients at centers in 20 countries worldwide. On entry to the trial, patients were required to
have a diagnosis of LN according to established diagnostic criteria (American College of Rheumatology) and clinical and biopsy features indicative of active LN. Patients also either had proteinuria of greater than or equal to 1.5 mg/mg or, in the
case of Class V LN patients, greater than or equal to 2 mg/mg. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patients were randomized to one of two dosage groups of voclosporin (23.7 mg BID and 39.5
mg BID) or placebo, with all patients also receiving MMF and oral corticosteroids as background therapy. All patients had an initial IV dose of steroids <FONT STYLE="white-space:nowrap">(500-1000</FONT> mg) and then were started on <FONT
STYLE="white-space:nowrap">20-25</FONT> mg/daily, which was tapered down to a low dose of 5 mg daily by week 8 and 2.5 mg daily by week 16. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g313671g0307140354215.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The primary endpoint was a measure of the number of patients who achieved CR at 24 weeks which had to be confirmed at
26&nbsp;weeks. CR required the following four elements: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">protein/creatinine ratio of <FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT>0.5 mg/mg </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">normal stable renal function (eGFR <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>60 mL/min/1.73m2 or no confirmed decrease from baseline in eGFR of <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>20%) </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Presence of sustained, low dose steroids (<FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT>10mg/day of prednisone from week 16&#151;24) </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">No administration of rescue medications throughout the treatment period </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Summary of 24 week Results
</U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The groups were generally well-balanced for age, gender and race, however, when considered together, the proteinuria and eGFR data suggest that
disease severity was greater for the <FONT STYLE="white-space:nowrap">low-dose</FONT> voclosporin group. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Efficacy </I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The primary endpoint of CR was met for the <FONT STYLE="white-space:nowrap">low-dose</FONT> voclosporin group in the ITT analysis (p=0.045). 32.6% of patients on low dose achieved CR, compared to 27.3% on high dose and
19.3% in the control arm. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The odds ratio indicates that patients were twice as likely to achieve CR at 24 weeks compared to the control arm (OR=2.03). </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The primary endpoint was <FONT STYLE="white-space:nowrap">re-analyzed</FONT> using the <FONT STYLE="white-space:nowrap">24-hour</FONT> urine data in place of First Morning Void collections, confirming the finding that
patients were twice as likely to achieve CR at 24 weeks compared to the control arm (p=0.047; OR=2.12). </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Both voclosporin groups had a statistically significantly faster time to CR (UPCR <FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT>0.5 mg/mg) than the control arm. Results of time to CR for
<FONT STYLE="white-space:nowrap">co-variate</FONT> analyses were broadly consistent with overall efficacy rates in those <FONT STYLE="white-space:nowrap">sub-groups.</FONT> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The secondary endpoint of PR (50% reduction in UPCR over baseline with no administration of rescue medication throughout the treatment period) was met for both voclosporin groups in the ITT analysis with 69.7% of
patients on low dose achieving PR (p=0.007) and 65.9% in the high dose group (p=0.024). 49.4% of patients in the control arm achieved PR. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Time to PR was similar (4 weeks) in the two voclosporin groups and was statistically significantly faster than what was observed in the control group (6.6 weeks). </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Safety </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The overall rate of adverse events (&#147;<B>AEs</B>&#148;) was similar across all groups. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The overall rate of serious adverse events (&#147;<B>SAEs</B>&#148;) was higher in both voclosporin groups but the nature of SAEs is consistent with highly active LN. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The overall pattern of AEs and SAEs was consistent with that observed in the following LN studies: Abatacept study, Ocrelizumab study and ALMS Induction study. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">There were 13 deaths across the trial: two in the high-dose voclosporin arm; 10 in the low-dose voclosporin arm; and one in the control arm, and one in the control arm, with the majority of overall deaths (11/13)
occurring at sites with compromised access to standard of care. All deaths were assessed by the Investigator as being unrelated to study treatment. No dose-dependent relationship was observed. The pattern of deaths in the study is consistent with
other global LN studies. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;29, 2016, we announced that in addition to voclosporin (23.7 mg BID) achieving its primary
endpoint of CR at 24 weeks, both doses of voclosporin when added to the current standard of care of MMF and a forced oral corticosteroid taper have met all <FONT STYLE="white-space:nowrap">24-week</FONT>
<FONT STYLE="white-space:nowrap">pre-specified</FONT> secondary endpoints vs the control group making AURA the first global study of LN to meet both its primary and secondary endpoints at 24 weeks. These
<FONT STYLE="white-space:nowrap">pre-specified</FONT> endpoints include: PR, which is measured by a <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>50% reduction in UPCR with no concomitant use of rescue medication; time to CR and PR; reduction in
Systemic Lupus Erythematosus Disease Activity Index or SLEDAI score; and reduction in UPCR over the <FONT STYLE="white-space:nowrap">24-week</FONT> treatment period. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:116.35pt; font-size:8pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Pre-specified</FONT> Secondary
Endpoint</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Control</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Low&nbsp;Dose&nbsp;VCS</B><br><B>(23.7mg BID)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>High&nbsp;Dose&nbsp;VCS</B><br><B>(39.5mg BID)</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Time to Complete Remission (&#147;TTCR&#148;)</B> [median]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">Not&nbsp;achieved</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">19.7&nbsp;weeks<BR><B><I>p&lt;.001</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">23.4&nbsp;weeks<BR><B><I>p=.001</I></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Partial Remission</B> (as measured by UPCR reduction of
<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>&nbsp;50% from baseline)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">49%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">70%<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>p=.007</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">66%<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>p=.024</I></B></P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B></B><B>Time to Partial Remission (&#147;TTPR&#148;)</B><B></B> [median]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">6.6 weeks</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">4.1 weeks<BR><B><I>p=.002</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">4.4 weeks<BR><B><I>p=.003</I></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SLEDAI Reduction</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">-4.5</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">-6.3<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>p=.003</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">-7.1<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>p=.003</I></B></P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Reduction in UPCR</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">-2.216&nbsp;mg/mg</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">-3.769&nbsp;mg/mg<BR><B><I>p&lt;.001</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">-2.792&nbsp;mg/mg<BR><B><I>p=.006</I></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP ALIGN="center"><I><FONT STYLE="white-space:nowrap">All&nbsp;p-values&nbsp;are&nbsp;vs&nbsp;control</FONT></I></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SLEDAI reduction and reduction in UPCR in the low dose voclosporin arm were each statistically significant when compared
to the control group. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;30, 2016, we presented detailed results on the AURA 24 week clinical trial. These included a number of <FONT
STYLE="white-space:nowrap">pre-specified</FONT> subset and <FONT STYLE="white-space:nowrap">co-variate</FONT> analyses and <FONT STYLE="white-space:nowrap">post-hoc</FONT> analyses on the data, which show rapid proteinuria reduction and early
remission. Based on recent literature suggesting that using a UPCR of <FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT>.7mg/mg has better predictive power regarding long-term renal outcomes in LN patients, we performed a post hoc analysis applying this
measure. In doing so, we saw both a greater treatment difference between the 23.7mg BID voclosporin arm and the control arm, and better statistical power, which improves from a <FONT STYLE="white-space:nowrap">p-value</FONT> of .045 to less than
..01. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on these data and the 48 week data we believe: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">voclosporin has shown statistically significant efficacy in multiple dimensions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">pre-specified</FONT> and <FONT STYLE="white-space:nowrap">post-hoc</FONT> analyses have provided valuable insight; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the LN Phase 3 clinical trial will be <FONT STYLE="white-space:nowrap">de-risked</FONT> based upon the AURA results; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">biomarker data suggest significant effect on the underlying immunologic process of the disease. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also released detailed safety data for the trial including an <FONT STYLE="white-space:nowrap">in-depth</FONT>
mortality assessment. The safety and tolerability of voclosporin has been well-documented in numerous studies. In previous studies, over 2,200 patients have been treated with voclosporin across multiple indications with no unexpected SAEs. Clinical
doses of voclosporin studies to date range from <FONT STYLE="white-space:nowrap">13-70</FONT> mg BID. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In comparing four global LN trials: AURA, Aspreva
Lupus Management Study (ALMS), Ocrelizumab and Abatacept, it is evident that the AURA clinical trial enrolled the most severe patients, as measured by proteinuria at baseline. The difference in UPCR and the eGFR in the low dose voclosporin arm at
baseline indicates patients had more severe disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No new safety signals were observed with the use of voclosporin in LN patients and voclosporin was
well- tolerated. The overall safety profile of voclosporin is consistent with other immunomodulators. The summary of AEs by system organ class (SOC) across arms in the study is as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="28%"></TD>
<TD VALIGN="bottom" WIDTH="17%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="17%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="17%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">System Organ Class</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Control</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Voclosporin&nbsp;23.7mg&nbsp;BID</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Voclosporin&nbsp;39.5&nbsp;mg&nbsp;BID</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(SOC)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N=88</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N=89</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N=88</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Any AE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">74&nbsp;(84.1)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">81&nbsp;(91.0)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">84&nbsp;(95.5)</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thirteen deaths have been reported in the AURA clinical trial&#151;a pattern that is consistent with other global active LN
studies. Eleven of thirteen deaths occurred at sites with compromised access to standard of care; and patients who died in the trial had a statistically different clinical baseline picture, indicating a more severe form of LN, potential comorbid
conditions and poor nutrition. The last death in the study occurred in February 2016. Both the FDA and Data Safety Monitoring Board have reviewed in detail each death that occurred in the trial. No dose-dependent relationship was observed. Between
the 24 and 48 week endpoints, these were one SAE in the control arm and two SAEs in the low dose voclosporin arm of the study. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;15, 2016,
at the American College of Rheumatology annual meeting, we presented speed of remission data from the AURA clinical trial in a late-breaking abstract titled &#147;Speed of Remission with the Use of Voclosporin, MMF and Low Dose Steroids: Results of
a Global Lupus Nephritis Study. The data presented are a <FONT STYLE="white-space:nowrap">post-hoc</FONT> responder analysis (median time to CR for those who achieve CR), demonstrating 7.3 weeks to CR for voclosporin 23.7mg BID vs the control arm of
12 weeks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;21, 2016, at the American Society of Nephrology Kidney Week 2016, we presented renal function data for the AURA clinical trial
in a late breaking session titled &#147;High Impact Clinical Trials&#148;. These data showed that in the voclosporin treatment arms, the renal function as measured by eGFR was stable and not significantly different from the control arm during the
course of the trial. Mean blood pressure was slightly reduced and was similar between all treatment groups. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>FDA Fast Track </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;2, 2016 we announced that the FDA granted Fast Track designation for voclosporin. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Fast Track program was created by the FDA to facilitate the development and expedite the review of new drugs that are intended to treat serious or
life-threatening conditions and that demonstrate the potential to address significant unmet medical needs. Compounds that receive this FDA designation benefit from more frequent meetings and communications with the FDA to review the drug&#146;s
development plan including the design of clinical trials and the use of biomarkers to support approval. Additionally, Fast Track designation allows us to submit parts of the New Drug Application (&#147;NDA&#148;) on a rolling basis for review as
data becomes available. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Manufacturing Collaboration Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective November&nbsp;22, 2016 we entered into a long-term agreement with Lonza Ltd. (&#147;Lonza&#148;) for the manufacture of voclosporin active
pharmaceutical ingredient (&#147;API&#148;). This agreement follows a successful multi-year clinical manufacturing relationship where Aurinia and Lonza have been refining the process and analytical methods to produce clinical and commercial supplies
of voclosporin. Under the terms of the agreement, Lonza has agreed to produce cGMP-grade voclosporin drug substance for use in our Phase 3 LN clinical trial program and for future commercial use. The agreement also provides an option to have Lonza
exclusively supply API for up to 20 years. We submitted a binding purchase order in the amount of CHF 2.05&nbsp;million to Lonza for the manufacture of API for future use. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Appointment of New Director </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;12,
2016, we announced the appointment of Lorin Jeffry &#147;Jeff&#148; Randall to our board of directors and Chairman of the Audit Committee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FINANCING ACTIVITIES IN 2016 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>December 2016 Offering </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;28, 2016,
we announced that we closed our US$28.75&nbsp;million financing (including US$3.75&nbsp;million pursuant to an exercise of the underwriter&#146;s over-allotment option), for the sale of 12.78&nbsp;million units (&#147;December Units&#148;) of the
Company at a price of US$2.25 per December Unit (the &#147;December 2016 Offering&#148;). Each December Unit consists of one common share of the Company and one half of one common share purchase warrant (each whole warrant, a &#147;Warrant&#148;).
Each Warrant entitles the holder thereof to purchase one common share at the exercise price of US$3.00 per common share for a period of 5 years after the closing of the offering. H.C. Wainwright&nbsp;&amp; Co., LLC acted as sole book-running
manager, and Cormark Securities Inc., as <FONT STYLE="white-space:nowrap">co-manager</FONT> (collectively, the &#147;Underwriters&#148;). The Underwriters received a fee of 7% of the gross proceeds of the offering </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">At-the-Market</FONT></FONT> Facility &#150; July&nbsp;22, 2016 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;22, 2016 we announced that we had entered into a Controlled equity Offering Sales Agreement with Cantor Fitzgerald pursuant to which the Company
was authorized to sell, from time to time, through <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">at-the-market</FONT></FONT> offerings (the &#147;July ATM&#148;) with Cantor Fitzgerald acting as sales agent, such common shares as
would have an aggregate offer price of up to US$10&nbsp;million. We also filed a prospectus supplement with securities regulatory authorities in Canada in the provinces of British Columbia, Alberta and Ontario, and with the United States Securities
and Exchange Commission, which supplemented our short form base shelf prospectus dated October&nbsp;16, 2015, and our shelf registration statement on Form <FONT STYLE="white-space:nowrap">F-10</FONT> dated October&nbsp;16, 2015, declared effective
on November&nbsp;5, 2015. Sales in the July ATM were only conducted in the United States through NASDAQ at market prices. No sales were conducted in Canada or through the Toronto Stock Exchange. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of October&nbsp;3, 2016, sales pursuant to the July ATM were concluded. We issued 3.31&nbsp;million common shares, receiving gross proceeds in the
aggregate of $8.0&nbsp;million ($6.14&nbsp;million in the third quarter of 2016 and $1.86&nbsp;million subsequent to the quarter end), (being the maximum value permissible in accordance with Canadian securities laws). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">At-the-Market</FONT></FONT> Facility &#150; November&nbsp;9, 2016 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company entered into a second Controlled Equity Offering<SUP STYLE="font-size:85%; vertical-align:top">SM</SUP>&nbsp;Sales Agreement (the &#147;Sales
Agreement&#148;) with Cantor Fitzgerald &amp; Co. dated November&nbsp;9, 2016 relating to the sale of the common shares having an aggregate offering price of up to $8.0&nbsp;million. We also filed a prospectus supplement on November&nbsp;9, 2016
with securities regulatory authorities in Canada in the provinces of British Columbia, Alberta and Ontario, and with the United States Securities and Exchange Commission, which supplemented our shelf prospectus. The prospectus supplement was amended
and an amended and restated prospectus supplement was filed on February&nbsp;24, 2017 to update changes to Company information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Sales under this ATM
are only conducted in the United States through NASDAQ at market prices. No sales will be conducted in Canada or through the Toronto Stock Exchange. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As
at December 31, 2016 and March 6, 2017, we had issued 138,986 common shares and received gross proceeds of $396,000 leaving the Company authorized to sell such common shares as would have an aggregate offer price of up to $7.6 million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Private Placement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;22, 2016, we
completed a private placement (the &#147;June 2016 Private Placement&#148;) of 3.0&nbsp;million units (&#147;Units&#148;) at $2.36 per Unit for aggregate gross proceeds of $7.08&nbsp;million. Each Unit consisted of one common share and a 0.35 of one
common share purchase warrant exercisable for a period of two years from the date of issuance at an exercise price of $2.77. Further information regarding the terms of the June 2016 Private Placement and the Units issued thereunder can be found in
our material change report dated June&nbsp;23, 2016, which is incorporated by reference herein. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Exercise of warrants and options </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also received proceeds of $1.90&nbsp;million from the exercise of warrants and $107,000 from the exercise of stock options in 2016. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RESULTS OF OPERATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the year ended
December&nbsp;31, 2016, the Company reported a consolidated net loss of $23.30&nbsp;million or $0.66 loss per common share, as compared to a consolidated net loss of $18.61&nbsp;million or $0.58 loss per common share for the year ended
December&nbsp;31, 2015. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recorded a gain on revaluation of derivative warrant liabilities of $1.73&nbsp;million in 2016
compared to a gain of $5.10&nbsp;million in 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After adjusting for the <FONT STYLE="white-space:nowrap">non-cash</FONT> impact of the revaluation of
the warrant liability, the net loss from operations for the year ended December&nbsp;31, 2016 was $25.03&nbsp;million compared to $23.71&nbsp;million for the year ended December&nbsp;31, 2015. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Revenue and deferred revenue </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recorded
revenue of $173,000 for the year ended December&nbsp;31, 2016 compared to $235,000 for the year ended December&nbsp;31, 2015. The decrease in revenue was primarily the result of deferred revenue related to the Paladin Labs Inc. fee payments being
fully amortized in June of 2016. The remaining deferred revenue relates to the 3SBio Inc. fee payment. This fee payment is being amortized on a straight line basis which approximates how the Company expects to incur patent annuity costs for certain
specified countries related to meeting its obligations under the terms of the agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Research and Development expenses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expenditures decreased to $14.53&nbsp;million for the year ended December&nbsp;31, 2016 compared to $15.98&nbsp;million for the year
ended December&nbsp;31, 2015. The decrease in expenditures reflected lower costs related to the AURA clinical trial as patients completed the trial, offset to a certain extent by planning and <FONT STYLE="white-space:nowrap">start-up</FONT> costs of
the Phase 3 LN trial (AURORA) including CRO and clinical site selections and regulatory submissions and initiation of the capsule manufacturing process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CRO and other third party clinical trial costs were $10.18&nbsp;million for the year ended December&nbsp;31, 2016 compared to $11.0&nbsp;million for 2015.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company incurred drug supply costs of $1.80&nbsp;million for the year ended December&nbsp;31, 2016, including drug packaging, stability, distribution
and freight for the AURA clinical trial and drug manufacturing activities required for the AURORA trial compared to $1.98&nbsp;million for 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Salaries, annual incentive pay and employee benefits were $1.62&nbsp;million for the year ended December&nbsp;31, 2016 compared to $1.43&nbsp;million for
2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recorded <FONT STYLE="white-space:nowrap">non-cash</FONT> stock compensation expense of $330,000 for year ended December&nbsp;31, 2016
compared to $862,000 for 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patent annuity and other patent related legal fees expensed were $228,000 for the year ended December&nbsp;31, 2016
compared to $313,000 for 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Travel expenses related to research and development were $292,000 for the year ended December&nbsp;31, 2015 compared to
$274,000 for 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Miscellaneous other expenses, which included items such as clinical trial insurance, phone, publications and trial courier costs,
decreased to $84,000 in 2016 as opposed to $122,000 in 2015 due to decreased activity levels in the AURA clinical trial. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate, administration and
business development expenses </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Corporate, administration and business development expenses were $6.97&nbsp;million for the year ended December&nbsp;31,
2016 compared to $6.26&nbsp;million for 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Corporate, administration and business development expenses included
<FONT STYLE="white-space:nowrap">non-cash</FONT> stock-based compensation expense of $1.05&nbsp;million for the year ended December&nbsp;31, 2016 compared to $2.36&nbsp;million for 2015. While the number of stock options granted increased to
1.67&nbsp;million options in 2016 compared to 1.46&nbsp;million in 2015, the decrease in stock-based compensation expense in 2016 primarily reflected a change during the year to a three year vesting term whereas previously it had been one year and
also that in 2016, the grant dates of the options in 2016 were later in the year than in 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other expenses were as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Salaries, incentive pay accruals and employee benefits were $2.64&nbsp;million for the year ended December&nbsp;31, 2016 compared to $1.72&nbsp;million for
2015. The increase for the year ended December&nbsp;31, 2016 from the comparable period in 2015 was due to; severance costs related to the replacement of the chief executive officer in April of 2016; a higher bonus provision in 2016 and the hiring
of 4 additional staff members during the year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Trustee fees, filing fees and other public company costs were $193,000 respectively for the year ended
December&nbsp;31, 2016 compared to $177,000 for 2015. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Professional and consulting fees were $1.66&nbsp;million for the year ended December&nbsp;31, 2016 compared to
$885,000 for 2015. The increase resulted primarily due to consulting fees incurred in 2016 for increased investor and public relations activities and significant work conducted in 2016 related to market and payor research in the major markets,
including the United States, Europe and Japan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Director fees were $261,000 for the year ended December&nbsp;31, 2016 compared to $308,000 for 2015 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Insurance, office, phone, information technology services and other tax costs increased to $457,000 in 2016 compared to $308,000 in 2015 resulting from
increased activity levels. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Travel and promotion expenses increased to $522,000 for the year ended December&nbsp;31, 2016 compared to $300,000 for 2015.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rent, utilities and other facility were $179,000 for the year ended December&nbsp;31, 2016 compared to $202,000 for 2015. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock-based compensation expense </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For stock option plan
information and outstanding stock option details refer to note 12(c) of the audited consolidated financial statements for the year ended December&nbsp;31, 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Application of the fair value method resulted in charges to stock-based compensation expense of $1.38&nbsp;million for the year ended December&nbsp;31, 2016
(2015 &#150; $3.22 million) with corresponding credits to contributed surplus. For the year ended December&nbsp;31, 2016, stock compensation expense has been allocated to research and development expense in the amount of $330,000 (2015 &#150;
$862,000) and corporate, administration and business development expense in the amount of $1.05&nbsp;million (2015 &#150; $2.36 million). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amortization
of intangible assets </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amortization of intangible assets was consistent at $1.46&nbsp;million for the year ended December&nbsp;31, 2016 compared to
$1.54&nbsp;million recorded in 2015. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other expense (income) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recorded other expense of $2.21&nbsp;million for the year ended December&nbsp;31, 2016 compared to other expense of $128,000 for 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other expense (income) included the following items: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revaluation expense adjustments on long term contingent consideration to ILJIN Life Science Co., Ltd. (&#147;ILJIN&#148;) of $1.63&nbsp;million for the year
ended December&nbsp;31, 2016 compared to $337,000 for 2015. The contingent consideration is more fully discussed in note 10 to the consolidated financial statements for the year ended December&nbsp;31, 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company also recorded an expense of $655,000 related to share issue costs allocated to derivative warrants incurred to complete the December&nbsp;28, 2016
bought deal public offering, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A foreign exchange gain of $26,000 for the year ended December&nbsp;31, 2016 compared to a foreign exchange gain of $159,000
for 2015 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Gain on derivative warrant liabilities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company recorded a <FONT STYLE="white-space:nowrap">non-cash</FONT> gain on the derivative warrant liabilities of $1.73&nbsp;million for the year ended December&nbsp;31, 2016 compared to <FONT STYLE="white-space:nowrap">non-cash</FONT> gain of
$5.10&nbsp;million for 2015. These revaluations fluctuate based primarily on the market price of the Company&#146;s common shares. Derivative warrant liabilities are more fully discussed in the section &#147;Critical estimates in applying the
Company&#146;s accounting policies&#148; and note 11 to the consolidated financial statements for the year ended December&nbsp;31, 2016. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LIQUIDITY AND CAPITAL RESOURCES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company is in the development stage and is devoting substantially all of its operational efforts and financial resources towards completing the AURA clinical trial activities for its late stage drug, voclosporin. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As at December&nbsp;31, 2016, the Company had net working capital of $33.49&nbsp;million compared to
$12.92&nbsp;million as at December&nbsp;31, 2015. For the year ended December&nbsp;31, 2016, the Company reported a loss of $23.30&nbsp;million (December 31, 2015 &#150; $18.61 million) and a cash outflow from operating activities of
$18.71&nbsp;million (December 31, 2015 &#150; $17.77 million). As at December&nbsp;31, 2016, the Company had an accumulated deficit of $281.05&nbsp;million (December 31, 2015 &#150; $257.75 million). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;16, 2015, the Company had filed a Short Form Base Shelf Prospectus (the Shelf Prospectus). The Shelf Prospectus and corresponding shelf
registration statement allows us to offer up to $250&nbsp;million of common shares, warrants and subscription receipts or any combination thereof during the <FONT STYLE="white-space:nowrap">25-month</FONT> period that the Shelf Prospectus is
effective. The Shelf Prospectus is intended to give us the capability to access new capital from time to time. The Base shelf prospectus has been utilized for the bought deal public offering and the ATM facilities done in 2016, and as result, the
remaining amount currently available under the Base Shelf Prospectus is $205&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The gross proceeds of $42.62&nbsp;million received from
financing activities in 2016 have provided the Company with liquidity in the short-term and sufficient funding to complete the Phase 2b LN trial and fund the planned activities for the Phase 3 LN clinical trial into the fourth quarter of 2017.
However, we will need to seek additional funding from such potential sources as debt financing, licensing of specific territories and /or additional equity offerings within the next 12 months in order to continue the development and
commercialization of voclosporin for LN, and in particular, the Phase 3 clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any sale of additional equity will result in dilution to our
shareholders. There can be no assurance that we will be able to successfully obtain future financing in the amounts or terms acceptable to the Company, if at all, in order to continue our planned operational activities. If we are unable to obtain
financing to fund the development program and our future operational activities, we may be required to delay, reduce the scope of, or eliminate the planned development activities, which could harm our future financial condition and operating
results. Without this additional funding, we will be required to review our strategic alternatives. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sources and Uses of Cash: </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Year ended<BR>December&nbsp;31,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Year ended<BR>December&nbsp;31,<BR>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Increase</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Decrease)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">$</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">$</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">$</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,713</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,766</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(947</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash provided by (used in) investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,776</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net increase (decrease) in cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>33,893</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(16,950</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>50,843</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2016, the Company had a total of $39.65&nbsp;million in cash and equivalents compared to
$5.76&nbsp;million at December&nbsp;31, 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities in fiscal 2016 was $18.72&nbsp;million, an increase of $947,000 from
cash used in operating activities of $17.77&nbsp;million in fiscal 2015. Cash used in operating activities in 2016 and 2015 was composed of net loss, <FONT STYLE="white-space:nowrap">add-backs</FONT> or adjustments not involving cash and net change
in <FONT STYLE="white-space:nowrap">non-cash</FONT> working items. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash provided in fiscal 2016 was $9.99&nbsp;million compared to cash used in investing
activities of $23,000 for fiscal 2015. In 2016 the Company redeemed on a net basis a bank discount note for $9.99&nbsp;million which was required to be reflected as a short term investment and therefore as an investing activity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash provided by financing activities for fiscal 2016 was $42.62&nbsp;million compared to cash provided by financing activities in fiscal 2015 of $839,000.
The Company received $1.91&nbsp;million from the exercise of warrants for fiscal 2016 compared to $685,000 for 2015. The Company also received $107,000 from the exercise of stock options for fiscal 2016 ($154,000 in 2015). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Use of Proceeds </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;14, 2014, we completed a private placement with net proceeds of $48.31&nbsp;million, the net proceeds of which were to be used to advance the
clinical and <FONT STYLE="white-space:nowrap">non-clinical</FONT> development of our lead drug, voclosporin, as a therapy for LN, and for general corporate purposes. A summary of the anticipated and actual use of proceeds from February&nbsp;14, 2014
to the date proceeds were fully utilized in 2016 from this financing is set out below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Expected&nbsp;use&nbsp;of&nbsp;proceeds</B><br><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual&nbsp;use&nbsp;of&nbsp;proceeds</B><br><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development for voclosporin</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other corporate purposes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate, administration and business development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repayment of drug supply loan</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment of financing milestone to ILJIN</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reduction in accounts payable and accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Actual use of proceeds higher than estimated for research and development activities as the AURA trial enrollment timelines
were longer than estimated requiring additional funds and AURION study conducted which was not originally planned for. These additional costs were offset by less costs for corporate, administration and business development than originally forecast.
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONTRACTUAL OBLIGATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
has the following contractual obligations as at December&nbsp;31, 2016 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Less than</B><br><B>one year</B><br><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Two&nbsp;to&nbsp;three</B><br><B>years</B><br><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Greater&nbsp;than</B><br><B>three years</B><br><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease obligations <SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase obligations <SUP STYLE="font-size:85%; vertical-align:top">(2)(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable and accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contingent consideration to ILJIN
<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,084</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14,217</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,795</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>338</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,084</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Operating lease obligations are comprised of the Company&#146;s future minimum lease payments for its premises. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">The Company has entered into contractual obligations for services and materials required for the AURA and AURORA clinical trials and other operational activities. The purchase obligations presented represent the minimum
amount to exit the Company&#146;s contractual commitments. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Includes a binding purchase order of $2,016,000 (2,054,000 CHF) to Lonza Ltd. for the manufacture of API for future use. This is exclusive of $1,043,000 already paid to Lonza in 2016 as a deposit which is recorded in
prepaid expenses. This deposit will be applied against the total cost of $3,059,000 for the manufacture of the API when completed. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Contingent consideration to ILJIN is described in note 10 to the consolidated audited financial statements for the year ended December&nbsp;31, 2016. </TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RELATED PARTY TRANSACTIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stephen P.
Robertson, a partner at Borden Ladner Gervais (&#147;BLG&#148;), acts as the Company&#146;s corporate secretary. The Company recorded legal fees, incurred in the normal course of business to BLG of $308,000 for the year ended December&nbsp;31, 2016
compared to $101,000 for the year ended December&nbsp;31, 2015. The amount charged by BLG is based on standard hourly billing rates for the individuals working on the Company&#146;s account. The Company has no ongoing contractual or other
commitments as a result of engaging Mr.&nbsp;Robertson to act as the Company&#146;s corporate secretary. Mr.&nbsp;Robertson receives no additional compensation for acting as the corporate secretary beyond his standard hourly billing rate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Compensation paid to key management personnel is disclosed in note 19 to the audited consolidated financial statements for the year ended December&nbsp;31,
2016. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">OFF-BALANCE</FONT> SHEET ARRANGEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To date the Company has not had any relationships with unconsolidated entities or financial partnerships, such as entities referred to as structured finance
or special purpose entities, which are established for the purpose of facilitating <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements or other contractually narrow or limited purposes. The Company does have <FONT
STYLE="white-space:nowrap">off-balance</FONT> sheet financing arrangements consisting of various lease agreements which are entered into in the normal course of operations. All leases have been treated as operating leases whereby the lease payments
are included in Corporate, administration and business development expenses. All of the lease agreement amounts have been reflected in the Contractual Obligations table above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of consolidated financial statements in accordance with IFRS often requires management to make estimates about, and apply assumptions or
subjective judgment to, future events and other matters that affect the reported amounts of the Company&#146;s assets, liabilities, revenues, expenses and related disclosures. Assumptions, estimates and judgments are based on historical experience,
expectations, current trends and other factors that management believes to be relevant at the time at which the Company&#146;s consolidated financial statements are prepared. Management reviews, on a regular basis, the Company&#146;s accounting
policies, assumptions, estimates and judgments in order to ensure that the consolidated financial statements are presented fairly and in accordance with IFRS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Critical accounting estimates and judgments are those that have a significant risk of causing material adjustment and are often applied to matters or outcomes
that are inherently uncertain and subject to change. As such, management cautions that future events often vary from forecasts and expectations and that estimates routinely require adjustment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A complete listing of critical accounting policies, estimates, judgments and measurement uncertainty can be found in Note 4 of the annual consolidated
financial statements for the year ended December&nbsp;31, 2016. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NEW ACCOUNTING STANDARDS, AMENDMENTS AND INTERPRETATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain new standards, interpretations, amendments and improvements to existing standards were issued by the IASB or International Financial Reporting
Interpretations Committee (&#147;IFRIC&#148;) that are not yet effective for the year ended December&nbsp;31, 2016. The standards impacted that are applicable to the Company are as follows: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>IAS 7 Statement of cash flows </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective for years
beginning on or after January&nbsp;1, 2017 IAS 7 <I>Statement of cash flows</I> was amended to require disclosures about changes in liabilities arising from financing activities, including both changes arising from cash flows and <FONT
STYLE="white-space:nowrap">non-cash</FONT> changes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>IFRS 9 Financial instruments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In July 2014 the IASB revised IFRS 9 <I>Financial Instruments</I>. IFRS 9 is a three-part standard to replace IAS 39 <I>Financial Instruments: Recognition and
Measurement</I>, addressing new requirements for i) classification and measurement, ii) impairment, iii) hedge accounting.&nbsp;The standard is effective for annual periods beginning on or after January&nbsp;1, 2018.&nbsp;Management is assessing the
potential impact that the adoption of IFRS 9 will have on the Company&#146;s financial statements </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>IFRS 15 Revenue from contracts with customers
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IFRS 15, Revenue from Contracts with Customers, deals with revenue recognition and establishes principles for reporting useful information to
users of financial statements about the nature, amount, timing and uncertainty of revenue and cash flows arising from an entity&#146;s contracts with customers. Revenue is recognized when a customer obtains control of goods or services and thus has
the ability to direct the use and obtain the benefits from the goods or services. The standard replaces IAS 18, Revenue, and IAS 11, Construction Contracts, and related interpretations. The standard is effective for annual periods beginning on or
after January&nbsp;1, 2018 and earlier application is permitted. We have yet to assess the impact of IFRS 15. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>IFRS 16 Leases </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2016, the IASB issued IFRS 16 <I>Leases</I>, which will replace IAS 17 <I>Leases</I>. Under IFRS 16, a contract is, or contains, a lease if the
contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.&nbsp;Under IAS 17, lessees were required to make a distinction between a finance lease and an operating lease. IFRS 16 now
requires lessees to recognise a lease liability reflecting future lease payments and a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset for virtually all lease contracts. There is optional exemption
for certain short-term leases and leases of <FONT STYLE="white-space:nowrap">low-value</FONT> assets; however, this exemption can only be applied by lessees.&nbsp;The standard is effective for annual periods beginning on or after January&nbsp;1,
2019, with earlier adoption if IFRS 15 is also applied. Management is assessing the potential impact that the adoption of IFRS 16 will have on the Company&#146;s financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RISKS AND UNCERTAINTIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has invested a significant portion of its time and financial resources in the development of voclosporin. We anticipate that our ability to
generate revenues and meet expectations will depend primarily on the successful development and commercialization of voclosporin. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The successful
development and commercialization of voclosporin will depend on several factors, including the following: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since its inception, the Company has
experienced recurring operating losses and negative cash flows, and expects to continue to generate operating losses and consume significant cash resources for the foreseeable future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The proceeds received in 2016 from the Bought Deal public offering, ATM, warrant exercises and private placement have provided the Company with liquidity in
the short-term and sufficient funding to complete the Phase 2b LN trial and fund the planned activities for the Phase 3 LN clinical trial into the fourth quarter of 2017. However, we will need to seek additional funding from such potential sources
as debt financing, licensing of specific territories and /or additional equity offerings within the next 12 months in order to continue the development and commercialization of voclosporin for LN, and in particular, the Phase 3 LN clinical trial.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These conditions raise substantial doubt about our ability to continue as a going concern without raising this additional required capital. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result, the Company&#146;s consolidated financial statements for the year ended December&nbsp;31, 2016, contain a going concern note (note 2) with
respect to this uncertainty. Substantial doubt about the Company&#146;s ability to continue as a going concern may materially and adversely affect the price per share of our common shares, and it may be more difficult for us to obtain financing. The
going concern note in the consolidated financial statements may also adversely affect our relationships with current and future collaborators, contract manufacturers and investors, who may grow concerned about our ability to meet our ongoing
financial obligations. If potential collaborators decline to do business with the Company or potential investors decline to participate in any future financings due to such concerns, our ability to increase the Company&#146;s cash position may be
limited. We prepared the financial statements on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company&#146;s consolidated financial
statements for the year ended December&nbsp;31, 2016 do not include any adjustment to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the
outcome of this uncertainty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other risk factors also include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">successful completion of our clinical program in LN, including the Phase 3 AURORA clinical trial expected to commence in the second quarter of 2017; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">receipt of marketing approvals from the FDA and other regulatory authorities with a commercially viable label; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">securing and maintaining partners with sufficient expertise and resources to help in the continuing development and eventual commercialization of voclosporin; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintaining suitable manufacturing and supply arrangements to ensure commercial quantities of the product through validated processes; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acceptance and adoption of the product by the medical community and third-party payors; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to raise future financial resources when required. Future additional sources of capital could include payments from potential new licensing partners, equity financings, debt financings and/or the
monetization of our intangible assets. There is no assurance of obtaining additional future financing through these arrangements or any arrangements on acceptable terms. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A more detailed list of the risks and uncertainties affecting the Company can be found in our AIF which is filed on SEDAR and EDGAR. Additional risks and
uncertainties of which we are unaware, or that we currently deem to be immaterial, may also become important factors that affect the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Capital
management </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our objective in managing capital is to ensure a sufficient liquidity position to safeguard the Company&#146;s ability to continue as a
going concern in order to provide returns for shareholders and benefits for other stakeholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We define capital as net equity, comprised of issued
common shares, warrants, contributed surplus and deficit. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our objective with respect to capital management is to ensure that we have sufficient cash resources to maintain
our ongoing operations and finance our research and development activities, corporate, administration and business development expenses, working capital and overall capital expenditures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since inception, we have primarily financed the Company&#146;s liquidity needs through public offerings of common shares and private placements. We have also
met the Company&#146;s liquidity needs through <FONT STYLE="white-space:nowrap">non-dilutive</FONT> sources, such as debt financings, licensing fees from our partners and research and development fees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There have been no changes to our objectives and what we manage as capital since the prior fiscal period. We are not subject to externally imposed capital
requirements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial risk factors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company&#146;s activities expose it to a variety of financial risks: market risk (including currency risk, interest rate risk and other price risk), credit risk and liquidity risk. Risk management is carried out by management under policies approved
by the board of directors. Management identifies and evaluates the financial risks. The Company&#146;s overall risk management program seeks to minimize adverse effects on the Company&#146;s financial performance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidity risk </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Liquidity risk is the risk that
the Company will not be able to meet its financial obligations as they fall due. The Company manages its liquidity risk through the management of its capital structure and financial leverage. It also manages liquidity risk by continuously monitoring
actual and projected cash flows. The Board of Directors and/or the Audit Committee reviews and approves the Company&#146;s operating budgets, as well as any material transactions out of the ordinary course of business. The Company invests its cash
in term deposits and bank discount notes with 30 to 180 day maturities to ensure the Company&#146;s liquidity needs are met. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s
activities have been financed through a combination of the cash flows from licensing and development fees and the issuance of equity and/or debt. As described in the Going concern note 2 to the consolidated financial statements for the year ended
December&nbsp;31, 2016, the Company is dependent on raising additional financing to sustain operations and complete the Phase 3 LN clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All of
the Company&#146;s financial liabilities are due within one year except for the contingent consideration to ILJIN and the derivative warrant liability. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest rate, credit and foreign exchange risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We invest our cash reserves in fixed rate, highly liquid and highly rated financial instruments such as treasury bills, term deposits and bank discount notes
which are all denominated in US dollars. We do not believe that the results of operations or cash flows would be affected to any significant degree by a sudden change in market interest rates relative to our investment portfolio, due to the relative
short-term nature of the investments and current ability to hold the investments to maturity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are exposed to financial risk related to the fluctuation
of foreign currency exchange rates which could have a material effect on our future operating results or cash flows. Foreign currency risk is the risk that variations in exchange rates between the United States dollar and foreign currencies,
primarily with the Canadian dollar, will affect our operating and financial results. We hold our cash reserves in US dollars and the majority of our expenses, including clinical trial costs are also denominated in US dollars, which mitigates the
risk of foreign exchange fluctuations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the Company&#146;s functional currency is the US dollar, we have foreign exchange exposure to the CDN dollar.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents our exposure to the CDN dollar: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>December&nbsp;31,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2016</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>December&nbsp;31,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2015</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable and accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,184</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(803</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net exposure</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,073</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(648</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Reporting date rate</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>December&nbsp;31,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2016</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>December&nbsp;31,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2015</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$CDN - $US</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.723</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on our foreign currency exposures noted above, varying the foreign exchange rates to reflect a ten percent strengthening
of the US dollar would have decreased the net loss by $107,000 as at December&nbsp;31, 2016 assuming that all other variables remained constant. An assumed 10&nbsp;percent weakening of the US dollar would have had an equal but opposite effect to the
amounts shown above, on the basis that all other variables remain constant. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONTINGENCIES </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i)</TD>
<TD ALIGN="left" VALIGN="top">We may, from time to time, be subject to claims and legal proceedings brought against the Company in the normal course of business. Such matters are subject to many uncertainties. Management believes that the ultimate
resolution of such contingencies will not have a material adverse effect on the consolidated financial position of the Company. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">ii)</TD>
<TD ALIGN="left" VALIGN="top">The Company has entered into indemnification agreements with its officers and directors. The maximum potential amount of future payments required under these indemnification agreements is unlimited. However, the Company
does maintain liability insurance to limit the exposure of the Company. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">iii)</TD>
<TD ALIGN="left" VALIGN="top">The Company has entered into license and research and development agreements with third parties that include indemnification and obligation provisions that are customary in the industry. These guarantees generally
require the Company to compensate the other party for certain damages and costs incurred as a result of third party claims or damages arising from these transactions. These provisions may survive termination of the underlying agreement. The nature
of the obligations prevents the Company from making a reasonable estimate of the maximum potential amount it could be required to pay. Historically, the Company has not made any payments under such agreements and no amount has been accrued in the
accompanying interim condensed consolidated financial statements. </TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INTERNAL CONTROL OVER FINANCIAL REPORTING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Management&#146;s Annual Report on Internal Control over Financial Reporting </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s management, including the Chief Executive Officer and Chief Financial Officer, is responsible for establishing and maintaining adequate
internal control over financial reporting, and has designed such internal control over financial reporting (ICFR) to provide reasonable assurance regarding the reliability of financial reporting and the preparation and fair presentation of financial
statements for external purposes in accordance with IFRS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management does not expect that the Company&#146;s internal controls and procedures over
financial reporting will prevent all error and all fraud. A control system provides only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitation in all control systems, no evaluation
of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgements in decision-making can be faulty, and that
breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons by collusion of two or more people or by management override of the control. The design of any system of
controls also is based in part upon certain assumptions about the likelihood of future events and there can be no assurance that any design will succeed in achieving the Company&#146;s stated goals under all potential future conditions. Because of
the inherent limitations in a cost-effective control system, misstatements due to error fraud may occur and not be detected. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become
inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management evaluated the
effectiveness of the Company&#146;s ICFR as of December&nbsp;31, 2016 based on the framework set forth in Internal Control-Integrated Framework (2013)&nbsp;issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based
on this evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the Company&#146;s ICFR were effective as of December&nbsp;31, 2016. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DISCLOSURE CONTROLS AND PROCEDURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Disclosure controls and procedures (&#147;DC&amp;P&#148;) as defined in National Instrument <FONT STYLE="white-space:nowrap">52-109</FONT> <I>Certification of
Disclosure in Issuers&#146; Annual and Interim Filings</I>, are designed to provide reasonable assurance that all material information required to be publicly disclosed in our annual, interim filings and other reports filed or submitted by us under
securities legislation is recorded, processed, summarized and reported within the time periods specified under securities legislation and include controls and procedures designed to ensure that information required to be so disclosed is accumulated
and communicated to management including the Chief Executive Officer and the Chief Financial Officer, as appropriate, to allow timely decisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives,
and, therefore, management is required to apply its judgment in evaluating and implementing possible controls and procedures. The Chief Executive Officer and the Chief Financial Officer, after evaluating the effectiveness of our disclosure controls
and procedures as at December&nbsp;31, 2016 have concluded that the disclosure controls and procedures were adequate and effective to provide reasonable assurance that material information we are required to disclose on a continuous basis in interim
and annual filings and other reports and news releases is recorded, processed, summarized and reported or disclosed on a timely basis as necessary. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UPDATED SHARE INFORMATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As at
March&nbsp;6, 2017, the following class of shares and equity securities potentially convertible into common shares were outstanding: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Common shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,428,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Convertible equity securities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative liability warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,600,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,183,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,622,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsequent to the <FONT STYLE="white-space:nowrap">year-end</FONT> we issued 1.97&nbsp;million stock options at a weighted
average price of $3.21 to the new Chief Executive Officer, other officers, directors and employees of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsequent to year end the Company
issued 610,000 common shares for proceeds of $1,814,000 upon the exercise of 74,000 warrants and 536,000 derivative liability warrants. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SUPPLEMENTAL INFORMATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Selected
Annual Information </B><I>(expressed in thousands of dollars, except per share data)</I> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of Operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expenses, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,200</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,943</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,925</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain (loss) on derivative warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,732</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,774</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss for the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,295</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,607</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,421</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.66</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.58</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.67</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of common shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance sheets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-current</FONT> contingent consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shareholder&#146;s equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,871</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quarterly Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(expressed in thousands except per share data) </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Set forth
below is unaudited consolidated financial data for each of the last eight quarters: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman"><B>2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Q1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Q2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Q3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Q4</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Annual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,534</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate, administration and business development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization and impairment of tangible and intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">365</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">365</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,078</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">966</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain (loss) on derivative warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(951</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">658</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,732</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss for the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,267</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,276</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,419</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,333</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,295</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Per common share ($)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per common share &#150; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.13</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.21</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.21</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.66</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common Shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,794</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of common shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman"><B>2015</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Q1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Q2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Q3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Q4</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Annual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate, administration and business development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,564</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization and impairment of tangible and intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">398</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,558</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense (income)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(55</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain (loss) on derivative warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,927</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss for the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,601</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(733</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,210</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,063</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,607</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Per common share ($)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per common share &#150; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.27</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.02</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.16</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.13</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.58</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common Shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,062</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of common shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary of Quarterly Results </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The primary factors affecting the magnitude of the Company&#146;s losses in the various quarters are noted below and include the timing of research and
development costs associated with the clinical development programs, timing and amount of stock compensation expense, fluctuations in the <FONT STYLE="white-space:nowrap">non-cash</FONT> gain (loss) on derivative warrant liability resulting from
required quarterly fair value adjustments and other specific <FONT STYLE="white-space:nowrap">one-time</FONT> items as noted below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We record <FONT
STYLE="white-space:nowrap">non-cash</FONT> gains (losses) each quarter resulting from fair value revaluation of the derivative warrant liability. These revaluations fluctuate based primarily on the market price of our common shares. An increase in
the market price of our shares results in gain on revaluation while a decrease results in a loss on revaluation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fourth Quarter Analysis </B>(See
<I>Quarterly Information</I> above for the fourth quarter comparative information detail). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recorded a consolidated net loss of
$8.33&nbsp;million or $0.21 per common share for the fourth quarter ended December&nbsp;31, 2016, compared to a consolidated net loss of $4.06&nbsp;million or $0.13 per common share for the fourth quarter ended December&nbsp;31, 2015. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The increase of $4.27&nbsp;million in the consolidated net loss was primarily attributable to the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Increased research and development costs of $1.81&nbsp;million in 2016 as spending on AURORA trial ramped up in the fourth quarter of 2016. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Corporate, administration and business expenses increased by $670,000 to $2.23&nbsp;million for the fourth quarter ended December&nbsp;31, 2016 compared to $1.56&nbsp;million for the corresponding period in 2015. The
increase was primarily the result of an increase in professional fees and in particular consulting fees in the fourth quarter of 2016 compared to the same period in 2015 as we increased investor and public relations, patient advocacy and market
research activities during the fourth quarter of 2016. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Other expense increased by $964,000 to $966,000 for the fourth quarter ended December&nbsp;31, 2016 compared to $2,000 for the corresponding period in 2015 as the Company recorded $655,000 of share issue costs allocated
to the derivative warrants issued pursuant to the December&nbsp;28, 2016 financing as other expense and recorded an increase of $319,000 on revaluation of contingent consideration. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The fair value adjustment gain on derivative warrant liability decreased by $802,000 to $658,000 in the fourth quarter ended December&nbsp;31, 2016 versus a gain of $1.46&nbsp;million in the comparable period in 2015.
</TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2017 OUTLOOK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Currently the Aurinia team is focused on preparations for initiating its Phase 3 program for voclosporin for the treatment LN. The Phase 3 AURORA clinical
trial will be a global <FONT STYLE="white-space:nowrap">52-week</FONT> double-blind, placebo controlled study of approximately 320 patients. We are finalizing the study protocol and regulatory submissions and in parallel are working on site
selection with trial initiation anticipated in Q2 2017. Patients will be randomized 1:1: to one of 23.7mg voclosporin BID and MMF or MMF and placebo with both arms receiving a stringent oral corticosteroid taper. The study population will be
comprised of patients with biopsy-proven active LN who will be evaluated on the composite efficacy endpoint of renal response at 24 and 52 weeks similar to that of the AURA clinical trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, we are working with both the EMA and the PMDA to outline plans for obtaining regulatory approvals in those jurisdictions. We have interacted
with both the EMA and PMDA and we believe study requirements have the potential to be constant worldwide. We expect the outcomes of these discussions to be finalized in Q2 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In conjunction with achieving these goals, we are also moving forward with the following key activities: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Manufacturing clinical drug supply; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Site submission and site activation for the Phase 3 trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Evaluating potential business development opportunities that can maximize voclosporin&#146;s value; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">In-depth</FONT> assessments of major market commercial potential of voclosporin; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Evaluating potential indication expansion for voclosporin; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Advocacy outreach to support patient awareness and assist in Phase 3 enrollment and eventual market uptake; </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect the additional following milestones for the first half of 2017: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Outcome of discussion with the EMA and PMDA; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Additional AURA <FONT STYLE="white-space:nowrap">48-week</FONT> secondary endpoint data (expected Q1/2017); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">AURION <FONT STYLE="white-space:nowrap">48-week</FONT> results; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Initiation of Phase 3 trial. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are confident we can execute a successful Phase 3 registration trial based on
the feedback from the FDA and the information gleaned from the AURA clinical trial. We will continue executing initiatives to maximize corporate value which primarily involves ensuring voclosporin reaches patients suffering from LN as soon as
possible. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.4
<SEQUENCE>5
<FILENAME>d313671dex994.htm
<DESCRIPTION>EX-99.4
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.4 </B></P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g313671ex994logo.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><I>Consent of Independent Auditor </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">We hereby consent to the inclusion on this Annual Report on Form <FONT STYLE="white-space:nowrap">40-F</FONT> for the year ended
December&nbsp;31, 2016 and the incorporation by reference in the registration statements on Form <FONT STYLE="white-space:nowrap">S-8</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-216447)</FONT> and Form
<FONT STYLE="white-space:nowrap">F-10</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-206994)</FONT> of Aurinia Pharmaceuticals Inc. of our report dated March&nbsp;6, 2017, relating to the consolidated financial statements, which appears
in the Annual Report. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">We also consent to reference to us under the heading &#147;Interests of Experts&#148;, which appears in the Annual
Information Form incorporated by reference in this Annual Report on Form <FONT STYLE="white-space:nowrap">40-F</FONT> which is incorporated by reference in the registration statement referred to above. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>(signed) &#147;PricewaterhouseCoopers LLP&#148; </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Chartered Professional Accountants </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Edmonton, Alberta </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>March&nbsp;9, 2017 </B></P> <P STYLE="font-size:72pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt; margin-left:5%">


<IMG SRC="g313671ex994001bnew.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>PricewaterhouseCoopers LLP </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>TD Tower, 10088 102 Avenue NW, Suite 1501, Edmonton, Alberta, Canada T5J 3N5 </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>T: +1 780 441 6700, F: +1 780 441 6776 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:8pt; font-family:ARIAL">&#147;PwC&#148; refers to PricewaterhouseCoopers LLP, an Ontario limited liability partnership. </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.5
<SEQUENCE>6
<FILENAME>d313671dex995.htm
<DESCRIPTION>EX-99.5
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.5 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION PURSUANT TO RULE 13a-14 OR 15d-14 OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Richard M. Glickman, certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">I have reviewed this annual report of Aurinia Pharmaceuticals Inc. on Form 40-F; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the
issuer as of, and for, the period presented in this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The issuer&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over
financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the issuer and have: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the issuer, including its
consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top">Evaluated the effectiveness of the issuer&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the
period covered by this report based on such evaluation; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top">Disclosed in this report any change in the issuer&#146;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to
materially affect, the issuer&#146;s internal control over financial reporting; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The issuer&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the issuer&#146;s auditors and the audit committee of the
issuer&#146;s board of directors (or persons performing the equivalent functions): </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the issuer&#146;s ability to record, process,
summarize and report financial information; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top">Any fraud, whether or not material, that involves management or other employees who have a significant role in the issuer&#146;s internal control over financial reporting. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: March 9, 2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">AURINIA PHARMACEUTICALS INC.</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Richard M. Glickman</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Richard M. Glickman</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chairman and Chief Executive Officer</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION PURSUANT TO RULE 13a-14 OR 15d-14 OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Dennis Bourgeault, certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">I have reviewed this annual report of Aurinia Pharmaceuticals Inc. on Form 40-F; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the
issuer as of, and for, the period presented in this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The issuer&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over
financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the issuer and have: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the issuer, including its
consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top">Evaluated the effectiveness of the issuer&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the
period covered by this report based on such evaluation; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top">Disclosed in this report any change in the issuer&#146;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to
materially affect, the issuer&#146;s internal control over financial reporting; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The issuer&#146;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the issuer&#146;s auditors and the audit committee of the
issuer&#146;s board of directors (or persons performing the equivalent functions): </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the issuer&#146;s ability to record, process,
summarize and report financial information; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top">Any fraud, whether or not material, that involves management or other employees who have a significant role in the issuer&#146;s internal control over financial reporting. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: March 9, 2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">AURINIA PHARMACEUTICALS INC.</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Dennis Bourgeault</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Dennis Bourgeault</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.6
<SEQUENCE>7
<FILENAME>d313671dex996.htm
<DESCRIPTION>EX-99.6
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.6</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.6 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Annual Report of Aurinia Pharmaceuticals Inc. (the &#147;Company&#148;) on Form 40-F for the fiscal year ended
December&nbsp;31, 2016, as filed with the Securities and Exchange Commission on the date hereof (the &#147;Report&#148;), I, Richard M. Glickman, certify, pursuant to 18 U.S.C. section 1350, as adopted pursuant to Section&nbsp;906 of the
Sarbanes-Oxley Act of 2002, that to the best of my knowledge: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: March 9, 2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">AURINIA PHARMACEUTICALS INC.</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Richard M. Glickman</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Richard M. Glickman</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chairman and Chief Executive Officer</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Annual Report of Aurinia Pharmaceuticals Inc. (the &#147;Company&#148;) on Form 40-F for the fiscal year ended
December&nbsp;31, 2016, as filed with the Securities and Exchange Commission on the date hereof (the &#147;Report&#148;), I, Dennis Bourgeault, certify, pursuant to 18 U.S.C. section 1350, as adopted pursuant to Section&nbsp;906 of the
Sarbanes-Oxley Act of 2002, that to the best of my knowledge: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: March 9, 2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">AURINIA PHARMACEUTICALS INC.</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Dennis Bourgeault</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Dennis Bourgeault</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g313671ex992p03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g313671ex992p03.jpg
M_]C_X0 817AI9@  24DJ  @              /_L !%$=6-K>0 !  0   !D
M  #_X0,J:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B \
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835 @0V]R92 U+C4M8S R,2 W.2XQ-30Y,3$L(#(P,3,O,3 O,CDM
M,3$Z-#<Z,38@(" @(" @("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<#TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+R(@>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]M;2\B('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(B!X;7 Z0W)E
M871O<E1O;VP](D%D;V)E(%!H;W1O<VAO<"!#0R H5VEN9&]W<RDB('AM<$U-
M.DEN<W1A;F-E240](GAM<"YI:60Z,T4Y,3E#-D8P,SDR,3%%-SE#,48X-$9$
M.3!",38P-48B('AM<$U-.D1O8W5M96YT240](GAM<"YD:60Z,T4Y,3E#-S P
M,SDR,3%%-SE#,48X-$9$.3!",38P-48B/B \>&UP34TZ1&5R:79E9$9R;VT@
M<W12968Z:6YS=&%N8V5)1#TB>&UP+FEI9#HS13DQ.4,V1# S.3(Q,44W.4,Q
M1C@T1D0Y,$(Q-C U1B(@<W12968Z9&]C=6UE;G1)1#TB>&UP+F1I9#HS13DQ
M.4,V13 S.3(Q,44W.4,Q1C@T1D0Y,$(Q-C U1B(O/B \+W)D9CI$97-C<FEP
M=&EO;CX@/"]R9&8Z4D1&/B \+W@Z>&UP;65T83X@/#]X<&%C:V5T(&5N9#TB
M<B(_/O_N  Y!9&]B90!DP     '_VP"$  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$" @(" @(" @(" @,# P,# P,# P,!
M 0$! 0$! @$! @(" 0(" P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# __  !$( $("Q@,!$0 "$0$#$0'_Q "J  $
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M[7E<'8BJ/IG:Y7)WJ'^UL[?[[M4XC?C+@#FKWGNG'\V'&VM_<:GS>K:VK/\
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MB+[7@]7W<9ZN[_PY9VT?\NSAX_L<GX\&?P<#?WU[?;YE7]S,5ANXQ&WPKOJ
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MV^U*RZ&UAED]PAR?A"7*,.GH? 5>QP5D\7B^VRY]GL_/VNQU]7U?'.ATL?\
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M':8_OTGXZ/2\GJM_87M][CA%][VMPV;QDO\ ;+O0$MY7JKJS*;\5<9^$O?\
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M$:O2XO59#,F3A#(193]02Q2Y<^4C,*JV^O(=)*FR4HLFXI=@MF0D0[.3L<<
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MI0[N:(,LLMS@XF22$FHH&@5L*!5)SGP]G*C.6PM?)D1'4%:(0CCL@P'(BS,
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M4*";8L>%=N)22Q+2RL0TI1(9-V9GQYLH"QXV-QX$^)CC:0RS,S4%TD\M&?\
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MOK0"?G!1J%KF]PZKF5C ]G%E&94KRE(P9'D?6+1W4^7W&-@RRR4[L38F1ES
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MK>2/%T?M&KO:>XH^LF;NA3OVLU*NT,05'#$;T*'G 4R5F:*ABCBJ:E! 4.3
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M:)94A0R2&BC_ -23^@  J22?  !)-  2=6QQO*XCC%6-?]  !4DD^   222
M "20 3J/M,;<TY=VNK?M.Q+7^*4ZZG3#UKQ8+&=%W58WP^;/L#R[DQ\1RQT\
M63NS ,QG($6%P7$*4^,)P'&X)Q9F?X&-#DY/@3XD&0%%2P3(A2=%8"OK$;J6
M5;@IKY-"=0QKLO*GQ,<$O!E2P$D6J7A<QR,I:GH#JRW,%!M)^%"=11G]C-'2
MV#:CV(SQ&[S(ONO+D4,I)<;6"\!8G)S%(E;4IFRD*XQNA:%TC,47O9'EGX4#
M:4XC.U@W&2<:EP\D]C'U3K9G28(RK6(%L7&Y;!C6E\<=%=%+$2,J"ZH.J9,B
M&/%GS"?HX^6^,W]6D3+7"!4?&QYF%C-;5:L0M"!E^XVVR'6)IJZ.,3&EF=U;
M 3PRMJ8A*U2Y)6M4Y-L?=)A-9M*SF-L?)$"#5K"616Z.(&U"M<EQ@$Z!&2-4
ML)^,*%I\P849"$8\V1(Y5G$6/ %W)+%H9&+R1111AE,DLJ LB!W3<L:IB/GS
M!C DL42J"JM)-.Q6*(,WI2ZUW>1@5CBCD>CL%C?2"W?]% ZZKZ11" ["_L+>
M[%<)P:XGZ9T]"0)ZV-A*]I8I&P3&,6;:U?KH!EGDBP: IL=W)?) *BE!:H&.
MSG(;IJ),D,,<IQC LJS$JR.LC,$(=:(S-:P C!"B-@QN!)HC20P/+D-&N0DP
MB:(!PRN$#MZ6JRJ 48F0BX2QL@*MXUFG_;\4XQO\I9/UL_LY?VI&@>'&2GME
M0:^A30XAD=GMJ5_D3NY;0M\>QD6(^H5A$B6+2P(NV<8(L)I?5!SMQB<UXQC5
MP_Z$,@DI3YKA&\<GRT*R):6)('L2M-,<6/SF"8Q[?[J@V5H/%#*)(O)N$D,J
MLHM!;H@'[08WL5,DC?&7);JG5+7*(A64IFU]0T)U@KK^E;1'I,&A4:5G<Y'4
M=8O$>;92U(7%TD+PK]@^N>&9K2&K$YYY71Q\!^4HD9)3)/*D$49-<@XS%,@W
MD+X6998$BB#S2M!/(I2)8WERS92+CNR*5VH8Y)Y'\"!9P3 ;!4DM%9.SNR1P
MQRP[BLSLJ>QO.?K1IQII\8_G_P _YS_YY_I_/_TQQIIQIIQIIQIIQIIQIIQI
MIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQII\8
MS_7'S\9^<?\ K_X_^O&FG&FF<?/\9_G&?XSC/_'C33C33C33XQC^G\?US_[_
M ,Y_]\\::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::
M<::<::<::<::<::<::<::<::\_MT==]A]AIIK&&N))2S+5=)7Y7NP4X8+#03
MU;(K!?:X%(!QN,(5$86HVEG9VMX=$3V6>H+6B&YM9 !$X*ZLYEUKMB=Y#V>1
M1L6&+(15'S79./)C-*"? :*.:2P4HQ;RRT!UYF73=1/U^.2LV08@Q/RE(<B+
M(VR/B1*\*(YKX2X!6N\3&6$6;FR&)0WN<$+J$$1?BI,SK&*0'60IGACFRBBZ
M]BD9,B(C"&))68#B!>D4-2A8>J,3#*4D@+-+-\BM!FWJD%(]JWQ1KGW3)6MR
ME=L1A;2K!RQ8$!4EQ$6S0,'?=KYJMJ[8CI2U@]Q<M<"I4*%().A-R]1*TW#I
M:>5O-(I"G64.]>SR)U_+IA'\2 ,">IDQC:POR-. Y,JQA,K+3G&!*-+&9V X
MP+&<8SRI8HQF09E!?%D8[M_5HXITE>.O]'567^@NJ0?AK9CY30JT3U,#*_IK
MXO:-D5O_ %6ZO]:?#4:]J=%9K,:'C&N&I;9KK3E8K[0JVRKA:I/')B!/-D]7
M6+ [ -AS:@A:E"6A1V%^#E-KHX'FFG)T0LX+)-%GY#N3+E'?87:/ZL+!RQD1
MQU^+C=* GX 1RM'.O@@R1 ,+3KF08>/%T67UK"O89F"^*\M!X62,1.]/BS-'
MN1T) "O4&HU/*T9G,83  +HS$C9I9#R>SQF,Q]K2NI\?S+WT0$A3E(G-.F,-
M8("PFY-6N2]1V\E($X@@ZE)A)1F29=W(&+B-8LKD"1Q41H 6:1P/!*H"5C!!
MEDMB4@N"+X6$<)GS!4I&"R(35W\ 1H2"1>Y"WLI6-299!8C:A_,--K):9SKG
M<E3V1&WRS:4_W@535JMUL>?PFX9;>+7&FV5VBXF1!2%QC%@Q@F.91,1H4[@F
M11]<H:2P%$Y+-+OAE7%RY6QUK@28 Q%5R6>%!D)D-*C?K+,Z?Y-0HF9KJI;:
MU61&V9BJ,AJ9JYHRB5^1V$$D"0NO@[,*2?X]*F,H"0[,6&G8Y^LMYIZ:UC>E
M*SF'&7/!+HVMNUYB4MC[NPT._2'<!NC#//4<9C,67K'6O0PUNAR$+0H)]@:K
M$8XB68$<YG'E3Q,CV^&/ Q%!P$ZML'U_.J/GCLFE2GI4F>Y!"*1K!M1!OH*S
M2FC.8TV3ELPRY>PAS#82$+P8+=>B2*35ZP->92;C.&DM"R-&)@4)J^MI-KO^
M5YG9$@V$V9G+Q9UF6R?%R2VI/+,1=NA%=,L>APG01H:_J6',+:VMC>I<35*L
MM,:<H4]]6:(-$I,?41=-U[-'CPF9U=@&9I\AS)-.X\+<[6A4%%2*.**K6%VM
MC*R=JW;9Z!V=8(S&I*JL$ M2%";B/FD=Y*5>6622U051?.R*:N;9 _8'7@7>
MTH8YQB@-9K6G(;K_ /BS.69%-+XV:?$D!.6KG]^V D['+K$B$6K'*PTLD\*9
MI9G$MN"@*3K$YJ6W 8)A]K)"=ECCX^#"#Y(#O)F3S(&J7I+#AF:1BV^]5+(T
M9N\R@NYUPG#3!\V7+GI0 C'1,:&%F4_2#19>8(454$80/24>!3Q76G<9HW]B
M#H5-*OFS/K=K%/)6V6')]=+/@45M6\=G9>ACLA+?)\*[Y]EXGK!$J<).5K$0
M5(&9J=BT &TLE2G&GGU\BQ8G:9$(5&9,7"BC8G^W=)F9$J5J[#<7%,KDL<B8
M%6>-HV9H9T=YP(969G>?(S)755-'AB3%QHWH0$!3(RQ%&H01(H8"4$*L]M -
M>;?UFHMTKJ\937$\L)ZMRX[6D,ZK5LE#&W2QXN2QI'9KRO<V>4K7-8W.#>Y2
M<QO* 4I/*$B1D"^0C$( 8.8!U>!UL0<)A8$6-Y/@[2T:0$>0TTADG<&MKR,%
M)4#46$DG:YW8N$49F4TP"U]-0$6/SX*Q1)'$A%"RH"0#J.=:_K;>H?!:BUSE
M4_C#QJSKILF?L_7*%H8'HFW9I)&^V)C>4(B]E/*MQ5,)#9!;'E12LY<V$"6R
M(#80$T*/NJ0G0QLI\5L#L,GSF=5@+C0V#TD1X!ZY9V4"[<&*TGTEJIF?=NHH
MB-O9QCLI.P@CJ,;MLK>GO8E@6R8\MX58FFVT\:@.YK' -D FDJ[3M#6E7O=3
M^P""UUTLK%FO"K)W2-1-_K3$<JK"MY00>VNL_=8^ZA1'E3*TS2"%#@VJ>P83
M'2DS8=V#C5^!YY<=UQ8_*^X//BY+5]2J,>>+)AQ6"M1EOC5LH ^J4F,$KCQ.
M;HLI5RSM@G"CCFA!%59WEB>"7)0LH:-T61X\5J&U0TPJ)V0819_Z^YGM:V$)
M]J;&C33^&T->-'5$Q:_M3ZPLL'=[WKHVJ)3>@G&5+U;LJL%N@*M2VLK<# &]
MF3+UGR<L,4A-(L[$+V)SLMJCL<^(1DM1TBC.0F5+&*VF5<B6''$Y:R^&+:54
M$DC-7T\C=,_78\063K>MRHIU4@!IW@B:&%G^98A$DLQ18[OJ2!V9MM%%U1:G
M6.6.@9W?TI@LA:=&(T^N&OU<T_ 9BJ9'ZQTE9JJMC%M3=@.<%T@<WZ/PMR<D
MC3&&;&$Z-0ZG'86J3 ILI]G8=EDSY^=]Q8Z+_P CS89XD!JT4!RI%>4)Y5G,
MK*D32.R60;B^-QY!1UN#!C]=B?;;,1TD$V.TC A'F3&%(5?PR(L9^M0!P\RQ
M-2D01MR3J+;>W#H^Y0?+G3E7[86?3JZ(RM_PWS);6,"E,QCBUE?)#&V-.\KY
M,<HC_L/*1(#W0\(5)>"3%AH ]X?.^X<#&SHI.MPV/!FC"2EJ,;6CI,J$!0P+
MED1R%JE'*U].MG09TV#D)V.6H.3!.7B"^%:R8F N&J16,*TB^2')4$#R+Y2.
MOC_2NNE:0V.HZK17Y5&M+#0<1F>&B3N5>D?A; G010MP9PNS'*%L,&^-:1:O
M1E+$JPS'< 6I +I,QT^^SY.S['-[/ 589,V5)&5JLBE#(R)X()6+?F6(^#:P
MN'Z#E]+@08&-AXF>3*F*KK>M$=A(8S,X\%5>;9C=_!4.OCQ\9((V9<]PA+'K
M()CK^YNT5(9IZ0T-RQ)$WI>O:0(I04V-+JN=5Z:.N*@T_!"=2I4G 3#" PTP
M6,CSDSH\.>66.%&X#,UJR$,UE3:'("J6MI<0H!-2 !XUKPY,N!(I9&49R!26
M0%5W!0DH"20+O*@DD"E23YU!BJ/UYTU1-L7Q==8U72R":S)YCTBI@/XF>S%5
MVX,53,D$4(%[JWY5+,-[Z_MJA8H,0D@,"0K&' 1CQ\YM&5-#U:8F, ,Q9IV9
MR2 R3%*(:5/I56']#=\ ->-!CSYJ3953B"&)2H )#QRS2;@KXJ1(@']+*U^%
M,FT4UZO#7UCOO%\2BJYG,;KV,LC8!5(*N;I@TI<'V,J3!(C3DAERQQ/R1!8R
MRM3(WGDG?]RB;P&&%EF9SC/B/%'TV#UH!W\2*5';X"5I<B7):6E25=Y9Y;EJ
M5 "6GX@1D$LO;9?8O;M9!@M7]R+!CQ8RH6\!@$A1KJ*2[R>D"FLY31:07U/9
M++903)H;7U?#E,(IQM4)%;%(5\T/1*HY*KY\)T1$J4"EHRH4M40&86+'C>6Y
M@ZRUR01>&?%.1U,ZF1HLS.QWC1EH'QX'#+<#6HGF\.P-K1Q+'&;6DR$UL3(.
M/V$2!$DQ<:6.216!*3RJ0XC/FUX(A3X"CSECYV(7,1:Q_7#*T\6T[K:Z9S G
MV*:'/OOJ<G5=1E[CMPV*^%5O+JT#)[$DSRZ.@HBY/Z28*':2)F<]4"1O> 'G
MG%$@$G-UYSKV63-V,RB#-FZS(P;(?3%'%D0+C,4KZK8X@VQ":I"Q1[I&B0ZH
M#/&CXJDR8DG91YI,I+L7BRSF(A'A3]2U'E\,\0DC"HLS4J*L_73,6>JM7]8[
M5L2&2'6G3R85],8&QQ&-NS7,KN=*@.5.=3J+M/=7%8R-9$6E6$3\X)&@!P'U
M[0$G&&I4^#$ANPY[3=I!WF0J^Y8N.(X544BCD&,,,9"U-X=8#((H@;(GE#W2
M&*/6-L-4P<KIX&9NNS9F>9I*/*Z29)RY(":6VM-8'FIN/&C+:AD8C/\ ]AD.
MV-35U/[SI:;M#PIIVF)P_5Y0BG7N770\RFZ"&IY%&9+&2H;;L$6JY<,X](@:
MP*FIX*:#,FK22LG"SD'SV;CSY&/-AH:R9NWC(P]#0+D,()'W*E44;E\DI6L<
M2,*V%PWT'6O#R81+8N/%(9I;Z%95A&Z$9: L/0;8@WU92E:LJ4A;:NI6WNN'
MZ\(Q'JVM&(V#+=>M1$54UO4L<U:G,N>%=P.K HA2>P8R2P["$'@G>#9 G :[
MKFYX):<$+7(A*2!0>0'M_<ZP]OV^3A8Q7@Y^1!@+)\NQAR-'B2,K&X1Q" F5
MR:L(T$32E 2W(^V,A\+%QNUS[UR\=9NPE1[I#-D@/FV.M%>21IKHD4%;GD!"
M*]I$@(?HWLS$)[^NA"&P-?7:CM"(<MC9$?3PZQ8M*9T[NE1DTPCEJ9 7+)/'
M8^Z06&*G,I$4<>XEN*ER-/&-)]!8-V3V297W+V/>RJ0N7BS01A30QK--C3NW
MFOAFQEB6.OTX68;DC:YN-B9,/VUB],"HE3*AR)J@$.T2SA4J//AY]YI!3<EB
M7T(A(U*79#6J96)=>MNRU4R"(M]KZV%VVQLD>L="\K8%*8G=T?86"7DJU,>.
M ]QZ2M(HRB4MZX@M0$985"0XKH4]TGCX;-AYN1E)0KEX/$DK6JH,B#)5T\T+
M*\ 5D- ZM\RLBG74R8X,O%BAFN$N-F#)B(I0N(,C&9''QM:/(8A@:HZJ0&!9
M3K*$:\2:G8XZ:]PM^DSK+]E+7M;8K9V^VY@5Q9F9O]P7Y.LFR2!_ W-MC\DD
MA.$,:CC>!<J7MC2F/=3S35"8(E-RIC308_6LO_TO7X]I#FKY+23RY#(U"M>1
MD2SS9!0!(H?H"UI86U[++,D\_:QT'9YDRA /*0+#!#CJ]?!K!CQ0K$7\SY%)
M"IC695WA)8BHGLSCE$,D85Q2@*J:XP\SG.&10UQ^>J$@ B@5,QG*E.2A=(<T
MDH2W*3#3]Y.,LM$UBR,*E>65['*V1D/VF6;I(Y:1J3Y::@8S,M/"0!D,)\!L
M@AEIQ2'C+&L6(,&*IWXVW&J&MA)*LA8DMNSD,')]2PARQNGC<1%._6T_N48M
MC71XL*+JM2[=VL=-MY8APPO)ETO3Z_W6T; /-1K'XYTS'$L--LAG*R![*+$Z
M!8PX;0)RQX"O#[U<PP$ZG<%9.C-<:WP'9)9YH'GK4EH9)@S!?&0T:NY2YT:6
M>\V3D=CD8Y$;]I (IB  8T;#BP9A$!13O8\5JEQ]'<:@>U"OK3S/IIQIIQII
MQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQII
MQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQII
MQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQII
MQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQII
MQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQII
MQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQII
MQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQII
)QIIQIIQIK__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g313671ex994001bnew.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g313671ex994001bnew.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ $@+& P$1  (1 0,1 ?_$ )   0$  @,! 0
M       % P0! @8("@$!  ,! 0$!              (#! $%!P80  $%  ,
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M_HF?JA^?1POKW6P+]#?,)K61U#\GR7+OF6H)=2/O5=_/[9'(DSYD:W^(+X;
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M2G%*<4IQ2G%*<4IQ2OD+Q9_\QV?_ +7_ .X=O_\ M_\ N?\ ];*_Y/\ X?\
MTO\ AYY'AO\ \S\?\\G'_P"U?1/LO_O,;T?]7B>GA_B''_S_ #_YKZ]YZ]?.
MZ<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4I
MQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%
M*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4I
JQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g313671ex994logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g313671ex994logo.jpg
M_]C_X0 817AI9@  24DJ  @              /_L !%$=6-K>0 !  0   !D
M  #_X0.J:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B \
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835 @0V]R92 U+C4M8S R,2 W.2XQ-30Y,3$L(#(P,3,O,3 O,CDM
M,3$Z-#<Z,38@(" @(" @("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<$U-/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(B!X;6QN<SIS=%)E9CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@>&UL
M;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(B!X;6QN<SID
M8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B('AM<$U-.D1O
M8W5M96YT240](GAM<"YD:60Z-T,Q-D8S,$8P,SA#,3%%-S@R1D1&0S4T-#4S
M-T,S-30B('AM<$U-.DEN<W1A;F-E240](GAM<"YI:60Z-T,Q-D8S,$4P,SA#
M,3%%-S@R1D1&0S4T-#4S-T,S-30B('AM<#I#<F5A=&]R5&]O;#TB06-R;V)A
M="!01$9-86ME<B Q,"XP(&9O<B!7;W)D(CX@/'AM<$U-.D1E<FEV961&<F]M
M('-T4F5F.FEN<W1A;F-E240](G5U:60Z,S8U,C(W,CDM-3DV,2TT-#$U+3EA
M.30M,S$P,#AA839B-C-B(B!S=%)E9CID;V-U;65N=$E$/2)U=6ED.F5A9CDQ
M8S8U+3<W-30M-&5C,RUA,SEC+6-B96-D,60Y9#EC,R(O/B \9&,Z8W)E871O
M<CX@/')D9CI397$^(#QR9&8Z;&D^979E;'EN(&-A8G)E<F$\+W)D9CIL:3X@
M/"]R9&8Z4V5Q/B \+V1C.F-R96%T;W(^(#PO<F1F.D1E<V-R:7!T:6]N/B \
M+W)D9CI21$8^(#PO>#IX;7!M971A/B \/WAP86-K970@96YD/2)R(C\^_^T
M2%!H;W1O<VAO<" S+C  .$))300$       /' %:  ,;)4<< @   @ " #A"
M24T$)0      $/SA'XG(M\EX+S1B- =8=^O_[@ .061O8F4 9,     !_]L
MA  ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M @(" @(" @(" @(# P,# P,# P,# 0$! 0$! 0(! 0(" @$" @,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P/_P  1
M" !1 &H# 1$  A$! Q$!_\0 S@ !  (" @,! 0            D*!@@%!P(#
M"P$$ 0$  00# 0$              0(#" D%!@<$"A    8! P(# @8*$ <
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ML;5*HE:*>5\PN6_+[,--/M;_ "3*YK99XEPOMXW-JBK1:*F].!M_^MCR@_\
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M!A[+5 R?+XHHF6Z[DAG1;+&6?Z%STE::FHRAYYS$KNF;.36+&.-T!4%5,43
M<I1 -[3U0E"6?TN>3N(=LX&T[CO:K1@V>Y*Q>6<Y6=/%5H&HO<H_1Q[8O?;.
M7B8*:1/-/X_W*@#D3M"JE202$Y^DI!$M3*4Z06U$&Z#5!)LU11;-D$R(H-T$
MR(H(I)E J:22292IIID*&P%    U60<3/UJN6R/&)M-?A++%"LDY&,GXIA,Q
MXN$!$4%Q92*#EL*R(F'H-T]1=_ = >->J]:J3 8NJ5V"K,89=1T:.KT1'PK
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I_P#:'C-_<+D7_P E;=J6=V#ZF6KY T T T T T T T T T T T!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g313671ex99aif.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g313671ex99aif.jpg
M_]C_X13?17AI9@  34T *@    @ " $2  ,    !  $   $:  4    !
M;@$;  4    !    =@$H  ,    !  (   $Q  (    >    ?@$R  (    4
M    G $[  (    .    L(=I  0    !    P    .P +<;    G$  MQL
M "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q-SHP,SHP." Q
M,#HR.3HU-@!$86QE($-A;7!B96QL      .@ 0 #     ?__  "@ @ $
M 0   I2@ P $     0   L,         !@$#  ,    !  8   $:  4    !
M   !.@$;  4    !   !0@$H  ,    !  (   (!  0    !   !2@("  0
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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MV@?\UNC;!7Z3_2;5Z(K]6S; I_9_J[=_](^Q?J_VC^>]-)2K?K1T6D$V76-
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MHK9[?^,_G$E.@DDDDI__T/2_VITS_N91_P!N,_\ ))?M3IG_ ',H_P"W&?\
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M       067X 8D,_8L0[9@2HN8?LS#A"24T$.@     !C0   !     !
M   +<')I;G1/=71P=70    '     $-L<E-E;G5M     $-L<E,     4D="
M0P    !.;2 @5$585    !$ 00!D &\ 8@!E "  4@!' $( (  H #$ .0 Y
M #@ *0       $EN=&5E;G5M     $EN=&4     0VQR;0    !-<$)L8F]O
M; $    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M    +@!< %P 4 !( %@ 1@!" %4 +0!- %< 10 M $8 4  Q #  +@!F &D
M;@!C &\ 80!D "X 8P!O &T 7 !! %H ,  Q #4 ,0 M %@ 10!2 $\ 6  M
M #$ .       #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @
M %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M
M#&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $
M  $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L
M  !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#
M8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
M    26YT<F)O;VP      $)C:V=/8FIC     0       %)'0D,    #
M %)D("!D;W5B0&_@            1W)N(&1O=6) ;^            !";" @
M9&]U8D!OX            $)R9%15;G1&(U)L=                $)L9"!5
M;G1&(U)L=                %)S;'15;G1&(U!X;$!RP           "G9E
M8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,
M3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M    4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O
M;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T
M;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T
M5&]P;&]N9P      .$))30/M       0 2P    !  $!+     $  3A"24T$
M)@      #@             _@   .$))300-       $    >#A"24T$&0
M    !    !XX0DE- _,       D           $ .$))32<0       *  $
M         3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"A
MF9H !@       0 R     0!:    !@       0 U     0 M    !@
M 3A"24T#^       <   _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@     _____________________________P/H   X0DE-! @
M !     !   "0    D      .$))300>       $     #A"24T$&@     #
M.P    8              L,   *4     P!! $D 1@    $
M             0             "E    L,                      0
M                       0     0       &YU;&P    "    !F)O=6YD
M<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE
M9G1L;VYG          !"=&]M;&]N9P   L,     4F=H=&QO;F<   *4
M!G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '<VQI
M8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE;G5M
M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M
M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M0G1O;6QO;F<   +#     %)G:'1L;VYG   "E     -U<FQ415A4     0
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M24T$$0       0$ .$))3004       $     CA"24T$#      3J0    $
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M&HTSQQ)#:[Q_!,;'>(4"?+^"B246:.)*]P('B@66;1($E*VT@Q&@A"=N>0!
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M6_W[=GI;/6W?3V_X7>DKB2%2_?.W]7YOW_E^95_G;__9 #A"24T$(0
M50    $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !,
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M(" @(" @(" @(" @/#]X<&%C:V5T(&5N9#TB=R(_/O_N  Y!9&]B90!D0
M  '_VP"$  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$" @(" @(" @(" @,# P,# P,# P,! 0$! 0$! 0$! 0(" 0(" P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M __  !$( L,"E ,!$0 "$0$#$0'_W0 $ %/_Q &B    !@(# 0
M   '" 8%! D#"@(!  L!   & P$! 0            8%! ,' @@!"0 *"Q
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MC]Z]G;IW[OWHO.;*IDW=-M$4V/7"T^:W#BY<7#M7:FW:A\C49J6+US22A%C
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MW'^;KW_#G7Q:_P"5_L3_ -%SN'_KU[]_K*<\_P"^K/\ [*(_\_7O^#O]@?\
ME+WK_N6W'^;KH_S._BR/K7]B?^BYW#_UZ]^_UE.>?]]6?_91'_GZ]_P=_L#_
M ,I>]?\ <MN/\W77_#GOQ8_Y7^Q/_1<;B_Z\^_?ZRG//^^K/_LHC_P _7O\
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M+C</_7KW[_64YX_WU9_]E$?^?KW_  >7W?\ _E+WK_N6W/\ FZ]_PY[\6/\
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MZ^+0Y-?V)_Z+G</_ %Z]Z_UD>>O]]6?_ &41_P"?JW_!P^Q/_*5O'_<NN/\
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M:!_C_O'_ !3W[KW7,<<>_=>ZYER1;CW[KW7E>W!^G^'U]^Z]US9K6(_/]?\
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M]>WU]^90*4Z5P0H-6#Y==< 7/^]V_P!XO[UJ88'2M8(V%2#7K&S _I_P^O\
MR/VX%!%3QZ=$2**9IU':4M:Q^EQROO?AJ#TJ%O)@^76-B""3^/Z'W;/2A8$U
M#!ZQ:R#=?I_C_P C][Z5P1JKDCTZZU+];F_U^HM?_>[7]^I\NE5/EU__U3V:
M%_I_O)_XK[Z(=?-'U[Q1'DZK_P"!X_WGWKKW7M"C@#C\7)][Z]UP:%/[-_\
M'4?^*>_=>ZX^$?X?[<^_=>Z]X1_A_MS[]U[KKQC_ %)_WGW[KW7?A'^'^W/O
MW7NO>$?X?[<^_=>Z[\/^M_MS[]U[KQAL+V!_UFN?]M?W[/IU[KAXQ_J3_O/O
MW7NO&(D$@ 6Y-R1?_6O]?I[]U[KR1WX/^W'XX_VWOW6P-1H.N1B _%_]O?\
MV/OW3GA'UZZ\8_H1_CSQ[]U5E*TJ>N/B(//(_P +^_=4ZZ\;7X'^W!/^]@^_
M=>ZZT,?Z?[ 6_P!Z'OW7NO>-K?C_ %[?\3;W[K8&HT'71C)%CI_VUO\ >1S[
M]U9D*BI/7'PC_#_;GW[JG7M.C\<?7^H_I^??NO=>]^Z]UU[]U[KWOW7NO>_=
M>Z][]U[KHL!P;^_=>ZXZQ_C_ +Q_Q7W[KW7$LW^(!^G ^GOPXCKW7+6W]?\
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M>.>/>^E*6U%HI%.L>HD<_P"O^/?NG@C  :3UP) OR/;F@^O2L1DTSUPU_P!
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MWE'^'_)0]^ZKUQ:0'ZD ?ZX][H?3K8%>'7:D_4?0V]V5>-1U[2WH>N'F-_\
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M!E'^J/\ O/OW3JKJKGK@95 /IOQ]?Z?[Q[WTXHIY]8_,O^^O_P 4]^Z>6/4
M:]<#+^03]?I<CW[K?A?TNN_(WU/^\<#_ (GW6O2M8\C/7O)?@+_O/_&O?NE
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M_P#%/?NO==ZP/HQ_WGW[KW7O(/\ 5'_>??NO=>\@_P!4?]Y]^Z]UQ+_TL?\
M;^_=>ZX%B?R1_K$^_=>ZXE[?5C_O/OW7NN)D/X-_]O[]U[KPF8?@D_XV(_V%
MS[T>O:M.:TZS+,G]N_\ AI'^W]^^SK8<G@QZ\SHP)6_].1S[WTXK+3OX]8BP
M'!/^]^_=4:A8TX=<"YY M_A[]CJO7&[?U/\ M_>NJZE]>NC?\D_[?WOK8(/
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M]J1J&KAT_';(K@KQZPW>Y]1'^QN/][]O#PSP Z5I"&)#"G6)RYMJ)_PY][
MX"G2A+>(5J>N%_ZD_P"Q][Z?$&.Q:KUP+/\ 0<C\7_Y'[]TJ6W?2/TQ_+K P
M8\W;B_Y][6E1TH"M45&.L85R>3Z?SR;_ .P^H]J.E"*A854?LZ[*(.26'^W_
M -Z]Z) X]+(H$D8J% QZ=<"$XMR?\;\>]:U]>EB6BK6O77^V][!!X=*4ATK1
M1CKBTEN!:_Y'/O=.E2VZ%06X]8&EO]#8B_TN.?>^E0@X4C'\NL19R;DG_;G_
M (K[UCI1'#)K74N/RZZ8@<_X_P!+^]#Y]+%MPQH% ZQE[?0C_'BW^]>[!2W
M=*H;<)JJ*]86E)/ OQ_L/]M>_O>AO3I2+;5D"@ZPF3D\V_P%[#_6]N*H  (S
MTH6V<* %J/RZP,Y/^'U^E_=M(].E:V[]OZ8_EUP9^+WN?]C_ +W[]TK2V[A^
MF!^SK#Y.>3;_  Y_WOW[I5';,&)&<=<?*;_7B_\ C]/?L]/^!)_!_@Z__]$\
MWOHAU\T?7%F O^3_ $_XW]/?NO=</(?]3;_7-_\ >O>NO==%B?\ C7O?7NO+
M^H>_=>ZDZS_0?[[_ &/OW7NO:S_A_O/_ !7W[KW7BY/^'^M?_BOOW7NL3/\
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MN+G_ '@^]UZ4I;U8:FQU@>4WO<_ZW!_'^M[]TLCM(]1^SK T@^O"WO?CZ_\
M(O?L]*DM0*Z2!UB:1?KJ!_Y-_P!X/OW2A(BHH3GK@901P0#_ %X]^Z>"+IS$
M3\QUC,M_K?B_Y]W\,^O1@ML.VD?6)I?R"/\ 6X)//NP2A!KTI6!@:Z^L+RW_
M ,#?ZFW]/=BM13I1'&2QSY=8O*;VO^?KQ;_D7NOA_/I[PSZ]?__5/(VK\?2W
M^'_$^^B'7S1]8B+<'W[KW7O?NM-6F./7?O7335KGCUW[UUKKWOW7NO>_=>Z]
M[]U[KWOW7NNO>^M@$\.O7'OW6]+>G7?OW5>O>]=>Z][WUX"N!UU<>_=6TMZ=
M>N/?NO:6].O7'OW7M+>G7KCW[KVEO3KUQ[]3KVEO3KWO>DCB.O:6].O7]Z )
MX#KVEO3KHL![L$;TZVJ\=0ZZU<7OQ[]H/IU;2OIUUJ']?]X/O>AO3JPH,#KV
MH<6Y_P!XM[OI%.&>M?X.NF8_0?[?W0+0]PQU6J#AQZX?FY]W!0<#UXDGX>/7
MN/>P:\#U7]3KH^[=.(KD<.O:@.+^]=;,1.2O6,R?7C_??[;WNG2D1"@[>N!8
MGZGW[K8BH:A<]8Q+&^LHZ/HE>*32P;1*A_<C>U],B$\J>1?WL@K2HI45_+UZ
MO&!(6TD&A(-#P(X@_,>8\NN]0/Y'^\>]8Z511?%5>NP3?CZC_#WOI\1D<%ZS
M"72H#?[S_KD_2WNA4$U(Z=6.J@E>HTA4VL!^?Q_K>]_9TI$(H/TQUB)Y%VL/
MZ?U^OO=/(<>KK%1EJN*]<A.4X4#C\W^M^?Z>]Z6].E(CID+GKA]SR;V/U_-O
M^(][T-Z=.(A:N.O?=#\J/][_ -YXM[NJXRO2B. $5,=<]<3,I)-E%_ZDG_>A
M?W;2OIT[X-/]#QUQ-6!QP+<7;@'_ %O;15ZF@QTK56TKCRZZ-4@/ 8C_ %A_
MR/W70W\)Z?6+N%4ZXM.&%[\$_I)M:W^'^P][T-Z=*1$ :A*'J.U01] !_B>;
M_P"\#W= 034=/(A->VO7C5+^1_R3[=$9?(:G2B./!JG6(U8+$?1?\?K?C\>]
M^&RXX]*4A4J/TQUC>=;#_7_'/^W'X][TGTZOX/\ 0QUA:<#^R2+?6PM[]I;^
M$]*UAR/T^L1J%86M_M_>U4@]PQTJ2%=0_2'7>IB 0+?[$<CW9UX:1TJ2W#$C
M2%Z[U@?2Q_UB#[;TGTZ4QVBT-6ZXES8GZ#_5$CC_ (GWO0W\/3PMRHHJ$CJ-
M)-P1S]>#<_[?Z>W0@H*C/2I58*HIY=06;D'26MS>YX]["IY 5Z6*DM0=!I7K
MB'.JY'']#]/I_K>[E2!PZ5!"QHRU'7)G%N %_P")]TST]' M32,=8C);_'_&
M_O="<@=.^$!C3UC+EO\ 6_PL?]Y][TGTZ5Q1OH&E#3K$TFGZ?[;^G^\>[ /3
MHQCC[%JN:=8=;<>KZ_3V]4=*UB.I>WSZ\78?4GWZHZ4^%7\/6%GO>X  -]1^
MG^]7]^/5T@))%-/4)Y/I]#Q]1<?[?CVY& 0:CI5'%HK4UZQEU(L2+'\7]N8X
M#ATH6(,*E*]8S*%_UOH/]];W[I2J* !IIU@:6_\ B3>W^'O=.E:Q1EE&D5)Z
MPF0CZG_8?3_BH]W"FHJ,=+EL]#!CBGGU@:1KDE@%)XM]?]B1]?;FE?3I3%$I
M8]VK'6-FO^GGZ_0VM[]I7TZ5HBI7M KUA+,/J3;_ 'CW84 QTZ(RPJ$J.N.O
M_:0?]]_K>_=*5M690:TZQM*1^?K?CC_BGOWY=*%MA4?J=1WE_I_MK_X_ZWOW
M2M+<!@=5>L32'ZD?[S_QKW[I6D8!^'K 9"2>+BYM_P :XM[W0GATICBU5S3K
M@S7^O _Q _XCWX*WITK2TU+757K@74 6Y_'MP**9&>E21:$"Z>'6$N?RQ_V/
MMSI8JN=(IUC9Q]!]?P;_ /&A[]TL6R.H GK [D?7U<_3G^GU_/OU>E,=GI:N
MD''6'4][^JU_I;_>/I[M4?+I[Z?_ (3U_]8]%O\ 'WT*\4^G7S15ZQNG!:_]
M/^('O:R:B!3KU>L/MWK?7=_>NJLM36O7=_?J=:T?/KU_?J=>T?/KOW[IL9('
M7 N!]?\ ??[Q[]3IS1\^N[^_4Z]H^?7 L?R/]Y]W5:USUL#3UX/_ %X_WW^M
M[MX?SZM7KG?VV10D=4*5S7K'Y/\  >]4Z]H^?7(R"QM];?X_G_8?CWZG6PM#
M6O7 -ZB3P+?3Z_T][ZMURUK_ %_WO_BGOW7NNG+"ZD:3Q^?I^?\ >O?NO==A
MC8?ZWNX6HK7ILN02*=<"Q) %Q_L?K_O7NOGTYUV=0X)(_P!C_P ;]O,*@@]5
M)H*]>Y_U1_VY]U"T->J^)\NO<GZF_NU>M:_EUZWXOQ[]7KVOY==6]^KU[7\N
MO6]^KUXO44IUZ_MH-J[>J@5-.NO=O#'KTXJT-:]<=2B_//\ L?K_ +;W95T]
M.HNNN>L1<W_I_K'W;I3''0'/GUC+-?Z7_P 2?>Z=7T?/KQ8#Z\7]^Z< X#K@
MS_TYX]^Z=,0H<]+CL!I6GV%YS,/^,0]>"'RI.G^3BER?A\(GHJ$O3VOH9!/$
MW.F>7D@JVK2%W733_DH7%:4XU6M:%L^H.D^JKYB[FE',W*?B%L<N[>!4$=NF
M2E-2)5?0KK4_AED\D%J /T!%_K_Q/LSX]!^-..>N1EL?3_3_ !'OW3FCY]=&
M2X_J?Z$FWO?3Z1 J,]<69C^DZ?Z\ W_V_P!/;@C'F>GAZ=8V;@GZG_$^[".A
M!KT\J L!JZPEB3]2/]8_X>[]*D@#&A8]<?\ 8GW[IY;=4KWGKAZEX'J_Q)_W
MCZ^_=*8XP :-Y]<"7^IX']!_QJY]^ZMX;UJ!CK@2HY-Q?_#_ &_X]^Z?$4E!
MV]=%U(X^OX_K_L./>J=*U0:E&KK"S:1JY^NG@\WM?\V_'OW2I8030L>L1D+?
MU'^Q]W5=73@A"5HW6)I"+<G_ &Y]NJNFHZ41H"#W=<&D-C<V']?S_M_K[MTL
MCB&@=W6(R6Y6YO\ 7ZC_ &-_?NMF)_(8ZQ?<$\$W_P!:XX_UO>^EBQY%#GKB
M9!]06O\ TY ]ZZ510R,X&G'7!J@C\C_>3_O?O72Z.V()U&G77W!7Z'3^>"W^
MW_H?;BIJ''IY8@@(U=<34R$_4-_C;W;P_GTJC0%!GK@]0UA<VY_!/^] \>_>
M&/7I:D<>D56IIUB,VKZ<<?0$_P#$^_", @ZNE C%0-76,RD"]_\ >3[L14$=
M/K;U("G/7C,MAS<_D&_'NGA_/I5%;,"=1H.L$DU_H !I-_K_ ,3_ (>[HND'
M/2N.W6AJ:]1_,0/2Q%OH.;?[;@>[4Z5I;J5%&(_+K&:@W]3#_>0;_P"P'OW3
MG@/Y<.N:L!^0O-^%O_O/X]^/1@L"DKW'KDT@L3JO_KW_ *_U]ZZ5K;58:6)/
M6!Y;@< \_P"/O>.E4-M1CK&*=0GD''/]?Z_\4]N1^?2H0QKP7K"S@"]Q;_;?
M[Q]?;O5Q;EQJ48ZP&4DGFX_US_O7NXCJ :]*%MCI ,=3UBU-_M7^WX]W$8J#
M7I<EO0J?#ZQM(0>03Q^#S^?I[O3I:L>HTXGK&Q+?U_UC^/\ B/?NGEMFKB.A
MZX&P!N0"0;?7_>+>_5Z50V[=VI:]8M1'))(_-[D>_=*5MF(PM.L;2BYL!;^M
MR/\ >/?J=*TMP%&IZ'KBPXN&)X)YXM[U7I:L$>*+GJ*QOR?H/]]_7WNO2I+?
MN&J,4ZPNP/  M?Z_[#_'W[I6D$=30=8BP'U('^W_ .(]V5M-<=*HK<'5I4'K
M@[ DF_''T^GMU345ITJ2U%,DJ>L!D(-AR/Z_3W>@Z5I;QA0./6%Y"+<7O?ZD
M\?ZWOW3XCCQV"O6-G -R2/\ #GWJM>E"ID9ZPO)?Z?[<'GZ?[#WZG2N&(NQ"
MG-.N-V_VK_;_ /&_?OSZ4?2R=?_7/-JN>/I^;_[[^GOH1X;>G7S14ZZ=A8K^
M>/\ B#[LJ,&!/#KP'6#V]UOKWOW7NO>_=>Z][]U[KOW[KU!Z=8VTWY)!M_OO
MQ[]U[KA>WY-OQS^/=E(''KW7K_X^[ZE'#K77K^_:UZ]UZY_J?]O[;.22.M]<
M?>NO=>]^Z]UW8@7_  ??NO==>_=>Z[]^Z]U[W[K5!Z=>]^ZWUZY_J??JGUZ]
MUZY]^ZU0>G78/OV>JLO"@Z]?WK/5=+>G7K_X^[A6.>JG'$=>/'Y_WOWL*W2@
M1&@[1PZX&06X^OMV@ZND1U#M'7 N3Q_Q7W[I_P /^CUP)O[]T['&37M'71-A
M<W'^N.?>^G!&WD.L+&Y)!X_U_?J]/* % (SUU8^]5Z>$+8.D==2-;C_#_8_[
M?CWH5Z?$9;%.EGOR,Q2[%'A,'EZFV!4 &F--YA-39*U2 <)@ON1-I_SX%<);
M?\#ZJUT+-K;4NZ=U:7\XXUI0KCXWI3^'LI_OI/,5\S6K1R<KUA"ZM@L3\.FM
M5D[O[&#57^.D^K_E*GI540;<6)O^?9J%)X=$$<9%>T==7][\-NE"PLPJ%'71
M-N3[=5:  C/3@A8"FD=8BQ)^MN?Q<>[=*UAP.T==ZP0;VOS]![]3I7X0_@'\
MNL9;BW'^O^??NKI&:_#UT)-/X#7_ *_CWHYZ4I'Q[1_+KHR"XM]/S<<^_=.>
M'3@HZZ9_]3_O/NC*Q)ITH2-M(QU%=R6/]!QQ?Z\W]W P.E00Z1CRZP:@>.>?
M=NE(A-<**]8R#?ZFU_R?S;^GOPR:#CTZD#ALJ*=<&MQ<D?ZU_;J*17I2J!:U
M4=1G8_[Q^?\ B.?=^E"*M#VC]G6,L0OUN1_L?S[T>E:)51113K%>_/\ 7W[/
MKTYH;^'J/K_UO;H1JBHQTI2V34ND9KUQ:3DW)!_PO[OI'H.E@B=3J(Z]R>?]
MC_M_=)* #I1"I8MCRZ]?2#?^E_I?W0!FR.E2H #51^SK"SDWX_VQM_O'MY 0
M*$YZ4I#$R@G!^SK S_B_T/\ L?>\]*E50  N/LZPLQ#6YX^I/X_UO>^E0ABQ
M2NK[.N#36)%_]O?_ (K[V 3@=/11.7%!UC,@/]H_[S;WLJ5X]+%B<'(ZQLW(
M(-_\+GWX*6X=*(H=0;5C/6-G_P!@?Z<^W5%!0\>ED<6E0 *CJ.TI!/ )O_B/
M^*^[8Z6+$^E:#KD)K#ZW_P!>_MC0WITL6W>H[17KKSG\D6_QO;_>_=@I!!/#
MI2L$BL"5'7$R7_3_ %_QM_L#[<H/3I5'"9"0W4=W!!_'!^E_>\=*H[-<YZCZ
MS^ #_B;^]Z2V1TKCMV5:*!2O6%Y;D@FUC^+^WUPH]>E C8  KUTLZ$$ _P"'
M(-_S]/>\]*% )"D&G6.20#BY^@YL;_7W5JD4''I4D42L&4FOV==!S8?2UOKS
M_P 5]Z4,#GHPCC;XM/;UQD<D6)_!M;_D?N_2J*(G51>HS.$'/)_I_L?Z^_?G
MTI6-@*$=8?./\!_K_P"]7X]^Z4+$2H.D=</*/ZG_ 'G_ (K[]^?2];,=IKUB
M9["QL/\ ;_U]^&33I4MFH85..HDL@6YO_K#GDV^G^'MU5(.1CIX6P'P9/6'S
M7!^E[?X_6WN]!Z=/QQ.E>WK'K:_/T_P_Y'[V.E"*3VD9ZY:Q;CD_XCWKI4(F
M IISUC<K]06/UO?\?ZW'O>>E*VT9*\?+J.Q!^A_V_P#OK>_=+19A6#<:=8CK
MOZ0"/\.3_MA[]7I5#$VLT45IUC]5_P#&_P!.?K_3WNO2GPI/3^?7_] ]%O?0
MH2,2!U\T5>L+J>6_''_$#V]UOKB5( /]??NO=<??NO=>]^Z]U[W[KW7O?NO=
M<''Y_ '_ !/OW7NL7OW7NLF@_P"'^^_V'OW7NN] _P ?]X_XI[]U[KV@?X_[
MQ_Q3W[KW7(*%^E^??NO==^_=>Z][]U[KQYX]^Z]UPT#_ !_WC_BGOW7NO:!_
MC_O'_%/?NO=<=!_P_P!Y_P"*>_=>Z["'\_3_  _Y%[]U[KQ0_CZ?X_\ (O?N
MO=>"?U_WC_D7OW7NNRB@7Y_WQ]^Z=1 PJ>N!/]+V]V#$"G3H50*4ZXN"0#_0
M$GWK6W5PHH.G:?;.?I]K8O>TV,G3:>;S^6VKBLX=)I:O<6"I*:ORN+4 ZTFI
M:.J1P6 5[.%)*, Q'?VTFX3;8LP-]'$LK)YB-R51OL)%/48KQ'1N^P[M!L5A
MS3)8N.7[J\EM8I\:7N($626+U!5'!J<-1@"2C ,/M?T@1=1H>NM0Y%C<?[W_
M +?WHXZ4QQJ-76-N3<_T]^J3T^L2D5->O?[ >_=/* H  QUP*WOJ_%[6]^Z4
M"-2!UC+:0=/T^O/]?]O[\.KI&H8<>EGOP"*;8Q$2Q>7JC8,S!*>.#RO+39$M
M4,(\3A_N'ET\S,*QY+<UE1:ZENV'4NYU:M+^<<:TH5QEWI3T[ /]]IYBOF:%
M4?EFB::[%8G"A:U63NQ%%J)\W/BEO.XEXA"F2_TX_P!<>S>/SZ#\<8-:UZXB
M0L/\/I]/;G2N*-=)^WK@7 -K?[[_ &_OW3OAKUA:4CZ_F_X_XW[WTH""@ZQ:
MQ_C_ +[_ &/OW3@%2!US$X0 &]Q_A?Z\^ZUZ>1!7SZQR2:@"/R;_ $_K[NB@
MUKTJC1:GK@LVG@B]S>_]/Q[\PH<=*%A0BIKUV9^>/I_K?\;]ZZ5QP1Z!QZX%
M@>1?GD_['^GNM>E2V\=!QZPL0M_K>UQ_3_8^]KD@=/*@U#K 9KG2W^\#_C?M
M\(%R.E*Q*30UZQEC^/I_C[M7I3'$@KCK'_O/^OS[]TKBC2AQUP=1R?SQQQ;\
M#Z>_=*%M2X!7AU$8$$F_Y/Y/OW2U85"J#Q ZP:R>#;VIZ>4 D"G78<!;6_WU
M_P#7]^Z4+&NH=8_,03IMQ_4?C_;^ZNH8"O2A84)..L0E)/+$BUN?K?\ WJWO
MRKI&!TJAM\-H&*^?7BU_I]/]Y_V_NW2Q(0%HPSUA+%3R01S8 W/^QY]^QTI$
M2Z1CRZB%R>!]#];_ /(_>QQ'2U85+"@S7KK\?C_>_;H4 U''I2MLY8#2!UB9
M_P  B]^;CC_>?=BH/&O3Z6TB$D4_/K"9"WT/T_H-/_(_>@ N .E$:E0=:BO6
M%Y""?J3Q_6W^]^]]*DII':/V=1VE!X(/!_ _XW[WTH$#L 0,=<"XM_R+_BOO
MW2Q8)=2_;UP\A/Y4?Z]O^*GW914@'ATMB@?Q%U#M_P!CKCYR"1?Z?FUQ_L/;
MGAKTL\&OP#/7 R7Y!^@YX_XK[UX:_/IU(2M=?6)IC:P_WH?U_P!?W8  4Z4H
MBTZX,UU7G^GT_P!8^[4Z7)')H0A1IIUB)_J?]]_M_?NE*6[EEJHI7TZQ/)8^
MF_T_//Y_U_>J]+A!$#4#KCYB/Q_Q/^\>_=*HR*:=(IUR$I;_  _Q(_XH?>^E
M"1F2ND#'6":3^A!%ARO/Y_XK[\.'#I]8 !W_ !=1?(;'Z6((Y _XD_7W[I4E
MJ2JE>%.L1=>?P?Q?\G_#GV]H%.EXC4:>/6)IB.&^A^MA_P ;]^$:KD<>E(C4
MD#J++(HY%_J/K_K?Z_NP/2B.W#$A2:TZCZQ<_7G^@'_$^]]*XK9AJP#UT9"I
MU#FW]1_Q%[>[JH(J>GQ'X;5*C5US\QTAKCG^R/J/K^+_ .'O1 !(Z7HBNBLR
MY/719;7Y_P!]_L?=0:GI6(TH*#K 9+<'_>A[=9  >G$10P-.NA*1^F]_\?\
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M3UU^?;H"4Z4+;KC],_SZZ+,/[)/'^^_'NU5]1TL6W34*H?Y]=7/UL?\ @O\
M3_8_7W5R-.#TK2W2N$_P]<K@"_TO_OK<^ZH Q-1T^+>OPK3KAY+@\<_BY'N^
MA?3I^.U>G'SZCR<BYM<D7_VW^O[N,"@X=*DMR% +9ZQW_P!]Q[]3I2+,D ]1
MKD V-_\  ?4_[Q[]^72I;/N&>N@1P3Q]>&X_P^OO=&].ED5MH?52N.O,RBUK
M'_6/_%+^[(O'4.E BK^ ]<-1^@XOQ;ZW_P!X]^=<B@Z<6.@^$]<"0/K]?Z7L
M?>U04%1GI5'#5 0A_GU%9P"3P>3Q?Z>[:%].E(CH -)ZQ,=7/T'T_P /]O;W
M?I<+<D@>&<_;UA>W-OKQS^/?O/I]+/2P9ACK%93^K_87-O\ BGOQ^72J.".I
M[/\ #UP8(/TB_P#K&X!_'U)][4OY=*XK<4.G K_JX]8&*W]2W/\ A8?[Q[MJ
MDZ61P-I'<.L!C0DFQY_J>!_L![=!-!7CTJ$?:!IZQD6XOJ!'/T_VW'OW2GZ=
M2<(:_GUA8(!^;_X$$_[8^]]/16AUBIQUC"J;\'G^O^^^OOU2.'2^.V4$U%1U
MB<+<6M_M[^]AW]>E<<0 -$_P]<; BQ]NJ214]*EA4KE/\/6-EC'X!/\ 34?^
M*^[5/3XC8  (:?9U%(06X!_UC[W4].K:]R_I&M?GUQ)!/ M_L;^_=+H[5@P)
M%1UB?2/Q<D\\GWX=+(X]!)TD=8R$/Z@!_2Y(_P"*>_'Y=*40O7M)ZPL%!X^G
M^O?WL GRZ?6"HS&?Y]8RP _!YM:_^O[UTK6(:5&@\/GU@8'_ %5OZ_[ZW%O>
MZ'R!Z6)9$,IIBHZQE44$ZP?]<C_6_K[NI>H!K3HP$" ZM%/V]8]0_##_ &!'
MMVG3\2C4= S3J.6M]>?]<_[U[]]G2M(W:OEUB8AC?Z<?0\_\4]^ST\MM459\
M]8V ( O:Q^O^W_Q][H?3I8D05%736@ZP'\^]@&HQTJ$=:=AZQM:_%K6]O]*%
MMDJ.RG[>L3*3_:%OZ6_XU[]TI6TCKW.M/MZQ,A^FH6Y'!!O_ +;Z>_'I7#:H
MFJ@K7[>L3(HYN+_T_/\ O?O53TJ6-@**AIU'9"6-C^?H?Z?ZY]O*$TBI%>E*
M))I'8?V=<2+7]^HG3ZQ9'8?Y]<"38D<6_'U)_P!O[V% /#I6(02!2G6(LU[G
M@_XV]V*@\>E$5LH:O''7M;?U_P!Z]ZT+Z=*/ 3^#_#U__],\WOHAU\U/A?TN
MO>_=>\+^EU[W[KWA?TNN_?NJ,ND@5ZZ]^ZIU[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[JRKJ-*]=:A_4?[?W[I]$TUSUQUW'''
M^\_\1[UTX!7KB23]3_O'OU>MZ?GU[WKI_P +^EU[W[J\<7>.[K&2MSQ?_&_N
MRC4:=*/"_I=<&;^IM>_%[?\ (_=_#^?3L<=*YZQ,_P"!_M_=U&D4KTJCCJM=
M76,O?@D?[P/=NK^%_2Z4&R9HUW[U\TH'B7L+8Q<D\:?[UXGD\>T6Y@G:MW"\
M?HY_^K3]"+EA57FGE$N>P;M95_[*HNMK'(M_N0KN/^4RJ_ZWO[P,B'Z47^E'
M^#KNO=#_ !FXS_HC?X3T3_HWH&FG^9WR2^0&8H U)C,OB-M=?F6*\/\ '<YL
MW;]9OK/4[ZU'W%+2R4^.0Z6MY:D7!/,C<S<V.OMQR9RG;R_J/&\D]..A)I!
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MQ_3_ !O_ ,:]^\/^ETLCM^[X_P"76%I?ZV_-N0+_ .\>[*NFN>E(@I^+^77
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M]"#S]+CZ?[;WOI2+=J #K"THL2#^/I_7_8V]^ J0.EBP/J%1BO6#R7/(^O\
MOOZ>W3'\^EL< #@EJCKEJM^/]]_MO>O#KY]*A"IPN.L!<#^A_P!C]/?O#^?2
MB*WP>_\ EUB:7ZD$?ZUP3_O7MQ1I%.E:6M5!\3^76 R,23_Q3_BGO=.E:VU%
M'?\ R_V>N#$#Z6/U^A]ZKTL$&1W?RZQZR#>]@/\ ??T][Z4+ =0HV?LZPM+S
M] >3^?\ C7OP'2N*W-3K&*=86D)M_:_V(X_WCW[I4EOQT#KCJ)''!_U[_G_6
M]V5](I3I3';$K4M0U].L?/\ A_MO=2:DGI8MNFE:\:=8W86L&^MP>./]B;<>
MU X#I6L#U%!U&8VNME/^(-_^*#WOCT_]._FM1UA9K#@@&_\ A?\ /^O[]T[%
M;E6)6.AIUC+?UY_I^+?[QS[]TNBBIJUKUC+@?4$_[?\ WH>[JE16O2R../3\
M/6%W^A%]/]#_ %YY]N@4 '3WTP8 AJ#[.L6L\WL1_KCC_>/>^E"V[57K@2 "
M;@_[;WJO2U8!J%6J/LZQ%S?ZV][Z4+:HQH%KUB9K?2Q//^P/^/'OW2Y+?4*4
MTT_GUA+?D_[?W[I3';47X_/T_P!GKB7 ^EC_ +'WZG2A8Z #5UB9U-R+?G^U
M]?;@CX&O3P@X'5_+K"9/Q]+_ )O_ ,5'MWI^.W.M=7P]8F;G^O\ C?\ P]^K
MTL2W0'MP>L>HW^O%_I8?[;WNO3G@?TOY=?_4/02#]!;WT0Z^:SQ$]>N/OW7O
M$3UZ][]U1W! TGKWOW31)/$]>]^ZUU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NK^&_IUQUC\<G^G(_P"(]^ZLD;:A48ZZ+$_BW^Q]ZZ4*H!^$
M=<"0/K_O7OW3@0MP'7@0?I[UUOPV].NM0'!/^]^_=*5B.D=@_EUP\G^'^^_V
MWN^AO3IT125';CK&SVX))_PN?>U0U%1CI0D?<**.L9<GZ7'^L?;M . Z>\)O
MX?\ !UB:0?DDD7X-_>^G8XCW54?RZQF2XMR/\>?^*>_4Z4")Z=JXZQDW_)][
MZ=6)J"JYZY15W\+JZ#+ V.'RF+S (O<?PC(TN1N/\1]K[JT8GCFMS_HD;)_O
M:E?\O2R*0V4UG?!16WFBE_YQ2+)_S[UMDK719.GI<O PD@RU!0YB!U((>'*4
M4&0B8$<'4E0/> QB:!Y+=Q1HW9#]JDJ?\'7=E;A+V*"^B-8IXDE!^4B!Q_Q[
MH4\111T-!!"L:([KYZ@HBJ9:F8!Y99"H!>0G@L;D@#V33R&21F)-!@?(#@.A
M;9P+;VZ(J@,<MCBQXD^I^?3G[:Z5=:QWS\[5R7:/R6W6M11Y/';?ZYIDZ^VG
M2Y2@JL=)5TM#4/5Y_<5-#50P25%#G\](XIYPI2:EI(F5B+>\V/:C88-CY+L"
MKH]W>-X\I5@P!84CC)!-&1 -2\0S,"*]<A?O,\X7G.?NYO0EMI8MLVI!96RR
M(R%E1BTTZA@"R33$A' HT<:$$CHEQDYX%Q_KV_WBWN2 .H&50 .T=82QY]1_
M/%_^->_47^$=7$"D@Z^N!<6-K$_TL?\ BGO8 &:=+UM&# UJ>EOO^262?81,
MDCZ.H>O8AJGEF\:)39/3"GFR.2\,<=^(T--&E_330W(8KVH*%W6@ KN%P> '
MFN<*M?M.HGS=O(5[^DGB\NL0<;)9KDDTHKX%7>@'DHT*/**/S0/D*DW'Y_K]
M;?[#V:@%OAZ*$1C6HZX,P8'TBUOK?Z'^MO;J+0=PST\J*!W**]8=8 XN?]C;
MW;2OH/V=/+;ZP&4X/7!I%/\ 06_%_K_O'OW2I8'HO9U',H)M<CCZ7//U][IT
MK6*2HJN.L;26XN2?Z<^_=*4C[O@ZX:P?JM_Z<_\ &O>P"> Z51V^NNH4ZX>1
M;&['_6)//O>A_3I2ENJBFD'/6-FU?0$?X@^W%6@&H"O2A88Z"I /6,NOY;D?
MX_3W;/ITI"I0#3Y>G6'R:00;7/YYN/\ 6/\ L/>^GUA-1^H3UC,IO;DC_7/_
M !3W[I5%$S/0)FG4=WO]+GD\7/'OW2Q(V2O;3K$S,>>1;_'WZHZ4(!0ZAGK@
M7%OP3_B#_O?^M[]TJCA5U#:J#K&9 >. ?SS[MI;TZ5BW-!2,''6(RD_\5N3[
MV$-148Z6?2!>XTQUB+_4$_[#VYI7TZ>B50X(4 ]8F<?\%M^>>?\ >O>Z <!T
MMCC64D,:4ZPN]OR3Q];GC_>_>^E4<"("* UZP&0_U!'^Q]^Z61VFM P%!UQ+
M$C@6_-P?=M+>G3X4* OIUQ=U_/IX_P ?]O\ 3VX5 !HN>EOADXIQZ;ZRI,*%
M(B1*55VD0(XI8"P#5$X:X2/@A>"S'Z ^TDTQ13I;O].C"WL00"17H+=U[DR5
M*\<6/RM=3*H$LSHRWF0KJ4P2%"R$MZ2MOQQ[2B>=R!5@.C7]WQ"-"$ )/ITD
M8.Q,]CI8V&1@RM(9(S4464A59V5U+2I2UJ:982O]H6(!M;\^S*)P5RV>JBR0
M<!0?9T+VW]R4FXL?]]31R4[1SM355+. 9*:8+K2SH LT,T9#(X OR#R/;@(8
MT!STHCL^P9\^GGR \W^O^#?\4]V((-.G/HV_BZQ&3@\'Z?6Y_P!O]/?NGUC-
M5[?/K$9!;ZD_X<_\3[]TMBA+.JJ*'K"SGZDD7/\ C_Q%_=DTU->E@M67XV-.
ML6L_A1_M_P#C7MT:#PZ5VZ*@?-:GKB9"!_J?\;^]T4^0Z4:0?P]</*?\3_B"
M>?\ ;#WK2/0=*T@8JI"8IUA:9>;&WUXYY_WCW;I8ML]5_4;K 7)/''^L3_QK
MWL G Z5I:MJ'<>L98?UYOS]?>]#>G2J.U922,XZX>50/4+7^E[_\0/?BC^0Z
M?$07XXQUA=UL2&_IS8_U]NH"!0C/3BVX<54T'4<R_C]0'YYY_P ?K[M3I?':
MKX:5;-.L9)_J?]O[]TL6(X&G'6-GXL+_ .O<_P!?Z>_=*A!Z1BOY=< Q/T+?
M[S[]T]% X8D1^76)WT_XGF_UXM_7CGWM036G2M(7->SK"TH87N#_ (#Z?[Q[
M<%%%&&>E4<#:?[/_  =826)N+C_"_P#QOW<:3Y#IX6RD5.#UQ9K?5?Z\W]^Z
M5+$.VB#K"3^3_M_>^E7A,<:>N!<?CGW[IR.!P36/R^77#S"]K<_3\_\ %/?N
MGO!/\ _EU__5/9XP.;_3_:E]]#ZCUZ^:/KAI!_2US_2Q_P![X'OW5E4,:5ZY
MB,$?4W_/T]U=BM*#JSJ$ (/7O$/ZGVWXI].FJ]8RI%^./]<>W5.H5ZWUQ]VZ
M]U[W[KW2BVAM/<&_=U[=V/M.A7);GW7E(<-@Z&2=*2">MFCEF)J:R6\5)24]
M-!)++*P(2.,FQ-@4>X7]IM5A>;G?RZ+*!"[M2I"B@P!DDD@ >9(Z.^6N7=XY
MOYBV7E3EVU$^_;C<"&!"P16<@MW.<(BJK.['X54FA- 3*=C?!WY&=5[+W!V!
MNS![1DVSM:D_B&<DP.[/XIDJ;'+(L<]?#CY<50FI@I-8>4!Q(L=V"M8CV#-G
M]S^3]]W*TVFPN;@7L[:4#Q:5+>2E@QH3P&*5Q7J<>=ONH^]?M]ROO/./,6T[
M:=BV^/Q)S;W?BR+&" TBQF&/4J5U. VH+4A30CHI/L?]8[H@:N>O$VY/^]>_
M=7\(>O7 N/QS_MQ[]U[PAZ]=$D_X?ZWO5>G](ZXV]^Z]0#/7?OW3B ,:5ZXD
MJ!ZA<\V^O_$<>]=*HHAW9Z';H+XX]B_)/-;CPG7E3MG'2;4QN.R69KMU5^0H
M:!4RU54TM!34HQ>,RM5/52FCF=KQJB1Q_J+%5(8YJYOV;DVUL[K>%G<7#LJ+
M$JLW8 6)U,H %0.-23PH">I>]I?93F[WHW'>=MY1N+*%["&.29[IW1 )698U
M7PXY69CH=CVA0J\:D @YNK;^6V;NC<NSL_#%!G]I9_*[;S<$,PJ*>+)X>KEH
MZL4]2%45%,TD6J-[*61@2 ;@".QN+;<;&RW&T<FTN(ED0D4.EQ45'D<Y'KT
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M)D5F % ?3KB7 '%_]B!;_>??LGRZ6I;OI&!UA+VYM>Y_%S_O1][TGTZ4B(
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MH1[K<X.3@\O$?]GD'11/E6Y_V9_Y \_\U/S(^@_%'C1_Q'N0.1'IR1RF*?\
M$)/\+=0)[ZQEO>[W9-?^6W-_QR/I1_"8_P#.6G1MO^>CS7_O';C]H?<J.G(7
M,Y_X2G_5Z/H1_=L4CWY]LS_R]S?]HEQT+7\THJ/DO+<D$=2[0X]-K?QC=?\
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ML/\ F$$__2BB_P".1]17RK$W_!6V,FH9YUNO^KMQU9[V7\**?O3YA9_M/LZ
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M6?\ *D#C\6O_ +"W/OU>E0M5# J.X=8==S<ZB?ZGZ_[<^_5Z510%FTN.VG7
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M::?=#FW/_+ /_:7!T4'Y7N1\HOD(+_\ -4LUP+C_ )0\;^?<@<B'_D$<I?\
M/"G^%NH)][TK[T>ZIK_RVI?^.1]*;X12%OEOT6#_ ,])FOR?^>-W'[0^Y?\
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M^;4X'R(ZY6]O^,,0_P!?SOC<OL.^PG_*H[Q_TLC_ -68^I ^^2FKW+Y6-?\
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M;<$8!9J6<VX!\BVO_0W%_>_IE_CZ?0* <#K@VXD6VJCD%_I^Z/\ >K7]^^G
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MG\NH?^XPS/[C\S.ZTD/+V1Z'ZN"H_(XZ)Y\N,]'3_*OY%P&GE8P]K9N,L'0
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M/JY6_P"?:E8V [E%>D/AG/8./6'^\%#<@><V_/C/_%?;@C>F!CIT*  .N/\
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MW/:/[-O^.GK84_F620I\"/C_ .6-G1]U]+*JJ ;,>N\\5)N;  ?GWBC[._\
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MO?<T&PX^Q'WK@,'@'I:C<R[7DQJ83)5V1%4*A<)FA7&K6N:/1HC,94-J(NI
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M\^N*2A=:_:T2&X!"M&IY'T //UY]O)\(Z5)$^D8\NL3SV.EJ2 %193Y(V/\
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M66GGTOB@9G"L.WKD\M.BV^W)8*#PL;#_ )/_ *^ZHI7CTI$ CJ5&3TWKDH9
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MM_6CD1JIL2S<,!_4I'9?=P !3J_A8^ _SZ[BK:9BR/-&A6UCJ;ZV^@!'JO\
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M%N:>"7E11-4 CPZGO!U#N';D9R.G;#E_?]TEOX]MV"\N'M*_4".%V,%"01*
MO805:JFC=IQ0'J.^QNPI-I[>["78.^!L'=N4I\%M7?,NV<O'M/<V;JZF:CHL
M3@L]]J*'*5^1KJ=X*5(F;[J=&CA+NK .?O;:/K[O:OWK;?O2W0O+#XB>+&@
M)9TKJ4*""Q/P@@M0&O5TY?WA]NL]X_<UT-FN9!'#<>$_@RN255(Y*:79F!5
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M'YT'EZ=9?XN%6YIWDDX&F*!VC'^)9@.?\/;B*"#J'2N.H!QUD_CQ/I6BJH5
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MMH7%.H=8W^9 ^BQ$G_D)BP /]0/=J'TZ>B@U T0ZJ#_9ZA&4%!S]1P./2?\
M'\'W[I3';NA)85%.H32?X\<W''X%S_MQ[]PZ51P,P-!3IMJI+$Z?S?\ H;+^
M!_K^ZE034C/2Z*W C =26J>D5N:0)!3'4"WEEM8CA="CD?D@GWK0OITMC1$
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M<5( ("")6B%_ZM8!B1<^[Q?VB5]>GI+<Z'JP..'5KO;O:^U*;Y79?J39/2N
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MVFBIG  UL*HHVO\ M#2>!8\<>_9Z5I&=-='72'(JO[=%''$> /O-=O\ :=+
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MX/"E:E<_ E:_Q=X/^_9/(UNH'9[*AK2TB'&O ''Q-3[.VG\"^89LF3L%ECU
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M<TD9OK)TFQM8@I;_ %++] 3_ %][5&!%>E2H=0.G'422D6.QBJ-0!_1+'JU
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MY255?Z+>PU2-^%%R?;<[+&K!S_EZ6F"3R4=9<<$JZZ!R?VPAFY!TK&L5UN+
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MIUZO7__4,$P -D426 OINS:OSI%OH??2DF@)/7%Q(D+J-!R>L#&H#6%)-;@
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MV;@<_4\'\W]^\-L"HZ5QVJ%>%.N%'F& 99-!6Q!^JM8\$\_4D>W * =*!!&
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M>H<W!'U_/%_=&)2E1@GIU%*DUZ[DRBA01IU>K_%;?T_J;^W0IT'Y];()92>
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M!.HH*TZ>2./2.WINJ,71:+^ 2@7ND=1*DUC^H/("4L#_ (#WNMQU?PX_-.L
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M*CLQUD5/VBTM6XF)U)"9(U"WYNY4?D?BWO1" 9 IT^D9U?!Y=1))GCU7K1$
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M5O?NO==>3_:3_K\?\5]^ZUU__]!CG67UZ [R,0L<8!UDG@ (.;_GWT2$",:
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M_P ,K@1SI:-F;C\"QT\_Z_MS4.'ACI9#;2*&H.L22Y"H D:EKJ;2PU1U"A;
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M[7& )(ZFC&O09Q(SZ407+,L8 (&HNP47N?SJY]I!F@Z-P@!K7H;X(6IX:>G
M&FG@B@50P( B0)QS_5?:E254J.B(4,MP/GUD N3S8\_0_P"/O6NGQ.1U;2OI
MUWH:XL01^;D_[U[WK!^&1NKBBX"CKG;^I'^P6W^\W/MERVKXCUNH_@'7,$\?
M[#_>/H?]<>[KD"O53QZ3>Z<4V2Q,KP0F6IH7:KC5"#)H>PJ#&K?J5@+LH/\
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M1?\ U*+_ +R;<>]@D=+8_/M_EUR,G&DEB/\ #WHDDUZ<\(-DJ>L9E51;G^A
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M=!'3DQ%:JYU4\D,C(W-A',A-P?P;?B_NI1:$YKT8,*JP^70TFQ9N+!CJL?\
M:K,.?^"D>VAPZ1LJJ,#KN^D?G^G'OW5.NR?R;FWOW7NN%@UFM]1S?^M_\/\
M#W[K77!E(Y_J; #Z\GCW[K?43*UD=!B,E/-4I335%%4T6.U?YR:KF&AO#&OK
M9(TOJ8"RDB_M\D:3GRZLE=:$ X/0,1'04L;A3>ZBQM?U"W]>?:?HR+EL'H;
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M[:P]^KTZL3%@"M1UC>0_7T7_ -?_ (W[UTJ2 :NV,@]8?.O-U!M_2W^Q]Z)
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MI_5, B2&5D_"&P/]?>NO>&WKTBJK;F6R+K49#,4$T\:&,R>>>2-4:5I%B@B
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M=D4MY]>KZGKS1U/XIJIB>#KF0%?^#!ZA@1_K>[&,^HZ:E\J=<?MZTL+TP_\
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M:6].E"QFG<N>L1F_K8_ZY%O^(Y]N!!05'2E;>JJ==.L9EL#P#Q^3_A_K#VV
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M^E^;WO\ X^[Z$].E"+QUCK'J X O_C?Z?ZW^(][H *#AT\J1G.FO6)BA)O\
MX<$D_C\_UO[WGIP1BF%QU@-N;?47M?E1_@%XXL.!_7W[I6J#M[>N.H6O<6_V
M'O=.E2Q#4*KCKB9N+7!4?3D ?[U[UT^L"_ACZCM4B_X6Q/.H"_\ O'OQ('$]
M*(H?BK&>L)G)/Z@W^-Q_MOI[UJ4>?2A;4.*TIUB:IYT@V(_-Q;Z?UM_C[KXB
M5H7'2J.S.D4ZP/4.;6/];VX_V][^V#<4)[>EHM'H.X_LZQ,SL#Z3]/K< C_6
M 'O1N"00%H?7I4MLU1W]8[D'ZG_8GW3Q)/XSTH6%D-:UZXZ6)ORU^?I_7_6]
MU9F:FMB>GE0FM5ZXZ!]-'U( :WTO?G^OIM[KJ(P#CI1&-((I3KGH4<$<_P"/
MO>MO7IRA/EUUZ?\ #_;^]<<].!108ZX,Y/Y-K&X-N;_3Z?T]ZZOX9XZ,]</>
M^G$0U[ACKWOW3H4#@.N(-_J+>_=6ZY>_=>ZXDZ?P3_K"_OW6NN[W^GOW6^N_
M?NO=<25/!(X/]1]?]O[UUKIMK\31Y.2E>I-6RT>HQ4T-4\5$SMJO+4TJJT53
M*NJX+W ('''OWY]/1OH!&KB>F=MFX9S>23+R&ZDL^5GU/I "^1D5"X 'T^@_
M ]V!(X-CISQ6_CZQG8^UGE:27%&HD-]4E3554S,;_7UR6!]W$LH%/$/5"JL:
MD9/4N+:6VHN$PE& +$:E=C]/H3K]TU-_%UO4.(;/4],-AXAICQM&@N?2J.!=
MOJ=/DT@D_FU_>]3<=77JAFKQ?K+_  Z@6ZBDIE'T(\8-A_AJ8@'W[4W\77NN
M8H*07_R>$ "]S&A%Q^/TW'OVMJ\>O5 XGKFM+3VMX(-/^I\*$?[RO]?>B:G/
M7M0\CUR%-"/]TPV_ \,?'_)OO6.O:OZ77C$@^D45OR1!$+?[9??L=:J!Y]<Q
M&EK:([?X1H/S_@/?J#KU0>!Z]XQ^ H_Y 7@?[;WN@Z\0#QZY#6MM+%;?32H6
MWXXMP/>L=;+5I5OY]1YZ*EK+?=P0U>CZ?<PQ5&@'\#RHUA?W4HI;53NZJTC@
M:5<Z?3J*,'B1P*"!5%R%B#TZ7-KG1 \:<_ZWNP'SZV&[14YZZ&#Q0/%$GU^A
MDG8?ZUFE(Y][U,/Q=5HG$ 5ZRC$8M;E*"F!8?4HS@@'^CNP/NQD<\6_P=5)?
MS)ZE+24J"RTU.O%N(8QQ_P D^]:V]>M:F]>LI5!:T4?^N$1;?T^B^_:V]>MZ
MG/F<=<OIQ91S_9(M;_86'U]Z))-3UZLGJ>O7 YO;_8GWKK=7^?718_VW+?T_
MP_K:WU]^Z]63U/78*D<$G_7'_%3<>_=:J_SZ]Z;\W_V )][!(X'K=7ZZ+$7L
M-5OQ>Q_%K _DW_VWOVIO7JI#'BIZXR2+"K-420P*%ULT\T<.A>+-JD9 5;^O
MT]ZJ2<]751IRN>L/WU"./OJ1S_J8IXI[G_47@:4ZK&_O1X]7TK_#TWSYNE@D
MAC:+)GSKJ22FQU550<OH,<KPHWCD ]7JXT\\^]];&/LZ<(Y9'0$QZ2RZU#'3
MP?TJ[F,"-C;D'D>_<?+KV/RZZ22<I>5(HI/H(UF-2B@']1=$A)UK]01<'WKK
M0 !J!URUO>_]GZZ=#VO:_P"OZZ;_ (_I^?>_SZWU_]57W4?G_>/^->^H&CY]
M86B-*B@SUA:3D\F_'%S[V$H0:]*42K 5ZQ%B?H+<\D'D^W.E @+8!ZPF0<^J
MY_%[G_?<^_=*8;:@;Q!Y]1R7Y)E<#_:> .;6M8^_=+$MQIPE1UP-OKK=C_B?
M^->]=*E@32*KGK"74"XL?J?SQ;WOI8MO'48\^L1D#&W _P /Q_7^GO8%33I4
MD":QCK T@!(! L?Q^?\ ;>[^'\^E26ZU.E*GK&7' #*U[W(N2!;BUN+W_K^/
M?O[/'&O2E+9LT2G7 O9#Z;M_JB+_ )'NZG4*]*XK9M/='4UZP$LX^A!O_@ 1
MS]!R?=JCI\1H  4SUP+@6OQ<77_:O]8<^]=*EC%5SBO6(L2;CC_ ?\3[]TK6
M,5&E>[K$QX'JMR>>3>_-O]A;WOI3%$=1UIBG6!F/Y-_K:_OV.E(A5OAC'6/7
M_4<_[[_#W[_!T^EN0OIUP+FYX]V"5%:]*U@[1W=86?Z7)'U^GY_WCV_Y4Z4B
M"E._K&S@BP_V_P#OA[UT_'&-8J<=86:PY8_7_??CWOI9&D88U6HIUC,@_K?_
M 'BW^\>]]*DC0UT"G6)Y!_O'TOQ]?];W[I]+<,*Z_P"77#7_ (?[S[UTH6WH
M -?\NL#.JGZ_4G^O_%/?J]/A:4%>N+R>DVM_M_\ '_6]^5J$'I2D4FH=O41Y
M2!>ZWO\ DW_!]N>+\NE2Q2,:4IU@-2%-CZB>.";?[UQ]??O$/ITJAM6;545X
M=8'J^/20O]/]OR;V_P /?O%0?$:'I4MKI%/#ZP-56Y9P+V%SR/I_2W^'MLW,
M8) /2V.SJBGP^L+5$WX-P;_[;_#D>]&ZCH<YZ6BSCH/7[.L+/+8\FWYY%_\
M;^V-;_QYZ>6WCU#'6/UL/J2/\3[]JDXZ^E,<":NN!O\ 0D\?UY]V5V%=1KTJ
M6%%KVUZ];W;Q/Z/2B.-"I[?/KJP_H/\ 8^VR:DGJQB'D<=>XO^D?[8>_4Z4!
M,#/EUQUCZ?Z_]?R;_P"\>]=66/(SUQ:Q_%C_ %]^KT_X?SZXZM'U+<\<?\C]
M^K7IR.,5-3UP,G]/]O>UO]X]ZITYH^?6,LQYN?\ ;GWOJP%!3KKW[IX1U .K
MKWOW3_70]^Z]UW[]U[KWOW7NO>_=>Z][]U[KJUOI[]U[KWOW7NNM(_U(^A/T
M'U_ _P!C[UUJ@ZY7/]3_ +?WOKW71%Q:]O\ 'W[K?75O\??J]7#T %.N7OW5
M.NK?G\_U_/OW6P:&O7&R?A3?\D_0_P"L/>^G%;43CKN_^^/_ !3\^_=>9:FM
M>NQ]/Q_L  /]M;W6F>FB*'CUW[WU[KK^O^Q_V(_XW[]UKKUOQ[]U8&AKUZQ_
M'/\ L0/S_C_3W[K;-4<.N_\ ??T]^ZKUUP/I<7^MS>_OW7NO$@?4^_=:Z]<?
MX_[!3_Q3W[K8.0>NKJ/]6;?[1;_>"??NKZM1IY==G4 &",0WTOZ2/ZW^M_\
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M'\VM];GZ\^]^(/7I5%&>ZB#KKQW^MS_L?^-D^]U#9K7IX1,?P_X.NQ$G]/\
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M_4#_  ]^ZT_$8ZE$ ?5E_P!?UC_>/I[]7JR?#UQ#J+@%K@6NJ2$7_I<)R/\
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ME1CK&TQ^G^PXO_O//MWPE]3TK6-:KUB+Z038?X_[Z_OV@?/I4$5NVG6!GO\
M0<WOR/\ C?NRJ%-1T]# @8\3CK@S$\_2U_I<7_U^>?=NE/A+Y=8)'+ )<Z;W
MM_L;V(O8BX]^Z41!533I!SY]8V>W)_K;C_BE_?J=+5 TC'4"65%8 L;\WTW-
MOI];'WZN#3I?!;M(02HIU!9R[$DL18@?T^AM?\?7VFD=BA'1E':!75BHIUC*
MWYN?]@>/]A[39_B/2Q(DKPZ]Z0"=*G_8<C_6L1[LK%?/I\*H\NNM18?0!?\
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M<BX(/%K_ .O_ +'W[KW7)E^JG_>/]O[]U[KA9P1;3HMS]=?^P/Z??NO==Z;
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MS[J]T!32O2J+;M0;6#7K \L[<%T4?T5!S_KDWOS[KX\C9!H/LZ71[>H2@'6
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MQV]=BU^?I[\>KI$-0[#_ #ZZ9@/T_7^OU%O]Y]UR>E*1Y^$]8RQ/U/T_UO\
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M .9_[]_K_P#M]_!N7_.&/_K=T^C*E<GK@W\E?YM'_E+Z)M_3_2#N6_\ M_\
M1_[]_K_^WW\&Y?\ ."/_ *W=7\1/,FO7 _R5/FS^*SHG_6_T@[F_WO\ T?\
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MZ<O^&-/G:+_[E^A6!%CJW_N$-JO<R CKGT\<:>1[]_P0?M[_  ;E_P X(_\
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MZ^;#Z7'^\+_T'UQ'\CGYS '_ "OH2]^+]C[G(_'_ '[H>_?\$'[>_P &Y?\
M."/_ *W];_KYL'I<?[PO_0?7$_R//G:!9*KX_?X$]C[IN/\ '_F75O?O^"#]
MO/\ ?>Y?\X(_^MW7OZ^<O_\ +S_O"_\ 0?4=OY&_SP(N:SX^DW^G^D?=(^OU
M-_\ 1S^/>O\ @A/;[_?6Y?\ .&/_ *W=.?U_Y?P--S_O"_\ 0?7'_AC7YW'@
MU?Q_L1S_ ,9(W1P?Q;_C'(]^_P""$]OO]\[E_P X8_\ K=UO^O\ R]_R\_\
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M/CSC<W\1_G]VWNS$25V*[S[4VMT-75-9&Q.6P77_ %UE,YN2CAJ)D8S15?\
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M !8?.?\ P-_?OOW7NC/^_=>Z][]U[KWOW7NO>_=>Z^!WV1_S,3?O_AZ;I_\
M=Y7>_=>Z^VS_ "NO^W:'\O+_ ,4>^*/_ +XG8GOW7NCU^_=>Z][]U[KYC?\
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M[CZW[;QN.$XIERL^P-W8G<YP\LY2414^7BQK4TI*L/'*UP?I[]U[KZT.X_\
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M^$_?>Y=US9'>N23+92"KRE!FL#CY**GK QIU2CCD19&#O( FGW7NMW3^2O\
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MNO=65JZSP"29:2*5*=':.%#[]U[HX'OW7NO>_=>Z+!W[_P S.^'?_BP^<_\
M@;^_??NO=&?]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__U-_CW[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T
M6#OW_F9WP[_\6'SG_P #?W[[]U[HS_OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO__5W^/?NO=%
M>[ ^353L+>.9V@GQQ^4.^$PYH0-U]?\ 6>*SVSLM][04]<3ALO4;OQDU8*,U
M'@GU01Z)XW47 N?=>Z1_^SDU?_>(WS1_]$YA/_L]]^Z]U[_9R:O_ +Q&^:/_
M *)S"?\ V>^_=>Z]_LY-7_WB-\T?_1.83_[/??NO=>_V<FK_ .\1OFC_ .B<
MPG_V>^_=>Z]_LY-7_P!XC?-'_P!$YA/_ +/??NO=>_V<FK_[Q&^:/_HG,)_]
MGOOW7NO?[.35_P#>(WS1_P#1.83_ .SWW[KW7O\ 9R:O_O$;YH_^B<PG_P!G
MOOW7NO?[.35_]XC?-'_T3F$_^SWW[KW7O]G)J_\ O$;YH_\ HG,)_P#9[[]U
M[KW^SDU?_>(WS1_]$YA/_L]]^Z]U[_9R:O\ [Q&^:/\ Z)S"?_9[[]U[KW^S
MDU?_ 'B-\T?_ $3F$_\ L]]^Z]T"O:GR,W5O#>GQ[SV&^(?S'>AZT[<R6\]S
MFIZGV]320X*KZ>[4V1'+21R]@"2NJ?X[O"B7PQ*[^-G<@*A/OW7NAJ_V<FK_
M .\1OFC_ .B<PG_V>^_=>Z]_LY-7_P!XC?-'_P!$YA/_ +/??NO=>_V<FK_[
MQ&^:/_HG,)_]GOOW7NO?[.35_P#>(WS1_P#1.83_ .SWW[KW7O\ 9R:O_O$;
MYH_^B<PG_P!GOOW7NO?[.35_]XC?-'_T3F$_^SWW[KW7O]G)J_\ O$;YH_\
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MF%[,F(_OABLG-$+*4CK8@54FWNFWSB9)$'!3C[.K[A 87C<\6&?D>DITT?\
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M/WC\6M]U79?4\>[]P['I-[2;-WOLS&9G<&U)*:#<"X"GW[MS;&4SF)H*NJ$
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M_,R?Y:7_ (L-E?\ WI^F/::^^.W_ -,/\/2NQ^"Y_P!+US_GH?\ ,\/Y9/\
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MW7NMG/\ X4Z5O\1_E[?&_(!='W_\P+X=5FC_ %(JLENB?1S<^G7[]U[I7_\
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M7QZ?;O8VZ=^]>X'+;@RU=N"GW;C9(MX4F/K<UN$Y."JS]./$BK74\4)8%6B
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MA\LNF&3W7NE%\Z/D]_LF_P 3N[?D72[(W/V;N+KS9M94;$ZVV;MS/;KW#O\
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MJ7_L_OOW7NO?\86_\&I?^S^^_=>Z]_QA;_P:E_[/[[]U[KW_ !A;_P &I?\
ML_OOW7NO?\86_P#!J7_L_OOW7NO?\86_\&I?^S^^_=>Z]_QA;_P:E_[/[[]U
M[KW_ !A;_P &I?\ L_OOW7NL-1_H4^WGU_\ #K&GPRZOM_\ AP+[C3H:_@\/
M[WFM^G1ZM5K<^_=>ZLXVE]K_ '5VS]C_ 'A^R_N]A?L_[V_QC^]7VO\ #:;[
M?^\W]XO]_!_>'Q6^]^^_RS[G7YOW-7OW7NE![]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
9NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g313671ex99mda.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g313671ex99mda.jpg
M_]C_X1/C17AI9@  34T *@    @ " $2  ,    !  $   $:  4    !
M;@$;  4    !    =@$H  ,    !  (   $Q  (    >    ?@$R  (    4
M    G $[  (    .    L(=I  0    !    P    .P +<;    G$  MQL
M "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q-SHP,SHP." Q
M,#HT,CHS-P!$86QE($-A;7!B96QL      .@ 0 #     ?__  "@ @ $
M 0   I2@ P $     0   K@         !@$#  ,    !  8   $:  4    !
M   !.@$;  4    !   !0@$H  ,    !  (   (!  0    !   !2@("  0
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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MFDFQDSW\8$J4#S49_P!82U\TK*J7@>)^])-\BDE913__U9%RB7+L/^8O3_\
MN5D_?7_Z12_YB=._[E9/WU?^D5I?>\7<_8PQPT\:7*)<NS_YA]._[E9/WU?^
MD%$_47IH<&'+R9=)&M7;_K/FE][Q=S]C(( /&%R8N*[7_F#TW_N7D_?5_P"D
M$W_,#IO_ '+R?OJ_]()?>\7<_8RC@#Q))\4R[?\ Y@=-_P"Y>5]]7_I!+_QO
M^F_]R\K[ZO\ T@E][Q=S]B\2@'ATR[G_ ,;_ *9_W+R?OJ_]()?^-_TS_N7E
M??5_Z02^]XNY^Q=[D'ADEW/_ (W_ $S_ +EY7WU?^D$O_&_Z;_W+ROOJ_P#2
M"7WO%W/V*]V/=X;5)=Q_XWW3?^Y>5]]7_I!+_P ;[IG_ '+ROOK_ /2*7WO%
MW/V*]V/=X?0<I3/"[C_QONF?]R\K[ZO_ $@D?\7W33_VLROOJ_\ 2"7WO%W/
MV)]V'=X=,8[_ '+N?_&^Z9_W+ROOJ_\ 2"7_ (W_ $S_ +EY7WU?^D$OO>+N
M?L5[L.[PP^"2[C_QO>E_]R\G[ZO_ $@DE][Q=S]BO=AW?__6]#^L;<D]$S'X
MEKJ,FBO[12]AVR^@C);4\_Z&_P!+T+_^!LL7,]'RNH9?7>CNOLR;ZLOI[^I.
MJKO<RNEV3D?::O78;JOM=&+3=]AIK_3_ /A?_1]K=57?4^FUH?7:TL>T\%KA
MM<W_ #50_P";W1_7P\AN/LMZ?4,?%<Q[V[*@-K:?8]OJUZ?0MWI*>!L^M&1?
MT+.R!FW9(_:E.6*\6\BYN%D[KJ^G-NH>VRBVMM%['4[J_37H'2OM'V'IWVJY
MF5D?9F^MD5F66/V5>I=6Z&;J[7^]GL2'0>D 4@8S8QFX[*=3[6XA>_!#?=_V
MG==;L_KHV/BT8;<7$QF^G1CU&JIDD[6,#&,9+BYWM:$E-;J7UAZ7TO-Q,'->
M^N[/>VK&(K>YCGO=Z;*_68QU3'N=^\]6.J=3PNDX%W4<^ST<7' -CX)B2&-&
MULN<Y[W-8N?^O_\ ZSG_ *?L+_T<J/\ C =F]0ZST+H&%57D&RRS.NQ[CLKL
M^SMW45W/#;/T+_TWJ5>G^D_1I*>UQ[FY%%=[ YK;6->UKVECP'#<!96^'UO_
M 'F/1%D?53KP^L/0L?JGI>A9;O;;3.[:^MSJG#=#?I;=ZUTE*22224I))))2
MDDDDE*22224I))))2DDDDE/_U_55P^']:>J58>+GY-S\AM_5K<;*K=2*ZZL:
ML9^]]&1Z3/M%6/7B5YE]K++OYFRGU%VC[V,<6D/)'@QSA_G-:5A8WU=Z;137
MC/MRLC$IONR:L:ZMI8TY#,NG)I_1XU=ME%G[1O\ YZRQ_P#-_I-B2G+Q/K%U
MQ[^FY3KVOI?B='=E8Y8T"Q_4[+L6^]MC0VRJRFQE-E;&_H?YS]'^YV#_ .?K
M_JN_[ZL&KZL=)JOPK/4S'5X%.+2S'+3Z=GV'U?L-V1LH;:^VE^0^WV6UX_J^
MF_T/T:VG9##:QVVR ' GTW]]O\E)3F_6CHN7U?\ 9/V9S&_L_J>-G7>H2)JI
M]3U&U[6OW6^_V*I]9>A=8OZSTWK_ $0X[LWI[;:GT91<UCZ[6[&^^IKG;JG.
M<_\ E_\ 5]!]JK_=L_[;?_Y!+[57^[9_VV__ ,@DIR_J?T&SZO\ U?QNF76-
MNR*][[[& AI?8YUKMF[\QF[T]WY_^CK6T@C)K)C;9K_P;_\ R",DI22222E)
M)))*4DDDDI22222E))))*4DDDDI__]#U58W5.F=7MS7Y?3,MN*]]=54O:'@-
M8<I]L-?79_./R,;_ +86LZZEAVNL:TCL2 5A]0_;?[4=D]-R:!064LV76%S-
M+-U^W';#66-J_P -O_25V?\ !5I*5F]&Z\[+NR<#J1I+V>G6+/>&C;0T^QS'
M5-=OHMLW[/\ #*67A_6B[(R'8N<W'HW/&.Q[6$EI;CFMV_TK=OZ7[<W^IZ"K
M/=]:;6EIRL5E9]L!P%FTU5-,VL'MM;D_:';ZO^H1<)_U@=78WJ5^.]GH.:QE
M%@KL=8:Z6MG('\T[U?M/Z6K9L?L_,24FNZ=]9'-H%74VM+*G"\EC9=:;&6LL
M_F_YMM+;*?3_ //G\Y76IZ)]9&NJ;=U!CZ!D5WVU 07;;[LN_P#2^GO_ $F[
M&VU>RK_M/_-U_K"95U9G1[\2V\W9=K*BR]F3L+7-JQ*;MMI_2M=]HKR\G]RW
M_2U^NH58_7ZV5_KM;W_:F.MWW;MU R+K;=L-:UCK*'UNV,_P?ZG_ #-22GIT
MD/[1CG06LD_R@B)*4DDDDI22222E))))*:/5^I_LW&;:&-LLL?LK8]XK!(:^
M^S](0[;^@IMV?OV?HTG]:Z:RIUQM/I,=M+PUSA/H_M#V[6G=^J_I/;_Q?\XK
M%N)1;?7?8W>^D.;7.H&_;O=L^CO_ $?T_P"O_I%1=]7>G^FZNL/#2(:QUEA8
MTFLX>_TP]O\ VE_0_2_XM)2[^NXU1M]5KQZ8+PQM=CK QC*[K7W,]/;5L9>Q
MWT__ &8_0(/4<^G(PGXKG>F_*>^BBQNXLWMM./2'Z,N]]PK9;Z5;V,W_ ,YZ
M?Z5&LZ798^VU[:G67M?7:9L +;&UU60!9[-S,>G^HHMZ*WUQ:6,'O8]X:^T!
MWIVOS*MWO][JLBVRRO\ P?O]/T_YO818-]E2B) Q.Q%%#]6^E]1P?M5W5+G9
M.=EO:^R[=+-K0=E%%>[]'74YUG^#J_G$EMI)E3K^<EQ?YRL?%_B\'M?U/YM?
MQ^KBH?W?T7__V?_M''90:&]T;W-H;W @,RXP #A"24T$!       /1P!6@ #
M&R5'' (   (  !P"4  -1&%L92!#86UP8F5L;!P"!0 74&]W97)0;VEN="!0
M<F5S96YT871I;VX .$))300E       067X 8D,_8L0[9@2HN8?LS#A"24T$
M.@     !C0   !     !       +<')I;G1/=71P=70    '     $-L<E-E
M;G5M     $-L<E,     4D="0P    !.;2 @5$585    !$ 00!D &\ 8@!E
M "  4@!' $( (  H #$ .0 Y #@ *0       $EN=&5E;G5M     $EN=&4
M    0VQR;0    !-<$)L8F]O; $    /<')I;G13:7AT965N0FET8F]O;
M   +<')I;G1E<DYA;65415A4    +@!< %P 4 !( %@ 1@!" %4 +0!- %<
M10 M $8 4  Q #  +@!F &D ;@!C &\ 80!D "X 8P!O &T 7 !! %H ,  Q
M #4 ,0 M %@ 10!2 $\ 6  M #$ .       #W!R:6YT4')O;V93971U<$]B
M:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7
M   !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L
M.$))300[      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,
M   7     $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP
M $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B
M;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC
M 0       %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O
M=6) ;^            !";" @9&]U8D!OX            $)R9%15;G1&(U)L
M=                $)L9"!5;G1&(U)L=                %)S;'15;G1&
M(U!X;$!RP           "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0
M  !09U!S     %!G4$,     3&5F=%5N=$8C4FQT                5&]P
M(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D            0
M8W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P
M       ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO
M;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 2P
M   !  $!+     $  3A"24T$)@      #@             _@   .$))300-
M       $    >#A"24T$&0      !    !XX0DE- _,       D
M  $ .$))32<0       *  $          3A"24T#]0      2  O9F8  0!L
M9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:    !@
M 0 U     0 M    !@       3A"24T#^       <   ________________
M_____________P/H     /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H   X0DE-! @      !     !   "0    D      .$))300>
M   $     #A"24T$&@     #.P    8              K@   *4     P!-
M $0 00    $                          0             "E    K@
M                     0                         0     0
M &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   K@
M    4F=H=&QO;F<   *4    !G-L:6-E<U9L3',    !3V)J8P    $
M  5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N
M97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M  !,969T;&]N9P          0G1O;6QO;F<   *X     %)G:'1L;VYG   "
ME     -U<FQ415A4     0       &YU;&Q415A4     0       $US9V54
M15A4     0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA4
M34QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU
M;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE
M;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4
M>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U
M='-E=&QO;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/
M=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
M    #     (_\        #A"24T$$0       0$ .$))3004       $
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M7)(_=<78_:O^\YZW'V/_T=-))):KR*DDDDE*23(F/1;DWLHI$V63M!TX!?\
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MS,EWN_G?4_L)FX;7XMY.(&,KKO?7E^L=Y-3G^E&-O_F_9Z/\W_PV]*4@00=
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M/_:S*^^K_P!()?>\7<_8GW8=WATQCO\ <NY_\;[IG_<O*^^K_P!()?\ C?\
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M7%_G*Q\7^+P>U_4_FU_'ZN*A_=_1?__9 #A"24T$(0      50    $!
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M :/,]4[C['VIAL/39G#FDW5L'+;LI,955U'6U<,4\3%E(M,A8>Z]T@_E9_,
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MWM14>3Q>,. CE@)F5Y68AU(L#[KW1^OY>'\M[MCXYTWR-^0'R/WKB.R/EO\
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M=WOM_P HO+W_ &27'_;9U[_ASGY._P#*EU/_ .@EG_\ [+_?O]93DG_?M_\
M\Y8_^M77O^#N]]O^47E[_LDN/^VSKW_#G/R=_P"5+J?_ -!+/_\ V7^_?ZRG
M)/\ OV__ .<L?_6KKW_!W>^W_*+R]_V27'_;9UQ_X<Z^3H_51=3W/TMM+/\
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M+JG_ -!'/?\ V8^_?ZRG)7^_+_\ YRQ_]:>O?\'=[[?\HO+W_9)<?]MG7O\
MASSY-?\ *EU3_P"@CGO_ +,??O\ 64Y*_P!^7_\ SEC_ .M/7O\ @[O?;_E%
MY>_[)+C_ +;.NC_,\^3G]FBZHO\ X[1SW_$;P/OW^LIR3_OR_P#^<L?_ %IZ
M]_P=WOM_RB\O?]DEQ_VV=<?^'//D]_RH]3?^@EG_ /[,/>_]93DG_?M__P Y
M8_\ K5U[_@[O?;_E%Y>_[)+C_MLZ]_PYY\GO^5'J;_T$L_\ _9A[]_K*<D_[
M]O\ _G+'_P!:NO?\'=[[?\HO+W_9)<?]MG7O^'//D]_RH]3?^@EG_P#[,/?O
M]93DG_?M_P#\Y8_^M77O^#N]]O\ E%Y>_P"R2X_[;.NQ_,\^3W_*EU-_Z"6?
M_P#LP]Z_UE.2?]^W_P#SEC_ZU=4;[^'ON*4M>7?^R2X_[;.N_P#ASSY/?\J7
M4W_H)9__ .R_W[_64Y)_W[?_ /.6/_K5U7_@\??C_E$Y=_[)+C_MLZ]_PYY\
MGO\ E2ZF_P#02S__ -E_OW^LIR3_ +]O_P#G+'_UJZ]_P>/OQ_RB<N_]DEQ_
MVV=>_P"'//D]_P J74W_ *"6?_\ LO\ ?O\ 64Y)_P!^W_\ SEC_ .M77O\
M@\??C_E$Y=_[)+C_ +;.NO\ ASSY/?\ *EU-_P"@EG__ ++_ '[_ %E.2?\
M?M__ ,Y8_P#K5UL??Q]]R0/I.7?^R2X_[;.O#^9W\GCP*+J7_P!!+/\ _P!E
M_O?^LIR3_OV__P"<L?\ UJZ<_P"#N]]O^47E[_LDN/\ MLZRC^9S\G?S1=3_
M /H)9_\ ^R_WK_64Y)_W[?\ _.6/_K5U1OOX>^XI2UY=_P"R2X_[;.O?\.<_
M)R_-%U/;\VVEGK_^]?[]_K*<D_[]O_\ G+'_ -:NMK]_#WW(J;3EW_LDN/\
MMLZY?\.<_)G_ )4^J/\ 6_NEGK_[$?WP]^_UE.2?]^W_ /SEC_ZT]6_X._WV
M_P"43EW_ +)+C_MLZR+_ #-ODR?K1=4\VM_OTL]^?Z_[_#W[_64Y)_WY?_\
M.6/_ *T]>_X._P!]O^43EW_LDN/^VSKF?YFOR8'!HNJ?]AM+/?\ V8>_?ZRG
M)7^_+_\ YRQ_]:>M?\'=[[_\HO+W_9)<?]MG7'_ASCY*WT_9]4@CDWVIGO\
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M8_\ K3U8??8]ZR1_BVP_]DL__;7UU_PZ!\GO^5'J7_T$L_\ _9A[LOL?R02
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M&V/_ +)9_P#MJZ[/\T?Y0CZT'4@O]/\ ?H;@/_RY>Z_ZQO(W^_=P_P"<L?\
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MU[KWOW7NNP2/I[]U[KDS7M_4?7_>/?NO==!2>1;W[KW60(+<CG_7/OW7NNP
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M'_$?\3[]0G@.O=9 Z#@?\1_Q7WNA]#UL G@.N6M;<D#_  N+_P"VO[UPZ>5
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M_BOO=&]#TX(@!0*:?GU@+W(T_P!>?I;_ (GV_I7C3/2A8$J.P_SZ\2#]2/\
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M\?[Q;WOI0L&D@Z_Y=87<V%^?]X_XCWOI1''4GNZXA[_BW^Q]Z)ITH6#5^/\
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M^H_V'_%/=_#^?2J*W[CW^7IUC\G/ZA]?IQ_MOI[]X?SZ4?3_ -/^77__UCX
M#\FW^PO[Z(=?-'UT?\#?_'W[KW71('U]^Z]UX>KZ?\4_WNWOW6^N_I[]UKKK
MW[KW7(*3]![]U[KVD_G@?U^OOW7NNO?NO==>_=>Z][]U[KD#;ZB_OW7NN/OW
M7NO>_=>Z][]U[KDI ^H!O;_8>_=>ZYW3_#_;?\:]^Z]UQ8@\  <_7_?#W[KW
M7#W[KW7( ?DV_P!A?W[KW7K+_JO]X/OW7NN>I;&W!M^!;_B/?NO=8[W^OOW7
MNN)8#@G_ 'OW[KW76M?Z_P"\'_BGOW7NO:D/UM_MO^->_=>Z]8/PMK_7Z6X_
MV-OZ^_=70J#W<.NO'_C_ +Q_QOW[IS5%\OV=<&2W-@?\;>_=58:C5!CK$4N;
MWM_A;W[IL@@T/'KG]!_K#_>O?NM=<2RD6U6_QL??NO=<=5N=1;_#D?['F_OW
M7NN!//\ KG_7]^Z]UU[]U[KWOW7NO>_=>ZX:S_J?]YO[\"*BO#JNI?7KHDDD
M_0G^G'MT%#@=>U#UZZM_7WN@].J,W"AZ\??J#TZLA)&3U[6!]6_XK[]0>G6F
M#5QPZX^3^C?[<$^]T'ITZ$>@QU[R@<W)MS;GGWZ@].K*C:A48ZX&H'U^G^L3
M_P 4][Z?"BN%%>N!G7_?7_XI[]T\B$U[>L;3B]M1!(_3<\_\C][Z<\-AP7KK
MR,?P?^2O?J]/I&=(JHKUP+ZK@<$'GG_7]VTL<TZOX7] ?RZZ\B_AO][]UT,,
MD8Z4K$:BB]=A[\EB!_6Y_P!]]?=>G_#8?AZZ+(/[5_\ 8'WL GAT[&AJ:KUT
M0K?20@6L;#_BH/O=*<1TICA# GPQQZXB+G@EA_B/K_R(^]5'3PMVIVQXZY%V
M3FU_Q8W]^Z5+ P45C\NN#/?GZ<?U]ZSTH\,_P]87E N/K]/S_K?X>W%4U&H8
MZNL+!@2G^#KI7O\ 7@6X-[^[.H(&D9Z4QQY/:.N1D7ZEFO\ CZ_[S[;((XCI
M2D-1\ ZQ/-8_J)-AQS_Q3VZ@[1TH6-%%"@KU@:6XN;CGZ\_\0/=^GA%4"B"G
M4=I0+<DW_P!?_BGO?3U!Z=8S+S>QM;GD_P"/^'OW' X]/PH3(H*U'^QUQ\Z'
MZV_V)/\ Q(]^T/Z=+?" X1CK!)-HL PLP-_]Z_V''MR->.I>G8TK7MZQ>?\
MP!_QN?=Z4X=*DB!&4'7!I >?K_A<V'O?2E8>T?ICJ.TRBX+,;W  )_WGWM1D
M=+1;BJ]WY=86E_H3_K<_[W;V_I7T'3X@->V,5_+K&96/Y8?[$^_:1Z#IZ.)T
M8G33'7#6P(XU7//UX]^HH_".E<8;->N>O_:?]Y_XU[]0>@Z5);^(-1Z]JN
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M_P!3_MS[]U[KUR?J3[]U[KB6 _U[<>_=>ZXK(UP+V'^%_P#BO]??NO=20O\
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MUFXM>W^(]Z/2L1*2,'KI[ %OK]. P_WKWM,L >'3Z01ZQVGK%K_U/'^N+_\
M$^W2B]*T@CJ<']O7$V_/^]^]J-/#IX1*. /6-G"W (O_ (\CWOCY=*$@9EJI
MQUA:6_!OP?P!_P 5]^Z4"T<@&G6$LS?7_>K>]XZ,1#+45 T_9UC+ &QO[W0^
MG2A44$8ZQ,!R1^3[L@J34=.^%KPASUC+:?SS_K C_8^W/#7TZ>CMWH<CK@6N
MI)-_ZVM_7CCZ^]@:<#ATJ2+2M"*GK#K;\$6_%P;_ .QY]^Z4K Q4$''7 G@F
M_P"/H"#_ ,3[]TO5> T]8"Y) '%[?46_WO\ 'O?SZ?2+4P !KUB9^3<D\_X
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MXZPNY^E[\#G5<_7W[I6MN=0I%0]868@?VOK_ %M_Q/OW2I+>2O#K#<W))/\
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M'F_^W]V"L14#'3Z1]HJHZZ9AQJY_I<7_ -?V\ *<.GA#)BB_X.N+7L?];WL
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M3_O?OVDCCTOC@52=(J>N_(W]DW'YO?W=2H'=QZ>$#GX8Q_+K&S'DGC_6O[N
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M4'_>/>Z]*! M "37KKS#_#_;'VWX8]3TL6W2JY/^K\NO>8#GZ_X<_P#$^]A
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M5ZTIUPT\V_QM_O/OU>G?!3U/7__7/+Y%_H?]X_XK[Z%"-@0:CKYHJ=<#I;Z
MW/Y/^'^Q_I[>ZWUYE  _K]#_ +;W[KW6/W[KW7O?NO=>]^Z]U[W[KW7%EO\
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M%.N&H_T_WGWZO3P2G =<;G\D^]=6 ]1UUQ_OA[]U?03D+U[WKI0$7';GKHL
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M@!0T%LI]"6:9P#_ #U39Y!_3_>3_ ,4]Y&JHH*CK Q(NT=O6%G!OS]+V%_\
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M /$>]]*UM-0!P!3K$SO8W O;_&_NP4@@E33I6+32=1.!UBUZ?4[!5'ZF9@%
M_P 6/ Y/MPF,"I(Z510U8,D?4"IS6(HU#565HZ92=(,TVFY)M8<$D$\7'%_=
M#) *5=>EHMY3EXCIZXTF4Q^2#-CJ^CJ_&2K)3U$;2!A<Z?"2LQN!Q92#^/=P
M$(J*4Z>C@ !K%3K,7)OQS_6]S[M@8'2N.!-(K&*]82W)Y][QTI$<8 &D=<&<
M$<<<>]9Z6B$$CL'6(N/K<$_Z]O>^E*0#4*J .L#2_P"U6Y^E[_\ $>]A2>'2
MF.*-"2&KUA+G_$?ZQ][T-Z=+8;<3!B/+KVL6]1X_-_\ C7OU)!PKTJ6U"BA0
M'KC=?P1;\>_:6\QGI6L9"J E!3K"[@_4 ?6PYN?];V]P Z4""*J_J#_5^74=
MV2_U(']"2??L]*1;QUP^>L+,#^/S]?I_Q7WO/3\5KJ8T<\.N%S8Z;V_-C_O?
MT]^^WI;%;R1AM()KUA9B.;V_U^1_MO;J!2O#I0@=!1A0]868L U[M]+C^G/X
M_ ]WP,#ATH6-&4,4!)ZPZP+V)_XK_O'O?2Q;/*GKBSBQ]-O\;_3WK\^EBP,&
M!\&G6'4OY-_]]_K'WOI3' 7:A%,=8V<DV^GXX/U_U_I[]TL2#B&[A_@ZQL=/
M_%/]C[V%)X=*(X%IB,4ZPM+_ (Z3_K^[:&].G/# QIQUC,C$&ZG\\W^G^/MS
M2N.%>E:VY[?TNL'E-_J2/=NE*6H1@PXCK@S7Y''^'O72E8]1H5ZX?F_Y^OY]
M[Z<\'_A?7__3//R?J?\ ??[?WT0Z^:CQ3Z==>_=>\4^G7O?NJL^K%.O>_=4Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NNB0/^(_WUO?NGO"
M'KUPUD\?3_$>_=66.C UZZY_))]ZZ> IUQ)(M87O[]TZB:JYZ]J _5P?^(_W
MGWKJWAC^+KCK_IR/Q[WTJ2(:5[O+K$7M]6//^O[<\,>O3PMP#76>N#/^!_M_
MH?>PE#6O3Z)5@*]8BX^A)_WD_P#$>[]/^$/7K$9#]+?UY][Z<CC U9ZX%C_4
M_P"W]^Z4+ &%=77$D#D^]].B$ 4U=1ZF:6""2IIP344H%936^OW%(PJ:>WYO
MYHE][0*S!'^!L'[#@_R/3T@DCB,L1_52CK_IEHR_S ZVN=IYZ#=^T-G;KHI%
MF@W5M+;&=@E0ZED?+X:BJ9""/J14RNI_H0?>!E_:MMVX;C82"C07$B$?Z1R/
M\ '7<O8MSCW[8>7]\MW#17MC;S CS\6)&/\ QHD'YUZ'JFA6FIX(% "PQ)&+
M?[2H!/\ L2/8:=BS,Q\SU(<2"*..,<% '7JFIAHZ>>JJ'$<%/$\TKL0 J1J6
M8\_FPX'Y/OR(TCJB"K$T'7I98X(I)I6I&H))^0ZU<?F]#N2'Y/=CUN[-QXG<
M>5SJX3.T P\=7##MO:E90F/:6T:V&L4-'E<1AH%DJ=!9))JAI!;R6&<?MDUD
MW)&S16%G)#!%K1M9!,DH:LLJD?A=S1:Y 4#RKUQV^\+;[LOO!S7<[WNT%U>W
M(BF3P@P$%LR4MK9PV1)%$H:2E0S.7%-5 4\L2;WM_A<^QWU#RQ.5!45'6(N.
M>?Z_[[Z>]]*EMV[:H.L>J_'TO^03<>]]+! E<8Z6V_2C3;%(D5]/4VP(V*20
MRZ9$ILD&CD\%96^.9+^I',$B_P!J"+@$JVLD+NE1_P 3Y_4>:^H%1\Q4'R9N
MA+OT2^)R^1)6FS6@Q0Y"OQHS4/J#I(\XT\T"6*DV)L2?R?9LBZZUZ*(XQG/7
M#R!K^H_3_&W^Q)]O*N@4KTI2-R.T5%>L6LL=*GG\6/\ A?Z_3WO'2E8ETC6O
M=UB,UN"+_P!"23_O0]ZITI%NN.X]8"[#ZBX_+$FX'^M[M3I2EMW+1B3UP9[\
M#Z?U%P?]Z]ZZ5+;LIJW#K'K(_M$?[$^[JNJM>E,,:@M7/6/RFUK W_-SQ_K>
M[>$/7I4L:D8P.N!?^K-_K6)'NX&D4Z5)&VD4C!'7 R'\ ?Z]_P#B+>_8Z4"&
M2@QU@,G]/][/^]?3WOI2MLQ( 3K"TG/)(_P%_P"GOW2F.U8-W&@IUA+ZC;Z6
MOR"23_B?Z>_<.E26U:Z&)ZX,0/KJ)MQP??J]/K!(N O6,OP?Q_M[_C^GOW2Z
M&!B@)CZPF5N1:_\ 2['_ &]O;@C! .KI2+<4'<1UC)X^I_V+'W8)0@UZ7>"O
MX1GK&7M]+'_>/=^K)#)J&.L#27O^>?I_3W[I?!"Y+52N.L+2 _0VX^G(O[]7
MI:ELY&%IUA+'_$?ZQ-O]XM[]TLCMU"#6.[KHM8<DV_V)]N!*@&O5_!?\*XZX
M-+_K'CZL2 /]<_@>W",'I4(Q45..FVL>65)0J,E-#&LTC.D9CK75N:5&)+01
MHJW9K:F!]/LLGD.8QBOGT<6ENC !5J>@,W1F$R=5IC*L:,^-5,3**:5H@&"O
MR7C_ #Q>Q-N/;$:$MER>CU;!WC72G#I"5,U2*B"IBIWCK('C:GK:&0PU$1C%
MBPD0AK2-S;\#Z?4^UZ3J@TMU[]VS?[['0X;#W!7YG&5462E^XK<;41QFJ8!)
MIH*A&>)*H"Q:HA92-=@&2WY'M^*7Q30<.O?2B+L=>[I;>3_#_>3[>(H2.O>!
M'Z=8V<CZD\_07//O73RVKU7/GUB9S8WX_P >?Z_ZWOV.EL5L?$75\/6(L/Q8
MG_8CWM6T^5>ERVP![!4]8R?\6_VY/MU6+5Z41PR"M%ZQEN."3_@21^?\?=Z]
M*%MY&%:=8RY'U)'^\^]=*EMNT5<UZPF4FXM_A_C[W3I:L*U7'IUC+?DW_P!B
M2?>U%2!7I8D*%ACK$TH7\"U[?GVYX?\ 2Z4I;K7!(ZP^6U[-<?F]Q_R/WXQC
MUZ>$!%=!KUP:8,IX4G_7(_/NRC2*5Z4Q6K,M2OGU')))(X_P!-A_O(][_/I2
MJ1HH0J*CKAK7^O\ O?\ Q3WOI4L0J,]8F8G_ (I^/?NE@A!--77 ,M[$_P"\
M>_'I^.W4'XSPZQ2/]!?^MA_JOI]?Z>[HNJO2J. &O<>L)9K6(T_ZQ][+:.VE
M>E26XT_&>L9X%R?K^2/;@:H'2A550 14]8V;ZV8GZW^HM[]TZJBJYZPEUMQR
M?Z&__%/>^EBP@D#5UP+DCZ6_X*23_O7T]^Z>6W5#77UB\IO:_P";?4_[U[]U
M?PQ_%U__U#UZD_"F_P"+Z?K^/Q[Z(=?-'UZQ/!4#_$?7_>[>]=64@&IX=<P!
M_0?[8>ZN"::>K2,K !>N5E/]/]M_QKVWI?UZ:IUB90 2+_C_ 'WT]NJ"!0\>
MM]8O=NO=>]^Z]T,?Q[ZP@[H[LZ]ZQK9JZFQ.Y<I62;@J<9)'#DJ?;N&Q5;F,
MJ]#/-%/%35,L=&L*RLC^,RZ@"0![#O-V]MRWRUN^]Q*K7$*#PPU2ID=E1=0%
M"0*DTJ*TI7J3/9GD*+W0]T^3.0[J65-NOKAS<-$0LJVT$4DTIC8A@K$($#%3
MIUU ) '5H/>_\N7IK9?3W8N\NNZG?Z[PVEM?*;FP\66W4V8QE2<'3ODJRAK*
M":A4S0U>/IY4#*ZR(Y5@W!#0?RM[Q<Q[ES#L^W;NEI^[KB=8W*Q:&&LZ0P8-
M@AB#PH14$>F?'NW]R7VRY8]M>=>9N2Y]X',NW6$MU")KOQHF\!3*\;QM&-0>
M-64$$,K48'!!I9219(TE0W1T612/H590RG_&X/O)(@J2I&1US AHR!QE6 (^
MP]>+\<&Y_P!C[UT]I!\NN!9CQ_OO][]^ZWH_H]>^OU_WGW[IP"II3KUO];WK
MIP0N30 5ZZ) _(_U@;GWL"N!TZD$BFK 4^WKBSFUA^;W]VT-TIBC(U=O1[O@
M1\=>L_D1NKLRB[.H\ODL=L_!;8J<30XO-Y+ J:S.5V9CJJJJJL344M74>.#%
MJD<9?0NMFL6TD1=[J<W[WR?M^R2;+)&D]Q+*'9D63M14H '! J6))I7 '#CE
MK]U#V;Y*]W=[YU@YXM)YK/;[:V:)(II(.^9Y@[,T3*[46(!5+:15C2M""C=N
M;6H-A]L]H[$Q$M1-A]E[_P!T;:Q$M9)YJU\9BLG-3T(JY]*^>HCIPJL]@7*Z
MCR3[D#8+Z7==@V/=+A5%Q<VD4CA10:F4%J#R%<@>7#J ^?N7;7E7G[GCE?;F
M9MNVW=KFVB+FKF**0JFHXU,%H"W$TJ<GH.C(/Z_[P?\ BOLXZ#@@04-37K&9
M"1;_ (K[]U=(SJ';UQY/Y_VY]^Z4"%F.%%>K/_B3\0^G^Z?C1OSM#?%+N&?>
M6/S&_L;A*[&;CR6,H\/#M?$P38R2+%TDL=#73&L=I9C4I,).$L%%C"//WN#S
M#RWSGM>R;9)"-N:.!G5HU8N96(:K$%E%,#213CQZS4]AO8'D#W!]G.9^<^9K
M>Z;F&.XO8X7CN)(TB6VB!C(C0A'.HEF\0/JPN%QU5C05,E304<\VGRSTT$LA
M1=*ZY(U=M(N=*ECP/P/<XS*$ED5?A#$=896>N6U@D<#6R FG"I )ZD,UN2?;
M?1@D1TCM'6,O_3_8WO[]U<1&H[1UL!_RX>Q8M_\ 0>W-JU,XES?4>XJG8V1A
M+%I1@)7EW!L^J>]R8YL;42P:OIJIBOX]XG>\.SMM7-=W?*M+;<(1,I\M8I'*
M/M# -]C5ZZD?=0YI3F3VQVO997!W#8[IK1QY^"29K5C\C&S)7UC(\NK-F945
MG=E1$4L[L0JJJB[,S&P55 N2?I[AH D@ 9ZRV)"@LQHHZ+3NCN#$[BS3;3VW
M1Y'/I"U0T2X_P1TNY<A0025"XZ"OFFCBI<:T\0C:LDM3J[!R2BW88V.P3V=N
M+^]D2(FGQ5)C5C345 J6H:A!W4QQ/46[KSI:;K?MLVTP2W*J6IHH%G= 6"*Y
M("I4:3(W8"=5=(J=9SNX=FKVSOFO[EVUF-G]C[DSE=N/+8'-4S0&&EK)O%CU
MP]2C2T.6P=!0114T-3222P.(AR"2/>:G+1V3]P;7%RY>QW.SPQ+&KH:U(%6U
MC#([,2Q5@&%>N47/MIS2><^8;KGS:IK+FF[N'GDBE6E%8T01,"4DB1 L:O&S
M(=/$$TZ"OU'G_B?9W7H.)%I4!0*=<2ZB_P#4?X?GWKI4(R:8ZQ._!)XL/Q_Q
M3GWM020!TX('!J5'2VW]4B:78>FH$WBZCZ^@)^Y%4(3%39(&E)7.9[[5H-7,
M!- T5^:"EO9R_:(R@W6J4!OYSPI6I7/P)6O\7?7_ '[)Y";>XO'EY?!:H&S6
M@XZJ45^W^UETT_@K$5_Y1X:T* :2_!/T_H#_ ,;]G&!PZ*A;B+@*UZPE@0=1
M(/\ 0?3_ &/O?2F(44]OGZ=8]0'U) _J/K_O%O?O\/2A878!@HIUC+'G@6Y_
MVW^MS[]CI2MH,'SZPAQ?\_[;VYI(RW#I5'$=:@+FO7%FOP+6_P!B#[N"I-!T
MM2W9FHP[>N&H+]>/]Y_WOWNGITHCM:5T '[>L4CB]P38#G\>]BO2I+74"645
MZCM)?@$V_P!C?WZG2E8M"A0,#KA<_P!3_O/O?3X7 %.N!;@\GZ?X^]8Z7K'5
M@",=82X!Y)O_ *P_I[]TJCMQK[34T\^N'D-S]+?CZ_\ $'WZG2J.W.=5!]G6
M,G\G\?[[\W]V"D\.E4=NE#DGK"SK<V)_'!!M_O!]NJN!49Z61VZ:1GK$9!^-
M/^QN/^)][X=7^D'&O6$MP;,2?Z&]C_K^]UZ5+:#4OV]8B_\ JK ?X7)]^^SI
M8EL0P*\>N#2 6T\\\W!'^M]#[U]O2R" ZFUXQU'+ ?7_ '@?7_;GCW8*3P'2
ML0'\&1UB=_K;A>/S<_[Q[MH;I];>0K72/V]8_(/ZD_[#V\. Z4+&P %,]8F:
M]R2. ?\ $'_"U_S[TQ*J2/(=*U@C4A@,@UX=)Y\U4',OA33*UJ66>%2CF.>-
MP#3S15$A6*2KC /D@_"_0_7V3RR.\NDKT(K:S7P#>#XAY?;\N@:WE3Q;;4SU
M<Z5%9/)'+XH'*DQ5!98WFAD1&A\KAK,I=%T6/) ]NQ1.2P%.'KT:0S)X(<)J
M6M,]N>D+3YLU"RF"DF/CB>9D,L9;3'8 ?2^J4$Z1]>+_ $]N&W!_M"*]*XI2
MR.RVH*@Y[NA$ZQSOWE=D(TH0TE9'#%//%4EOLJ?'Q-)"\J%/&RU$DQ0V8.'
MM=> L@BTQ@)2E3T7SUGG-(BIH,'_ #]#(TAL-1X']!;_ (G^G^/M_0_3HLQ0
M5X]87E' _K<<CV]0=*@AJ,=8@P'))]ZH/3I2J'4,=>,JGA3<CZCWJ@].E4<(
M).H8ZP/*3:QM];CGG_;^]@=*XX@E0O6$DL;C_BGNW2F-&;%,]8:B>.FB\LS
M"Q(%S<V_P]M231Q_&W2Z.S#T%.[SZ8$W3B&9EEDDI+$KJGB<I;_5%X]>F_\
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MOD.L!<\CCD?T_P"-^[* .E<=O+0\.L9< V)_W@^]_ETKC@D"CAUQU>]5Z6*
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M<_[ >]^&?4=*EAC"@%37K"[*?I8?6_\ C_K\GWOPS\NE0C-!0XIUB,@_UO\
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MFN.1L(6J<?5""&1U2:DEO/2RDW=:6+&R!X)&/^TA' YU#Z^W8OU2*<.O&S@
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M_=/=8KO_ (_[;_C7OW7J'TZ[#'^O^]>]=7"$BND]=ZN/Z'^OOW6]!_A/7 D
M$G@ 7)_H![]TH\-/3JYG&#_1'_*DK:I2U!F=_P"T:^H -UDER7;&ZS20*O\
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MU/ZK;0!\/[P_ZPOTI^X@@7W4YO;31OZO'_M,@Z*)\JS_ ,Y0?('_ ,2AF?\
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M'^''O>D^AZ7I$BM710]83)R;C\GG^O\ O'NZK6M1T]H4\%ZQL_Y)'^'T'MP
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MX'^P]M*YU+4XKTL-D=)ITM$E$T:2*P*RHLBL2#8.-6GCCT_3VN!!R#4=,);
M.H+@'KB3_5K\_P!>/]AS[WTLC@(8_BZPES^./]L?][]^Z4K:ZZU%.F//8MLQ
M1I#%]C#51.3'7U=.\\M/'(!K2E$9&B1B =7-K>TEW 9U"TI3@?+HWV]OH\!J
M@DXZ"K-X')XN.HJ9*F*N@B"?<U<+R!XO(;))412KY/&S^EGN0K'GZ^R5XM#,
MLAU.#D^OSZ$]IHN@@5/#6GG_ +/2;K\#D*:CIY9J6J K1]U!"5)UNR%?,VDD
M!S$>3PVD@?3W9*1,M3I6HK7TZ="*:A0*]!_DX3''#$#<@6?1<J39E;23R4#&
MU_\  ^U4$C.\K:JH#@^76GMSI-2"/3I_VA79J&=:;#SSK*EY$HEFLLZ#F5((
MI6T1RI]0J^F07N#[U(E"LD8.NOEZ=*H8@8@)8L?/R/0]8'/U.2$E)D*"HQ^0
MIHB\K2T[PT]2H8)J2ZZ8IA?E 2#]5_I[.K:XDGCI)&RZ,9'&OIZ])KJRC!33
M(K5KP(Q]O3^S_P!"/]?_ 'P]J.DPM:<.L1?CU$?7\V][Z?6W32*I4]<2PMP
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MRCN/[:<D@*&8DD@  $DDDX  R2< 9/6 EA&YL[,(A8E$  !))( "@"I))(
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M]%L_^O\ SN-V?X^R3V* /)2FG_+0E_XY%U('WS(R_N\U%J?W':_]7;GHWO\
M-'?1\>.@SQSOK##D7_YIYGS[CWV/%>;^:A3_ (BO_P!I$?4[_? 1G]K_ &V
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MKH3]XU:^Q/(8I_Q*V[_M$EZP?R]6U? [OD_TW#W4/]ML##^]^[0(]TN5P?\
M?-G_ -7WZ]]W9 /83GQ:4!N=R_[18^B,?RLNN<5V#\CL!E\U!%6TG5?7LV_:
M*EJ4$L1W)//B]NX"M -U\^*.1J*B$G],R*XY4>Y.]\=VN-HY/NH+=BLE]=B
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MTX(P*=HZQ%B?S;_6O[=TCT'3H6IH!GK@6 /)Y_V/OVE?0=.I'0]RBG76I?\
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M=N>CD_S8:FHI_C7\>I(3(';?V##Z ";'K;<).H'\7'N/?8I _./-@).+1_\
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M&P>:QF-I:FI2-P<UG\E6I'0TH_<E2.64Z8HG<$_NYN>V;/R#O4-[-IN;U!#
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M-5Y.JJ8P*.&98L+&TWE84Z("]54E0JEEM:,'FWUY]L+!'&[$#]O2YIFG14C
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MR[$@JWOFCD[V=DY7]N^2K&*/=;V_MA,!WM%#+*BR3W+DEGFE7MB#DL:ZZ"-
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MV6SD?0^]<#\^E8MXP%ZQ/D<.7\9J<>K:1PU7;G_@E[/S[N$8$''3ZK;!E*R
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ML21]/?NK^&?*G7*]9HU7CT_3^UJ^G]-/OW7M#?+]O7__U#1 DAM,B_0D22L
M#8?J-N% ]](.'7SH+;O4=PZ@5$TBW5JNF>]O3',I_P!Y(X]V2A.>E'@D99A3
MJ/%40Z3&\<$NFY),J,0I/U/U-B?Z#WMU4 :>KI&M3@]>BJ5:145(6N0R^*2X
MTW^FD@ 6_-_=:'I0B#4,&G4R28K<A8--OTO87/T(N??J'Y]& B110 TZCF5(
MQJ\=/_K*;W_X*%^OMT("!4'KWAC^'I=[9[B[AV3@ZO:VRNR]Z[/VE73UU56[
M;VSN7)8?"U=5E(E@R5354-.P@EGR$"*DS'EU4#V57G+O+^XW27VX[):W%\@
M$DD8=P%-5 8Y 4Y \NAALW-_/7+^W2;+R_SCN5CLTK,SP03M'$S2 "1F1<%G
M  8G) IT'4482-8HH<?%&HT)#'$0%118!2 +64>SDDFI)JQZ(([ (450 H%
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M;HS@YA23U.*AIH(LHK0JSHC,)/V#F3=;NS7;HN4;A=PAV>VN+6*2:)'O(NR
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MU<< D64"WTN=5O=E?5BG6NLGWU/J_5Q>WZ?3;Z?TT_3\^[=>_/K_UC'-5QQ
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M%^8"M^%UV8<'ZD#VVT;%B1PZ4K;II'8>L+4E8/K%&U_IZH_^1\^ZA",UZ7K
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MZL$=8OLY1])E/^.EDO\ [!6('MQ'"BAZ61VY"G012O7(K,#I=E8#_4NRF_\
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MWTICCH"$X5Z\0"0BTN@6U%SJU?7Z7)M]?>QTH56 X=<'TJ1Z8V7^UK9[WM^
M@-K>]:A_$.G/"D-#I/7!&#6*Q1K8FW+D7MR26^@M[]5>&H=+!%(",$]8VFY8
MZ4-A^@*S<_0&RC^O^/OW2A8Y%-2N.H[M46XIX_5];:D//T^I_)_'MR,@5J:=
M/JC&M%/6)UFC ]"Z[\IJYM;GFP7_ 'GW<R*/.O3@1@#5>L0DEU1LD=V\D1LN
MIM(UBYO:UP/KS[J5+Y'#IV*!]7B8 Z1N\$6*NCC@1X_*DDTR +X]1<JIC/\
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MYC#*M^;VU$_CVX(T9 63)&>E B  4-CK)7YBKCB5BCN"VFZAK FUBYL=(/\
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M69KZ*0D#ZDRHOU^A:R7/^/NGB)PU9Z]QQ3KC(*__ '3]A$?P)/N)KG^OH\8
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M34/5Z_/K@<LCW5E(!6P,7ZUL."5(T^WEL]0JK5'3J,* :L]8Y*N%U8H9H9;
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MK0074IJTEE+D&Y%R W/^/LT@N*0H& "J*=$;Q:IKE@>ZO3F:VWYY_)" 7/\
MMS[<:ZC(H3U7P9.N(K1] #?\$*!8_C_6]U^HC_BZNEO(P/'KHU4E_HQ_Q,EC
M_MK'W1KN,&E>K_2R^G7'RL]PX 5K>H,6:-@;K( 0%)4_C\CW2:<3HJE!I XY
MKU=(O#-:G5T$FZL1)CZE<A$H--62,)1R#35:^IE%QZJ>H'JC/]DW!_'LE-*$
M='<,A>A(ITJ-F5,IQ]1"K ""IUHH%V43("Y-SQJ9?9E;S-';D #RZ07<8,NL
MGI7B62_+-<_6Y72/]@!?WIKB5A2O2;2O\(ZZ J/RZ@?GU2$V_P +D6/NOBOZ
M]>TK_#TZ8U2'F+,3:(+<W(&I@1>Y)MQ[764C$35R:=,3GP_#*CXC3H)MPU(J
M,S72\LHD\2:C](XO3&JD$^@"_'MA9#08Z7J-*J > Z:Y6M# G!!\LO\ AZR%
M%OP5])M[KU:E2OSZ5VU)U,=53,!Z")XA?A%)$<BA?Z%K'_#W5_A/3<ITD+TK
M[I_A_MO^->V.F^O:D'TX_P!A_P :]^Z]UT7_ *6(_P!C[]U[KP?^M@/]C[]U
M[KUX_P"@_P"2?^->_=>ZZ.@_FW^L/^->_=>Z]9/]5;_7-O\ >Q[]U[KWH%Q>
M_P#L+_[;CW[KW76H*>%+#^MP#_K"_OW6NNO*Q('B*K?]1D4V']=*B_OW7NO%
MFO\ J]-_P+$_TY-R![]U[KL.1_C_ *]_^*^_=;Z]K-[_ .\<V_WOW[KW7'4]
M_P!?%_II'^V]^Z]U_]?E5;8RNHP^'B4J6FCLP2/\R:+A[#WT;6)F913!/7--
M&1ZE>L:[-ECE+Q533LG*$B*)-=K736=2DC\FX_P]K%M=!!!S]O5B@D&CUZ4$
M6#KUABC:2CI85YM).)I)&?DZ_"H _KQ]/9@LA10!\76X[-:G/EU@J-L2N08Z
MO'2W.J36LL)1A^EXFA<R._\ KD6][\4M\8H>E4=DM#U&CVM*9O(^8G<JK>*"
M.&H:GBE(_P ZD@"MJ4_@DCWOQ%]33I6ELP4!0"O4A<#70*&7(I,P:[(U$Y9F
M8D:@ 2 Q_P!>_P#A[=6Z*@ # '5EM/$) '=_+\NI5-BZU%'W#0)9F90?*Y(/
MYLPU)?\ U//^O[OK'$5KTL%@ 0<4Z])AZF0G544:1DW9C%(\MAR6 8*&_I8G
MW[QW_A'2A+1=0Z;#A*UGD=,M3Q@<"-*4R,1]+N;*B/[WXQ.&%/LZ5):*"20>
MN_X14:2G\94N5:Q:G4-]."!K4?ZW'/OWBKZGI1';QT.#^SKT&$J-+B6O:J9-
M+>5H$AU7^L;%+W#?ZRV_K[V"& /2R.U4H"*TJ>L[T,[:%%12(RM95!$X1K<E
M2KJ$X_KS[WTL6S&E<]<XH*V)^:J(W<+$?&L6G\>L!P"0?H?I[\14&@Z5BT *
MD'/620NOUKI5=N?V4U7-[-^KTB_]?;2HP()Z5);L6 8#3U&K#"^@*T<$C\$2
M2@N1]-5H]=_Z_P!6]OJP!J>E4=FM?RZP24=6NEH*@:3>[.KQ'3;E@ I=E/\
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M97E<CM)Z[ L3QQ^/>C)IRN3UL==E5/)'T_Q/_$'W[Q"WQCK>?7KD  +!0/\
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MGWO\^KZ6Z[\B_P"/^V]^IU[0W7=P?[+'_D G_B/>Z=>T-UUKL3J!7^EP0?\
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M[S[]7IU8!^.AZQF8@V)/^L0H_P!X]W1PHITICABH<>?6%YR#]8_Q^H^KZ?D
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M^DDV O[4+A13TZWI;R7'060.I1E4_NJ%>-B+7:-PZ@DV"M9>+?GWYJZ6J.C
MBM1T-,<@F2.96U),B2JW]1(BO_O;>V/+I)(:'3Y]<S?\&Q]^Z:Z[/TX^IO\
M[#B_/OW7NO &P)Y(%K_[&_OW6NN#*#<@@6-V)/ 6_-R>%'^)]^Z]TDL_N.CI
MZ*JQM%HKJC(P24M7.NO[6EIA):2&-P+5%66 U:"4CMR3>WMPN#44Z410%B&#
M"@S^SH.8$:66&.$#RR,BHJ_\='<*H(L+$GZ^VJ^72L>70XM%((U")K=$168E
M@A9$",;A38%@?>R>D7^BM]G4>9I:=3---CZ6DC4&6IJIJAFC-S?T($5CQ95!
M+.W 'O:J6K3J_02;@R4N7R/F!(I:2+[6@CL1II]6N29[^KRU,I+M?D<+^/;R
MB@IU=7"BE#TNMHP&#!4S1NT35$U9.P$8#2!Y/&)06&IHWC0 $_[#CVRWQ-Z5
MZJ34DTQTI2HA22:65%IZ=!-/.X 6").2SD?VS_94>IC]/=Q'D5(Z:+AJK0YZ
M"'/U\69S5;E::"6DAJI(RGE/[C!(A"U3+H]*S5.G5:Y()L23[=^?3B'0A0C/
M0EX?(P5N/IVDD19Z>-:>I,LBJS/&-,<O+ $2Q $V_(/MM^ ZUCIQ-32(;^>
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M1C214]<"US<'Z_Z_MP+@5&>E21@HI""E.L3/:WY^OY]WZ5B$^2#^76%IE/\
M:('].?\ BGOU.G4A<,#H_P '6-I%MQR?]B/^(]^Z611RECI7-.L1?5^F]Q^
M?J?Z?CWOI4D4F=:_X.L+2W!!N+7O<\C21?Z7^E_>AT\BHHHRBOV=</(H ):P
M_J20/]O[]TH5%*@Z!3[.L+RC^R#Q?^H_X@>]Z6XTZ4"!ZCLQ^749ZM ""7_'
M]?Z^ZY'2M+/N&3U$DJDTC]7U_J?Z'WLN1Q;I9'9%F(R<=1S5\@ E!^;W-Q_A
M_2WO7B5_$>ET%B1JJ/3K"]0S<$7N/ZM<<_07'NOC%< 5'2CZ2G XZQF5_P"R
MM_\ !B0/]Y'MIIY2308Z61VRZ%J3UC(U?ZH'^GXY_P!?ZV]Z\:8\1_/I9X5
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M]<>_=;Z[]^Z]UU[]U[KUO?NO5/KUW[]U[KK_ 'W(M_O?OW7OLZ\=1^IN/P+
M6_V/Y]^ZLK9R>NK'WOJ^I3QZ[' M8_[8V_V_T]ZQ7IIJ5QUW[]U[KK_BI/\
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M  O[U7I<L2U  SU'UD_@'^MQ_MK?U]^KTH$!6C%13K&9!<^D_7\'_B/Z>[H
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M7 H .NC>_P!2/]8V]^Z=$;>HZQZKD#\'@_U]^ZLL9# DXZZ8@647X-^?]O\
M\3[]T]UTB@W']  .1_Q'O76J]<?>^M]<M-^00 ?IJ_XT#[]U[KL+?Z+(3_@I
M/^V%KV]^Z]UV8R.2&4?[4"#_ (VXM]/?NO==%5_##_8L /?NO=>T'^H_V_\
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M+K*A1E!32RF]F0!O]>Q'OW6RK**E2.NS_A;_ &/'^\<^_=:H3PZ[ D/Z8_\
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MA'T)I@;<_P"U,1[<5PH IU;Q.IJT]#!_FJ.C0 $#QT\( '_)!L#;W0C/6M'
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MGVO_ &30_P#0'5QMUJ."']IZZ_X9L^#!^NSNPC_Y5W?_ /\ 7KWK_7X]Q?\
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M_!,_79_8O_HW^P?_ *]>]_Z_GN/_ ,IUK_V2P_\ 0'6_%?Y?LZ]_PS%\$O\
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MX^P__KW[\/O >Y.?\?M/^R6#_H#JPYRWL5_4B_YQI_FZZ_X9.^ _XV7V0/\
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M_<Y[]_K_ /N3_P I]K_V2P?] =>_KUS#_O\ B_YQI_FZ[_X9-^ WXV7V./\
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M92_ZW<O8@_\ DW[]_K_>Y/\ RGVO_9+#_P! =>_KUS#_ +_B_P"<:?YNN/\
MPR3\!?\ GC>R_P#T<O8G_P!?/>_]?_W)_P"4^T_[)8?^@.O?UZYA_P!_1?\
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MG8O_ -?/>O\ 7^]R/^4^T_[)8/\ H#KW]>^8?]_1?\XD_P W7?\ PR7\!?\
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MD_S=.)_DB?R_SS_<;L0$"P([@[!!"_70+9H66_X]^_U_O<C_ )3[3_LE@_Z
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M A9:PW/J'OW7NCL_\*\?^W-N]?\ Q/\ T3_[O<G[]U[K2O\ A_\ \* OD?\
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MA_\ "6+_ +<<?#O_ +6OR-_^"=[B]^Z]UI(_/CXU;&^8?_"I/M7XN]E9;=6
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M5_@S(6!_0[ W!(/NO=4<?\(AM[5V0^+'S?ZYDG=L=M3O_KS>E'3ER4AK-_\
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M;86_FWY!L%.R9(EV56UE3)B!MF3>>Q%9LK#6LBU'WX^W8!C%*+H?=>ZU7O\
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M@_Y=?]YQUG_I-_4O_7[W[KW7O]!_RZ_[SCK/_2;^I?\ K][]U[KW^@_Y=?\
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ME_@KDL?4D\/3[>NEOW3N6)[;V5]M]\WZS<;@]F? C([Q"LK".0KQ&M:44T8
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MWWUA+L3 9CK;85?7[<P>UNK*/-[HKVIWDDI,1@,?BX8:N:DADBD'NO=5EO\
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MW&-H[@\<]/783>V"ZL1,_M?+PA*;<FT*O.8JO@H,G"JT]?%3>:+T,I/NO=;
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M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>/^'U_%^/]YL;>_=>ZKX_EX_
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M5^]?&.*D1Z-7@.OZ>T;*38F(4\2G^7I5K'UOB?@K_DZL-_E;;1W;L/\ E_\
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M]JYB&M[>RNZ?CSAND:?<&V)VRDL&V<?35N->O>&K^YD,1$8)8EA[KW0!5/\
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M)_*__EH=O?$CMWY?_+_Y;=\[6^1/S(^:^XMAU79.ZM@;'J-@=<[+V=UAA*C
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MN%P^2>*3(XG&U\D%+74,,E;04M4\-%E(HX,G1Q-/%(T=+D8(D2>,629% <$
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I>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g313671g02v84.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g313671g02v84.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MJ #_ (2G3O\ G\L__ R+_P"*H /^$IT[_G\L_P#P,B_^*H /^$IT[_G\L_\
MP,B_^*H /^$IT[_G\L__  ,B_P#BJ #_ (2G3O\ G\L__ R+_P"*H /^$IT[
M_G\L_P#P,B_^*H 0^*M-49-W:?A=QG^M &A:ZI#<R>6 4?&0&'4>HH O4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 U_N-]* /FWXF_\
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M (0CPU_T ['_ ,!T_P * #_A"/#7_0#L?_ =/\* &6$7A32BYL9=+MO,QO\
M*>--V.F<?4T ;4%Y#=)OM)(IXQQNCD##/IQ_GF@ ::Z4D+:!@.A\P#- #/M%
M[_SX?^1A0 Y9[LCFRQ_VU% #?M%[_P ^'_D84 *D]V74-9;5)Y/F@X% %N@
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M $&(?^_$_P#\10 ?\+3\,?\ 08A_[\3_ /Q% !_PM/PQ_P!!B'_OQ/\ _$4
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MC <FU2WY_P!Q"5%2M"F4J8@H TO#W_(RZ5_U]Q?^AB@#Z;MO]0M $U !0 4
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M_3_XW0 ?\*>T3_GOJ'_?]/\ XW0 ?\*>T3_GOJ'_ '_3_P"-T '_  I[1/\
MGOJ'_?\ 3_XW0 ?\*>T3_GOJ'_?]/_C= !_PI[1/^>^H?]_T_P#C= $]E\)]
M&LKZWNXY[XO!(LBAIT()!R,_)[4 =]&GEQA?2@!] !0 4 % !0 4 % !0 4
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M:;XBT36)GATO6;"^EC7<Z6URDC*.F2%)P*=G:X/1V>YI4@"@ H * "@ H *
M"@ H @N;E+6(NY^@]: .=BU&\O=2$<#$J#\Y'0>PH Z=,A!GK0 Z@ H * "@
M H * "@ H * .<UJ%K>626-<[U+*/>@#"FL9;N&*]VNDF/N%B5)H Z+0]1M9
MT$7EB*9>"N,4 ;U !0 4 % !0!#=(TEG/&@RS(P ]\5G5BY4Y16[3-*;49IO
MN><P^$];31=.TQK("#3WMYH1YJ?>8H9>_&PB3ZA^*UK^_*37]Y+T:E;\XI>F
MIC13C",7_<;\FG&_X)M^;[CK3PKK46EZ7ISV0%OITEO-$/-0_,2C2]_X")/J
M'XIUGS3E)?WDO1J5OSBEZ:DTTXTXQ?\ =;]4XW_!-OS?<Z[PMI-[I&C6T-]J
M=W=2"WC4Q3B'; 0N"JF-%R.W);H.?6JDDY.W=ZE16BZ>1S<>E>)6.H(%U*&9
MX9UDFDU ,D[EP8F@7>?*PN[^%.H^]U&5->[%2_N7[Z/WG?L]=/316L5-_%;?
MWK>EG9>M[:VZ/7OW=K;I:6L=O$TC)&NT&65I&(]V8DD^Y)JF[B2L2TAA0 4
M% !0 4 0W%PEM$7<\=AZT <M<W%QJU[Y$)/HS#H@]![T =%IVG16%NJ(O/<T
M 7: "@ H * "@ H * "@ H * &21)* '4''2@!GV6'R3"4&P]J .9U72);:8
M3P,58?=?U]C0!?T?6Q<?Z/<_).O!![T ;M !0 4 % !0!5U*_BTO3+F^GR8[
M>-I"%&2<#H!W)Z 5$Y.,;I7?3S?1%15W9Z'(Z5XAN-0\/WD.HZC?66H0.A\R
M.R\F9A)RJI'-'S\VZ,':<[>N<FM)+1<NNMO6WY:6;VMKT1">K;T3U]/+S:VZ
M[KJR+4]8UOP_I=A:2WEY>ZI,[W,FVR^T.D2\B(B", 9)5=^T=6P>!4\R4DGL
MEKYZ^?E>VU^75*]AV;BWM?:_3S\_/>W-N]#MK.[AO[*"\MG#P3QK)&P[J1D&
MKE%QDXOH).ZN3U(PH * "@ H * (IYTMXB[G % '+7=U<:I>>1!UZ$CH@_QH
M Z#3=-BL( BCYNYH S]2\7:=IT.I,(KR=["-GD$=G,4)&/E$@3:3R,@$D<^A
MI)W2:ZNWXV^>HVK:?UM?\B=/$VE/?FR$\JS 'E[>14W!=Q0.5VEPN24SN&#Q
MP:&TDY=%?\-[=_D"3=DNMOQVOV^?==RO;^--"NIH(HKBXS-MVLUG,BC<<)N8
MH NX_=W$;N,9R*KE=^7K_ET]?+?[R>9-77]+OZ>>VC[,CG\96$)@A4&6YEG2
M+;&DAC3=+Y8W2;-JGJ=IP3CC/6E#WVDNJ_\ ;>;Y_G;5I#E[M[]+_@VOEJK=
MKZ)LZ.@ H * "@ H * "@ H * &NBR(4< J>H- ',ZOHQC830DC;]UQU7V/M
M0!-H^N,SBTO!LE7H3WH Z($$9% !0 4 % $<T$5Q'Y<T22ID':Z@C(.0<'T(
M!H\P*NHZ)I6KJ%U/3+2]4# %Q LG_H0-*RO?^OZU8[O^OZ\D0:7I^@Z3>7%C
MI.GV5E<)&DDL=M L?R,6"D[0,Y*/^1JKO8FR-&&"*WB$4$211C.%10 ,G)X%
M+R&24 % !0 4 (3@$T 8G]JNKJYY3S"I^G4?R- &=J%_/?W0M[<?.>@[(/7Z
MT ;>DZ5'I\ XS(>230!I4 <K?^"--N]7O=5N;V:.>\B:W)2.",J' 0#>(P[=
ML!V89QQP,$?<5EZ_<[^G3[OF.7O6OT_R:_5_,2+P!I47B!M9$CM=29,A:VMB
MSL4VEM_E>8">N%8#/;'%+E7+*"V=_E??^G<$W=-[JWX?\-TM]Y:?PC:M<0,M
M]>I;HL*R6P9/+G,1RA;*[@00,[2H..<U?,W-S[MOYM6O^7W$**45%=K?+M^+
M\]?08/!EJEPLD.H7L,7FI-+ ACV3.DF]2V4+<' ^4C@#-3#W+6Z?_(J-_N2\
MBI>]=][_ (MNWWM^9TE !0 4 % !0!F:]J5SI.DR7EI8M>RJRCREW]"<$_(C
MMQ_LJ3^&2);LTOZ_KH4E>_\ 7]?UU.6D\=7T"3W9L(9X&BMA!' \SMYLC.&#
M 0[P 4(^X3\OW02<4]-.[LO3E4NE_E^A*UOY+7UYN7_A_P +EJ7QO>QZ?#=#
M0FC_ '$DTZ7,KV[)L<(-H>,$AB006"?+R0#Q3M[UE_=^^5TK^C6OY,3?*KOS
M?RBDW\[/TNM^HMUXPN;)'%[8+%=VT[02PV]SYD3,8@Z_.R X^9<\#'/4=4M6
MN7K^?-&/Z[^NE]G+W5>7K\K2?_MNWIKN:WAZ_P!0O9-574HXHIK>Z$0BBD\Q
M$'E1M@-M4GEB>0#SBGIR)KS_ #:%K>S_ *_K^NYM$!E*D @]0:0SG-8T0;?-
MBR%'((ZI_P#6H GT&[NV!M[E"2G1O6@#=H * "@ H * .7T^_M)?B'JOEW$;
M>;IUHB8;[S++=AA]00<^F* .HH * "@ H * *>IS>39-CJWRB@#G "WRC.3Z
M4 2V.G_V?, )O*ED^8*^7=N>N!S0!TEL9?*4R_>QR/2@":@##\56$NH:7 L-
MO<3O#=P3>7;S^4Y"R MSN4=,G!/ZXHCI4B^U_P F@?P27];HXV:W\66<GB&]
MN#?P6KVTWEE[D<2;QY90B5P!MW8(CC[9!-*GI"*ENW#\]5\[][>26@3WDULE
M+\G;[K=K^;U9+J&D>*9-)"Z?'J<%M]L+BTFO3-<B/RP.9!<H<;PQQYIX(X_A
M [WCZ/\ /2_?2_?=*VEQZ:V\OGO>WX=MG\^FT#3=22\2\U6XNY)5LX8QOEV*
M7P?,)B1V3=G;SS[&M'9.5NK_  M';MK<C5M=DOQO+[]+;_F='4%!0 4 % !0
M!5O]-L=5M3:ZC96]Y;$@F*XB61"1T.",4FDQW:.?DG\#""_2Y318;>R*Z?<&
M=8510 &6(YXV@GA3W!XXH;4DI/J_O:_5?D"33LMU^3_S_$NQGPIIS6^CQG2+
M4SQF.&S7RD\Q&Y*JG<'K@#FJ:<FXO7O\N_I^!*:C::^_U_SM^ VU/A&"VNM/
MM#H\=O8;OM%O%Y06WW AMZCA,\@YQGFI;4HW>VWX[??T[E).,K+??_@_=U+^
MC6VCVVFQG0X+**PE_>(;)46-\C[PV\'@#FK=]F2K=#0J1A0 @55.0 * &-<0
MH<-(H/N: &_:H/\ GLGYT 'VJ#_GLGYT 'VJ#_GLGYT 'VJ#_GLGYT <[IWA
MS3].\9:GXA6Z5GO(4B2/.!" S,^/]YCN^N?6@#HOM4'_ #V3\Z #[5!_SV3\
MZ #[5!_SV3\Z #[5!_SV3\Z 'K+&_P!UP?H: *6H6S7$L>=QC'9!R3^/ H 8
MNF"2)%W-;@-D^4^&<8(P6Z]^V.E %^*".%=J+CU[D_4]Z )* "@ H * "@ H
M * "@ H * "@ H Y'6/!]]J4MR8=6B@26Z^TJ/(E#IF(1L-\<J-VZ@@8)!#5
M/+=)/S7WN_\ GO=/1VNAWZKR_!6_JVN^MF06O@Z^ANX[;[9$NG0P6<;LUN&D
MG,!+#:V[Y.0,Y#=>,'FM5.\G)_S-_P#DJ7Y]/T9%K:+^6WWN5_G9[D=K\.S;
M37H;4O-MYH9881()W>)9'#$?-,8\<#.U%S@?C%/W(Q7;E_\ )7I_7X="JGO\
MWG?[VFOU_K<[F@ H * $;[IH \.\<^*?$UCXPU2UTVYD%G:I$[!(%<1@QH22
M2IP-S=_6C97#=V.>7QEXU>6&);F=I)UWQ*+1"9%YY4;>1P>GI1M_7S_(!L7C
M7QG,H:*[FD4AB"MJA&%&6/W>PY/I1M_7R#=V+%GXH\?:@,V1O+D;=W[FQ5^,
MD9X3ID$?@:=F%R677OB-! T\T.H1PI]YWT\!1SCD[/7BD!1E\;^,8#*)KR6,
MPOY<@:U0;&Y^4_+P>#Q[&E>ZN.S0]_&7C6-IE>YG1H%#2AK1!Y8.,%OEX!R.
MOJ*>WY"6NB)(O%7CR>&:6%[N2*% \CI9*0BD;@2=G QSGTH>BNP6KLAUQXG\
M?6=FMY<F\@M6QMFDL55#GIABF.:'[KLP6JNBBOQ#\4J<_P!I@_6WB(_]!H ]
M#\#>,K[6H7DG"+<6TB))L&%D5LX..Q!4YQQR* /5T.Y ?44 +0 4 % !0 4
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DHR=RA=NTGW]Z ._0;4 ]!0 M !0 4 % !0 4 % !0 4 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g313671g0307140354059.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g313671g0307140354059.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !V IP# 2(  A$! Q$!_\0
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M^YOR3_XFIZ* (/L\G_/W-^2?_$T?9Y/^?N;\D_\ B:GHH @^SR?\_<WY)_\
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M>3_G[F_)/_B:/L\G_/W-^2?_ !-3T4 0?9Y/^?N;\D_^)H^SR?\ /W-^2?\
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M,:I \QC8LPW-A<].U:W]GZ?;0-_HT*1*IS\O&.IK+_M;0E:"]6#+29*R+'R
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M>:EXAT^01W=Q=0NPR [8R*?]GN]N9!_;D>7F]F['N=%>"?\ "1:M_P!!"?\
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M TS_ )X7'Y#_ !KS:I(462>-'<(K, 6/8>M'UZL)Y1A4KV?WGHO_  L#3/\
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MER-++NC XR5%81\'^)&QG3ISCIEAQ^M(?!GB(G)TR8GU++_C4QA27Q37W_\
M!+J5L2T^2DU?R]?+S.K,6H/XEAU*&Y4:&$4[O-&P)CE2/6F07^EQV.F)<+*(
M9KB7RGCE*!/FXR!U%<O_ ,(=XDV[?[.GV^FX8_G1_P (;XCP!_9LV!T^9?\
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MF8U*BIN=F^Z7^0IX3#1CS<M_G_P33_X2Q?\ GU/_ 'W_ /6H_P"$L7_GU/\
MWW_]:L*WM!=7K11OB,;FWGLH[TZZLD@M8;B.?S$E9@/EQC%)9IF;@ZBGHO*/
ME_FA_5,+S*-M?F;?_"6+_P ^I_[[_P#K4?\ "6+_ ,^I_P"^_P#ZU94.C336
M#7 *YR-J[AR#5:TM/M+2%G$<<2[G8C.!5/,LU3BG+XM5HO\ (2PN$=[+;S9O
M?\)8O_/J?^^__K4?\)8O_/J?^^__ *U9B:0KL&%P/(:(R+)M[#J,4EOI274;
M-%.3@$KE#C ]35K'9LVDI;_X2?J^#WM^9J?\)8O_ #ZG_OO_ .M1_P )8O\
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M7YG3_P#"6+_SZG_OO_ZU'_"6+_SZG_OO_P"M7,45C_;N/_G_  7^17]GX?\
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M3M^"/*Q]&%*HHP70BN/^/:7_ '#_ "IT/^I3_=%-N/\ CVE_W#_*G0_ZE/\
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M]?+_ ")>/HN:G9Z'"B:186A#$1L02/4CI4EK=/:NQ55977:Z-T85VW]D:?\
M\^L?Y4?V1I__ #ZQ_E64>'<7%J2J*ZVW+>946FG%ZG('5)<D+&BQ^48E0=%!
MZTZ#5YH((XA&C>6" 3Z&NM_LC3_^?6/\J/[(T_\ Y]8_RK99+CT^955?^O+R
M(>.P[5G XB>Z>X6%64#REVC%32:D\J?-#'YN /-QSQTKL?[(T_\ Y]8_RH_L
MC3_^?6/\JS60XQ-OVBU_KL5_:%'3W7H<A)JLKJ^(HUDDP'<#EJ0:G*+U[G8I
M+KM93TQBNP_LC3_^?6/\J/[(T_\ Y]8_RJWDF.;NZJ_KY>9*QV'6G(<@-5E7
MRP(TV*A0IV(-(NI,KMM@B$3KM:/'!KL/[(T__GUC_*C^R-/_ .?6/\J/[$QW
M_/U?U\@^O4/Y&<A_:DGF[VBC*A0JIT"CVH;59G>=G1&$P (],=*Z_P#LC3_^
M?6/\J/[(T_\ Y]8_RH_L7'_\_5_7R#Z]A_Y#CY=3DF"EXD\P$$OSDXI!J4OV
MF:4HC+-]]#T-=C_9&G_\^L?Y4?V1I_\ SZQ_E0\DQS=W57]?+S']?H6MR,X]
MM4F;> B*C1>4JCHH]J>=7E9),PQ^9)'Y;R8Y(KK?[(T__GUC_*C^R-/_ .?6
M/\J?]BX__GZOZ^0OKV'_ )#D)-4E>T: 1H@< ,5[X]JH5WW]D:?_ ,^L?Y4?
MV1I__/K'^595>'L75:<ZB=O7_(N.8T8?#%G T5WW]D:?_P ^L?Y4?V1I_P#S
MZQ_E67^K.(_G7XE?VK3_ )6<#17??V1I_P#SZQ_E1_9&G_\ /K'^5'^K.(_G
M7XA_:M/^5G T5WW]D:?_ ,^L?Y4?V1I__/K'^5'^K.(_G7XA_:M/^5G T5WW
M]D:?_P ^L?Y4?V1I_P#SZQ_E1_JSB/YU^(?VK3_E9P-%=]_9&G_\^L?Y4?V1
MI_\ SZQ_E1_JSB/YU^(?VK3_ )6<EH?_ "&+?ZG^1KNJJQ:;9PR"2.W177H0
M.E6J^@RG 3P5%TYM.[OH>=C,1&O-2BB*X_X]I?\ </\ *G0_ZE/]T4VX_P"/
M:7_</\J=#_J4_P!T5ZIR#Z*** *WDSK+*T<L861@V&C)QP!ZCTIVR[_Y[0_]
M^C_\5110 ;+O_GM#_P!^C_\ %4;+O_GM#_WZ/_Q5%% !LN_^>T/_ 'Z/_P 5
M1LN_^>T/_?H__%444 &R[_Y[0_\ ?H__ !5&R[_Y[0_]^C_\5110 ;+O_GM#
M_P!^C_\ %4;+O_GM#_WZ/_Q5%% !LN_^>T/_ 'Z/_P 51LN_^>T/_?H__%44
M4 &R[_Y[0_\ ?H__ !5&R[_Y[0_]^C_\5110 ;+O_GM#_P!^C_\ %4;+O_GM
M#_WZ/_Q5%% !LN_^>T/_ 'Z/_P 51LN_^>T/_?H__%444 &R[_Y[0_\ ?H__
M !5&R[_Y[0_]^C_\5110 ;+O_GM#_P!^C_\ %4;+O_GM#_WZ/_Q5%% !LN_^
M>T/_ 'Z/_P 51LN_^>T/_?H__%444 &R[_Y[0_\ ?H__ !5&R[_Y[0_]^C_\
M5110 ;+O_GM#_P!^C_\ %4;+O_GM#_WZ/_Q5%% !LN_^>T/_ 'Z/_P 51LN_
M^>T/_?H__%444 &R[_Y[0_\ ?H__ !5&R[_Y[0_]^C_\5110 ;+O_GM#_P!^
MC_\ %4;+O_GM#_WZ/_Q5%% !LN_^>T/_ 'Z/_P 51LN_^>T/_?H__%444 &R
M[_Y[0_\ ?H__ !5&R[_Y[0_]^C_\5110 ;+O_GM#_P!^C_\ %4;+O_GM#_WZ
M/_Q5%% !LN_^>T/_ 'Z/_P 51LN_^>T/_?H__%444 &R[_Y[0_\ ?H__ !5&
MR[_Y[0_]^C_\5110 ;+O_GM#_P!^C_\ %4;+O_GM#_WZ/_Q5%% !LN_^>T/_
M 'Z/_P 51LN_^>T/_?H__%444 &R[_Y[0_\ ?H__ !5&R[_Y[0_]^C_\5110
M ;+O_GM#_P!^C_\ %4;+O_GM#_WZ/_Q5%% !LN_^>T/_ 'Z/_P 51LN_^>T/
M_?H__%444 &R[_Y[0_\ ?H__ !5&R[_Y[0_]^C_\5110 ;+O_GM#_P!^C_\
M%4;+O_GM#_WZ/_Q5%% !LN_^>T/_ 'Z/_P 51LN_^>T/_?H__%444 &R[_Y[
M0_\ ?H__ !5&R[_Y[0_]^C_\5110 ;+O_GM#_P!^C_\ %4;+O_GM#_WZ/_Q5
M%% !LN_^>T/_ 'Z/_P 51LN_^>T/_?H__%444 &R[_Y[0_\ ?H__ !5&R[_Y
M[0_]^C_\5110 ;+O_GM#_P!^C_\ %4;+O_GM#_WZ/_Q5%% !LN_^>T/_ 'Z/
M_P 51LN_^>T/_?H__%444 &R[_Y[0_\ ?H__ !5&R[_Y[0_]^C_\5110 ;+O
M_GM#_P!^C_\ %4;+O_GM#_WZ/_Q5%% !LN_^>T/_ 'Z/_P 51LN_^>T/_?H_
M_%444 &R[_Y[0_\ ?H__ !5&R[_Y[0_]^C_\5110 UXKIT9#/#AA@_NC_P#%
15.B[$5<YP,444 .HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g313671g0307140354215.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g313671g0307140354215.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %+ IP# 2(  A$! Q$!_\0
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M2.$*4!DPP^F,&@#T^BFQG,:G=NX^]ZTZ@ HHHH **** "BBB@ HHHH ****
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MDMX]C7$GF2').YO6LJS\+6]IK(U3[3-),%*\@#=GJ6QU_&MZ@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBD)"@D
M]!0!%;])/]\U-5.RN89FE6.0,0Q/%7* "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ($_X^Y/]
MT5/4"L/MC\C[H[U/0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX@F\M^H%1+!T(;MFM/-L95UBE_7S.^_X6%X?_P">\O\ W[H_X6%X?_Y[R_\
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MCH?;(JLFD6=Q/=1074VZVCD=]Z#DKZ>QJ/JE#NS1YGC5NE_7S/2_^%A>'_\
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M LI9>@R3P/RH6#H-V38I9KC81YI15OZ\SU3_ (6%X?\ ^>\O_?NC_A87A_\
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M%+^0/[%J;^V?W?\ !/,SJ^JF59/,?<K;E(CZ'&../2J]M=7UFTI@,B&4 /\
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M3TU+4GSM"\#<<Q@<4?VU%_8&N'TG?VGX?\$XWXB([:U:[48_Z,O05R'E2?\
M/-_^^37KW]L:@PW%@1TSY8_PI1JFHLVT#+>GDC_"HI9O&$%'EV-L1DGMJKJ<
M]K^7_!/(/*D_YYO_ -\FCRI/^>;_ /?)KV%]1U*-MK!=WH(P3_*F?VO?X!RN
M"< ^4.?TJ_[:C_(8_P"KZ_Y^?A_P3R'RI/\ GF__ 'R:/*D_YYO_ -\FO8/[
M2U(H7VC:#@GRAU_*F_VKJ'/ XZ_NA_A1_;4?Y _U?7_/S\/^">0^5)_SS?\
M[Y-'E2?\\W_[Y->O_P!J:A@GY>#C'E#/Y8ITFI:E$<.%'RAO]6. :/[:C_(P
M_P!7U_S\_#_@GCWE2?\ /-_^^35F&[OH+*>SB:5;><@R(%^]CI7J?]LWO]]/
M^_8H_MF]_OI_W[%)YU![P&LA<=54_#_@GF3ZKJLD:HTLO!4[@F&.W[N3U.*>
M-9U42^8&(8AE.(1@[NN1CG->E?VS>_WT_P"_8H_MF]_OI_W[%3_;%+^0O^Q:
MG_/Y_=_P3S./5M4A4K&S*I8L (A\I(P2O''X4D.JZI! L,3R*JD$8CYX.>N/
M6O3?[9O?[Z?]^Q1_;-[_ 'T_[]BC^V*7\@?V+4_Y_/[O^">6PWM_!<2SH9-\
MN?,RF0V?4'BIO[8U<.7$TNXN'^[W P/TKTS^V;W^^G_?L4?VS>_WT_[]BG_;
M%)_8$LDFMJK^[_@GFO\ ;>L#;MFE7:01M3&,'([5'!J>I6\UQ+&S![CB4F/.
M[]*]._MF]_OI_P!^Q1_;-[_?3_OV*7]L4OY!_P!BU-_;/[O^">9C5M46)8@[
M!%Z#RQZ8]*KRW-[//'/)YC21!0AV],=*]4_MF]_OI_W[%']LWO\ ?3_OV*:S
MBFMH">1S>CJO[O\ @GFZ:YJRS+(TDC8/(*=1NW8_.GZCKM[?75K<)!]G:V),
M>Q3P2<YKT7^V;W^^G_?L4?VS>_WT_P"_8I?VO2O?D*_L>I;E]L_N_P"">;?V
MYK&_>)I%/R\+'@#!)'&/4G\ZJWMW?:C(CW.]VC0(N$P H[<"O4_[9O?[Z?\
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M*'AV^H')-J1*L!"XW \ENA/I[4Y]3#0^6(''RE<EO7\*ZO ]*,#TI^QE_-^
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MR](_Z"#?E4<=DKQ1,7.9#U X%2?V?$HWO(VW(^7 SR<553 X>K)SG33;]?\
M,F.+K17+&6@?V7I'_00;\J/[+TC_ *"#?E4DVG1 DJ6"C/R@9)YQ48TY"JDR
MD9QDXXY[#WJ/[,PO_/I?C_F5]=Q'\P?V7I'_ $$&_*C^R](_Z"#?E4HTN+YT
M,AW!AAO;&:C.FQ94><WS/L&1[9H_LS"_\^E^/^8?7<1_,)_9>D?]!!ORH_LO
M2/\ H(-^5.338V3[Y&=IY'(X/'Z4Z738BCLC%"D0;:>YQFC^S,+_ ,^E^/\
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MZ9)7?[1C<2<;:9_PC9_Y^?\ QVGR^,-%AE>-[DAD)4C8>M,_X330_P#GZ/\
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M<JM8W]OJ5JMS:OOB8X!QBK-=,;<JY=CGE%Q=GN%%%%4(**** "BBB@ HHHH
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M/SOIMM=J_P T[A=A7[H/0YJC!?SV\<L:;&24@NKH&!Q]:F;6;]@P,YVLH7:
M  !TP.U:WI=CGY<0M$UN6(=(MI]0:TCO'WQAO,R@'W?3G^=36N@172,XN651
M((Q]T\XSGK_*J(UF]$HD#1AN<XB7YL]<\<T1:Q=P+MB\E5W!PHA7 ;U''!H4
MJ75$RAB+:/\ K[BR=#"-Y+W!%T8C,$V?+M'J?7%8]7?[6O3$8S+G*E=Q4;L'
MJ,]<52J)N+^$WI*HK\["BBBH-0HHHH **** "BBB@ HHHH **** /5?!/_(L
M0?[S?SKH:Y[P3_R+$'^\W\ZZ&OH:'\*/H?#XS_>)^K"BBBM3F"BBB@ HHHH
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M_I1]K@_O_I0 &SMB23;Q$GJ=@H^Q6O\ S[1?]\"C[7!_?_2C[7!_?_2ERKL
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MR_[\'_&C[-XE_P"@C9?]^#_C1R^8<J[F[16%]F\2_P#01LO^_!_QH^S>)?\
MH(V7_?@_XT<OF'*NYNT5A?9O$O\ T$;+_OP?\:/LWB7_ *"-E_WX/^-'+YAR
MKN;M%87V;Q+_ -!&R_[\'_&C[-XE_P"@C9?]^#_C1R^8<J[F[17.Z%J>HS:[
MJFF:@\,AM!&5>--N=PS714FK$M684444A!1110 4444 %%%% !1110 4444
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M'U]+^WM$D1_M4@.\!< 8 .>O0Y&/K6W0!SGCO_D3-0_W5_\ 0Q7B%>W^._\
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M]_\  R3_ !H_X1+3?^>E[_X&2?\ Q5;M%'/+N'M)=S"_X1+3?^>E[_X&2?\
MQ5'_  B6F_\ /2]_\#)/_BJW:*.>7</:2[F%_P (EIO_ #TO?_ R3_XJC_A$
MM-_YZ7O_ (&2?XUNT4<\NX>TEW,+_A$M-_YZ7O\ X&2?XT?\(EIO_/2]_P#
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/]'BXX'R#BHI].@GE@=EPL+[PB\ G& 3]* +*;O+7?C=CG'K3J** .<\=_\
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MJ/=ARX>^[.@D\9:'#:073WF(9RPC;:>=IP:BB\<:#/((XKS?(02JA3DX!/\
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M[GZFC['!_<_4U/10!!]C@_N?J:/L<']S]34]% $'V.#^Y^IH^QP?W/U-3T4
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32UA1PZI\PZ'-344 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g313671g64o35.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g313671g64o35.jpg
M_]C_X11N17AI9@  34T *@    @ " $2  ,    !  $   $:  4    !
M;@$;  4    !    =@$H  ,    !  (   $Q  (    >    ?@$R  (    4
M    G $[  (    .    L(=I  0    !    P    .P +<;    G$  MQL
M "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q-SHP,SHP." Q
M,#HT,3HU, !$86QE($-A;7!B96QL      .@ 0 #     ?__  "@ @ $
M 0   I2@ P $     0   L,         !@$#  ,    !  8   $:  4    !
M   !.@$;  4    !   !0@$H  ,    !  (   (!  0    !   !2@("  0
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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MX1M-,VUM:9&AXGG3YJ6OC^"C*4I6JF6OBDHS\?N22LHI_]61<HERZG_F(?\
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M;VP     "W!R:6YT97).86UE5$585    "X 7 !< %  2 !8 $8 0@!5 "T
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M=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M    $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO
M;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG
M:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0
M$ $L     0 ! 2P    !  $X0DE-!"8       X             /X   #A"
M24T$#0      !    '@X0DE-!!D       0    >.$))30/S       )
M       ! #A"24TG$       "@ !          $X0DE- _4      $@ +V9F
M  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M      $ -0    $ +0    8       $X0DE- _@      '   /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H     /__________________
M__________\#Z   .$))300(       0     0   D    )      #A"24T$
M'@      !      X0DE-!!H      UT    &              +#   "E
M !0 1@!) $X 00!. $, 20!! $P ( !3 %0 00!4 $4 30!% $X 5 !3
M 0                         !              *4   "PP
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   "PP    !29VAT
M;&]N9P   I0    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
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M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M +FX_P#VZS_R22\^D)(_<X_O%=]\R?N1?__1TTDDEJO(JE*4R22ETDR<!QF
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M_&+'<=&_#^)5OJ?5&9XJ QFT.JF7AQ<XS^9NVL]F[W^_>]47.^C\/XE'%$B
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M7>DKB2%2_?.W]7YOW_E^95_G;__9.$))300A      !5     0$    / $$
M9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0
M &@ ;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-! 8       < "
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M  (1 0,1 ?_=  0 4__$ :(    & @,!              <(!@4$"0,* @$
M"P$   8# 0$!            !@4$ P<"" $)  H+$  " 0,$ 0,# @,# P(&
M"74! @,$$042!B$'$R( "#$403(C%0E10A9A)#,74G&!&&*1)4.AL? F-'(*
M&<'1-2?A4S:"\9*B1%1S148W1V,H5597&K+"TN+R9(-TDX1EH[/#T^,I.&;S
M=2HY.DA)2EA96F=H:6IV=WAY>H6&AXB)BI25EI>8F9JDI::GJ*FJM+6VM[BY
MNL3%QL?(R<K4U=;7V-G:Y.7FY^CIZO3U]O?X^?H1  (! P($! ,%! 0$!@8%
M;0$" Q$$(1(%,08 (A-!40<R811Q"$*!(Y$54J%B%C,)L23!T4-R\!?A@C0E
MDE,88T3QHK(F-1E4-D5D)PIS@Y-&=,+2XO)59756-X2%H[/#T^/S*1J4I+3$
MU.3TE:6UQ=7E]2A'5V8X=H:6IK;&UN;V9W>'EZ>WQ]?G]TA8:'B(F*BXR-CH
M^#E)66EYB9FIN<G9Z?DJ.DI::GJ*FJJZRMKJ^O_:  P# 0 "$0,1 #\ W^/?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U_]#?X]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7_T=_CW[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=%H^8'R;VY\/?CUO_Y";JVSN#>>*V+'@D&UMKR8
MZ#-9NOW'N/$[8QE'2U>7J:/%T48KLPCS33R*D<*,1J;2K>Z]U1[6?\*5^D,=
M*M/D/C%VO03M&LJP5G8/4U-*8F)"R+'/N"-S&Q4@-:QM[]U[H_\ \/OYJFR/
MFAT7\H>Y>N>H-Z8:J^,^/R=16[/RN=VSG:W>M=3]>5F_<;CL'7[0JLW'!59(
M49H_%)&9TD='".KK?W7N@8_E*?S5>T_YAN[^WMJ=A]-[,V/3=?[/V9O'%[IZ
MZSFYLW@O+NC)YC'3[-W!)N#'0+%N*F3'K4PM'+&TL"REZ>/2I/NO=7@^_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NB=_/GY-;A^'OQ/[
M6^0NU=CP=@Y_8E)M_P#ANWLA4U]#@EFW!NG"[;;,[FR&,I:W(4&V\#%EFJZN
M2*)F\<.F\88R)[KW0&?RK_G7OOY]]&[T[.W_ -;8+8&5V?V=D]@TU;LZOS.3
MV1NZCI=O[>SR93 5N<IXJO[K'29QJ.NB62HBBJ(?3)=BB>Z]U9O[]U[KWOW7
MNM>;^:!_,Y^3WQ'^8G472G3]-U6VP]P[5ZOW#N2+>6TLSGLYEZG>G:66VAEJ
M6#*T.ZL)%B*6GPV.7[<I3RR+.[.Q9;(/=>ZV&??NO= G\AOD-U-\6>IMS]U=
MU;GCVML7:T=,D\Z4U1DLOF<OD:A*+";9VSA*))<CG]S9_(2I!1T=.C/([:FT
MQJ[I[KW5 F:_X4G=?TN8R7\$^(G9.0VGC:G3/F\QV;LS"9B"B?UTU3D\-18K
M<&$PM14TY#K#4YA.#8O^??NO=7>_#3Y>]9?-_H_$]Z]54&Y\/@:S-YS:N5P6
M\,=38_.X+=&VJB.FS6,G;'UN3Q.3I8WF22GK*.IGIJF"1'5@Q9%]U[J/T_\
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M\OBWVEN)<974^Z\4M&5SV.; Y,2QYW'C'U%JN$Q2Q^%_W!I;GW7NM;?^9/\
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M'=U; [D?X#]R=&=:;?QW86#A[-PG9.$QV4W'D]RU.T*%\'F*"6LV!O'P;>&
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ML7E]TS;]EH>SMJY7!X3%U&&J=LTN&IJ_&U>4#5<@R$D7CB)CU%@H]U[HPO\
M-V^"O<_SHZTZ:VUTKFNO<5FNM^RLIN[,P=A93.X>CR.*R>S<SMQ(\7783!;@
M9:VFK<A'(R30JC1!K/J !]U[H3:3^7YA^POY;O7?P5[VS%')EML]3['VO5;X
MV(LDZ[8[$V1#25F#WKLUL]1P35'\#SU&DB+4PQ?=TWDBD5$E8#W7NJ1MG?RG
M/YOWQUR6?V)\<ODQM#:_7FZ\F:K-[AV3VMNGK[#Y::2*.A&X\AL/);'W97[8
MW(V.@C2HFP]7)4OXU454GCC9?=>ZLJP'\KWM38W\JGN?X18OM7:^^>[>WLSN
M??V7W]N5-QXW9\V]]V[_ ,!O7+4E1D9O[S;PKZ3P84PG)UBU%;65<C5$L:!S
M&GNO=+;X"?RZ-X=*?!CNOXE_)7*;1S![OW5VA4YENM,IE:^EQ>U.P-G[>VI$
ML.5SV#P\C;BHGQ,M2I%(U/$QBYDLP]^Z]U6?U!_+'_G!_#;<F]]D_$[Y!],4
M?7O8<\%/G-^9.K@I%K8Z2*3&8K>.2Z^W-UWO:;;6^Z'#E(YY,1554,NA5!94
MB\?NO=#/\8/Y./R4^/GSPZ@^1&X^Z=E=N;)VL<OO+LO?.Y<ENI.UMX]D;OV'
MNO"[O>'#56+RE+/CY-T9Z.2EJJW-35342L9?W D0]U[H1_YF7\K7Y&?,+Y=]
M4]Y=5;KZCQ&R=L[6ZRV]N"GWOEMU8_<%%4;)[.RV\LG5T5#AMLYFBRM-68G(
MJE.IJ*=_N$97 0A_?NO=; /OW7NJI?YI/\O??_SEP726X.G^W*3J/MSX_;HW
M3N79>4R2[AH:'(?WOQF)QV2BAW;LZLI-W[)S%'_!()*:OH5J05,D4L#I("GN
MO=5";E_ED_SK>]<<>J.\?E!@LQU5+54SUT>\^\-R[LVSD%QU1'4T,^8VWMWK
MW![AWHM-4P)-%2Y6K\33HCNRNH=?=>ZOM^ /P3V!\">G*KKK:^;K=[[QW=F_
M[W=I=DY2@I\77;RW1]E!C:5:/$TTM3%@ML8#&4R4F,H!-4-!"&>2::>665_=
M>ZH[[N_DT?-[K+Y2[W[R^#7:^SL!BMW[RWAN_:F8?>V7ZX[#ZVC["KYLON[:
M%9(VU=WX3=.VI,G7SB"0^J6D\:34WEA65_=>Z-[\H_Y3'=GRB^%?Q@V!O[O/
M#[K^7WQZV]F*3/\ 8N])]P9[9G;0WF(GWKMC<V=FI#N^*(R45$V.RWVTCQRT
M7[M&T<[+%[KW1=,+_+B_F\]^]:XOXZ_*/Y4[.V5\<]EX7[&@VSM;+TNZ=U]@
MC X^0[(VSNW/XC8NV*[,;3Q^7HZ/SOF*JO/V\09J*JG2.2/W7NK%OY1?PC[I
M^#W37:.S.\<MUWD]S[][37>U#%UOE<]F<10XR+9>U]MF*JKL_@MOU+54U?A9
MI%186"P,FIRY8#W7NJJ>U?Y,7SHZ>^2^].W/@QV[M# X+=.ZMY;AVCN%]\Y?
MKCL38&)[!RDN;W+LC-*=I;PPFZ,#!DJR1()TN9J:& R4L<\0D/NO=68]Z?RO
M=R_*;X,]!=&]Z]TU.8^5/16W:.OQ7R'FBR>[*3+;^J\5]CO&CW/0YFIQ^7W3
MLO=\(CIZMWDI,@'I*:KC,<D7A?W7NJZNOO@[_/BZ(VW2=+]1_)+KF@ZLPB?P
MS;<\?86-RE!MW$CT1T^V1OKIC.[SP.(IP28*$3314BV2$*@ ]^Z]U<9\"/BY
M\D_C[TQV=MSY0?(JM^0G;':.\\SNN;<57D]SYO#[2H:[:F&VW1;=Q%9N>6&M
MFHXYL6]5*M-1XRC62<K#3)8N_NO=$?\ Y1G\L'Y$_!;N'N#?W<^Y^ILSA=X]
M;8+86WZ?KW,;HRN1GKL7NVLST^6KX\[MC 4^/Q\E'(BI&'FF\C$&RK=O=>ZB
M_P S/^5S\B_F'\N>H^\>JMU=1XC96U-J]9[=W#3[XRVZ<?N"CJ-E=HY?>N3J
MZ&BPVV<S1Y2FK,1DECIU-13O]PA5P$(?W[KW5E'\P_X[;Z^5WP^[@Z&ZUR>V
M<1O;?%+M7^!5N\:C)4>W!-M[?&VMT5,&1K,3092OI!5T.&EBBD2FF"S,FI=-
MR/=>Z _^6G\'=Y_%[X<;L^-OR)?86\JC?N^.U,ON7%;.K\WD]LU>S>QJ*BQ$
M^WJVNRN+V_7SU-3C()DJ3%"B*LP".2"WOW7NJG9OY._\P?X==HY_>7\O#Y'8
M ;3RZC%X^DW3N [2WF-IP3356)VOV'CLML_>O7?8J[<>I:.CRO@H:TC4_BB>
M24R>Z]T<'XH_#;^:Y5?(_JWO+YG?,.DK]A=<5^?RE3TOLW<N0KZ'==7DMJYG
M;U!2Y7&;7VGUUL=,=3U.8%4[U<67F#TRB)8F/E7W7NFW^:I_*^^1?S8^2?3O
M;74.Z.I,-M79_7VW]E;AI]^YC=.-S5+6XCLO)[RJ,E04N$VQG*3)4,N+R0C1
M#/!+YXR#Z&#CW7NK3OF_T?NSY*?$GO[HC8F2P&'WCVCUUF=J[<R6Z9*^';U+
ME*SPR4SY>;%TE?D(:)FATL\4$KIJOI:UO?NO=%-_E)_"3N#X.]-]H;*[GS.P
MLKN'?G:LF]\;%U_DLUE\=C\.FT-L[<C@R%?F\)@)),C-5X6633% 8TB9/66+
M >Z]U5'VY_)D^<O4GR;WKW'\&>V]GX'";KW9O+<NTL^^^,OUQV)U[CNPLG-F
MMT;*RP;:>[\'NC;\>2K9$@F6YFI8H?)3)-$LC>Z]T?7O;X)_S#MQ_'/X6P]2
M?,JIQ'RL^,NV]QT79>\<GNG>5+@^ZLGNW&89<K)D,U/C\Y%F)L=7X1(H/[P8
M.OIZJ"9V,=))8^_=>Z)#N[^5=_-*^=&]=FK\^OD)UWBNN]FO/11G:57C<YGJ
M3"97QQ;E.QMK;4V+LC:>/W=N&AITIGS64GJ9:6/24@E5/"WNO=;/VT-JX38N
MT]K[(VS2?P_;>SMNX3:NWZ#R23?8X3;V-IL1B:3RRLTLOVU!1QIJ8EFTW)O[
M]U[I1>_=>Z][]U[K_]7?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7_UM_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=?_7W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M_]#?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7_T=_C
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?_2W^/?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U_]/;M'\SOXLGZ5_8
MG_HN=P_]>O<M_P"LISS_ +ZL_P#LHC_S]8:_\'?[ _\ *7O7_<MN/\W7?_#G
M7Q:_Y7^Q/_1<[A_Z]>_?ZRG//^^K/_LHC_S]>_X._P!@?^4O>O\ N6W'^;KH
M_P SOXLCZU_8G_HN=P_]>O?O]93GG_?5G_V41_Y^O?\ !W^P/_*7O7_<MN/\
MW77_  Y[\6/^5_L3_P!%QN+_ *\^_?ZRG//^^K/_ +*(_P#/U[_@[_8'_E+W
MK_N6W'^;KW_#GOQ8_P"5_L3_ -%QN+_KS[]_K*<\_P"^K/\ [*(_\_7O^#O]
M@?\ E+WK_N6W'^;KW_#GOQ8_Y7^Q/_1<;B_Z\^_?ZRG//^^K/_LHC_S]>_X.
M_P!@?^4O>O\ N6W'^;KE_P .=?%K_E?[$_\ 1<[A_P"O7OW^LISS_OJS_P"R
MB/\ S]>_X._V!_Y2]Z_[EMQ_FZ]_PYU\6O\ E?[$_P#1<[A_Z]>_?ZRG//\
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M]>O?O]93GC_?5G_V41_Y^M?\'E]W_P#Y2]Z_[EMS_FZ]_P .>_%C_E?[$_\
M1<;A_P"O7OW^LISQ_OJS_P"RB/\ S]>_X/+[O_\ RE[U_P!RVY_S=>_X<]^+
M'_*_V)_Z+C</_7KW[_64YX_WU9_]E$?^?KW_  >7W?\ _E+WK_N6W/\ FZ]_
MPY[\6/\ E?[$_P#1<;A_Z]>_?ZRG/'^^K/\ [*(_\_7A]_+V )H+O>O^Y;<_
MYNO?\.>_%C_E?[$_]%QN+_KS[]_K)\\_[ZL_^RB/_/U;_@[_ &!_Y2]Z_P"Y
M;<?YNN0_F=?%D_\ *?V)_P"BYW#_ ->O?O\ 64YY_P!]6G_91'_GZT?OX>P
MXW>]?]RVX_S==_\ #G/Q:)M]_P!A_P#HN=P_]>O?O]93GG_?5I_V41_Y^MC[
M^'L">%WO7_<MN/\ -UR_X<W^+?\ RO\ 8?\ Z+G</_7GW[_64YY_WU9_]E$?
M^?K?_!W^P/\ RE[U_P!RVX_S==C^9M\7#]*_L/\ ]%UN'_KU[]_K)\\_[ZL_
M^RB/_/U[_@[_ &!_Y2]Z_P"Y;<?YNN_^'-/B[_RO=A_^BZW#_P!>O?O]9/GG
M_?5G_P!E$?\ GZ]_P=_L#_RE[U_W+;C_ #=>_P"'-/BY_P K_85_Z?Z.]P7_
M -B/%[]_K)\\_P"^K/\ [*(_\_7O^#O]@?\ E+WK_N6W'^;KW_#FGQ=_Y7NP
M_P#T76X?^O7OW^LGSS_OJS_[*(_\_7O^#O\ 8'_E+WK_ +EMQ_FZ]_PYI\7?
M^5[L/_T76X/^O7OW^LGSS_OJS_[*(_\ /U[_ (._V!_Y2]Z_[EMQ_FZ]_P .
M:?%W_E>[#_\ 1=;@_P"O7OW^LGSS_OJS_P"RB/\ S]>_X._V!_Y2]Z_[EMQ_
MFZ]_PYI\7?\ E>[#_P#1=;A_Z]>_?ZR?//\ OJS_ .RB/_/U[_@[_8'_ )2]
MZ_[EMQ_FZ]_PYI\7?^5[L/\ ]%UN'_KU[]_K)\\_[ZL_^RB/_/U[_@[_ &!_
MY2]Z_P"Y;<?YNN)_F;?%L<&O[#_]%UN'_KS[]_K)\\_[ZL_^RB/_ #]>_P"#
MO]@?^4O>O^Y;<?YNN!_F=?%H<??]B?\ HN=P_P#7KW[_ %E.>?\ ?5G_ -E$
M?^?KW_!W^P/_ "E[U_W+;C_-U[_ASKXL_P#*_P!B?^BYW#_UZ]^_UD^>?]]6
MG_91'_GZU_P=_L#_ ,I>]?\ <MN/\W7O^'.OBS^<AV&/]?KK<('_ %J]^_UE
M.>?]]6G_ &41_P"?K?\ P=_L#_RE[U_W+;C_ #=9!_,V^+;?2O[#/_E.MP_G
M_IU[]_K)\\_[ZL_^RB/_ #]>_P"#O]@?^4O>O^Y;<?YNN_\ AS3XN_\ *]V'
M_P"BZW#_ ->O?O\ 63YY_P!]6?\ V41_Y^O?\'?[ _\ *7O7_<MN/\W7O^'-
M/B[_ ,KW8?\ Z+K</_7KW[_63YY_WU9_]E$?^?KW_!W^P/\ RE[U_P!RVX_S
M=>_X<T^+O_*]V'_Z+K</_7KW[_64YY_WU9_]E$?^?KW_  =_L#_RE[U_W+;C
M_-U[_AS7XN?\KW8?_HNMP_\ 7KW[_64YY_WU9_\ 91'_ )^O?\'?[ _\I>]?
M]RVX_P W7'_AS?XM_P#*_P!A_P#HN=P_]>??O]93GG_?5G_V41_Y^O?\'?[
M_P#*7O7_ '+;C_-U[_AS?XM_\K_8?_HN=P_]>??O]93GG_?5G_V41_Y^O?\
M!W^P/_*7O7_<MN/\W7O^'-_BW_RO]A_^BYW#_P!>??O]93GG_?5G_P!E$?\
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M[_6-Y\_WU9_]E$?^?JX^^9[*$5%SNW_9!/\ YNN'_#H_Q3_YV'8W_HMMQ?\
M7GW[_6-Y]_WS9_\ 91'_ )^M_P#!E^RG_*3NW_9!/_FZ[_X=&^*?_.P[&_\
M1;[B_P"O7OW^L;SY_OFS_P"RB/\ S]>_X,OV4./J=V_[()_\W7$_S2?BD#;^
M(=C_ /HMMQ_]>??O]8SGS_?5G_V4Q_Y^G%^^-[+NP47&[5_YX)_\W7$_S2_B
M@.3D>Q@/\>MMQ?\ 7KW[_6-Y\_WU9_\ 91'_ )^GA][_ -FCPN=U_P"R&?\
MS=<?^'3?BA_SL.R/_1:[C_Z]>_?ZQG/O^^K/_LIC_P _5O\ @O?9O_E)W3_L
MAG_S=>_X=-^*'_*_V1_Z+7<7_7KW8>Q7/IR(K+_LIC_S]6'WN_9TBHN=T_[(
M9_\ -UT?YIWQ/'UK^R/_ $6FX_\ KS[W_K$\_?[ZLO\ LIC_ ,_3@^]M[/D5
M%SNE/^>&;_-UC/\ -2^)H^N0[)_]%IN3_KS[W_K$<_?[ZLO^RF/_ #]7_P""
MR]H?^4C<_P#LBF_S==?\.J?$S_G8=D_^BSW'_P!>O>O]8GG[_?-E_P!E,?\
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M.0[+_P!AUEN4_P#7'VY_K"^X'^^;+_LIC_S];'WF_:TF@GW'_LCE_P W6/\
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M;<V_P'%_]>WU]^90*4Z5P0H-6#Y==< 7/^]V_P!XO[UJ88'2M8(V%2#7K&S
M_I_P^O\ R/VX%!%3QZ=$2**9IU':4M:Q^EQROO?AJ#TJ%O)@^76-B""3^/Z'
MW;/2A8$U#!ZQ:R#=?I_C_P C][Z5P1JKDCTZZU+];F_U^HM?_>[7]^I\NE5/
MEU__U3V:%_I_O)_XK[Z(=?-'U[Q1'DZK_P"!X_WGWKKW7M"C@#C\7)][Z]UP
M:%/[-_\ '4?^*>_=>ZX^$?X?[<^_=>Z]X1_A_MS[]U[KKQC_ %)_WGW[KW7?
MA'^'^W/OW7NO>$?X?[<^_=>Z[\/^M_MS[]U[KQAL+V!_UFN?]M?W[/IU[KAX
MQ_J3_O/OW7NO&(D$@ 6Y-R1?_6O]?I[]U[KR1WX/^W'XX_VWOW6P-1H.N1B
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MKJ^G'UY'OPR0*]+!;9'Z=.H[3'ZEB?\ &]O^(]N>'_2Z?6#20=?6(SC\"_\
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MIT0,0#H'\NL=V_U3?[<_\5]^8QT-*5^SI0L?<.T?RZYAS:P/^QYO_M_;8!.
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M_@Z__]$\WOHAU\T?7%F O^3_ $_XW]/?NO=</(?]3;_7-_\ >O>NO==%B?\
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M>NPP;_#_  OS[WTJCC)4Y\^N6EB+@V_QM<>VVD"DBG5_#/KU&) /)'U]N U
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MYY/^'_%/?NE4<4=3V]8S<\A@MA]#S?\ UK^_5ITJ2, '3@=8BS#ZL/\ >/\
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MCWZG6PM#6O7 -ZB3P+?3Z_T][ZMURUK_ %_WO_BGOW7NNG+"ZD:3Q^?I^?\
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M/^] \>_>&/7I:D<>D56IIUB,VKZ<<?0$_P#$^_", @ZNE C%0-76,RD"]_\
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MI-^?\![UTK5#J&1UQ][Z5(C*:]='W[I5$C-JQ3K@R%N1;@?G_D7OU:=+(XR
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M<@W'T'XL+^_'I6D#ZAD=<'8V!'Y-_P ?GW[I4EN:G4*CY=8VDM]+@ ?D _\
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MW5"#4GI0L"H:J,]8FFO]+VY_ ^G^W]N=*H87?50C'6%I"/I>W]+"_OW2M('
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M^72J.".I[/\ #UP8(/TB_P#K&X!_'U)][4OY=*XK<4.G K_JX]8&*W]2W/\
MA8?[Q[MJDZ61P-I'<.L!C0DFQY_J>!_L![=!-!7CTJ$?:!IZQD6XOJ!'/T_V
MW'OW2GZ=2<(:_GUA8(!^;_X$$_[8^]]/16AUBIQUC"J;\'G^O^^^OOU2.'2^
M.V4$U%1UB<+<6M_M[^]AW]>E<<0 -$_P]<; BQ]NJ214]*EA4KE/\/6-EC'X
M!/\ 34?^*^[5/3XC8  (:?9U%(06X!_UC[W4].K:]R_I&M?GUQ)!/ M_L;^_
M=+H[5@P)%1UB?2/Q<D\\GWX=+(X]!)TD=8R$/Z@!_2Y(_P"*>_'Y=*40O7M)
MZPL%!X^G^O?WL GRZ?6"HS&?Y]8RP _!YM:_^O[UTK6(:5&@\/GU@8'_ %5O
MZ_[ZW%O>Z'R!Z6)9$,IIBHZQE44$ZP?]<C_6_K[NI>H!K3HP$" ZM%/V]8]0
M_##_ &!'MVG3\2C4= S3J.6M]>?]<_[U[]]G2M(W:OEUB8AC?Z<?0\_\4]^S
MT\MM459\]8V ( O:Q^O^W_Q][H?3I8D05%736@ZP'\^]@&HQTJ$=:=AZQM:_
M%K6]O]*%MDJ.RG[>L3*3_:%OZ6_XU[]TI6TCKW.M/MZQ,A^FH6Y'!!O_ +;Z
M>_'I7#:HFJ@K7[>L3(HYN+_T_/\ O?O53TJ6-@**AIU'9"6-C^?H?Z?ZY]O*
M$TBI%>E*))I'8?V=<2+7]^HG3ZQ9'8?Y]<"38D<6_'U)_P!O[V% /#I6(02!
M2G6(LU[G@_XV]V*@\>E$5LH:O''7M;?U_P!Z]ZT+Z=*/ 3^#_#U__],\WOHA
MU\U/A?TNO>_=>\+^EU[W[KWA?TNN_?NJ,ND@5ZZ]^ZIU[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[JRKJ-*]=:A_4?[?W[I]$TU
MSUQUW'''^\_\1[UTX!7KB23]3_O'OU>MZ?GU[WKI_P +^EU[W[J\<7>.[K&2
MMSQ?_&_NRC4:=*/"_I=<&;^IM>_%[?\ (_=_#^?3L<=*YZQ,_P"!_M_=U&D4
MKTJCCJM=76,O?@D?[P/=NK^%_2Z4&R9HUW[U\TH'B7L+8Q<D\:?[UXGD\>T6
MY@G:MW"\?HY_^K3]"+EA57FGE$N>P;M95_[*HNMK'(M_N0KN/^4RJ_ZWO[P,
MB'Z47^E'^#KNO=#_ !FXS_HC?X3T3_HWH&FG^9WR2^0&8H U)C,OB-M=?F6*
M\/\ '<YLW;]9OK/4[ZU'W%+2R4^.0Z6MY:D7!/,C<S<V.OMQR9RG;R_J/&\D
M]..A)I! A^1.J0_8G6/7MM[40M]XOWA]UMPMZP0SQ6]C48\::T@:]G4U^)5,
M=N,&FJ88KU8M[B'K+;JK/^:UV+'@>F=G]:TTY7(]D;TI:NLCCE4,-M[)1<U7
M&>(>LPU&:EQ\8)LI)(Y/TG#V*V@W7,>X;RZ_HV=L0/\ FI-V+3YA!(>L+OOL
M\U+MWM_L/)\,M+O=]Q5F /\ Q'M!XSU'&C2F!:\./5"EP?R/]N/>52I4 UZY
MHI'VC/6)G/-N+7_V/NO ]7$61W=8C(+'Z'C^O_(_;FK5V^O2D15(&KI:;]J&
MFFV(1-YO%U)U_3_\"?NO!X:;)#[6_P#',]]MX-5O!>@\5[?84E]+EFU0Z5W3
MRK?SGA2M2N?@CK7^+OK_ +]DX@4<PQM))RY2765V2S7XM5**_;_;3::?P5AT
MU_W&AK1D'?D_[S[-E6E<]%$5NW=J-.L1EM^ /QR?^1>[?GTI6%%'=D]<20W)
M(_WW']?>NE*11Z1V]1C]3_K^WA'4#/3PM^%&_EUV76QL;FW _K[UX7]+I];=
M]0K@=8S)Q_3_ !O_ ,:]^\/^ETLCM^[X_P"76%I?ZV_-N0+_ .\>[*NFN>E(
M@I^+^77 R6_'X^M_I_O'N_3\<=%.?/K$TWX(O_L?^*>_4Z6QQ1E!J&>L1<_6
M]K_0<?[X^W E0,]*A$*"AQUB#\_3_;\'_;6]["4-:].+ ^I:\*]<7-QR;#_?
M?GVY7I8D&?BZP^0*3>W^W^O^\>_'/2E+<FM#7\NL;S<\ 'C\'_C7OPZ5Q6^#
MK&:]8&F(N?\ 6XN+_P"]7]^ITK2W&D4:@ZQ>7_:?]Y]^Z4"&,  C/7%CS];<
M?2_U]ZKTI5,C/6-I+7%KC^M_^->_=*HHM3@<>H[2DW!!L#QS_P :]W5=1X]+
M%@52=4?7'R@?BW^)/_&O;JK3SZ>6!6^$T'6%I.;FQ_QO_P :][Z4):U4=_\
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M>./]B;<>U X#I6L#U%!U&8VNME/^(-_^*#WOCT_]._FM1UA9K#@@&_\ A?\
M/^O[]T[%;E6)6.AIUC+?UY_I^+?[QS[]TNBBIJUKUC+@?4$_[?\ WH>[JE16
MO2R../3\/6%W^A%]/]#_ %YY]N@4 '3WTP8 AJ#[.L6L\WL1_KCC_>/>^E"V
M[57K@2 ";@_[;WJO2U8!J%6J/LZQ%S?ZV][Z4+:HQH%KUB9K?2Q//^P/^/'O
MW2Y+?4*4TT_GUA+?D_[?W[I3';47X_/T_P!GKB7 ^EC_ +'WZG2A8Z #5UB9
MU-R+?G^U]?;@CX&O3P@X'5_+K"9/Q]+_ )O_ ,5'MWI^.W.M=7P]8F;G^O\
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MRD_\5N3[V$-148Z6?2!>XTQUB+_4$_[#VYI7TZ>B50X(4 ]8F<?\%M^>>?\
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M'^\_C_8^]=*UM5*J2<TZQ/+8'CBWY^O^VO<^] $D#I4D;EEH//J.TM_I>_\
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M,K#R*D'HT6!^<WRSVUC8\30]SYC)TL,?BIY=TX;;VY\C3QJH5%BRN2QKUSE
M!9I7E;CDGV"+KVNY#O9FGEY=B1R<B)Y(U/\ M5;3^0 '4Q;9[V>[VVVHM(>=
MY98E% 9XHIW ^4CIK_-BQ^?0&]B]K]G=O9*GR_:>_MS;[K:)F?'KGJ_7C<47
M)+'$X6E2EPV-?DC7% LMC8L1[$VT<O;-R_"]OL>UP6L;?%H7N;_3.:NWV%J?
M+H'[_P S<T<V7,=WS3S!<W\Z$E/%?LCK_ON-0L:'YJH;Y]!^6 %_Q_A;_BOL
MX44%//HH57H,'K@6//K'YXL/]M[W7Y=/K;OVG6/Y]1RQ'(-@/Q;W[I6L#%@
MPZ76_P *)MA:51-?477LCZ(X8]<C4V2UR2>"DI!)*UO4[B:5O[4TG!!9M(+#
M=14_[GS^OJOJ3CY"@]%'0BWJ J^RE:?\DJUK0 9H]2:*N?4G4Q\V;I!%@/H;
MG_ ^S;PST6PQN=6.L32_X_CZ7'MQ%H*=+H[<,*N,UZCM-R3>W^''NU.E"Q:
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M;@V^I_XW[]ZXZ?$+8.H?SZX&WOW3J1'4,]<2X!_K_C[]TMCC(8Y\NL6H7O\
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M\$4,BP,%^2PRM^0Z(3_*@8M\@>Q@6)(Z<<V/_A[;?Y^GN4_?C_E5-G_Z6/\
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M3XT'@!UC;<$8!9J6<VX!\BVO_0W%_>_IE_CZ?0* <#K@VXD6VJCD%_I^Z/\
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M?5_2WOQZ5)&,Y\^L"K"[ZI9*@M]$U1!21_K_ $X!]^\\=7\-?*O69HX1=;2
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MW?2*U9O3K L2F0F.@>/0MC(5Y/U_!<_0#WOI^.V9@:J1UV1+<$O(T9%Q9'(
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M4!LH*]1VKZV/E9H9BQ_MJOIO<>E@/][O[W4CAT\L;ELU7Y]8TJ:\WUR&3Z,
M6@4(?ZJ?&M_=U(/QGI;;QD,_<6QUV:GR$+)/(KGTAO#)I%_R'5#&P']?I[OJ
M08!Z5"W:3(QUC'AIM3O.:B7ZG6LEV^EF5 "H('^W]^U+3CT\ENZJ!H)^?7 5
M$4KW\<T#!OUM%8$6O]0UP#]/I[]J7^+I2+? _1S3K%)-$Z%DJ%:U[*S,W/\
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MI6E2!UC.'5RQJ*25P0%"*RLBD6N0#;4&/^W][UJ,AL];TK_#UQ3&M!+Y88E
M!&A/ ZM'8?7@L">/Z6]UD8,H&JN>O!0."]2)JJ2#F>6-K@IH:%";$B]M,?I(
M/NL?XNO9ZC).TA-X(A'^&8@7 _JAMS[>!(P&Z\0#QZD*(UOKIH95/Z0 "0?R
M--[ #_B?>O$(-->>M:5_A'7)C1LZJ].BL0;ADU$CCT_GCWO6WKCJWRZY^2FB
ML(Z:/BVD)3C5?_"P'O>IOXCU6@\AUF,_%VI78-QI*E!_AJTG4!Q[T22,GK=
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MF*6P*F_J*-];?T]NK?.P)\(?M/3ZV.G\/74U?26TO3!P;<%0I/T/ZOKQ[O\
M7 ?$H!^WI7%852NGSZB?>8^,7C@>$D\VYCOS]%_)_P!?VT=TC4D>$QIZ=+$V
MXZ5[>LAKZ<:;1E5^K: %YM^J]S:U_>Q=1#(IZ]*_W?PQGJ/)5TE0=*U$\:\J
M571;5^238&X_P]NB]1B 1TXEBVH=QKU%,#"[QY0E>"J'4647]6N_U ]N?4J?
MA )Z5)8OJ.3U'JIH'(7[UE;3I?6 UW^A,9T^E6_WCW9;K374@'[>E"[>S<6/
M[!U"2+0A)R;2@'TK,ZL0>.%.B_ _Q]V^N3T'2B/;"#JUFOV#J7%]TT9*2&9-
M7&EX'4"W^U)K4_X?3W<7)(!""G2@V3\=77'P9$ER)0/R%T0D?X#UJ/Q_3V]X
MAQ@=*A8O5<GK$RY$(ZR12L;^E84A0L"/U+*EP"/?O$/ITJ2Q<,,GJ*]-7SC2
M(9T_H9*A01;@_H :Y]V5RQITJCL7U<3PZZCQ51I/G\2FWH!FE(8_[5I(/N_2
MN*Q?NR>N_P"&5:*%@J88?Z^/RR:OZ6\CV4C_ 'GW[ATI2Q>E 3_+KCX,D %6
MLI90 2?)'ZN+WOZ@/I_3W[I;'9'0M4KU FILW)95JZ235J(M%$K(H LJOR0+
M?['CW[I2+)\&IITW''Y=;L[02'DZ@@D8 _@6L0/=@=)!IT^MN=0 C /0A=F'
M)O-UL8IHIC#T=UA2.PF6I$$D-)E@]*?#N#</VDE/JL:=FQ[Q7]6.I+Z7+=F8
MTW<%*5W&X/"E:E<_ E:_Q=X/^_9/(UNH'9[*AK2TB'&O ''Q-3[.VG\"^89L
MF3L%ECU J0&6_!%N &)X:_\ A[.>M16[#55:]81)-&#&8EU6L=,N@G_ @H%O
MQ_QOW[[.ED=NU#^F*=8I&J]#&+1#?^R&ULQ/^J"%;GCCW[I4MLV@?ICIG$F6
MC<EI(EL3I55>Y!O^I26?GW[CTI%K)BB]98ZQQ<3*P)Y/!=) O_-HFP'^'OW2
MM;:34,>?7-JR'2=-+#(;EC^RL36/]+ BP'T]^Z4I;NC:M->NHZN$E5\1CUW(
MU+91;ZWL+@?T_'NZC57I0D>3J33UR+LQ)\L2,1I+*A4V_'%AS_C]?;BJ%P#T
MH2)J'3D=8))6BTLT\9 '%U;4Y^GJ)U+]1[O_ (>E*0,5!,8KUU)D0$&JD9W8
M!0T9CL1_K&UE_K^?>NE0MVH*QCIJ^]HHY&$B/$K&Q#(UBW^%[DBWY]^X=+8H
MHXR !7J=%4XV9=,59"#_ ,<I5"M?_:?TM8_XGW[I8L:,:%1UYX&0W6*"12+C
M2KFP/X]+&_NZC57I]+?42$'6 HIL- 4#@!9Y$X^O"MS?W;PQZFO2B.U>G#/4
M*KII7'IR$\5S<*)-(4?ZD7!X_P![]ML-+4Z?$$@ %.HZ19".P6M$X!X65DD+
M#\7].KZ>W @H#JZ4K%)11IZPZZV(MJQ\#<ZM4;<V/UX/!8>]B,5!KTN6-@RU
M@%*_/J0SP2)^XBQO_:\Z^,"_T TDCZ?[?VYTK"1DT\,=1GCB<$*8R#]=#+P/
MQ^I>1[UT\D"&NG!ZQ1T)5CXZV>-W) 'F!4BWT"@D%A^+^]]." K\ )'2AP0J
M*>J^W,IG^X+R$U"D.#%"1&L3@\+K]1M>X_UO;,N 7Z7VBE0Z-@M_+I.[FJXZ
MQTJ4KI8V6]-+CDD@:HI95)$C1Z4*U--):^KZ#_"_M'6IKT<V=HZ@*/AZ0=0[
MF[^5IQ87CJ%70;'@(Z:2K <@C\^V3(2"*#HRAA="%([2>L R2_<PT;):>>&H
M<!BQ.F)!)<$+H)L?H2#Q]/;?GT8);KJ%'/6:$$JU[DZK&XYMQP?]C[N@!)J.
MGU@5#76>H; ?0_["X'!^EQ_B/>W %*#IZ-1JTUX]0ZFE69&4LRW*(LH8AH07
M#RE;&X:15"\?4?7WI7H *=+DB1&KQ/SZB9>BEG@I&I=2>-WEFC\@/W+^J\BE
MB!$V@BRCABMO>_$/\/2K0&[JTZ<,1LNLJ)4J<N*9<;XEG@I_,DD]8D@!2"98
MW26C:,<LQ+?T Y]F-O;2,RN1P(/3$]TD:E$-;CS'H/7I?>&F$861PRQ!57GB
M-1940?2Z@<#^GLQ)6F%%>B:-5#NS#4S>O7J:.C6HA$3$:9 ]@#H;3]0P#6(Y
M_/NM>E*(I)H*8Z4^5F5J:%E8J))#'<_JTJH:Q4?I)*_Z]A[WQ\NE21@USY])
MQB"Q9A<#^O(*@WY'O72J.(:/BZ9ZO_.1%7TVU/K^A*&Y/T'  ]T5!)(RUIGR
MZ7( $0#TZPB)B6E:PC*A0Q5B&M]2 2NI_P#'\>U 0#SZKX8SGK S<<\6/%@H
M(%^387'T']>?=GPIZLD8U#NZPLS707U'AP+*O+&PO;@#1S[3LNH#-,]*XXQ5
MNXUIT].,>!J9X=8 L02C,0.2+$^JX]N%ZIIITB:$.^DL>/0.YN,4V9R$E,+1
M)6"HB(N0M]$Y%["[:R?]B?:*@6>E?(="2$#Z<M\M/[//H2'H\3700U:5'CBK
M(DF4AVCOY$#.NI74ZT<V(_!'LS4Q!5U/0]$S1*'8!NLL6,IU2T57(X91I82N
MS#^ANQ:YXXO[;T YU=,&@/'KML5.5)&1J4/XNZ6_UR+7(]^\,>O6J]0S09)"
M0:I94^@/G(+?0W( !7W[PQZ];KU*@H@3:42.[$$!9&DMI^I]87\_[U[LHT]7
M5=5:GK.^)1V+*A8WOZW4B_\ B--[>[=6\+/Q=26I(XUN\1(7ZE1JOQS:P]T*
M DFN>O>&/XCUAE@AD7TTTY?Z*3"2>>+*W%A[MPZ]X8_B/6-,<\;!C#*!_J=;
M K_B$4D\^_$T%>O>&/XCUG$8;]<L@_VG[>0D$<#U:1?CW5'U&E,=>\('\76;
M[:+3^A_I>_@D_P!?5;5_L?=ZCK7ACUZ__](:TR%)&19!R0;/^XX'YN$N0/\
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M?2%M5VI8K 7(Y6_U)N.3[/X%=+>.-_[0'.?+[>B.;2UV\JCMIQZD&B@TE;
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M(9X7OZFBU#4C?D&WX]O*2R!CQZ>\-?SZSQN;,/P3_P 1[;DXC[.G4C4 ]=,
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M>HE@>.IJ*E*L-"[)()PFD0O=>5"D@>TYOZ,104Z4C;GHK/* #P\_\'31'N'
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MLQ154E?]J/\ O(]Z_P '7NL0QU,$=342R,6"ZFU:EXY4,..;?3WO'EU[KO\
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ME0AKN-*_V;@<_4\'\W]^\-L"HZ5QVJ%>%.N%'F& 99-!6Q!^JM8\$\_4D>W
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MNLJ#GZ?VO]B/;O2A+==1[&ZX"HN>9XP/S9K<?F]_=@I/#I5' 1JT*>NVGB0
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M/ B].GB00,%T1BVFX#V)N%!*_P! ?P?>QX@_L^/3D<$53CIGGR$:C]Q4C4,
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M%E-O^)][T0^@Z?02$'C3IFW3%+N/!BFHU$]?1S_=1T[GUR4PA99?MP>#47
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MNNL2#2>>2R&_NWA  *IH.GPE0&+9ZX5.W:B9 DM-JTD,DD4D@TD"QX9?4/\
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M08  J+V)M^/;P=3Y]*5C-5[.I/WU X8)-3:E_P!4[*?]@ITD@_U ]VZ5)'W
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MJ3$PFIQ-! 5#%A&LK2?NV(O(&:S"/GCBY][Z?%H@49SUPF?Q1EY'*LGZD4L
M/]=B2+>]=+%MD!7/IUP"RM9G9A$P#>-'L?I?4S6-P?\ #W[\^EBQEF%4ZPN\
M1U1FL9;@W70MP/IP6'U_WGWL DT''I0D2ALQCK S*L9564E0/5^J1A>U[@W)
M-_I8^[:7'#I5% CZO*GRZB"I OH5Y!'PZJK W'#$AD]9_P!;^GMQ0U,\>E M
MR!1%J/7KF9HW+JJN\VD%(3I4A;?J;Z6O?\GW8U]>E"V[Z!^GU'2=1"PJ#&KK
M<AP59BW^I"BY>PX_I[MH?R'2D6PQW=0)<I3HK%P2;KICMHUJ>"054FX(_'N_
MANO<Z=O2M+<:U*FI].HR9"@F?2!3K?E5+322-_4!8E-B.?K;W5BE.WC]G2V.
M!Z_V?^#K,9:0%6>E1"Q(A?2ZZP=(U%I -!)]U +5H.E*6[&M8O\ !UGC7Q#4
MZ*A!93&=0N;VU%BY&JWO>EO3I3'9ZE-5IGKJ2H2,/+("8POZ4NVG_'@WM_7V
MZ%%!49Z5)9#2!TV024M3KM,AT$W3R$&U_P ZF!(/YM[KXL7#7GI8MJ<5BQCK
MN2.%" +>L_C2P _U*BY(/]/K[=Z?$.12,5ZPF65 =%#'I%_3)*1)P?[0 +*?
MZ@>ZX(Z>2!]7]GY=-SU%7+%Y/M)(5+LJLC1RDD7X140N; ?D<>_$JO''2J.V
M9M513J73%WIDFG!35_8D*EBMR 18:K\?GWM>\545'2J.V<*0%KUB\E*)PDBJ
MZL#<RR($!_'H_6=('X]N H!1OBZ4"$JH!3/4>5*1CJ@,%SQHA!T&W^&H6(_-
M_;VJ@P<=*EA%!^F.HKK31GE8Q<$ED"V 'UU%+L./;7B!L+& 3\NGDM>]=1[:
MYZXK&SV;1!%3D76;[B9FD)O8-#I]'^'/ORAJ]W#I8ENE:QG4WIUY1">'?2VK
M3Z8M*DGZ#7*!J)]W  X=/);:JZUIUQ\M%3LJ2SQ$.6]11 %TBQU!1RO^M^?>
M^E,=NJC"@CK%]Q2^LK*&4@>%EN%+'\A1ZB?]?W8*QX#'2M(1I'Z8KUQ]; NM
M9H,8%E1ET@M];A_Z^_:&].K^&?X.HH(CURFJGD<+8( C*"QX*K'=W%_S]/;V
ME?X1TX(I*CLQUD5/VBTM6XF)U)"9(U"WYNY4?D?BWO1" 9 IT^D9U?!Y=1))
MGCU7K1$ .&C2.3R/]-,C2/=5_(('U]^&AL #I0L3'X4ZQN@J%3R3B8V_SG!=
M#];#Z%M1/^P]W7M!"FGV=/QVSO4M@]1)*-E8:/),@'TUI&03_@S _7VZLQ4
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MHYRQUGU^H<<D$\GZ>J_%Q[=^G%/B-:=/AQ4=@ZR_Q-CJ<L(R%(TL2P<_ZP(
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M<QR4B6(F9M7U=R;?3GZW^G^'O7ACUZ5)#+IX#K"(LC>Q=P!]&TMIO_L3J/\
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M]L]-=>NW]3_O/_%??NM=8G>16MX99!;]8,84'_'5)>WO77J]<E9_[2:..?W
MQO?_ &D6 ]^SU[/7(,_YL/Z6+&_^O?WOK?7=S_4_[<^_=>ZZNW^J(_WW^-_?
MNM=>U$WY/'U^OOW6^NB ?K8_XM;_ 'L^_=>ZX_MJ;@*"/[047_Y* N??NM==
MZU_K_O!]^ZWU[6O]?]X/_%/?NO=>U"U[\>_=>Z[OQ?\ 'U]^Z]U__]%>2PPS
M.96Q\;,MM!6$,WI/$A;R(RR6'']/?2T01J58<1US1AC9,,<]=A%/K,(>^HR&
M5$)_U@3J'^O?V[]G2I48,"1UD2K"A50M3H/Q#3@$V^@NB@'W[I3$K,6 7RZQ
M25T@8K&:R:YMK%*J@K;GAG5B??JTX=+(XWH>WJ)_$8U)#4N3E<7N_P"E&'_!
M1-8 #\>_9Z610NR# X]8?XU2LWBDHLD8V8!K@K&A!'+^HC2M[DCFP]U+T\CT
MKAM I+/Y]2C70QL8PU.+.RQ_;SW#J#96>ZDHS?T)/M97'2CPB<4ZPSUE<E@@
MB1'8HNMRPU6Y?5J )M_A[UT_%;G6NL#3]O6$U>FF]5:GEU6<L?V1S^B...34
MW_!C]/Z>_=+!;(:T/4(5C7'^617)9650&C;\@AB=2W'Y^GOWV=/1VBYSU*CJ
M8P& 822N "0&?@<B^B_IM_7V^GPCI7';,%HM-/V]<D,S$,[L?[8 @2.,7XL;
M+J:P_P /=OETK6"30M*<.L9+>16)550ZE41&1K_B[. @7C_8>_=*!&U1PZ;*
MVNIHVTR5)1@I*B:8(+FY]2#@K<>]J*F@&>E*QL&!TXZ;5RU Q0MDXH0A.J*+
M3&C_ .U(55B;D?7_ &WO94J*GI5$K%C0>74PY>C )%33E%M:SR&1B?J=;$D-
M;^G^O[O'P;I9'&]&[>FMZRFJW9):2MG3Z>1Q)XP0VI6206N#]+_3W<L%-*GI
M4D;:> ZXR0TJH\<>//KCL9'25Y4&H&RLC(_U_-[_ (]Z\1?4]*EMU*J6!K\N
ML204T>DK31 @?F%]1O\ 6[23M:WO7B+ZGI<MFATD#TZSZ8&'%/"?KPT:,">+
M7)<\>]B2II4UZ5+9H""1U&DN=*&DB"ZO]5#PS?E46-AIM_L?=ZU\^E$=O%7\
MNL!CC!.F",<GZO9;WX-DB M];^]9Z51VT1U=>3]NY$-('/\ :T.Y'^Q;2;^]
M_GTJCB"BB@4ZY_<3W(62->!PL T_XV]8/OV1TZ+4.*D\>NFJ)RQ!F!5;?2&,
M$7_5R2Q/_$>]5^9Z5K ^,#RZC>>3U7D<W)-U(2P_ L!^/>ZGU/2I87!!-*=1
M)"SNUY:H#_"I>_T^AL 2/=X^)KT^D6IJ-PZQZ56Y0RZB;^N5V'^PNW'MWI5'
M"%KIZX,UOJQO;^TS6_WOZ>]Y]>E<:-IQ3CUT)!?FQ'^%_P#B3[]GUZ<\%VR*
M=12Y!;\W)^O^O_K^_4Z>4$%1I/7$N2+6'^^_V/O?2Y(VUCAUC) Y/O8!. >E
MB1L#GAU@,BW/U^I_WOVXJD5KT^L3-72!UUYGTE01I-KBQYM[O3Y=7T,F#UB/
M)OQ[W7I5&M4'7 O] .?P>/I_K>]=*5B.,#K%?W[I5X?V=<68A>/]M^/][]^Z
MND9U8IUA+$_X?[Q[WT^(';@!UUSQ_L>?]87/^]^]?+IQ8VC%&&>N)90;'Z_Z
MWNX0D5'2R-:HIIUP+W_P_P!;VZ!@=7T'Y=8=8_'U_%_>_P NE2QD,.%*]8V:
MUV)M]/I?_6^@N?>F8**GATI6,L: "O7 2)S]?^26_P"*>Z^(OSZ=2W<UI3KC
MYX_ZO_R0?^*^]@@\.E"0.H.H"O6-JA+E;V']2-)_'^/NW5_";TZXF= .7]Z[
M?4=7^GDXTZP&I4@VYX_ _P")_'NGBQ_Q=*Q;N6 *XZP?<J#;2U_]<?\ $>]&
M:,<3TJ2S&KK@:D_Z@6_VQ_V)_/MI[C \.M?GT[](OKUA:8_0"P(YOS_Q3VT;
MF0<0.GH[1:&IZQ^0_P!%_P!M_P ;]MM<2$U'3ZVR 4Z:MPQ?<[=R:Z0STST=
M8IMR@6812,G/!*L+G\"_O=2PJ>O(/"O(OX:=!EC!Y,A1JWT-9!_A<+,MCSQ9
MO:7HV>1=#_9T-%K,_P#P=_\ >S[V#CCT6EE(-!UQ+J/U&W-N0?K>WXO[]U3K
MB)HVOI):W]%?D_T%U'U]^Z]US!)%]+ ?XBW_ !/OW7NN7OU3Z]>ZY*55*IF^
MBT%:Y_UXX'=?]@"+_P"P]OQ]D;AO0]6CIXD9I^(= 7B:VKI:J.KIP?()/*58
MBTAD)+ZCQ=7U&_M/T:RBJ-Z]#C<&VDW!"D$&XL1?@_D<_7\_7WOHF*E9&KPZ
M\>.?Z?T]^ZMUW4R>#"5]26EU&2,4Y!'IJ%TQQOP+A5+DM_4"WM5"P6.AK6IZ
M3,";@XQ0= :\[JD@C M$C/'*H*DH\QBC;2EP#8EC;@'CV_4&AKT8+P'0E9^C
M6LQ%*L-EDQ.-IG,854G-+,V@RR2 VFB1_P#.( -#M?F_M-+WLI7R/3$-4)#<
M3^?2,Q-6T.2II+\K(GC"C]:%]#+P?[6HK_K^_=/L"5( ST+!<!B/P. ;<\?[
M'W1QC\^FM!ZXF0?CG^MQ[:Z]H/7$N2+6^O\ 0?X^_=;T'UZYDE5!L?P.1_A[
M]3K6@]80Z$KZ[AR0I0ZUN 6-V34J@?XGZ\?7W[\NG:=<5D5[Z4F4_@S#QAA^
M& !+%&MP?R/?NO8&2,=8W-9;]L48:]K2R5; #\F\:IS;\>_=:#*30==KYP3Y
M&A_%A L@!_K=IG8BW^M[]GS'6S3K*3_0G_D*Q_WCZ>_#Y]>'7O'(Q#>1QRI
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M+5D_BY:26%?]X]^\0>AZ<?*G/7EQ=2>9:Z,M^?!CZ=>?Q<L7]-OQ[]X@].F
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M_A_K#VV :C&*]+1:L""3CK%Y6/'T'^'T]NE5],]*(X5UBB9ZQN_'UOS]./\
M'WX* <#I;'"P)IVXX]83(!;D#G^MK_3_  ]VSZ=*%@#5\24?GU&9G/UF+>L,
M&5(E.BW,!%B"O^U<-[]TIB@31A0V>/7$N3]2/K]!]!_2W^P]^QTM2,!% 3%.
ML3FUK-_6]O\ 8?X>[4;^'I6+<U'=7K@S\'F_^'^Q][4&HJ,=/B(*:A.L1DO^
MK@?X\\C_ %Q[<*+Z=/QZB3CRZQO(!].;W^GX]^"@<!TI2-FKVD]86<VO>_\
MA_L?=NE*14&4SU@9[D\L/\ +C_8'\^]CI;'&^A=,I ]*<.N!<?AB?\"+>_=*
M1%7\'7 O;Z"_^/'OP%30<>G$A.L?IGK$S GDV_UC8_3_  M[NB9[ACI6D3*:
MZ*=8&(/X^E^;WO\ X^[Z$].E"+QUCK'J X O_C?Z?ZW^(][H *#AT\J1G.FO
M6)BA)O\ X<$D_C\_UO[WGIP1BF%QU@-N;?47M?E1_@%XXL.!_7W[I6J#M[>N
M.H6O<6_V'O=.E2Q#4*KCKB9N+7!4?3D ?[U[UT^L"_ACZCM4B_X6Q/.H"_\
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M^A!O_@ 1S]!R?=JCI\1H  4SUP+@6OQ<77_:O]8<^]=*EC%5SBO6(L2;CC_
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MQ_K'W=5(KJ'2N*)5#:,]8B3<G4P_V]OZ?7Z>[T'\(Z?\%6RQH>L9D/\ 6_\
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MA_%O]C?_ (K[]TM117K$6 ^OY_PO[]TH2 R E?+K&TEN1]/];_C?OW3ZP!0
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M]M[<UGACJGSZ>A'#"@2"*.&)%"K%#&D4:@?0+'&%0#_8>Z=.!R3GKCK'^/\
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MXO;WOIU4+"HZZ]5O[-_\38?[S[]UOPF]1UW_ +[CZ>_=/C@.L>BQ!'TX^O\
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MHEIA.(E)](:$2!9'4<7XO];>_=74*1W=)@X3=DC:I-Z26+:F$./"_P"P6Y
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M_AESYK?\K71?_HP=R_\ V >[+[^>WP-=.X_\X(_^M_3P@8$9'6,_R6OFP?\
ME+Z*_P !_I!W+Q_[#_W?_7_]OO\ ?>Y?\X8_^MW2A$TDU;KC_P ,L_-C\571
M7_HPMRC_ .9_[]_K_P#M]_!N7_.&/_K=T^C*E<GK@W\E?YM'_E+Z)M_3_2#N
M6_\ M_\ 1_[]_K_^WW\&Y?\ ."/_ *W=7\1/,FO7 _R5/FS^*SHG_6_T@[F_
MWO\ T?\ O?\ P0'M]_OO<O\ G#'_ -;NG1/$ ,G]G7%_Y*_S=L=-1T2W!X_T
MB;D6_'TYZ]-O=?\ 7_\ ;[^#<O\ G#'_ -;NGENH3Q+#\O\ 9Z;W_DM_.@ Z
M(.AW/%@>T=Q)?^IO_HV:UO>Q[_\ M]7*;E_S@C_ZW=76ZM@15VI_I?\ 9ZR0
M_P E;YR2*3,_0U,W%@.R=RU%_K<$CKF.UO\ 6]^_U_\ V^K_ &>Y4_YHQ_\
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MC_Y7.@__ $8FZ/\ [7GO?_!!^WG\&Y?\X(_^M_5EYPV4&OZ_^\+_ -!]=?\
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M]X7_ *#ZY?\ #'WSF^OWG00/Y/\ I$W0;_[#_1Y;WO\ X(/V]_WWN7_."/\
MZW]>_KYL/I<?[PO_ $'UQ_X8\^<I)O6]!_X?\9$W0;_[#_1YQ[U_P07M[_OO
M<O\ G!'_ -;^O?U\V#/;<?[PO_0?7O\ ACSYR_FMZ#_]&)N@_P#S/![W_P $
M'[>_[[W+_G!'_P!;NO?U\V#TN/\ >%_Z#Z[_ .&//G)_RN]!_P#HP]T?_:]]
M^_X(/V]_@W+_ )P1_P#6[KW]?-A]+C_>%_Z#ZZ_X8]^<H_Y2^@F_\J-N@?\
MS//?O^"#]O?]][E_S@C_ .MW7OZ^;!Z7'^\+_P!!]<?^&/?G/_RM] _^C&W1
M_P#:[]^_X(/V]_WWN7_."/\ ZW]>_KYL/\-Q_O"_]!]=-_(]^= 4E:GH%V'T
M7_2/NE;_ .NYZ[( _P!A[T?O!^WOE'N7_.&/_K=UX<^;!YBX_P!X7_H/IID_
MDD?S P\@BH_CDR!CX7/;.[0Q7^LJ'J\@$G^A-O=A]X+V[/%=R'_-B/\ ZW];
M_KWR_P#\O/\ SC7_ *#ZB_\ #(O\Q M_P'^,RI?@_P"E;>K.1^=7_&,@H/\
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MPW'^\+_T'UB/\CWYUBVE_C_Q]"W9FZ18WXL!UQ:WO7_!!>WG^^]R_P"<$?\
MUNZ\.>^7_,7'^\+_ -!]<O\ AD#YW_\ *Q\?N;7'^DG=/X_Q_P!'/X][_P""
M"]O*?V>Y5_YH1_\ 6_K?]>^7_2X_WA?^@^N_^&/?G8?K5_'\'^G^D;=)_P!Y
M_P!'8O[]_P $'[>?P;E_S@C_ .MW7OZ]\O\ _+S_ ,XU_P"@^N_^&/?G9?FL
M^/\ _K_Z1=TG_P"9YS[]_P $%[>?P;G_ ,X(_P#K=U[^O>P?\O/_ #C7_H/K
ME_PQY\Z#]:[H#_&W86Y[?^^[]^_X(+V\_@W+_G!'_P!;^M?U\V#TN?\ >%_Z
M#ZY#^1Y\Y@/^!O07^P[%W0/]ZZ\]Z_X(+V]_WWN7_."/_K?U[^O>P?PW'^\+
M_P!!]>_X8\^<W_*YT%_Z,7='_P!KSW[_ ((/V]_WWN7_ #@C_P"M_7OZ^;!Z
M7'^\+_T'UU_PQ[\Y_P#E;Z!_]&-NC_[7?O?_  0?MY_!N7_."/\ ZW]>_KYL
M/\-Q_O"_]!]<7_D>?.@"Z5?03-SZ6[(W4JDVXN1UV3:_OW_!!^WO^^]R_P"<
M$?\ UNZ\.?-@KE;BG^D7_H/I/5?\CG^8I,]J/*?&:CB/U\O86]:I_P#@MVZY
M0<_U]Z_X(+V]\H]RK_S0C_ZW=6'/7+M17ZBG_--?^@^LT'\B_P#F":%:JW+\
M=_*;%TI=W;C$8M8:%>?8):Q'YL/];WO_ ((/V](RFY5_YH1_];^G#S_RV#VQ
M7/VZ%_Z#Z<O^&-/G:+_[E^A6!%CJW_N$-JO<R CKGT\<:>1[]_P0?M[_  ;E
M_P X(_\ K=U5^?N7V\KFO^D7_H/K+'_(W^="*P?(="RDFX9^Q=R#2+?I7Q]<
M)Z0?ZW/OW_!!^WG\&Y?\X(_^M_3?]?-@' 7'^\+_ -!]<O\ ACGYS_\ *YT#
M_P"C%W1_]KOWK_@@_;W_ 'WN7_."/_K?U[^OFP_PW'^\+_T'U[_ACGYS_P#*
MYT#_ *_^D;=/^]?Z.K#W[_@@_;W_ 'WN7_."/_K?UK^OFP^EQ_O"_P#0?7)?
MY'7SE%]57T"?Z?\ &1MTC_>NN^?>_P#@@O;W^#<O^<$?_6_K?]?-A]+C_>%_
MZ#ZY?\,=?.;_ )7.@5/X([$W3_O1Z\]^_P""#]O/]][E_P X(_\ K?UO^OG+
M_P#R\_[PO_0?6,_R.?G2?KD.@R/P!V%N8$?XW/7GO7_!!>WO\&Y?\X(_^MW5
M?Z^;%7A<4_TB_P#0?7(_R.?G.1S7=!D_@#L3<Z_Z_/\ H[/O?_!!^WO\&Y?\
MX(_^M_6_Z^;#Z7'^\+_T'UQ'\CGYS '_ "OH2]^+]C[G(_'_ '[H>_?\$'[>
M_P &Y?\ ."/_ *W];_KYL'I<?[PO_0?7$_R//G:!9*KX_?X$]C[IN/\ '_F7
M5O?O^"#]O/\ ?>Y?\X(_^MW7OZ^<O_\ +S_O"_\ 0?4=OY&_SP(N:SX^DW^G
M^D?=(^OU-_\ 1S^/>O\ @A/;[_?6Y?\ .&/_ *W=.?U_Y?P--S_O"_\ 0?7'
M_AC7YW'@U?Q_L1S_ ,9(W1P?Q;_C'(]^_P""$]OO]\[E_P X8_\ K=UO^O\
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MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=%@[]_YF=\.__%A\Y_\
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M>I(6-/20^5HS(X+LS'W7NM33^8A_.K_G=[?_ )R_?G\OCX0=WX2HAJ.]-O\
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M\_\ "OC_ +<X[I_\6(Z+_P#=CGO?NO=:FW\J:/\ X5 /\,=HG^5R^X5^(/\
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MTK[KW6WS_P )8_\ MQQ\._\ M:_(W_X)WN+W[KW6HOV1_P!QDF._\7_ZJ_\
M>&V?[]U[K>%_GVI _P#)R_F%BIT^,?'?<;KJ^GGCR.(>EM_M7W2I;_'W[KW6
MM[_PAU><]3?S#XVU?:KV)\=GAO?1YWVUVTM3I'Z=7CCBO;FUK_CW[KW6]Q[]
MU[KWOW7NBP=^_P#,SOAW_P"+#YS_ .!O[]]^Z]T9_P!^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU__2W^/?NO=>]^Z]U[W[KW7O?NO=:O/_  KX_P"W..Z?_%B.B_\ W8Y[W[KW
M2@_X20?]N8.JO_$T=^_^]W4>_=>ZV9O?NO=?.2_X1F_]O"?G[_X@Z3_W]V(]
M^Z]U7)_PHUZ:[%_EX?S$?FUU?UX3A/CG_,HV[L#O^LP<-(\&&R-1'V93=@9Z
MEI_ Z4465VKWKM+,3P1*H^VQ67C3QJ)58^Z]UNZ_\)8_^W''P[_[6OR-_P#@
MG>XO?NO=:B_9'_<9)CO_ !?_ *J_]X;9_OW7NMO;_A4#W5A.FOY+GRJI<C6Q
M4V:[CGZSZ5V=2O,D,F5S>[.Q-NYC,T5.'N9I:?8.V,U6,B@L8Z5SP 2/=>ZK
M-_X12=2Y7;'P.^3O<.1HI*2D[8^346W<#+*-/\2Q'5W7FW4ER%.-1U4JYW>U
M;2AK"\M+(.=/OW7NMS?W[KW7O?NO=%@[]_YF=\.__%A\Y_\  W]^^_=>Z,_[
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[K__T]_CW[KW7O?NO=>]^Z]U[W[KW6NC_P *D.AN[OD?
M_*IW#UI\?NHNR>[>Q*KOGI7*T^QNJ=E[AW]NR7%4&5RT>1RJ;?VQC\GE#C,;
M]U&U34>+PTT;:Y65 6'NO=:HOP&^4/\ PID_EP?&S;WQ8^//\L;M*HZVVWN?
M=^[*&M[!^$_?>Y=US9'>N23+92"KRE!FL#CY**GK QIU2CCD19&#O( FGW7N
MMW3^2O\ ([Y^?*+XA9OLC^9!TED.@_D!2=V[YVKC=D9+J/>/2U14=<8?!;,J
M=O9Y=H;XK:[,U%/79K)92&.O5_MZI*8>.^@NWNO=:T7_  D^^%7S!^,GSG^;
MN[_D7\7/D!T5M/=O3KXK:VY^V^I-]=?;?W+DV[EI*T8[ 9G=.#Q>/S%::"@E
MJ?%3R2/]L%FMXY(V;W7NK'/^%8_\M7LGYP?#GJ?N#X\]6[K[8^0/QF[*9*79
M?7>U<ANW?F[>I>U(Z'!;TQN$P6!IJK/9RIP&Z<5@LH(HHIQ3T,-?*$4%V]^Z
M]T>W_A.!TSVY\?\ ^3O\5NJ.\^L]]=/]G;;R'>\VX>ONR=KYC9F\L'%G?D-V
MGN##/E]MY^DH<MCAE,'E*:K@\T2&2GG1QZ6!/NO=::_\QGXL?S4>J?Y_7?7S
MQ^*WP!^0_=%+UQ\D]J]H]5;C?X\]O[SZBWQ58#8NSTIY?XGLZ#"R;DVX]5')
M#,^-RD+>6-XQ,DB.%]U[IV[W^'?_  I2_G]=N];8?Y9='9GX\=/[(RD\V+IN
MQ]H2_'GH_JK^,)%39O=\.P=QY')=M]C;GJ*.G$$#^+/5T*N8HY*.EEJ']^Z]
MU]!KX$?##K/^7S\2.E?B-U--49+:O46V&QM5N;(4=-0Y?>V[<QD*S<.]M\9B
MFI7EBI\ANO=65JZSP"29:2*5*=':.%#[]U[HX'OW7NO>_=>Z+!W[_P S.^'?
M_BP^<_\ @;^_??NO=&?]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__U-_CW[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]T6#OW_F9WP[_\6'SG_P #?W[[]U[HS_OW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO__5
MW^/?NO=%>[ ^353L+>.9V@GQQ^4.^$PYH0-U]?\ 6>*SVSLM][04]<3ALO4;
MOQDU8*,U'@GU01Z)XW47 N?=>Z1_^SDU?_>(WS1_]$YA/_L]]^Z]U[_9R:O_
M +Q&^:/_ *)S"?\ V>^_=>Z]_LY-7_WB-\T?_1.83_[/??NO=>_V<FK_ .\1
MOFC_ .B<PG_V>^_=>Z]_LY-7_P!XC?-'_P!$YA/_ +/??NO=>_V<FK_[Q&^:
M/_HG,)_]GOOW7NO?[.35_P#>(WS1_P#1.83_ .SWW[KW7O\ 9R:O_O$;YH_^
MB<PG_P!GOOW7NO?[.35_]XC?-'_T3F$_^SWW[KW7O]G)J_\ O$;YH_\ HG,)
M_P#9[[]U[KW^SDU?_>(WS1_]$YA/_L]]^Z]U[_9R:O\ [Q&^:/\ Z)S"?_9[
M[]U[KW^SDU?_ 'B-\T?_ $3F$_\ L]]^Z]T"O:GR,W5O#>GQ[SV&^(?S'>AZ
MT[<R6\]SFIZGV]320X*KZ>[4V1'+21R]@"2NJ?X[O"B7PQ*[^-G<@*A/OW7N
MAJ_V<FK_ .\1OFC_ .B<PG_V>^_=>Z]_LY-7_P!XC?-'_P!$YA/_ +/??NO=
M>_V<FK_[Q&^:/_HG,)_]GOOW7NO?[.35_P#>(WS1_P#1.83_ .SWW[KW7O\
M9R:O_O$;YH_^B<PG_P!GOOW7NO?[.35_]XC?-'_T3F$_^SWW[KW7O]G)J_\
MO$;YH_\ HG,)_P#9[[]U[KW^SDU?_>(WS1_]$YA/_L]]^Z]U[_9R:O\ [Q&^
M:/\ Z)S"?_9[[]U[KW^SDU?_ 'B-\T?_ $3F$_\ L]]^Z]U[_9R:O_O$;YH_
M^B<PG_V>^_=>Z]_LY-7_ -XC?-'_ -$YA/\ [/??NO=>_P!G)J_^\1OFC_Z)
MS"?_ &>^_=>ZQR_,RLBBDE_V4+YJR>.-W\<73>#:630I;1&IW\ TCVL!<7/O
MW7NC@X/)G-X7#YEL;E,,<OB\?DSB,Y3)19K%&OI(:HXW,4<<U0E)E*$R^*HB
M61Q'*K*&:US[KW3I[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[K__UM_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW2:WAO/9_7NV\KO/?VZ]M;'V?@H(ZG.;KWAG<7MG;>&IYJB&DB
MJ,KG<U546+QT$M741Q*\TJ*TCJH-V /NO=/U-4TU;34]91U$%71U<$532U5-
M+'/35--/&LL%13SQ,\4T$T3AD=2592"#;W[KW6?W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW23S^_=C;4S.T]N[IWIM/;6X-^Y
M.JPNQ<%G]QX?#9G>F8HJ-\C6XG:>,R-935NX\G28^-IY8*-)I8X5+LH47]^Z
M]TK/?NO=>]^Z]TE=I;[V/OZERM=L3>6U-ZT6"S^4VIG*S:6X<1N.EPVZ<'(D
M6:VWE:C#UE9%CL_AY956JHYBE13LP$B*2/?NO=*KW[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]T7WL_Y,=8=1=B]6=:;SR<E#F^UZNNI<35
MJ(CB\(L!BI<;6;DJ6E4XV@SN:G3'TLVED-4UG*J&8'.V[#N6ZV.Y;A:0%H+8
M MYD@GRIY@=U/3H"<S^XO+?*._\ *_+F]70COMTD*)4J!'0'2SU(HKN/#!'X
MN- *]#ZLMQ=ETV'-V4V(X*D _@_[#V2:A0DFE./R_P"+Z';=I;5P!X_+R/Y]
M)C>&_-E=>X6?<F_MW;8V1MRF95J,_N_/XG;6%@=D=PDN3S-714:L40D O<V/
M]/;]O!/=/X5M \DGHJDG]@'5X8Y;A]$$+NW]$$_X,]);J#O'J'O_ &S6[TZ4
M[%VGV?M''[@RFU:O<NR\O3YS"1[BPGV_\6Q*Y&D+4LU50?=1^0(S*-8Y]N7=
ME=V$W@7MNT4U =+"AH>&.G;JSNK*7P;R!HY: T/&AX&G0J^TW2?KWOW7NO_7
MW^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6D=_('_E]_#;Y%Y7M_P"8'=F=
MWM7?*#I7^:EW^O4\0[^WE@L;XNN,_M+>^T:>7K*#<L&&W!#_ ![-Y"6=9:.1
MJV,NDA:(,OOW7NK[NROYZ7\O/J?Y.YCXN;NW[V%'F=H]H[8Z+[)[EQG4V]LI
M\;.J.\=YK,=L=1=D=VTN.;:NW=YY)J>5)%O+0T#T]2M94TS45:*?W7NE[\K_
M .<-\)?AGWU)\7^X]R]DU/?]7U)A^X-G=5=<]1;[[*W=V9B-P[KK]G8':O6^
M,VCB<C)NG?F4RF(K)1CH] IZ"CGJZB6&GADD7W7NCY=M]P[3Z3Z>WQW?OBEW
M5_<WKW9N1WSN.CVWM/.[MW@N&Q5"<A608O9VWJ/(9_,9A(00*2FADF9P0!P?
M?NO=:/'9/\R_L?\ F5?\)@_YFF[.\=S9G>7=?6/9>QL+N3.3]2CK7;)V/N+Y
M;]8U_5N,P%;B,!AMF[CR&$V]BI:?()1O-DJ I#_$?W9XIJCW7NMD7^77_-K^
M&OR<W;L#X7]99WLRA[EVA\7^LNSL!%V+TYV'U9MGMCKBEVOM;%5^]^HLGO[!
MX"NW;MBCR-<L<54])219*&.6JQQK*.*2H7W7NECGOYU?P3VW\HI_BWE-S=G1
MUV/[LQ_Q@SW?D/46]9_BIMCY3Y6G-7C?C1N+OY,?_<['=R5-.K%L>6:FIFCD
MCJ*F*2&9(_=>ZLJ[2[$P'4'6?8?;&ZX<Q/M;K'8^Z^PMS0[>Q53G<\^WMF8*
MOW%FAAL'1!JW,Y08S'2F"D@#3U,NF.-6=E!]U[HDVYOYIOP]VQ\3OCS\T)]X
M[FRO2GRHWOUAUMT;+@-E9W+;SWMOSMS(Y'%[2VG2;,@@&9ASGW>&KA50.@>G
M^RFN"5 /NO=!Y\L/YR_PD^&O=63Z.[<R_;>3SNQ,+L?='?V\>L>E]^]F=8_%
M?:79N1BQ/7.Z/DEOK:N+K<7UKC-[Y"HB3'QD5=:ZSP2/3QQ5-.\ONO="7\SO
MYH'Q.^"Y^/\ 1=N9_>V[]T?*#<38/H_8?1>P-P=T[ZW[CZ.GQ-;G=XX';.R(
M,A6Y3:.W<?GJ*HJ)Z7SU%1'51BB@JG)0>Z]T#V)_G=_R]MP?##O#Y_;?[+W=
MFOC#\?NX!T?O[>U%UEO5,BV]YLSL/"4/]W]KUF+I,_F<)DJKLO#O#6+ B"*I
M)D"&.15]U[HW_P 2?F;TG\W-G[P['^/TV]\]UGM?>U3LC#]B[DV!NG9&T.SW
MH\+ALQ4;MZER&ZL?BZC?O7HDS!HHLW2P_85592U IWEB197]U[H%_F]_-$^,
M7P)W!LK8_:]+W#V#V9OG:^Z.Q:'JKX^=1[L[I["P?4.Q"G]_NZ-X8+:M.Z;3
MZLV4C,];DZV:+6D,YIHZC[6I\/NO=1.^OYM'P2^./QFZ ^8O8G<,T_QO^36[
M=D[.ZE[-V;LS>.]*'+Y#?V SVY\-4Y/";?PE9N?!TU)B-L5QKXJFA2MH:FF>
MEEIUJ@8/?NO=8OB%_->^('S0_P!F7I>N\WV%UYN#XAU,;]^[-^0'6FY^E-Z;
M#VW58_/9;&[VRNV-Z4U'E*+:V0Q>V:Z?54)!6T<< ^]IJ8RPB3W7NM>GY+?S
M,_BM_,F_F+?R%=X_&C)=B5&'VE\TN_*>DG[(ZKWIUH-\[6?:.W<!2=C=;U>Y
M\738[>6Q*S<6V*_'R34LYK<?D*-Z?(4M),8T?W7NKXOE5_.:^$7P[[MS/1?;
M69[9R&:Z]QFP<[\@]\];=,[\['ZH^*>WNUJVGQO5^=^2W8&V,968GK.BW_6U
MD*XV-Q55<BSPR20QQ5$#R>Z]T*'S+_F?_$OX,5WQ^PG<6X]Z;EW;\G]QM@^F
M-B])=>[G[IWQN_%T46*JMP;WQNUM@T>6RV1V;MJ@S=)45$U''4U=3',!0TU9
M(&1?=>ZJN_X2_;FV]O7XO_S MY[0RM-G=I;N_FY?,7<^ULY11U$5%F=N9[ ]
M-Y3"96CCK(*6KCI<ACJJ.6-98HY K@,JM<#W7NMEOW[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=='Z'_ %C[TWPM]G7NM:C^87F*G</RL[&H:R20
MTFWL)L[:^,B+O_DE$FWJ?,2O3\CQ-+D<S+*"MO4%/U /O(KV\MTM>7;$HQI<
MNPD]""2,>A X'UZYF?>,O9MT]X=^MYP0UK;VL4+"HT:U$NH?TRY-&_AQ3H7O
MDM_-YI?B[\1^C3A<?B>P/EAVMU\3@]JYB6=L#M6BV[6U&U<EVIV4U+419)\-
M4Y#&$T%!$\53FJLN(Y(H8YIHP):<A'=>9]VA"/%L4%Q1F/Q,*DJJDBA('$TQ
MYBM.NB?W>(]R]R?;GDOF+<Y!X+VBK.X%"\D;&-@M:YJM3Z:J]:DO>_>/;7R)
MW5D>ROD+V/NCMK<SF>ICDW)4&;"X9'E:=,5LK95(L6V=K422R:*>FQ]+&[$A
M6>5R6::]KVVQVR 6^U(EM#%Q>@U&OF6(J3\SUEQMEC!ML)@L0EO%%Q8@<#P)
M)&2?7K?&_E7?'+*?%WX-](];;FQW\)WSD\-7=C]AXT@I)C]Y=D9&?=60Q,\;
M(CQ5.!HZ^GH)5-R)*8\^\:>;MT3=^8]TNHY-2*^@'U"XK_MJ:A\CU O-&Y-N
MV^WUWJK'JT@^H7 /YT)_/JP[V'.B'KWOW7NO_]#?X]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=::O_"<7^73\,>W\?\ (7YP]C=(8W<GRGZ8_FA_*O%=:]M2
M[M["QU?MK'X"GVG/AZ1=MX?=N/V5EH:"?>62D05V-JKR5 =KM%$8_=>ZJ#[8
MFI,5_(Z_G\==[U,,'><'\\;*138*ML=XU^Z,[W'TE)C!244FK*U-7DZ+:^Y9
M*7QJ6GBIJIH]0$A]^Z]UL&[*Q>0_Z"D.I4WA2K4[JPG\C;;LN0FK4$U71;H7
MO&LQ69JXY)=4D5:XK:N%W!U%)G4FS'W[KW6TS[]U[KY\6QF9_P#A'3\[BS,Q
M_P!F-WMRS$GGYO=-L>2;\L23_4GW[KW5P.V41/\ A01_*_"1QQ@?R0\BBB.-
M$"HF[,R$C4*!:.,$Z5^BW-OK[]U[K7UZ$Z&[![;^#_R.Q/R._F1[8^+G06%_
MG7;RVSO3I.D^'L_>?=5=\QGWUMBKV;6T^[MM=C;5W_3R[RK=41B^S\5'!BIY
M-<P66-/=>Z^DW74-'DZ&KQN2I*>NQ^0I*BAKZ&KB2II*RCJX7@JJ2I@E5HYZ
M>HAD9'1@592018^_=>ZT7?Y='4VZ-Y_S'/C5_*,SVW]S)U'_ ".OD[\Z/E/G
M*C<,T=7@]W[9WIN_ 93X"5V+J*F26MCSFVZCN&LSJI*"S0%Q'9(_(?=>Z!GN
MOJOM/L;Y@?\ "G';78'SPV5\*?C]!F^A<U\J:+=OQ?I_D-OCL#H;,;'SE/UA
MF=BZ-Z[-W5B3MO$UM)1TL&,\[U=1G*4*T3^$O[KW5A&Y<-MWK7^<O_PF;V]E
M-X5.^^O\+_+Q[-Z^ZV[(W/MG);+?>^[,7\9,Y@Z#=,NTL_69"NV?N?=U!-BI
MGQE143UM%4UT5+)))*%9O=>ZJ&S>7V_G_P#A-)_/-S^T:JAK=IYS^<;NK+[7
MK,6\3XRKV[DN^OA[5X:IQTD'[#T%1CIHVB*>@QL+<>_=>Z^AOTK14>-Z;ZEQ
MV.I8*''X_K+8=%0T5+$L%+1T=+M;%04U+30H D,%/#&J(H "J ![]U[K43^=
M&QODGN__ (4<]IX3JOY4[&^'=5N'^3W4ST'9_:/2&'[SP&X^D<'V95UG:.R]
MO[<W!N/:U-09"'*T>2S,];35,DU/2XJI#1-')(1[KW1:.\^M>KNJ/Y,?_">_
M8G3'>N5^374-#_..Z%K=@]R[@ZDW%TE7;SV[N'MGY-Y[1/U7O#.[GSFW*+#U
MV2GQ].L]9-'6TU-'51A89T1?=>Z,UVY1Y>?Y^_\ "N2GVQ#,<]4_RR.GUQJ4
M(T5<M=-\%LP (-%G:IE(L+>IFL!S;W[KW16NE=V=9Y7:W_"-K";7R."J]PTN
M?[LJYJ/'5%+-7445!C-M;:WQ-50P.\M.E3V)B:J"0N 'K:.=?UQ.%]U[H/.X
M^JNT>R?D[_PIQVWV/\]]E?"SXZ4/8W2V7^5>*W3\8*;Y#;\WSTEG]NYM.HLY
MLH1;YV9N[$_P3'3T%%14^-6<U4V8I[20N8O)[KW5D>Z</MKKG^=G_P )O]O9
MG=TV]-GX3^71V?L/KGL7=.W:W9K;UW=C/CON;"46Y&VMGJNOK]J;HW9BY**5
ML;45$U91U-=%3-))* S>Z]T:'_A+_E]N[@^+W\P#/[.JJ&MV?G?YN'S&S&TJ
MO&2138VJVSD\%TY68.HQ\T#-!+13XZ:-XF0E&C8$&UO?NO=;+7OW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NN+$@<"YN!:]OJ0/KS[]PZ]QZ(OAOYF/P/S_:E)TGAO
MDSU[D.T*_>TO7%'M6!LZ9*K>\.5J,$VWJ?*OADP<E6V;I7I$85)BDJ%\:,S$
M T$L3&@D6OVCJYAE0:BC4^P]'J!!^AOS;C^H^H_UQ[OU3KWOW7NO>_=>Z][]
MU[KWOW7N@Z[:[8Z\Z+ZXW;VWVON:DV;UWL;&?QG=>YZZGKZNEQ&-^X@I!42T
MV+I*[(U&NIJ8XU2&&21F< *?>BP4%F..MA2Q"CB>HG37<W6?R"ZWVUV[T]NJ
MDWMUUO""LJ-N[EHJ;(T4&0CQV2K</7J:'+T>.RE'-29+'S0O'/!&X9#Q:Q.E
M=7%5-1UXHR$JU:]"A[MUKKWOW7NBU=[_ # ^-_QESO7>VN]NTL/UWFNV<M)@
M^O*')X_/Y"3<>1AK\/BY8HWP>(RD6.ABR.?HX3-5M3P!YU]?UM5F5::F ^TT
MZL%9JZ5)^P5Z,K[MU7KWOW''7NM?S^9[UO4[+[IHNWZB.VS^P-J119'((@C@
MH=R;"QTW\3HIY 6$=3D=KQ13P,VDR?;RA;E#[G#VQW2.[V:XVYF FM9RP!P=
M+&E0#Q 85QPP?/K /[S_ "1O,?/VQ[]LP4C?S!8)4=J7(8+$['@&I@-QH"/+
MK4/WUO:O[!WCGM[Y>=YJ[<^3UT,)9Y6@Q<1:#;V"Q\)+.(*#'Z$B@C%@[.0N
MIC>78UC9)!(RK:QJ7E8T58P>#NQH$#4-&8@&G'KK-[>\G<O^W/(G)_(^S+))
MM5A:(JQJI$\TDG=*S@#4)?'+ZB1J\/23BG5EW\JKXH[V[2^:'460W;TC4;LV
M-U[D%[&W;C.PH,YM;;>WZ#$@R;<WCE4:@=MQ9/&[@6!\1@)$>#(URK+5>.FI
MW;W O,WNYREO:;ARWR+S-MU]<(=-T;>Z@G9 #32/"D<@_A;';7-#U._-WM='
MRS[*\P^XGN#OZ[/?W+B#9;")TN+J\G.)3.H;]&R2"KR2S:724 058@=;X,>D
MHI4@ZE!)N"6X')( N?\ 'W%(\,,0"-1S\S3%:?RZP<0AD5EII(\C4?M\_M.3
MUD]WZMU[W[KW7__1W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW0!?'?XN=
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MY>]W[.^1WR2^)O6/;'<^QH\7!B-Y9^//TIRU+A)!)AZ'?FWL)G,7M7M#'8H
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M$%+4;IV=#V)M;;2;GQE/)51M-'2L];3PL)98(XO7[]U[KJL_G5?RU,?\T%^
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MZKG_ )]/_,R?Y:7_ (L-E?\ WI^F/::^^.W_ -,/\/2NQ^"Y_P!+US_GH?\
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MD:+"8W,;E@J,E4T6%HZZJ@QM&9HDDG=1$C2*&8%E!]U[I'?\*4>KNU*OJOX
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?]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g313671g81w35.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g313671g81w35.jpg
M_]C_X  02D9)1@ ! 0$ T@#3  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M 2(  A$! Q$!_\0 'P   04! 0$! 0$           $" P0%!@<("0H+_\0
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MZ?WI/^_C?XU-10!#]G3^])_W\;_&C[.G]Z3_ +^-_C4U% $/V=/[TG_?QO\
M&C[.G]Z3_OXW^-344 0_9T_O2?\ ?QO\:/LZ?WI/^_C?XU-10!#]G3^])_W\
M;_&C[.G]Z3_OXW^-344 0_9T_O2?]_&_QH^SI_>D_P"_C?XU-10!#]G3^])_
MW\;_ !H^SI_>D_[^-_C4U% $/V=/[TG_ '\;_&C[.G]Z3_OXW^-/>6./'F2*
MF>FXXIP((!!!!Y!% $7V=/[TG_?QO\:/LZ?WI/\ OXW^-2LRJ,L0!ZDTM $/
MV=/[TG_?QO\ &C[.G]Z3_OXW^-344 0_9T_O2?\ ?QO\:/LZ?WI/^_C?XU-1
M0!#]G3^])_W\;_&C[.G]Z3_OXW^-344 0_9T_O2?]_&_QH^SI_>D_P"_C?XU
M-10!#]G3^])_W\;_ !H^SI_>D_[^-_C4U% $/V=/[TG_ '\;_&C[.G]Z3_OX
MW^-34AZ4 1?9T_O2?]_&_P :/LZ?WI/^_C?XU$FHVKWAM5ES*"5QM."0,D9Q
MC(],YJ2WNX+EI1!(',3F-\=F SC]:+#LQ?LZ?WI/^_C?XT?9T_O2?]_&_P :
MER*,B@1%]G3^])_W\;_&C[.G]Z3_ +^-_C1'<Q2SRPHV7A(#C!XR,C]*FH A
M^SI_>D_[^-_C1]G3^])_W\;_ !J:B@"'[.G]Z3_OXW^-'V=/[TG_ '\;_&IJ
M* (?LZ?WI/\ OXW^-'V=/[TG_?QO\:FHH A^SI_>D_[^-_C1]G3^])_W\;_&
MIJ* (?LZ?WI/^_C?XT?9T_O2?]_&_P :FHH A^SI_>D_[^-_C1]G3^])_P!_
M&_QJ:B@"'[.G]Z3_ +^-_C1]G3^])_W\;_&IJ* (?LZ?WI/^_C?XT?9T_O2?
M]_&_QJ:B@"'[.G]Z3_OXW^-'V=/[TG_?QO\ &IJ* (?LZ?WI/^_C?XT?9T_O
M2?\ ?QO\:FHH A^SI_>D_P"_C?XT?9T_O2?]_&_QJ:B@"'[.G]Z3_OXW^-'V
M=/[TG_?QO\:FHH A^SI_>D_[^-_C6?JX,/E>6\@SG/SL?3WK6K*UW_EA_P "
M_I0!?M?]4?\ KH__ *$:FJ&U_P!4?^NC_P#H1J:@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BJ6I:G:Z:J&Y?&_.T#J<=:A&M6IN1"OF,"R+Y@3Y<N,KS[T[
M,?*S.\40RO?VDB6\DRK&X)6T\\ DKU!P!TZT127PN[,1QW26BI$)E$)3#8.,
M+V7IN /''O5Q]?@$P*H[6_E22&3:>0A ^7U')_*I_P"U[8AEVR^8)!'Y6P[R
M2-PX^G-7K;8UO*R5CGG:_O=(8+]KN T0:0,F06\U=NWU^7=G'MG!J_,VJ[KC
M9]I\T+-O&WY N#Y90XY/3ID]<]JN1ZO9Q*HA7$)5-JQH<@LS+C'U%2P:Q%/=
M001Q2DRJYW%<;"AP0?QH;?8&WV,V[.IPW%NL+7;*JQ,YV%]^6^?.!P0.QSQT
M YIJ+>PQLC-?^6LT^\HA9LY_=XR.5QZ<9ZUH:UJ[Z:8Q'$C[D=SN)'W<<< ]
M<]3P,5:N]1AM%4S9 9&<8&<XQQ]>>!1=VV%=V6ACL=32"ZNKF22.2WCBD"9P
MC$*"XZ<YP16OI)F?3XIKDDR2@R$'^$,<A?P! _"JEYK>F*ACNB'0L00RAA@8
MR?H,_P"<4^77;-9I[>)P\T2N0.Q91DBD[M;"=VMC5HK)37K7[$EQ)N 9E0$#
MAG*Y(!]L'\L5I0RB:%9%# , 0&4@CZ@]*EIHAIK<DHHHI""BBB@ I#TI'8*A
M8G  R36$GB.1X976Q+%!&R;68AE8D;ONY[=@?;--)O8I1;V)I[/4+G4'E?RX
MT566W=6R8R1C>5QR?QX!HT[298+:]MKEXFAN#A?+0KQL"GJ3Z?U[\1OX@9$M
MY#:_NY%)DDW-M0AL$?=ZCG[VVE'B'-U-"MG(X02;"H;YRG4=,<X/0GWQFKM*
MQ=IVV*IT/47AE\RXC69XV.Y2?]:Q _+: /Q-1R>'[XV:1(ZA1([>3N7:,J ,
M?)@8()X4=3WJXWB"3[()$L]T@E\MU!?"?+D$_)N&?]W\:5O$$AEQ#:)(F8@&
M,V,F0<=NE/WBKS[#8-&NHM46Z>59D!CRKGKB/:7Z?>ST]B?6MZL%O$C*ZJUD
MV5.)=I9MGSE.,+@\J>NVFW/B"X2*5DM(Q@3"-FD)R8SSD8Z8YZ^WO4N,GN0X
MSEN=#14<+.T*M*JJY W!6R ?8X&?RJ2H,PHHHH **** "BBB@ HHHH ****
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M/\:/^$VL_P#GTG_3_&CV%7L'UW#_ ,QU-5K^W^TVS(,;ARI/K7/_ /";6?\
MSZ3_ )C_ !H_X3:S_P"?2?\ 3_&CV%7L'UW#_P QTL$2PPK&O11BI*Y;_A-K
M/_GTG_3_ !H_X3:S_P"?2?\ 3_&CV%7L'UW#_P QU-%<M_PFUG_SZ3_I_C1_
MPFUG_P ^D_Z?XT>PJ]@^NX?^8ZFBN6_X3:S_ .?2?]/\:/\ A-K/_GTG_3_&
MCV%7L'UW#_S'4T5RW_";6?\ SZ3_ *?XT?\ ";6?_/I/^G^-'L*O8/KN'_F.
MIHKEO^$VL_\ GTG_ $_QH_X3:S_Y])_T_P :/85>P?7</_,=317+?\)M9_\
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M .?2?]/\:/\ A-K/_GTG_3_&CV%7L'UW#_S'4T5RW_";6?\ SZ3_ *?XT?\
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M.\DGRH#W)P,?3GZU<EUFP^U&^ABN?M2P") VW83MQN/.>YXJ,:S;,(X98Y3
MUBEM+MQN#+DY7GD?6I3JV+<:%]RIJFFK86MG)YF]YU<L58,O!P"OU%9QK2U2
M\M;BTL[>T255MU<$R8RV3G/'^16;BMZ=^7WCDK<O/[NVAZMIO_(,M?\ KBG_
M *"*\UUG_D-WW_7Q)_Z$:]*TW_D%VO\ UQ3_ -!%>:ZS_P AJ^_Z^)/_ $(U
MPX3XV>OF7\&']=!=(MK>\U**VNG9$E)4,IP0V./UX_&I[?2P]K*TI99C<K;1
M#.!O)^;/L/:LV-WBE26,X=&#*?0BM?5]9CN;JWEL8VB6%S-M<#F0G)/!Z<"N
MR:GS>Z>92=/D][=?K_D3+I6DRW[:9#<W?VP902.J^47 YXZXR"*@33K"TL(+
MC59+K=<%MB0!?E ..2:G&KZ9'=MJ4%I.+]LG8S@Q*QSEO4]:@AU&QN;*"WU:
M*X8VY8QO 1E@3DJ0>U9+VENMCH;HWTM?6W;IOY[D;:?:-:ZE/;W#RI;&/RFQ
MMW!C@Y!%1Z58Q7?GS74CQV]LF^0IC<?0#-6[?4].;^T8[JVE@@NS&52VV_+M
M.>_^%-@U#3;.:2*VBN9;*XCV3+,5#YSU7''%5>=FM3/EI<RE=6^?G;Y;!)IM
MA<6J7>G33I"LZQ3"YVY0'HW':I=9T>SL;:5D%\DB$;7E56CDSZ%>GXU#-J5C
M#:)9:?!*8#*)9C<$;I,?P\=JEFU:PCT^X@L8[O-PNTQ3.#%%W^45/[RZM<TO
M1L[VO;\?(NOX<L?M3VJ+J2L$W"=U7R0=N>N/PK.%CI=G:6SZG+=F:X3S0L&W
M"*>F=WK46L:Q->WDK6]Q<);.J@1,Y X4 \ XZ@U+'J&G75I;QZI!<&6V0(CP
ML,.HZ!L]/PH4:BBKL'.BY-12^>Q:B\/VZ7%\LYNITMQ&T?V8 M(K9[$?YQ1_
M8%HVH:? &NHENA(6CFVB1-H)!X&!G'^>U>;7C,FI-B2*6Y\H0^6>$5#W/T]*
MD@UNT_M"QU"XBD^U1!EN"BC$ORD!NO7U_P#K"IM5W_K8KFPVR_K7_(@?1E;P
M[#J,#LTK%C+'QPH;&5[\<9^M5=:LX]/U:>UA9F1-N"_7E0?ZU;AUE;>WTU(T
M9C;>8LRL!MD5VR1U]/7O536[R/4-6GNH594DQ@/C/"@?TK6'/S:[:_F85?9>
MS]W?3\M2YING:7>0K$;FX-TT;2,RKB*(#GYL\^G2DMM.T^?29IUGG,\41D9M
MH$0.>$YYW'\N:DMK[2(](6S;[?&[C,[PA!YA]"2<X'I4=GJ=A:VA=+1Q>>28
M3@CRW!_B8=<^W2I?/K:^YHO9:7MM_7S*.G)9R3^7>K=,&P$%OMW%L^]/UFWM
M+347M[)Y72/Y6,A!.[N!@=NGX&I-/NK&RU2UN0L[I&F9%8*3YF#]WVSCWK.9
MB[%F.6)R2>]:I-SOT.9N*I\NE[FM)X=O$#YEM2R*'9?-P0A_BYZ 5'_8EU]N
M-MOAP(O.,V_]WL_O9]*L2ZQ;O>WTX27;<6GD)D#(; &3STXJU97L>HRBUCBD
M9#8);R*"JN64YRN3@_0XK+GJ)79T*G0E*T3'U#39M/2!YGB=9P2AC;=D XS^
M-73H+RP6LEK*@>>#>$DD +MW"C\NOKUI?$0C@MM/LT4QO"C[D9@Q&YL@G'&3
MUQVS3HM4TX"PEEAN&GLH@%"X"NPY&><@ _\ ZJ?--Q37F)4Z49RC+R_2Y571
MYYH;+R4_>7)D!W/P-IP21@;<?4T7NEI::4EWYRRL\Q16B<-&5"]1WZY'/I5J
M+78E6S\R)V*>>)P,#(D.?EYJM>WEDVDI8V2S_+,9"TN/FR,=CQ_]:A.I=7%)
M4>5M;V_R_P""9=>E^&/^1=L_]P_S->:UZ5X7_P"1=M/]P_S-9XSX$=.5?Q'Z
M&K65KO\ RP_X%_2M6LK7?^6'_ OZ5YI[Y?M?]4?^NC_^A&H=6_Y!%W_UP?\
M]!-36O\ JC_UT?\ ]"-0ZM_R"+S_ *X/_P"@FIELRH?$CSBBBBO /L0H-%%
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M7]OQ\_P#^Q*?9?>R'_A!X?\ G_?_ +]C_&C_ (0>'_G_ '_[]C_&IO[3O?\
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M?XU-_:=[_P ]S_WR*/[3O?\ GN?^^11_;R\_N0?V)2[+[V0_\(/#_P _[_\
M?L?XT?\ "#P_\_[_ /?L?XU-_:=]_P ]S_WR*/[3O?\ GN?^^11_;T?/\ _L
M2EV7WLA_X0>'_G_?_OV/\:/^$'A_Y_W_ ._8_P :F_M.]_Y[G_OD4?VG>_\
M/<_]\BC^WH^?W(/[$I]E][(?^$'A_P"?]_\ OV/\:/\ A!X?^?\ ?_OV/\:F
M_M.]_P">Y_[Y%']IWO\ SW/_ 'R/\*7]OQ\_P#^Q*?9?>R'_ (0>'_G_ '_[
M]C_&C_A!X?\ G_?_ +]C_&IO[3O?^>Y_[Y%']IWO_/<_]\BG_;T?/\ _L2EV
M7WLA_P"$'A_Y_P!_^_8_QH_X0>'_ )_W_P"_8_QJ;^T[W_GN?^^11_:=[_SW
M/_?(H_MZ/G^ ?V)3[+[V0_\ "#P_\_[_ /?L?XT?\(/#_P _[_\ ?L?XU-_:
M=[_SW/\ WR*/[3O?^>Y_[Y%+^WX^?X!_8E/LOO9#_P (/#_S_O\ ]^Q_C1_P
M@\/_ #_O_P!^Q_C4W]IWO_/<_P#?(H_M.]_Y[G_OD4_[?CY_@']B4^R^]D/_
M  @\/_/^_P#W['^-'_"$1?\ 00D_[]C_ !J;^T[W_GN?^^11_:=[_P ]S_WR
M*/[?CY_<@_L2GV7WLA_X0>'_ )_W_P"_8_QH_P"$'A_Y_P!_^_8_QJ;^T[W_
M )[G_OD4?VG>_P#/<_\ ?(H_M^/G^ ?V)3[+[V0_\(/#_P _[_\ ?L?XT?\
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M/]?\:/[:G_YYQ_K_ (T ;E%8?]M3_P#/./\ 7_&C^VI_^><?Z_XT ;E%8?\
M;4__ #SC_7_&C^VI_P#GG'^O^- &Y16'_;4__/./]?\ &C^VI_\ GG'^O^-
M&Y16'_;4_P#SSC_7_&C^VI_^><?Z_P"- &Y16'_;4_\ SSC_ %_QH_MJ?_GG
M'^O^- &Y16'_ &U/_P \X_U_QH_MJ?\ YYQ_K_C0!N45A_VU/_SSC_7_ !H_
MMJ?_ )YQ_K_C0!N45A_VU/\ \\X_U_QH_MJ?_GG'^O\ C0!N45A_VU/_ ,\X
M_P!?\:/[:G_YYQ_K_C0!N45A_P!M3_\ /./]?\:/[:G_ .><?Z_XT ;E%8?]
MM3_\\X_U_P :/[:G_P"><?Z_XT ;E%8?]M3_ //./]?\:/[:G_YYQ_K_ (T
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M &U/_P \X_U_QH_MJ?\ YYQ_K_C1[.'8.9]S6^R6W_/O%_WP*/LEM_S[Q?\
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<VI_^><?Z_P"-0W-Y)>[=ZJNS.,#U_P#U50C_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g313671g87w15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g313671g87w15.jpg
M_]C_X  02D9)1@ ! 0$ ?0!]  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
MQ@#+ -  U0#; .  Y0#K /  ]@#[ 0$!!P$- 1,!&0$? 24!*P$R 3@!/@%%
M 4P!4@%9 6 !9P%N 74!? &# 8L!D@&: :$!J0&Q ;D!P0') =$!V0'A >D!
M\@'Z @,"# (4 AT")@(O C@"00)+ E0"70)G G$">@*$ HX"F *B JP"M@+!
M LL"U0+@ NL"]0,  PL#%@,A RT#. -# T\#6@-F W(#?@.* Y8#H@.N [H#
MQP/3 ^ #[ /Y! 8$$P0@!"T$.P1(!%4$8P1Q!'X$C 2:!*@$M@3$!-,$X03P
M!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&
M609J!GL&C :=!J\&P ;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E
M!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)
MN@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X +F NP
M"\@+X0OY#!(,*@Q##%P,=0R.#*<,P S9#/,-#0TF#4 -6@UT#8X-J0W##=X-
M^ X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[! )$"800Q!A
M$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3
M(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/ 5$A4T%585>!6;%;T5X!8#
M%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$ 891B*&*\8U1CZ&2 9
M11EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H< APJ'%(<>QRC
M',P<]1T>'4<=<!V9'<,=[!X6'D >:AZ4'KX>Z1\3'SX?:1^4'[\?ZB 5($$@
M;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8CE"/"(_ D'R1-
M)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH#2@_*'$H
MHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K BLV*VDKG2O1+ 4L.2QN+*(LURT,
M+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C U,&PPI##;,1(Q2C&",;HQ
M\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U336'-<(U_38W-G(VKC;I
M-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[JCOH/"<\
M93RD/.,](CUA/:$]X#X@/F ^H#[@/R$_83^B/^) (T!D0*9 YT$I06I!K$'N
M0C!"<D*U0O=#.D-]0\!$ T1'1(I$SD42155%FD7>1B)&9T:K1O!'-4=[1\!(
M!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I- DU*39--W$XE
M3FY.MT\ 3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4
MVU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF6O5;15N5
M6^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB
M\&-#8Y=CZV1 9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(
M:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R
M2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&
M>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$> J($*@6N!S8(P@I*"
M](-7@[J$'82 A..%1X6KA@Z&<H;7ASN'GX@$B&F(SHDSB9F)_HIDBLJ+,(N6
MB_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1/Y&HDA&2>I+CDTV3MI0@E(J4
M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M 2(  A$! Q$!_\0 'P   04! 0$! 0$           $" P0%!@<("0H+_\0
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M_#NH6&OVUY?V>]8[>> /YBL8\S;DSSG&S(XS7=48H !THHHH **** "BBB@
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MZ1_SYWW_ 'RG_P 51]5K?RL/[1PO_/Q'<45Q'_"S](_Y\[[_ +Y3_P"*I/\
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M$,TTD<P/FR*ZC:PC+;<8RIRIZYR!FLDW&J&W-OFX\HC:5VGIG./IGM3A>ZN
M@$ES^[X7@\?+M_EQ2<9])#4J2?\ #9=NM)TZVLS>F66:(>4C112HS([ D@N
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MB"7!N9#]P_WC7*FOK#]#T)QE]2BK?:9F45-]EN/^>$O_ 'P:/LMQ_P \)?\
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M"SR;2S#<IX).2:F6\U=1&%>Y BV[!@_+M! Q] 2/QIOGM[LB8^SO[\'8FO-
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MJ*E^RW'_ #PE_P"^#1]EN/\ GA+_ -\&CF7<.278BK4\)_\ (SZ9_P!?,?\
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MO^>__D-?\*/[9OO^>_\ Y#7_  JA11[2?<+%_P#MF^_Y[_\ D-?\*/[9OO\
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M_,PLA9=1U2%F620C;P?D4@?I4?\ ;-__ ,]__(:_X4ZXU-9HID,1'F'@ENG
M]O:LZIE.2VDPL7_[9OO^>_\ Y#7_  H_MF^_Y[_^0U_PJA14^TGW"Q?_ +9O
MO^>__D-?\*/[9OO^>_\ Y#7_  JA11[2?<+%_P#MF^_Y[_\ D-?\*/[9OO\
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M^=']K7__ #]R_G7S?^L%!?89ZG]F5>Z.]P/:C ]JX+^UK_\ Y^Y?SH_M:_\
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MU@H?R/\  /[,J]T=[@>@HP/05P7]K7__ #]R_G1_:U__ ,_<OYT?ZPT/Y'^
M?V95[H[W ]!1@>@K@O[6O_\ G[E_.C^UK_\ Y^Y?SH_U@H?R/\ _LRKW1WN!
MZ"C ]!7!_P!J:B?^7J7D9&#UH.J:B!DW,P![T_[?H_R,7]FU/YD=YQZ"C ]!
M7"?VGJ(.#<S#C-(-4U%LD7,Q^E']OT;VY&']G3WYD=Y@>@HP/05P8U74< _:
M9L>N:4ZGJ((!N)LGMGK1_;]+^1A_9U3^9'=X'H*,#T%<(-3U(G N9B1U -(=
M4U'&?M,H_&C^WJ7\C#^SI_S([S ]!1@>@K@_[5U'./M,N?3/-']J:CC/VF;
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M?]!*#\A_C6CPF-EO37W^5B%6PRVE^'_ *OVJ$1$B7Y?(,7E8/WO7T]ZDBO8
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M34F123Z=)E0B $M]U-I^\-O...,TW41!;S6K#RP1(S,8QCY<C'Z58'AZ,?\
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MU@4QIDAD""2,\E2<XP1VIW]EDQJ?,4-EMV[@  XJT=+U4L&,JDC_ &O_ *U
MTO51TD3J3][U_"CV?]U@4CIS* 6EC PS<9/ [T[^S'"DLR@*3ELG&, ],>]6
MO[*U3<&\Q<KD#Y_7K2C2]5!R)5R23][U_#V%'L]?A8%2ZTTQ+,\;ADB(!'?H
M/\?TJA6T^EZK(&#RJ0W7YNO^<5#_ &!>_P#3/_OJIE3D]D!ET5J?V!>_],_^
M^J/[ O?^F?\ WU4>RGV RZ*U/[ O?^F?_?5']@7O_3/_ +ZI^RGV RZ*U/[
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M "%[W_KXD_\ 0C6KQK5-3Y3F64IUW1Y]E?8]C^W6G_/U#_W\%'VZT_Y^H?\
MOX*\1HK+^T7_ "_B=/\ 82_Y^?@>W?;K3_GZA_[^"C[=:?\ /U#_ -_!7B-%
M']HO^4/["7_/S\#V[[=:?\_4/_?P4?;K3_GZA_[^"O$:*/[1?\OXA_82_P"?
MGX'MWVZT_P"?J'_OX*/MUI_S]0_]_!7B-%']HO\ E#^PE_S\_ ]N^W6G_/U#
M_P!_!1]NM/\ GZA_[^"O$:*/[1?\OXA_82_Y^?@>W?;K3_GZA_[^"C[=:?\
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M$5\/?]!*Z_3_ .)H_P"$5\/?]!*Z_3_XFCZI/N@_MC#>?W'#45W/_"*^'O\
MH)77Z?\ Q-'_  BOAT_\Q*Z_3_XFCZI/R#^V,-Y_<8O@$9\3V_\ NO\ ^@FL
MO6?^0O>_]?$G_H1KNM&T?0])OUO(+^=W0$ /R.1CLM5[KPWH%S=2SOJ%R&E=
MG(&,9)S_ ':V>'DZ2A=7N<D<SH+$NKK9I(X*BNY_X17P]_T$KK]/_B:/^$5\
M._\ 02NOT_\ B:Q^J3[HZ_[8PWG]QPU%=S_PBOA[_H)77Z?_ !-'_"*^'?\
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MC_Z]'L)]@,*BMW_A&G_Y^5_[X_\ KT?\(T__ #\K_P!\?_7H]A/L!A45N_\
M"-/_ ,_*_P#?'_UZ/^$:?_GY7_OC_P"O1["?8#"HK=_X1I_^?E?^^/\ Z]'_
M  C3_P#/RO\ WQ_]>CV$^P&%16[_ ,(T_P#S\K_WQ_\ 7H_X1I_^?E?^^/\
MZ]'L)]@,*BMW_A&G_P"?E?\ OC_Z]'_"-/\ \_*_]\?_ %Z/83[ 8UNBO<Q*
MPR&< CVS6X-,LPS'9E6<;1N/"YP?US3/^$;<'(N1_P!\?_7IP\/2C_E[_P#'
M3_C6D*<H[QN C:99J&95W!G39ACPNX _J369,D;7JQP1;@&V[1D9Y]<FM/\
MX1V7&/M?'^Z?\:!X<D!R+H9]=G_UZ<J<GM$"C+:1MJ'D)\F$RP7)Y Y S44E
MHBWL<)D*JX4[F&,9[<?6M:/09XY%D2\ 9>AV9_F:270)IGWR7:L>GW*3I-]
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MY,G_ #\R?DO^%'DR?\_,GY+_ (4 3T5!Y,G_ #\R?DO^%'DR?\_,GY+_ (4
M3T5!Y,G_ #\R?DO^%'DR?\_,GY+_ (4 3T5!Y,G_ #\R?DO^%'DR?\_,GY+_
M (4 3T5!Y,G_ #\R?DO^%'DR?\_,GY+_ (4 3T5!Y,G_ #\R?DO^%'DR?\_,
MGY+_ (4 3T5!Y,G_ #\R?DO^%'DR?\_,GY+_ (4 3T5!Y,G_ #\R?DO^%'DR
M?\_,GY+_ (4 3T5!Y,G_ #\R?DO^%'DR?\_,GY+_ (4 3T5!Y,G_ #\R?DO^
M%'DR?\_,GY+_ (4 3T5!Y,G_ #\R?DO^%'DR?\_,GY+_ (4 3T5!Y,G_ #\R
M?DO^%'DR?\_,GY+_ (4 3T5!Y,G_ #\R?DO^%'DR?\_,GY+_ (4 3T5!Y,G_
M #\R?DO^%'DR?\_,GY+_ (4 3T5!Y,G_ #\R?DO^%'DR?\_,GY+_ (4 3T5!
MY,G_ #\R?DO^%'DR?\_,GY+_ (4 3T5!Y,G_ #\R?DO^%'DR?\_,GY+_ (4
M3T5!Y,G_ #\R?DO^%'DR?\_,GY+_ (4 3T5!Y,G_ #\R?DO^%'DR?\_,GY+_
M (4 3T5!Y,G_ #\R?DO^%'DR?\_,GY+_ (4 3T5!Y,G_ #\R?DO^%'DR?\_,
MGY+_ (4 3T5!Y,G_ #\R?DO^%'DR?\_,GY+_ (4 3T5!Y,G_ #\R?DO^%'DR
M?\_,GY+_ (4 3T5!Y,G_ #\R?DO^%'DR?\_,GY+_ (4 3T5!Y,G_ #\R?DO^
M%'DR?\_,GY+_ (4 3T5!Y,G_ #\R?DO^%'DR?\_,GY+_ (4 3T5!Y,G_ #\R
M?DO^%'DR?\_,GY+_ (4 3T5!Y,G_ #\R?DO^%'DR?\_,GY+_ (4 3T5!Y,G_
M #\R?DO^%'DR?\_,GY+_ (4 3T5!Y,G_ #\R?DO^%'DR?\_,GY+_ (4 3T5!
MY,G_ #\R?DO^%'DR?\_,GY+_ (4 3T5!Y,G_ #\R?DO^%'DR?\_,GY+_ (4
M3T5!Y,G_ #\R?DO^%'DR?\_,GY+_ (4 3T5!Y,O_ #\R?DO^%)!O6XDC>0N%
M16!( /);T^E %BBBB@"!O^/V/_KFW\UJ>H&_X_8_^N;?S6IZ "BBB@ HHHH
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MK0CVA7_"CW0]T=_;6E_]!*S_ ._Z_P"-']M:7_T$K/\ [_K_ (TG]C:5_P!
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M24445) 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@W%6.".H(Z=:W+2^@NI&2"3>456. < ,,CGZ4 .M[.&WEFEC#;YVW.68G/&
M.>@]JGHHH YOXD?\B9J'_;/_ -&+7B7>O;?B1_R)FH?]L_\ T8M>)=Z]#"_"
MSU<%\#]2[J?^JL?^O<?^AO5[P/\ \C78?[S?^@FJ.I_ZJQ_Z]Q_Z&]7O _\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %0I_P ?LO\ US3^;5-4*?\
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M_!_\34G_  KG1?LWV??=[-^__6#.<8]*KZQ!E/%TW8\=J[KW_(;U#_KYD_\
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M88Y2#(N2.E-^R0_W/U-344 0_9(?[GZFC[)#_<_4U-10!#]DA_N?J:/LD/\
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;44 0_9(/[GZFGQ0QQ$F-<$]:?10 4444 ?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
